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Abstract 
 
Successful interaction with the environment requires flexible updating of our beliefs about 
the world. By learning to estimate the likelihood of future events, it is possible to prepare 
appropriate actions in advance and execute fast, accurate motor responses. According 
to theoretical proposals, humans track the variability arising from dynamic environments 
by computing various forms of uncertainty. Several neuromodulators have been linked 
to uncertainty signalling but comprehensive empirical characterisation of their roles in 
perceptual belief updating and motor response modulation has been lacking. This thesis 
interrogates the contributions of noradrenaline, acetylcholine and dopamine to human 
learning and action within a unified computational framework of uncertainty. 
First, I use pharmacological interventions to characterise the impact of noradrenergic, 
cholinergic and dopaminergic receptor antagonism on individual computations of 
uncertainty during a probabilistic serial reaction time task. I develop and employ a 
hierarchical Bayesian model to quantify human learning and action under three forms of 
uncertainty. I propose that noradrenaline influences learning of uncertain events arising 
from unexpected changes in the environment, while acetylcholine balances attribution of 
uncertainty to chance fluctuations within environmental contexts or to gross 
environmental violations following a contextual switch. In contrast, dopamine supports 
the use of uncertainty representations to engender fast, adaptive responses. 
Second, I extend these results by focusing on the effects of natural inter-individual 
variations in dopaminergic function. Specifically, I employ the same task and model to 
assess individual learning and action under uncertainty as a function of COMT genotype. 
Third, I focus on the role of noradrenaline. Uncertainty computations have been linked 
to changes in pupil diameter, and pupil dilation to noradrenergic neuronal activity in the 
locus coeruleus. Combining an auditory probabilistic learning task, pharmacological 
manipulations, pupillometry and computational modelling, I demonstrate that pupil 
diameter offers an indirect measure of dynamic noradrenergic computations of 
environmental uncertainty and volatility. 
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1 Introduction 
This thesis addresses the neuromodulatory mechanisms employed by the human brain 
to support learning and action in uncertain environments. It builds on a large body of 
theoretical, physiological, pharmacological, behavioural and computational work 
proposing roles for noradrenaline (NA), acetylcholine (ACh), and dopamine (DA) in 
computing different forms of uncertainty, and in supporting adaptive motor responses to 
environmental events. In this chapter, I introduce three theorised forms of environmental 
uncertainty, and review the existing literature on the neuromodulatory bases of 
uncertainty representations and response modulation. I highlight several open questions 
addressed in this thesis, define the key terms that will be used throughout, and present 
an overview of the following chapters. 
1.1 Uncertainty is an inherent feature of the environment 
Successful interaction with the environment requires flexible updating of our beliefs about 
the world (Conant and Ashby, 1970; Körding and Wolpert, 2004; Yu and Dayan, 2005; 
Behrens et al., 2007; O’Reilly, 2013). By tracking the environment’s regularities, an 
individual can form and manipulate internal estimates of the world’s statistical structure, 
and learn the causes of their sensory input. In so doing, it becomes possible to predict 
the likelihood of future environmental events given particular sensory cues (Friston, 
2005; Bar, 2009), in turn facilitating anticipatory action preparation and the execution of 
fast, accurate motor responses (Bestmann et al., 2008). 
However, the world with which humans, and indeed all animals, interact is incredibly 
complex; a multitude of statistical dependencies relate the sensory stimuli and events 
within our current environment, and these relationships are liable to change over time. 
Further, random events can occur due to environmental stochasticity. While our senses 
offer a means by which to track the myriad of entities within our environment, they only 
give us partial access to the true relationships that exist between entities. As such, the 
environment’s richly complicated sources of noise and latent structure present us with 
various forms of uncertainty. 
For instance, a London commuter predicting her journey time to work faces three distinct 
forms: 
First, there is irreducible uncertainty, which captures the randomness inherent in any 
complex environment and is undiminished by learning. An unplanned station closure or 
1. Introduction 
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a faulty train could cause journey delays and thus influence the accuracy of the 
commuter’s estimated arrival time on any given day. 
Second, estimation uncertainty arises from the commuter’s incomplete knowledge of 
the probabilistic relationships within her current environmental context. After moving to 
a new part of town, the duration of the commuter’s chosen route to work may be unclear, 
producing uncertainty about how likely she is to arrive at work on time. Over repeated 
journeys, this estimation uncertainty falls as the commuter learns the contextual rules of 
her environment. For example, she learns to predict the frequent delays on this new 
route due to congestion during the morning rush hour, although these delays may vary 
with local dips and surges in the number of passengers using the service. 
Third, volatility uncertainty arises from the commuter’s beliefs about the stability of the 
environment, and thus how quickly probabilistic relationships are changing between 
contexts. A major sporting event, such as the London Olympics, may bring a large influx 
of additional passengers for an unknown period of time and with unexpected effects on 
transport performance, making it harder to predict future journey times until these 
changes have been learned. 
1.1.1 The brain computes different forms of uncertainty 
To formulate accurate predictions about the likelihood of future events, and thus facilitate 
anticipatory preparation of appropriate motor responses, it is necessary to take these 
forms of uncertainty into account (Ma and Jazayeri, 2014; Meyniel et al., 2015; Pouget 
et al., 2016). In line with this notion, an assortment of theoretical, behavioural and 
neurobiological research has suggested that the brain computes uncertainty estimates 
relating to the environment’s sensory events, contextual associations and their changes 
over time (Averbeck et al., 2006; Ma et al., 2006; Behrens et al., 2007; den Ouden et al., 
2010; Fiser et al., 2010; Mathys et al., 2011, 2014; Payzan-LeNestour and Bossaerts, 
2011; Bach and Dolan, 2012; Bland and Schaefer, 2012; Friston et al., 2012; Iglesias et 
al., 2013; Payzan-LeNestour et al., 2013; Vossel et al., 2014a, 2014b; de Berker et al., 
2016; Diaconescu et al., 2017). 
Uncertainty estimates influence our perceptual beliefs about the world. In psychology, a 
distinction has been made between two forms of information processing within the brain 
(Gregory, 1970, 1997). While bottom-up processing focuses on incoming sensory 
information from the environment, top-down processing uses past experience to guide 
the interpretation of environmental data in an expectation-driven manner. Uncertainty 
about the validity of one’s own perceptual beliefs about the world should have the effect 
1. Introduction 
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of suppressing top-down prior expectations relative to new bottom-up sensory evidence, 
promoting learning about the sensory stimuli and events within the current environmental 
context (Yu and Dayan, 2003). With their broad distribution and extensive connectivity, 
the brain’s neuromodulatory networks are well-placed to facilitate the widespread 
changes in neuronal gain required to support such a function (Berridge and Waterhouse, 
2003; Aston-Jones and Cohen, 2005a; Warren et al., 2016). Indeed, neuromodulators 
profoundly alter the dynamics and topology of cortical networks (Marder, 2012; Eldar et 
al., 2013; Polack et al., 2013; McGinley et al., 2015). In particular, NA and ACh are known 
to enhance bottom-up, feedforward thalamocortical transmission of sensory information 
relative to top-down, intracortical and feedback processing (Hasselmo et al., 1996; Gil et 
al., 1997; Kimura et al., 1999; Kobayashi et al., 2000; Yu and Dayan, 2002, 2005; 
Hasselmo and McGaughy, 2004; Sarter et al., 2005; Dayan and Yu, 2006a; Deco and 
Thiele, 2011; Moran et al., 2013). 
 
 
Figure 1.1 A schematic of the noradrenergic and cholinergic networks. Both 
neuromodulatory systems show a broad distribution and extensive connectivity. (A) 
Noradrenaline (NA), also known as norepinephrine, is a catecholamine synthesised from 
an amino acid precursor, tyrosine, via a sequence of enzymatic steps (Cooper et al., 
2003). The primary source of NA is a brainstem nucleus called the locus coeruleus (LC), 
which innervates the cortex, cerebellum and hippocampus (Sara, 2009). Functionally, 
NA has been linked to arousal and attention. (B) A major source of acetylcholine (ACh) 
is the basal forebrain, located below the striatum, which sends cholinergic projections to 
the cortex and hippocampus. An additional source of ACh lies within the 
pedunculopontine nucleus and laterodorsal tegmental nucleus of the brainstem. 
Functionally, ACh has been linked to arousal, attention and memory (Himmelheber et 
al., 2000; Jones, 2005). Figure adapted from Purves et al., 2011.  
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1.1.2 Neuromodulatory computations of uncertainty 
A seminal body of work by Yu and Dayan has had lasting impact on the theorised 
contributions of NA and ACh to uncertainty computations (Yu and Dayan, 2002, 2003, 
2005; Dayan and Yu, 2006b). Specifically, the authors hypothesised that ACh signals 
the uncertainty that arises from ignorance about, and the unreliability of, a stable set of 
probabilistic relationships that link sensory events within an environmental context. As 
such, the quantity is notionally similar to estimation uncertainty. In contrast, Yu and 
Dayan suggest that NA signals the uncertainty that arises from unexpected events that 
occur between environmental contexts, i.e., following a contextual switch. Contextual 
switches arise due to environmental volatility and bring about a change in environmental 
rules. As I will address next, two types of experimental paradigm have highlighted 
different cholinergic and noradrenergic effects on behaviour within and between 
environmental contexts respectively, supporting a notional functional dichotomy for the 
two neuromodulators. 
1.1.2.1 A proposed role for acetylcholine under estimation uncertainty 
Within a stable environmental context, humans and animals show faster, more accurate 
responses to validly and predictably cued events than to those believed improbable 
(Posner, 1980; Downing, 1988; Bowman et al., 1993; Vossel et al., 2014b). This so-
called validity effect is modulated by pharmacological (Witte et al., 1997; Phillips et al., 
2000a), surgical (Voytko et al., 1994; Chiba et al., 1999), and neurodegenerative 
(Parasuraman et al., 1992) manipulations of ACh. Specifically, reaction times (RTs) to 
invalidly cued visual targets have been shown to decrease in both rats and rhesus 
monkeys following systemic injections of the cholinergic agonist nicotine, which boosts 
ACh neurotransmission. Similarly, RTs to invalidly cued targets are lower in human 
cigarette smokers compared to non-smokers (Witte et al., 1997; Phillips et al., 2000a). 
In each of these experiments, responses to validly cued targets were unchanged, 
meaning that the validity effect was either reduced or completely abolished. Conversely, 
the cholinergic (muscarinic) antagonist scopolamine, which reduces ACh 
neurotransmission, increases the validity effect in rats by disproportionately increasing 
RTs to invalidly cued targets (Phillips et al., 2000a). Moreover, lesions of the cholinergic 
basal forebrain in rats and monkeys have also been shown to selectively increase RTs 
following invalid cueing (Voytko et al., 1994; Chiba et al., 1999). The same behavioural 
effect is observed when patients with Alzheimer’s disease, and thus a cholinergic deficit, 
are compared to age-matched healthy individuals (Parasuraman et al., 1992). 
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Together, these results suggest a role for ACh in learning within environmental contexts 
defined by particular probabilistic rules. More recently, it has been demonstrated that 
blood-oxygenation-level-dependent (BOLD) activity in the human cholinergic basal 
forebrain reflects an individual’s estimation uncertainty about the probabilistic 
relationships linking environmental cues and outcomes, as quantified by a computational 
learning model (Iglesias et al., 2013). Moreover, pharmacological cholinergic stimulation 
under the drug galantamine has been proposed to increase the rate at which humans 
learn probabilistic relationships under estimation uncertainty (Vossel et al., 2014a), 
supporting the idea that ACh enhances learning accorded to stimuli with uncertain 
predictive consequences (Bucci et al., 1998) by suppressing the use of outdated top-
down cues and boosting bottom-up sensory processing (Yu and Dayan, 2005). 
1.1.2.2 A proposed role for noradrenaline under environmental volatility  
While NA plays no consistent role in learning within environmental contexts (Clark et al., 
1989; Witte and Marrocco, 1997), it is thought to offer an interrupt signal when volatility 
uncertainty arises between contexts (Clark et al., 1989; Arnsten and Contant, 1992; 
Smith et al., 1992; Coull et al., 1995; Witte and Marrocco, 1997; Bouret and Sara, 2005; 
Dayan and Yu, 2006b). Learning to make accurate predictions from the strongly 
unexpected observations that follow a contextual switch necessitates heightened 
sensory vigilance and a disregard for outdated top-down expectations. NA, with its role 
in regulating arousal and its broad neural network capable of triggering multiple, 
simultaneous changes across the brain (Bouret and Sara, 2004), is well-placed to rapidly 
coordinate this process. 
At a cellular level, NA increases neuronal gain by boosting the efficacy of synaptic 
interactions between neurons and thus increasing the responsivity of target neurons to 
their afferent input (Servan-Schreiber et al., 1990; Berridge and Waterhouse, 2003; 
Aston-Jones and Cohen, 2005a; Warren et al., 2016). This noradrenergic effect on 
synaptic transmission within cortical structures is believed to upregulate the processing 
of external sensory stimuli relative to intrinsic top-down information (Hasselmo, 1995), 
therefore promoting experience-dependent neuronal plasticity (Harley, 1987; Sara et al., 
1994; Aston-Jones et al., 1997; Bouret and Sara, 2005; Yu and Dayan, 2005; Corbetta 
et al., 2008; Tully and Bolshakov, 2010). By selectively increasing gain following 
unexpected sensory events that accompany a change in environmental context, the 
neuromodulator would be well-positioned to regulate an individual’s learning rate under 
environmental volatility. Indeed, neurons in the locus coeruleus (LC), the primary source 
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of cortical NA, show strong responses to unexpected environmental changes in rats and 
non-human primates (Sara and Segal, 1991; Aston-Jones et al., 1997). 
Pharmacological manipulations of NA have been shown to alter performance during 
tasks that feature contextual switches. For instance, administration of idaoxan, an α2-
adrenoceptor antagonist that increases both the firing rate of LC neurons and 
noradrenergic release in the cortex and hippocampus, accelerates the detection of 
unexpected switches in the predictive properties of sensory stimuli in rats required to use 
visual or spatial cues to navigate a linear maze (Devauges and Sara, 1990). Similarly, 
systemic administration of an alternative α2-adrenoceptor antagonist, atipamezole, 
improves attentional set-shifting in rats; an effect that is blocked by microinjection of the 
α1-adrenoceptor antagonist benoxathian (which decreases NA neurotransmission) into 
the medial frontal cortex, an area homologous to the primate dorsolateral prefrontal 
cortex (dlPFC) (Lapiz and Morilak, 2006). 
It has also been demonstrated that noradrenergic, but not cholinergic, deafferentation of 
rat medial frontal cortex impairs adaptation to contextual switches during attentional set-
shifting tasks (McGaughy et al., 2008). Moreover, 6-hydroxydopamine-induced lesions 
of noradrenergic projections from the rat LC to the medial frontal cortex impairs set-
shifting to novel stimuli (Tait et al., 2007). Importantly, since 6-hydroxydopamine can 
destroy both NA and DA neurons, the authors of this study verified that their neurotoxic 
lesioning method depleted NA in the medial frontal cortex, but caused no significant 
changes to DA neurotransmission. Further, systemic administration of atomoxetine, a 
selective NA reuptake inhibitor (SNRI) that increases extracellular NA concentrations, 
has been shown to improve attentional set-shifting in noradrenergically lesioned rats but 
has no effect in non-lesioned rats, highlighting the importance of optimal levels of cortical 
NA neurotransmission for optimal adaptive performance in dynamic environments 
(Newman et al., 2008).  
With regards to whether humans depend on noradrenergic neurotransmission to detect 
and adapt to environmental volatility, BOLD activity in the human LC has been shown to 
dynamically track volatility uncertainty, as estimated by a computational learning model 
(Payzan-LeNestour et al., 2013). Moreover, pupil dilation, which is influenced by 
noradrenergic afferents (Joshi et al., 2016) correlates with unexpected events, such as 
those that occur due to changes in environmental context (Preuschoff et al., 2011; 
Nassar et al., 2012; Browning et al., 2015). Finally, SNRIs, thought to increase NA 
neurotransmission, are used to treat individuals with attentional deficit hyperactivity 
disorder (ADHD), a condition associated with deficits in reversal learning following 
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contextual switches and abnormal cortical catecholaminergic neurotransmission (Itami 
and Uno, 2002; Seu et al., 2009). 
In sum, an extensive body of physiological, pharmacological, behavioural and 
neuroimaging work is compatible with the theory that ACh underlies learning of the 
relationships within stable environmental contexts, while NA supports learning under 
environmental volatility. 
1.1.3 Motor responses are sensitive to uncertainty 
As discussed above, representations of the uncertainty existing within and between 
environmental contexts are crucial for optimal predictions about the probability of future 
events. Optimal predictions, in turn, facilitate anticipatory preparation of appropriate 
motor responses. Indeed, previous work has demonstrated that the relationships 
between sensory events within probabilistic contexts can pre-emptively modulate the 
output of the motor system, thus speeding RTs to predictable events (Hick, 1952; 
Hyman, 1953; Requin and Granjon, 1969; Näätänen, 1970). Moreover, human 
corticospinal excitability (CSE), as measured with transcranial magnetic stimulation, has 
been shown to vary with uncertainty during a probabilistic RT task such that CSE is 
increased under low uncertainty about the required motor response to an upcoming 
event (Bestmann et al., 2008). Accordingly, high CSE is also accompanied by faster RTs. 
However, good predictions are not in themselves sufficient for adaptive performance in 
dynamic environments. An additional mechanism is required to modify action selection 
based on one’s own beliefs about the latent changes in the environment and/or the 
occurrence of unexpected events. Humans are indeed capable of engaging resources 
to inhibit a prepared response and replace it with an alternative when a unexpected event 
occurs (Hikosaka and Isoda, 2010; Isoda and Hikosaka, 2011), albeit at the expense of 
a prolonged RT (Galea et al., 2012; Bestmann et al., 2014). Unexpected events arise 
due to prediction errors that capture a mismatch between expectation and reality. As I 
will discuss in detail in Chapter 3, prediction errors provide the brain with an important 
teaching signal (den Ouden et al., 2012) that can trigger the modifcation of neuronal 
plasticity in target structures (Houk et al., 1995; Wickens et al., 2003; Frank, 2005), thus 
facilitating learning and behavioural flexibility. 
1.1.3.1 A proposed role for dopamine in response modulation 
DA neurons are known to fire in response to prediction errors (Mirenowicz and Schultz, 
1994; Schultz et al., 1997; Schultz and Dickinson, 2000; Zink et al., 2003; O’Doherty et 
al., 2004; Bayer and Glimcher, 2005; Bunzeck and Düzel, 2006; Pessiglione et al., 2006; 
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Joshua et al., 2008; Matsumoto and Hikosaka, 2009; Zaghloul et al., 2009; den Ouden 
et al., 2010, 2010). Furthermore, there is considerable evidence linking DA to flexible 
behaviour (Figure 1.2). For instance, DA depletions due to Parkinson’s disease are 
associated with specific flexibility impairments in both motor (Cools et al., 1984; Galea 
et al., 2012) and cognitive domains (Beatty and Monson, 1990; Cools et al., 2001a), with 
performance restored by dopaminergic medication (Cools et al., 2001b; Galea et al., 
2012). Specifically, Parkinson’s disease patients off dopaminergic medication show 
impaired switching between different cognitive task demands, such as naming letters or 
digits (Cools et al., 2001b). This effect, which is ameliorated by pharmacological DA 
stimulation, has been shown to be independent of both rule learning and working 
memory load since it occurs even when a contextual cue explicitly signals the required 
behaviour and any task switches (Cools et al., 2001a). Moreover, patients with 
Parkinson’s disease have been shown to produce fewer motor responses in a finger-
tapping task following a switch in the required finger-tapping sequence (Beatty and 
Monson, 1990). However, it should be noted that, in the latter study, patients’ medication 
regimens were unchanged during testing sessions, meaning that pharmacological DA 
stimulation cannot be excluded as a possible confounding factor in this case. 
 
 
Figure 1.2 A schematic of the dopaminergic network. Dopamine (DA) is a 
catecholamine synthesised from the same amino acid precursor as NA, namely tyrosine. 
Like NA and ACh, DA neurons show a broad distribution and extensive connectivity in 
the brain. The principal sources of DA are the substantia nigra (SN) and the ventral 
tegmental area (VTA), both of which are components of the basal ganglia, located at the 
base of the forebrain. The SN sends dopaminergic projections to the dorsal striatum. 
This so-called nigrostriatal (or mesostriatal) pathway has been linked to motor, reward 
and associative learning functions. Dopaminergic neurons of the VTA project primarily 
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to the prefrontal cortex via a mesocortical pathway, which has been linked to cognitive 
control and behaviour. A smaller group of DA neurons project from the VTA to the 
nucleus accumbens via a mesolimbic pathway linked to reward, aversion, pleasure and 
reinforcement learning. Together, the mesocortical and mesolimbic pathways constitute 
the mesolimbocortical pathway (Björklund and Dunnett, 2007). Figure adapted from 
Purves et al., 2011.  
Recently, there has been renewed focus on the role of DA in modulating flexible motor 
responses. For example, Parkinson’s disease patients off dopaminergic medication 
show an impaired ability to make adaptive responses to unexpected sensory events 
occurring within a broadly predictable context (Galea et al., 2012). Specifically, in a 
probabilistic serial RT task, responses to unexpected imperative stimuli, which elicit large 
sensory prediction errors and require replacement of a prepared action with an 
unprepared one, are slower than those made by healthy controls or by patients receiving 
dopaminergic medication. Importantly, the same effect is also observed when healthy 
individuals undertake the same task after having been administered the D1/D2-receptor 
antagonist haloperidol, which reduces DA neurotransmission (Bestmann et al., 2014). 
Overall, it appears that DA plays a key role in modulating behavioural responses to low-
level sensory prediction errors that necessitate motor flexibility. However, it remains 
unclear whether DA supports accurate response selection by facilitating perceptual belief 
updating (i.e., learning) in light of sensory prediction errors (Iglesias et al., 2013), or by 
modulating the sensitivity of motor response selection to perceptual beliefs. 
1.2 A unified framework of uncertainty 
To summarise, a considerable body of physiological, pharmacological, behavioural and 
theoretical work has suggested separable neuromodulatory involvement in the 
computations of, and responses to, uncertainty. However, attempts to characterise the 
relative contributions of NA, ACh and DA within a single computational scheme have 
been lacking. Computational models offer a sophisticated means by which to probe the 
brain’s mechanisms of learning and action in uncertain environments. As such, they have 
brought significant advances to cognitive neuroscience in recent years (Daw et al., 2011; 
Takahashi et al., 2011; Iglesias et al., 2013; Diaconescu et al., 2017). By designing task 
paradigms in which key learning parameters change over time, and correlating these 
parameters with fluctuations in neural activity, it has been possible to infer the types of 
computations that underlie learning and behaviour. Indeed, in an assortment of studies 
of human learning, measures of neural activity have been linked to computations of 
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perceptual quantities such as uncertainty, prediction error and volatility (Hampton et al., 
2006; Behrens et al., 2007, 2008; D’Ardenne et al., 2008; Hare et al., 2008; den Ouden 
et al., 2009; Cooper et al., 2010; Daw et al., 2011; Klein-Flügge et al., 2011; Boorman et 
al., 2013; Iglesias et al., 2013; Payzan-LeNestour et al., 2013; Diaconescu et al., 2017). 
Given the array of perceptual quantities supposedly tracked by the brain, it is important 
to construct unified computational frameworks of uncertainty, prediction error and 
volatility. In so doing, it becomes possible to probe the relative contributions of different 
neuromodulatory systems to computing these quantities, and to modulating learning and 
action as the quantities fluctuate. 
In the work I present in this thesis, I employ a Hierarchical Gaussian Filter (HGF) model 
(Mathys et al., 2011, 2014), in conjunction with a series of probabilistic learning tasks, to 
capture individual human learning under three distinct forms of uncertainty: 
1. Irreducible uncertainty arising from the randomness inherent in any 
probabilistic environment; 
2. Estimation uncertainty arising from an individual’s incomplete knowledge of 
the probabilistic rules underlying the current environmental context; 
3. Volatility uncertainty arising from the instability of these probabilistic rules over 
time. 
Further, I develop a novel instantiation of the HGF to track the modulation of motor 
responses that occurs in light of an individual’s uncertainty estimates. 
As I will discuss in detail in Chapter 3, the HGF was first introduced by Mathys et al. as 
a generic hierarchical Bayesian framework for individual learning under the various forms 
of uncertainty inherent in the environment (Mathys et al., 2011). It has been successfully 
applied in several recent studies of probabilistic learning under volatility (Iglesias et al., 
2013; Diaconescu et al., 2014, 2017; Hauser et al., 2014; Vossel et al., 2014a, 2014b, 
2015; de Berker et al., 2016). The core component of the HGF is a three-level perceptual 
model that tracks an individual’s learning about the environment’s underlying structure.  
A novel second component, which will be introduced formally in Chapter 3 and applied 
in Chapters 4 and 5, is a response model that maps an individual’s beliefs about the 
environment, as provided by the perceptual model, onto his/her observed behaviour, 
here RT responses. This extension of the HGF makes it is possible to estimate the 
degree to which an individual’s perceptual beliefs influence his/her motor responses. 
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For this thesis, I sought to characterise the relative contributions of NA, ACh and DA to 
computations of distinct forms of environmental uncertainty. Further, I aimed to 
disentangle the effects of the neuromodulators on individual perceptual belief updating 
from any effects on the sensitivity of motor responses to perceptual estimates. In the 
following chapters, I utilise two probabilistic learning tasks and a unified computational 
framework of uncertainty to quantify individual learning and response modulation in 
dynamic, probabilistic environments. In a series of experiments, I aim to pinpoint the 
relative impact of NA, ACh and DA on learning and action by utilising: 
1. Pharmacological manipulations of NA, ACh and DA; 
2. Genetic characterisation of baseline DA function; 
3. Pupillometric measures of dynamic NA neurotransmission. 
1.3 Pharmacological manipulations of neuromodulatory function 
The notion that endogenous neuromodulators and exogenous drugs produce their 
physiological effects by interacting with cellular receptors was first introduced by John 
Newport Langley and Paul Ehrlich at the beginning of the twentieth century (Cooper et 
al., 2003). The idea was based largely on observations that some drugs could trigger 
specific biological responses while others prevented them. Since then, advancements in 
electrophysiological and pharmacological brain slice techniques, and the development 
of molecular cloning (Caulfield, 1993; Gingrich and Caron, 1993; Schwinn et al., 1995), 
have facilitated the identification of a vast array of cellular receptors. Drugs that bind to 
these receptors offer a useful tool with which to modulate endogenous neuromodulatory 
function. By combining pharmacological manipulations with cognitive tasks, it is possible 
to identify the contributions of different neuromodulators to human learning and 
behaviour (Pessiglione et al., 2006; Stelzel et al., 2010; Beierholm et al., 2013; Bunzeck 
et al., 2013; Chowdhury et al., 2013; Galea et al., 2013; Bestmann et al., 2014; Guitart-
Masip et al., 2014; van der Schaaf et al., 2014; Vossel et al., 2014a; Crockett et al., 2015; 
den Ouden et al., 2015; Rutledge et al., 2015; Tomassini et al., 2015; Jepma et al., 2016; 
Warren et al., 2016; Diederen et al., 2017). 
1.3.1 Pharmacological modes of action 
Drugs can induce biological effects in several ways. A pharmacological agonist has both 
affinity and efficacy for a receptor, meaning that it can bind to that receptor and produce 
the same biological response as the receptor’s endogenous ligand. An antagonist has 
affinity, but no efficacy, for a receptor. As such, it attenuates or blocks the biological 
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response produced by the receptor’s endogenous ligand by competing with the ligand 
for receptor binding sites. An inverse agonist binds to a receptor but triggers a biological 
response opposite to that of the endogenous ligand (Stephenson, 1997; Bradley, 2014). 
1.3.2 Types of receptor 
1.3.2.1 Ionotropic receptors 
There are two main classes of membrane-localised receptors: ionotropic and 
metabotropic. Ionotropic receptors are ligand-gated ion channels. They are composed 
of multiple subunits and a central pore. When an ionotropic receptor is activated by an 
endogenous ligand or pharmacological agonist, the pore opens, permitting the passage 
of Na+, K+, Ca2+ or Cl- ions. The change in ion permeability can trigger excitatory or 
inhibitory action. Specifically, the influx of positively charged cations evokes 
depolarisation of the membrane potential, while the influx of negatively charged anions 
evokes hyperpolarisation, in turn making action potential firing more or less likely, 
respectively. For instance, ACh acts as an endogenous ligand at ionotropic (nicotinic) 
ACh receptors, and evokes excitation by increasing membrane permeability to NA+ and 
K+ ions. The effects mediated by ionotropic receptors are fast, occurring within 
milliseconds (Cooper et al., 2003). 
1.3.2.2 Metabotropic receptors 
Metabotropic receptors are G protein-coupled receptors (GPCRs). They are activated 
when an endogenous ligand or pharmacological agent binds to the receptor, inducing a 
conformational change and triggering an intracellular signalling cascade that ultimately 
results in the phosphorylation (or dephosphorylation) of proteins, and therefore protein 
activation, inactivation or functional modification. As such, GPCRs mediate slower 
responses (across seconds to minutes) than ionotropic receptors. These responses are 
generally modulatory, enhancing or dampening a neuronal signal. There are several 
classes of G proteins, including Gs, Gi, Gq and G12, each of which activate different signal 
transduction pathways (Cooper et al., 2003). NA, ACh and DA act as endogenous 
ligands at different GPCRs located on the membranes of postsynaptic neurons within 
the brain. By administering pharmacological agents that interact with particular GPCRs, 
it is possible to disrupt the neuromodulatory function of the NA, ACh and DA systems.  
1.3.2.3 Autoreceptors 
At least within cognitive neuroscience, it is the ionotropic and metabotropic receptors 
located within the membrane of postsynaptic neurons that receive particular research 
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focus. Importantly, pharmacological agents acting at postsynaptic receptors have the 
capacity to modulate the firing rate of the postsynaptic cell in response to neuromodulator 
release from a presynaptic neuron. However, an additional presynaptic mechanism can 
also regulate postsynaptic firing. Presynaptic autoreceptors are sensitive to 
neuromodulators released by the neuron on which they are located. When a 
neuromodulator is released by the presynaptic neuron, it will activate these 
autoreceptors in addition to the receptors on the postsynaptic cell. Such presynaptic 
activation often serves as part of a negative feedback loop in signal transduction, with 
the autoreceptors typically inhibiting further release or synthesis of the neuromodulator, 
in turn modulating postsynaptic firing rate (Stephenson, 1997; Cooper et al., 2003; 
Bradley, 2014). 
1.3.3 Reuptake and degradation of neuromodulators 
Once a neuromodulator has been released by a presynaptic neuron, diffused across the 
synaptic cleft and activated receptors on the postsynaptic cell membrane, its action is 
terminated by a mechanism of reuptake and metabolic degradation. For instance, NA is 
absorbed back into the presynaptic neuron via reuptake mediated primarily by the 
noradrenaline transporter (NET). Once back in the cytosol of the presynaptic cell, NA is 
broken down by the enzyme monoamine oxidase (MAO), or repackaged into vesicles for 
future release. Similarly, DA reuptake is primarily mediated by the dopamine transporter 
(DAT). Once in the cytosol, DA is broken down into inactive metabolites by a set of 
enzymes that act in sequence: MAO, catechol-O-methyltransferase (COMT) and 
aldehyde dehydrogenase (ALDH) (Eisenhofer et al., 2004). ACh is inactivated primarily 
by the action of the enzyme acetylcholinesterase (ACHE), which catalyses degradation 
of the neuromodulator (Cooper et al., 2003). 
Importantly, these transporters and degradative enzymes offer an additional means by 
which to study the function of the brain’s neuromodulatory systems. Indeed, the action 
of NET, DAT, MAO, COMT and ACHE can be modulated using an assortment of drugs 
that target these proteins.  
1.3.4 Pharmacological manipulations of noradrenaline, acetylcholine and 
dopamine 
An understanding of the molecular and cellular mechanisms by which receptors, 
transporters and degradative enzymes regulate neuromodulatory function reveals 
relevant targets for psychopharmacological investigations. Indeed, by administering 
drugs known to interact with particular receptors, transporters and degradative enzymes, 
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it is possible to up- or down-regulate noradrenergic, cholinergic and dopaminergic 
neurotransmission in humans. Assessing any drug-induced changes in performance 
under carefully designed experimental paradigms offers the potential to implicate the 
different neuromodulatory systems in human learning and action under uncertainty. 
1.3.4.1 Pharmacological manipulation of noradrenaline 
The physiological targets of NA are the (nor)adrenergic receptors, otherwise known as 
adrenoceptors. Adrenoceptors are a class of metabotropic receptors with several 
subtypes: α1, α2 and β. A high density of α1-adrenoceptors exists in the human 
neocortex (Zilles et al., 1993). Since α1-adrenoceptors are the targets of noradrenergic 
neurons projecting from the LC, they form a sensible pharmacological target for 
investigations of the noradrenergic contributions to learning and action under 
uncertainty. In Chapters 4 and 6, I utilise prazosin, a drug that antagonises 
noradrenergic neurotransmission via a mechanism of inverse agonism at α1-
adrenoceptors (Zhu et al., 2000), to investigate the contribution of NA to learning and 
action under uncertainty. 
An alternative means by which to pharmacologically manipulate noradrenergic 
neurotransmission is to target the neuromodulator’s reuptake machinery. For instance, 
the selective NA reuptake inhibitor (SNRI) reboxetine blocks the action of NET, in turn 
reducing the rate of NA reuptake from the synaptic cleft and supposedly increasing 
extracellular concentrations of NA (Wong et al., 2000). It has therefore been proposed 
that the drug’s net effect is to increase NA neurotransmission. In Chapter 6, I use both 
reboxetine and prazosin in order to characterise the respective impact of up- and down-
regulated NA neurotransmission on learning in uncertain environments.  
1.3.4.2 Pharmacological manipulation of acetylcholine 
There are two major classes of cholinergic receptors: nicotinic and muscarinic. Nicotinic 
receptors are ionotropic, while muscarinic receptors are metabotropic. There are five 
subtypes of muscarinic receptors (M1-5). Muscarinic M1-receptors, abundant in the 
neocortex and the hippocampus, are a major target of cholinergic neurons projecting 
from the basal forebrain (Volpicelli and Levey, 2004; Abrams et al., 2006). In Chapter 4, 
I utilise the M1-receptor antagonist biperiden to characterise the impact of reduced 
cholinergic neurotransmission on learning and action under uncertainty.  
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1.3.5 Pharmacological manipulation of dopamine 
The physiological effects of DA are mediated via a class of metabotropic DA receptors. 
There are five known subtypes: D1-5. Research efforts have focused primarily on D1- 
and D2-receptors. D1-receptors are the most abundant dopaminergic receptors in the 
central nervous system. The highest concentrations of both D1- and D2-receptors exist 
within the basal ganglia, particularly in the caudate nucleus and putamen. Aside from the 
basal ganglia, D1-receptors have a wide distribution in the neocortex, amygdala and 
hippocampus. In contrast, the most significant densities of D2-receptors outside the 
basal ganglia occur in the hippocampus (Palacios et al., 1988; Hall et al., 1994). In 
Chapter 4, I administer haloperidol, a drug that, at sufficient doses, blocks both D1- and 
D2-receptors. The net effect of haloperidol is thought to be antagonism of dopaminergic 
neurotransmission. As such, I assess the impact of reduced dopaminergic 
neurotransmission on learning and action in uncertain environments. 
1.4 Genetic variations in neuromodulatory function  
An alternative means by which to examine the neuromodulatory underpinnings of 
learning and action is to adopt a behavioural genetics approach (Frank et al., 2007, 2009; 
Tan et al., 2007a, 2007b; Green et al., 2008; Ullsperger, 2010; den Ouden et al., 2013; 
Doll et al., 2016). It has been suggested that a considerable proportion of inter-individual 
variance in cognitive function can be accounted for by genetic factors (Friedman et al., 
2008). Moreover, genetics influence the degree to which cognitive processes are 
disrupted under pharmacological manipulations, and in neurological and psychiatric 
disorders (Kimberg et al., 1997; Mehta et al., 2004a; Roesch-Ely et al., 2005; Frank and 
O’Reilly, 2006; Cools et al., 2007b; Clatworthy et al., 2009, 2009). Exploiting inter-
individual differences in the genes that regulate neuromodulatory function offers an 
opportunity to identify the neural mechanisms that contribute to human learning and 
action under uncertainty. Additionally, a behavioural genetics approach permits the 
effects of different neuromodulatory systems to be assessed within individuals and in a 
single experimental session. 
1.4.1 Types of genetic variation 
Genetic variation can arise in several ways. First, a single nucleotide polymorphism 
(SNP) is a variation in a single nucleotide that occurs at a specific position on the genome 
(Sachidanandam et al., 2001). Second, a variable number tandem repeat (VNTR) is a 
location on the genome where a short nucleotide sequence is repeated, with the number 
of repeats commonly varying between individuals. Third, an insertion/deletion (INDEL) 
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polymorphism arises when a specific nucleotide repeat is present (insertion) or absent 
(deletion) (Rodriguez-Murillo and Salem, 2013). Approximately ten million SNPs and 
several thousand VNTRs and INDELs contribute to the vast genetic variation within 
human populations (Frank and Fossella, 2011). Among them are several genetic 
polymorphisms that influence noradrenergic, cholinergic and dopaminergic 
neurotransmission by modulating the availability of target postsynaptic receptors or the 
activity of neuromodulatory reuptake and degradation mechanisms. As I discuss next, 
the inter-individual variations in NA, ACh and DA function induced by these particular 
polymorphisms offer a potential means by which to characterise the neuromodulatory 
contributions to human learning and action under uncertainty. 
1.4.2 COMT 
The Val158Met SNP in the COMT gene is one of the most widely studied polymorphisms 
in the behavioural genetics literature. The COMT gene encodes catechol-O-
methyltransferase, an enzyme that catalyses the degradation of catecholamines, 
including DA. The COMT enzyme plays a significant role in regulating DA levels in the 
brain, providing the primary mechanism of DA degradation in the prefrontal cortex (PFC) 
(Gogos et al., 1998; Akil et al., 2003; Tunbridge et al., 2004; Yavich et al., 2007) but 
having little to no effect on striatal DA (Gogos et al., 1998; Sesack et al., 1998; 
Matsumoto et al., 2003; Tunbridge et al., 2004; Meyer-Lindenberg et al., 2005; Slifstein 
et al., 2008). The Val158Met polymorphism results from a missense mutation that causes 
a nucleotide substitution from guanine to adenine, and therefore an amino acid switch 
from valine (Val) to methionine (Met), at rs4680 (codon 158). The Met isoform has 
reduced thermostability at body temperature, resulting in a three- to four-fold decrease 
in COMT enzymatic activity relative to the ancestral Val isoform (Männistö and Kaakkola, 
1999; Chen et al., 2004). As such, synaptic DA concentrations are thought to be higher 
in Met carriers, particularly in the PFC. In contrast, the Val allele is associated with higher 
COMT activity and lower synaptic DA availability. Since the Val and Met alleles are 
codominant, heterozygotes show intermediate levels of COMT activity, explaining the 
trimodal distribution of COMT activity (corresponding to Val/Val, Val/Met and Met/Met 
genotypes) observed in human populations (Floderus et al., 1981). 
It appears that COMT activity levels have decreased during human evolution (Palmatier 
et al., 1999; Chen et al., 2004), suggesting that the Met allele may have a beneficial 
effect on PFC function (Egan et al., 2001). Indeed, the Val158Met polymorphism has been 
found to influence cognitive processing in various tasks that depend on the PFC (Egan 
et al., 2001; Malhotra et al., 2002; Goldberg et al., 2003; Winterer and Goldman, 2003; 
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Foltynie et al., 2004; Blasi et al., 2005; Frias et al., 2005; Meyer-Lindenberg et al., 2005; 
Diamond, 2007; Frank et al., 2007, 2009; Tan et al., 2007b; Diaz-Asper et al., 2008; 
Solís-Ortiz et al., 2010; Dumontheil et al., 2011). Carriers of the Met allele tend to show 
superior executive function compared to Val/Val homozygotes (Egan et al., 2001; 
Malhotra et al., 2002; Goldberg et al., 2003; Frias et al., 2005; Frank et al., 2007; Diaz-
Asper et al., 2008). In the context of DA’s proposed role in behavioural flexibility, it is 
particularly interesting to note that Met carriers are frequently better at switching between 
the demands of different task rules. For instance, task-switching performance in the 
Wisconsin Card Sorting Task, a widely used test of executive function in which 
individuals are required to match cards according to criteria that switch without explicit 
warning, is higher in Met carriers than Val/Val homozygotes (Egan et al., 2001; Malhotra 
et al., 2002). Since the Met allele has been linked to increased DA neurotransmission, 
this echoes the aforementioned finding of impaired task switching due to DA depletions 
in Parkinson’s disease, which can be ameliorated with pharmacological DA stimulation 
(Cools et al., 2001b). Similarly, it has been shown that Met/Met homozygotes are more 
likely than Val carriers to switch their behaviour in response to instances of negative 
feedback (Frank et al., 2007), adding further weight to the proposal that DA has an 
underlying role in behavioural flexibility. 
Although some alternative studies have observed the opposite effect of COMT genotype 
on executive function (i.e., that Val/Val homozygotes show better executive function than 
Met carriers), these experiments have not required behavioural task-switching. For 
instance, Parkinson’s disease patients with a Val/Val genotype were found to 
demonstrate improved working memory and planning ability in the Tower of London task 
(Foltynie et al., 2004). However, it should be noted that this effect is likely to have been 
confounded by disease state and concurrent intake of dopaminergic medication. Higher 
task-switching performance has also been observed in post-menopausal women with a 
Val/Val genotype (Solís-Ortiz et al., 2010), but this finding is confounded by the fact that 
DA levels decline across the adult lifespan (Kaasinen et al., 2000; Bäckman et al., 2006; 
Li et al., 2010), inducing changes in cognitive performance (Bäckman et al., 2000; Dreher 
et al., 2008; Eppinger et al., 2013). 
Nevertheless, the COMT enzyme appears to play an important role in regulating cortical 
DA neurotransmission, with associated effects on behavioural flexibility. More 
specifically, it has been proposed that the impact of DA on PFC function adheres to an 
inverted-U dose-response curve (Tunbridge et al., 2006). As such, it is thought that PFC-
mediated cognitive processes are optimal within a relatively narrow range of intermediary 
DA activity, with insufficient or excessive baseline DA neurotransmission having a 
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relatively deleterious effect (Williams and Goldman-Rakic, 1995; Goldman-Rakic, 1998). 
Consistent with this notion, pharmacological studies in animals (Granon et al., 2000) and 
healthy human individuals (Kimberg et al., 1997; Mattay et al., 2000; Mehta et al., 2000) 
have shown that the effects of dopaminergic agents depend on baseline PFC function 
and COMT genotype (Mattay et al., 2003; Farrell et al., 2012).  
In Chapter 5, I exploit COMT genotype to probe any natural inter-individual differences 
in DA-mediated behavioural flexibility by assessing learning and response modulation 
under uncertainty as a function of genotypic variations in cortical DA neurotransmission.  
1.4.3 DAT1 
Flexible learning and behaviour in dynamic environments depends not only on the PFC, 
but also on subcortical activity in the basal ganglia, particularly the striatum (Kehagia et 
al., 2010). The PFC and striatum interact via multiple serial and parallel loops (Alexander 
et al., 1986; Haber et al., 2000), which are under neuromodulatory influence. Indeed, 
cortical DA activity, regulated by COMT, has been shown to modulate subcortical DA 
neurotransmission (Grace, 2000), supposedly by indirect cortical feedback (Tunbridge, 
2010). Further, it has been demonstrated that prefrontal lesions in rats can cause 
secondary impairments in striatal DA neurotransmission (Pycock et al., 1980). 
A key target for investigations of striatal DA neurotransmission is the DAT1 gene. A 
VNTR in the 3’ untranslated region of DAT1 influences expression levels of the dopamine 
transporter (DAT) (Mill et al., 2002). Since DAT plays a pivotal role in synaptic DA 
clearance in the striatum (Lewis et al., 2001; Frank and Fossella, 2011), the 
polymorphism modulates striatal DA availability (Caron, 1996; Heinz et al., 1999). The 
VNTR commonly occurs as nine (9R) or ten (10R) repeats of a 40 base-pair sequence, 
although between three and eleven repeats are known to exist (Forbes et al., 2009). The 
exact functional consequences of the polymorphism on DA neurotransmission are 
currently unclear. In vitro, the DAT1 polymorphism causes natural variation in the 
expression of DAT (Mill et al., 2002). However, while some positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) studies 
have indicated that the 9R allele is associated with increased striatal DAT expression 
(Jacobsen et al., 2000; van Dyck et al., 2005; van de Giessen et al., 2009; Spencer et 
al., 2013), and a putative decrease in DA neurotransmission (Wichmann and DeLong, 
1996), others have identified greater DAT expression in 10R carriers (Heinz et al., 2000; 
Fuke et al., 2001; Mill et al., 2002; VanNess et al., 2005). It should also be noted that a 
recent meta-analysis reported that there is currently no evidence to support the 
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hypothesis that the VNTR in the DAT1 gene is significantly associated with inter-
individual differences in DAT availability in the human striatum (Costa et al., 2011). 
Nevertheless, the DAT1 polymorphism has been associated with specific behavioural 
effects (Forbes et al., 2009; Gizer et al., 2009; Franke et al., 2010; van Holstein et al., 
2011). Despite having no established effect on task-switching performance in a paradigm 
based on the Wisconsin Card Sorting Test (Garcia-Garcia et al., 2010), DAT1 genotype 
has been linked to variations in behaviour during (rewarded) probabilistic reversal 
learning (den Ouden et al., 2013). Specifically, 9R carriers were found to make more 
post-reversal perseverative errors than 10R/10R homozygotes. This suggests that 9R 
carriers are more reliant on their previous experience, being more likely to select a 
previously rewarded stimulus following a contextual switch. This finding is compatible 
with rodent conditioning studies demonstrating that increased DA levels augment 
responses to previously rewarded stimuli (Parkinson et al., 1999; Goto and Grace, 2005). 
A related observation is that dopaminergic medication impairs reversal learning in 
patients with Parkinson’s disease (Cools et al., 2001b), possibly due to dysregulation of 
reward-related dopaminergic processing in the ventral striatum (Cools et al., 2007a). 
Pharmacological inhibition of DAT under methylphenidate evokes similar impairments in 
healthy individuals (Clatworthy et al., 2009). Furthermore, increased reward-related 
activity is observed in the ventromedial striatum of 9R carriers (Dreher et al., 2009; Aarts 
et al., 2010). In light of this evidence, it has been suggested that the 9R allele may be 
associated with increased striatal DA concentrations, increased reward sensitivity and 
decreased behavioural flexibility. Alternative work has shown that flexible responses to 
a previously non-rewarded stimulus are impaired under neurological DA depletions due 
to Parkinson’s disease (Peterson et al., 2009). 
Despite conflicting reports of the impact of DAT1 genotype on DAT expression and 
dopaminergic neurotransmission, the polymorphism holds the potential to offer finer 
insight into the contribution of DA to learning and action under uncertainty. In particular, 
assessing any impact of COMT and DAT1 genotypes on learning and response 
modulation in uncertain environments could uncover evidence to suggest that specific 
processes are linked to cortical or striatal neurotransmission, respectively. One might 
hypothesise that, by altering cortical DA neurotransmission, different COMT genotypes 
might introduce variations in the ability to adapt behaviour in light of a (non-rewarded) 
switch in task demands. While the ventral striatum is linked to reward-related learning, 
the dorsal striatum is associated with motor function (Cools et al., 1984; Purves et al., 
2011). As such, it is possible that altered striatal DA neurotransmission under different 
DAT1 genotypes also influences an individual’s ability to modulate motor responses 
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under environmental volatility. However, the aforementioned literature suggests that any 
effect of DAT1 genotype on flexible behaviour is more likely to be linked to rewarded 
reversal learning than to rule-based behavioural task-switching.  
1.4.3.1 DRD2 
Inter-individual variation in DA-mediated task-switching behaviour has also been 
observed under different DRD2 genotypes. The DRD2 gene encodes the dopaminergic 
D2-receptor. D2-receptor density has been linked to individual capacity for switching 
between different task demands (van Holstein et al., 2011). A known SNP in the DRD2 
gene, namely the ANKK1-Taq1A polymorphism at rs1800497, results in an amino acid 
substitution from glutamic acid to lysine at position 713 and gives rise to the A1 allele. 
A1 carriers have a 30-40% reduction in DRD2 expression compared to homozygous 
carriers of the A2 allele (Thompson et al., 1997; Ritchie and Noble, 2003), this effect 
being most prominent in the striatum, but also affecting the PFC (Noble, 2003). Increased 
D2-receptor expression in A2/A2 homozygotes has been linked to  inferior (non-
rewarded) task-switching performance compared to A1 carriers, which manifests as 
increased RTs, increased cortical switching-related activity, and increased functional 
connectivity in corticostriatal circuits (Stelzel et al., 2010), indicative of an association 
between D2-receptor density and increased task-switching effort. In line with this finding, 
it has also been demonstrated that pharmacologically stimulating human D2-receptors 
with the agonist bromocriptine increases switching-related activity in both the striatum 
and the posterior lateral frontal cortex (Stelzel et al., 2013). In contrast, the agonist 
decreases activity in sensorimotor regions supporting motoric hand-switching activity 
under task switches, indicating that dopaminergic stimulation likely has varying 
influences on different types of flexibility (e.g., cognitive and motor) due to complex 
interactions across the DA network. However, it should be noted that impaired task-
switching behaviour has also been observed under D2-receptor antagonism with 
sulpiride (Mehta et al., 2004b). 
The finding of a link between D2-receptor expression and task-switching is in line with 
studies that have related increased striatal D2-receptor density in schizophrenia (Wong 
et al., 1986; Abi-Dargham et al., 2000) to increased cortical DA and to deficits in 
behavioural and cognitive flexibility (Thoma et al., 2007). The fact that different studies 
have observed that both increased and decreased cortical DA neurotransmission can 
impair cognitive and behavioural flexibility likely speaks to the aforementioned inverted-
U relationship between DA levels and executive function (Tunbridge et al., 2006; 
Vijayraghavan et al., 2007). Related to this notion, van Holstein et al. have highlighted 
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the importance of optimal D2-receptor signalling for adaptive human behavioural 
flexibility. Specifically, the researchers demonstrated that D2-receptor stimulation by 
bromocriptine could improve cognitive flexibility, but only in individuals with low baseline 
DA levels, as reflected by the aforementioned VNTR polymorphism in the DAT1 gene 
(van Holstein et al., 2011). The behavioural effect of bromocriptine was abolished by pre-
treatment with the D2-receptor antagonist sulpiride, providing further evidence that the 
effect is mediated via D2-receptors. 
In light of the variations in behavioural flexibility associated with different levels of D2-
receptor expression, examining any impact of DRD2 genotype on learning and action 
under uncertainty might offer further insight into an underlying dopaminergic mechanism, 
particularly when contrasted with any effects of the COMT and DAT1 genotypes. 
1.4.4 NET 
The NET gene encodes the NA transporter, which functions to reuptake extracellular NA 
and thus modulates NA neurotransmission. Although a SNP occurs in the promoter 
region of the gene at rs2242446, it has been studied far less extensively than the 
polymorphisms discussed thus far. Variations in NET genotype have been found to 
correlate with conditions such as ADHD, depression and alcohol dependence (Huang et 
al., 2008; Zhao et al., 2013; Oh and Kim, 2016), and with sensitivity to antidepressants 
that target the NA transporter (Owens et al., 2008; Jeannotte et al., 2009; Sekine et al., 
2010), but any specific impacts of the polymorphism on noradrenergic neurotransmission 
and behaviour are currently unclear. NET genotype offers a potential means by which to 
probe inter-individual differences in NA-mediated learning and action in uncertain 
environments. However, any results would be speculative until the impact of the NET 
polymorphism on NA neurotransmission has been better established. 
1.4.5 ACHE 
The ACHE gene encodes acetylcholinesterase, an enzyme that hydrolyses, and 
therefore inactivates, ACh. It has been shown that, in patients with Alzheimer’s disease 
and therefore cholinergic impairment, an A/A genotype is associated with a better 
response to treatment with the acetylcholinesterase inhibitor rivastigmine (Scacchi et al., 
2009). However, again, any specific effects of the polymorphism on cholinergic 
neurotransmission and behaviour are currently unclear. Nonetheless, variations in ACHE 
genotype might offer a means by which to speculatively study inter-individual differences 
in ACh-mediated learning and action under uncertainty. 
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In sum, these five genes are of potential physiological relevance to the noradrenergic, 
cholinergic and dopaminergic mechanisms underlying learning and action in uncertain 
environments. As such, I had originally planned to characterise the effects of COMT, 
DAT1, DRD2, NET and ACHE genotypes on human learning and response modulation 
under irreducible, estimation and volatility uncertainty. However, as I will discuss in detail 
in Chapter 5, due to unexpected methodological constraints, I focus instead on inter-
individual differences in dopaminergic neurotransmission evoked by COMT genotype. 
1.5 Pupil diameter as a proxy for dynamic noradrenergic 
uncertainty computations 
For half a century, pupil dilation at constant luminance has been considered a marker of 
central arousal (Hess and Polt, 1964; Kahneman and Beatty, 1966; Bradshaw, 1967; 
Kahneman et al., 1967; Beatty, 1982). Inspired by recent proposals that pupil diameter 
might offer an indirect measure of noradrenergic neural activity in the locus coeruleus 
(LC) (Rajkowski et al., 1993; Phillips et al., 2000b; Aston-Jones and Cohen, 2005a; 
Murphy et al., 2014; Varazzani et al., 2015; Joshi et al., 2016), and that NA might 
modulate learning under volatility uncertainty (Yu and Dayan, 2005; Payzan-LeNestour 
et al., 2013; Marshall et al., 2016), researchers have started to probe whether transient 
changes in pupil diameter can be used as a proxy for physiological autonomic processes 
that occur during behavioural tasks (Siegle et al., 2003; Aston-Jones and Cohen, 2005a; 
Critchley, 2005; Satterthwaite et al., 2007; Einhäuser et al., 2008; Hupé et al., 2009; 
Einhauser et al., 2010; Gilzenrat et al., 2010; Privitera et al., 2010; Jepma and 
Nieuwenhuis, 2011; Preuschoff et al., 2011; Fiedler and Glöckner, 2012; Nassar et al., 
2012; Wierda et al., 2012; Eldar et al., 2013; de Gee et al., 2014; Browning et al., 2015; 
de Berker et al., 2016; Korn et al., 2016; van den Brink et al., 2016; Urai et al., 2017). 
The sensitivity of the pupil to such processes means that pupillometry might offer a 
simple, non-invasive and cost-effective tool with which to measure individual 
noradrenergic computations of uncertainty, without the need for pharmacological 
interventions or behavioural genetics analyses.    
1.5.1 Pupil diameter as an indirect measure of noradrenergic 
neurotransmission 
As I will discuss next, there is converging evidence from electrophysiology (Rajkowski et 
al., 1993; Aston-Jones and Cohen, 2005a; Varazzani et al., 2015; Joshi et al., 2016), 
pharmacology (Phillips et al., 2000c) and human neuroimaging (Samuels and Szabadi, 
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2008; Murphy et al., 2014) to suggest a relationship between NA and pupil dilation under 
constant luminance. 
1.5.1.1 Electrophysiological evidence of a link between noradrenaline and pupil 
diameter 
In the last decade, the theory that changes in pupil diameter are directly related to 
fluctuations in noradrenergic neuronal activity in the LC has been the focus of a 
considerable body of research (Aston-Jones and Cohen, 2005a; Gilzenrat et al., 2010; 
Nieuwenhuis et al., 2010; Jepma and Nieuwenhuis, 2011; Eldar et al., 2013). The LC is 
a brainstem nucleus in the dorsolateral pons. As mentioned previously, it is the primary 
site of NA synthesis and the principal source of NA for the cerebral cortices, cerebellum 
and hippocampus (Moore and Bloom, 1979; Aston-Jones and Cohen, 2005a). The notion 
that the pupil might offer an indirect measure of LC-NA activity was largely inspired by 
an observation that the baseline firing rate of a single neuron recorded in monkey LC 
aligned closely with simultaneously recorded changes in pupil diameter (Rajkowski et 
al., 1993; Aston-Jones and Cohen, 2005a). 
While neuronal activity in several brain regions, including the inferior colliculus (IC), 
superior colliculus (SC), anterior cingulate cortex (ACC) and posterior cingulate cortex 
(PCC), has been associated with changes to pupil size (Wang et al., 2012; Ebitz and 
Platt, 2015), the link between LC and pupil diameter seems most direct. In 2015, 
Varazzani et al. provided novel data to suggest that LC neurons are involved in mediating 
changes in pupil diameter by demonstrating that spiking activity in the noradrenergic LC, 
but not the dopaminergic substantia nigra (SN), is positively correlated with changes in 
pupil size during decision-making in rhesus monkeys (Varazzani et al., 2015). 
Importantly, in the last year, Joshi et al. have offered the most convincing evidence of a 
causal relationship between LC-NA activity and event-driven changes in pupil diameter. 
By recording activity in the LC, as well as the IC, SC, ACC and PCC, of rhesus 
macaques, the authors established that, during passive fixation, fluctuations in the firing 
rate of many of the recorded neurons in these different regions correlated with 
fluctuations in pupil size. However, when the LC, IC and SC were electrically 
microstimulated, it was the LC stimulation that was found to consistently trigger transient 
increases in pupil size in a 250-700ms window following stimulation onset (Joshi et al., 
2016).   
Moreover, the NA-LC system also appears to show phasic activations during perceptual 
decision-making (Rajkowski et al., 2004; Aston-Jones and Cohen, 2005a; Bouret and 
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Sara, 2005; Sara, 2009), presumably triggered by feedback connections from the PFC 
(Aston-Jones and Cohen, 2005a; Dayan, 2012). It is therefore possible that pupillary 
responses to perceptual estimates, such as prediction error, uncertainty and volatility, 
reflect noradrenergic activity in the LC.  
1.5.1.2 Pharmacological evidence of a link between noradrenaline and pupil 
diameter 
Pharmacological evidence also suggests that NA modulates pupil diameter in humans. 
Specifically, α2-adrenoceptor agonists, such as clonidine, which decease the activity of 
central noradrenergic neurons, have been shown to decrease baseline pupil diameter 
and increase spontaneous pupillary fluctuations. In contrast, α2-adrenoceptor 
antagonists, such as yohimbine, which have the opposite effect on central NA, have been 
shown to have the opposite effect on pupils, i.e., an increase in baseline pupil diameter 
and decreased pupillary fluctuations (Phillips et al., 2000b). 
1.5.1.3 Human neuroimaging evidence of a link between noradrenaline and pupil 
diameter 
Until recently, the lack of reliable non-invasive measures of LC activity had limited 
investigations of the functioning LC-NA system in humans. In 2006, Sterpenich et al. 
used fMRI to correlate human pupillary dilation with neural activity during emotional 
memory retrieval. Activations in an area of the dorsal tegmentum of the ponto-
mesencephalic region were identified, consistent with (but not definitively indicative of) 
LC activity (Sterpenich et al., 2006).  
The decreased signal-to-noise ratio in the brainstem, resulting from the effects of cardiac 
pulsation and respiratory movement, means that it has been traditionally difficult to 
accurately locate the LC’s small structure using fMRI (Astafiev et al., 2010; Payzan-
LeNestour et al., 2013). However, Shibata et al. demonstrated that it is possible to image 
the neuromelanin (a by-product of monoamine synthesis) contained in noradrenergic 
neurons of the LC (Graham, 1979; German et al., 1988; Shibata et al., 2006). 
Furthermore, Keren et al. developed a probabilistic LC atlas using high resolution T1-
turbo spin echo MRI (Keren et al., 2009), which some researchers have used to locate 
LC responses under volatility uncertainty (Payzan-LeNestour et al., 2013). Furthermore, 
by taking advantage of these two methodological advances, Murphy et al. were able to 
use simultaneous pupillometry and fMRI to generate empirical evidence of a relationship 
between pupil diameter and BOLD activity in the human LC (Murphy et al., 2014).  
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1.5.2 A proposed link between pupil diameter and perceptual beliefs 
At the start of the decade, there was a move to integrate pupillometry into contemporary 
studies of human learning and behaviour. Motivated by proposals that different 
behavioural states might be mediated by two modes of LC-NA activity (Usher et al., 1999; 
Aston-Jones and Cohen, 2005a), and that pupil diameter might reflect these LC-NA 
activity profiles, researchers quantified pupil dilation during shifts between exploitation 
and exploration behaviours. Behavioural exploitation is defined as engagement with a 
particular task, while behavioural exploration is characterised by switches between 
tasks. According to adaptive gain theory, two LC modes promote exploitation and 
exploration by adaptively adjusting the responsivity of cortical neurons (Aston-Jones and 
Cohen, 2005a). A phasic mode, characterised by an intermediate level of baseline LC 
activity and large phasic increases in noradrenergic activity, produces selective 
increases in neuronal responsivity to task-related stimuli. The phasic release of NA 
temporarily increases the responsivity (i.e., gain) of target cortical neurons to their 
afferent input, thereby potentiating the processing of task-relevant stimuli (Servan-
Schreiber et al., 1990; Doya, 2002; Berridge and Waterhouse, 2003) and optimising 
performance in the current task (i.e., exploitation). In contrast, a tonic mode, 
characterised by elevated baseline LC activity, tonic NA release and the absence of 
phasic responses, produces a more enduring and less discriminative increase in 
neuronal responsivity. Although this impairs performance within the current task, it 
facilitates the disengagement of attention from that task and the processing of other non-
task-related stimuli and/or behaviours (i.e., exploration). 
Accordingly, changes in pupil diameter have been detected under exploration and 
exploitation behaviours (Gilzenrat et al., 2010; Jepma and Nieuwenhuis, 2011). Gilzenrat 
et al. showed that baseline pupil diameter decreases gradually when individuals engage 
in a new task, while increases in baseline pupil diameter are associated with decreases 
in task utility and upcoming task disengagement and exploration (Gilzenrat et al., 2010). 
Similarly, in a four-armed bandit task in which individuals aimed to maximise reward by 
making choices between four slot machines whose mean payoffs changed gradually and 
independently over time, exploratory choices were preceded by a larger baseline pupil 
diameter than exploitative choices. Furthermore, individual changes in baseline pupil 
diameter were predictive of an individual’s tendency to adopt exploitation behaviour 
(Jepma and Nieuwenhuis, 2011). 
Although perceptual estimates and decision variables were present in these task 
paradigms, they were not the principal focus of the experiments. Nevertheless, this work 
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inspired an important methodological shift; subsequent studies focused on developing 
quantitative models to formally test the hypothesised association between human pupil 
dilation and the perceptual estimates underlying learning and behaviour in uncertain 
environments. As I will discuss next, a range of studies have investigated the modulation 
of pupil diameter by perceptual quantities such as uncertainty, prediction error 
(commonly conceptualised in the pupil literature as surprise), and volatility. 
1.5.2.1 Evidence that pupil diameter is modulated by irreducible uncertainty and 
surprise 
Preuschoff et al. sought to explicitly quantify the impact of distinct perceptual estimates 
on pupil diameter during an auditory gambling task (Preuschoff et al., 2011). On each 
trial, two cards were drawn in succession from a deck numbered 1-10. Before the 
auditory presentation of either card, participants were required to place a monetary bet 
on whether the first or the second card would have a higher value. The paradigm was 
designed to dissociate perceptual estimates of expected reward, irreducible uncertainty 
(which the authors conceptualised as risk), and surprise (here conceptualised as risk 
prediction error). The first card served as a probabilistic cue and the second card as the 
trial outcome. Irreducible uncertainty about the trial outcome captured the inherent 
randomness of the probabilistic relationship between the cue and outcome cards, and 
therefore the unreliability of the trial outcome. Following cue presentation, irreducible 
uncertainty showed an inverted-U relationship, with maximal irreducible uncertainty 
occurring when the value of the first card was 5 or 6, and minimal uncertainty when the 
first card was 1 or 10. Surprise was defined as high when expected reward prior to the 
second card was positive and the actual outcome was a loss, or when the expected 
reward was negative and the actual outcome was a win. Surprise was low when the 
expected reward had been positive and the outcome was a win, or the expected reward 
had been negative and the outcome was a loss. 
Both irreducible uncertainty and surprise were found to have modulatory effects on pupil 
diameter (Figure 1.3). More precisely, pupil dilation occurring after the presentation of 
the first (cue) card was increased when there was low irreducible uncertainty about the 
relative value of the second (outcome) card (i.e., when the first card was 1 or 10, meaning 
the second card was certain to be higher or lower, respectively) compared to when there 
were medium (first card was 2, 3, 8 or 9) or high (first card was 4, 5, 6 or 7) levels of 
irreducible uncertainty about the value of the second card (Figure 1.3A). Pupil dilation 
occurring after the presentation of the second card was augmented under high surprise 
compared to low surprise about the reward outcome (Figure 1.3C). 
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Figure 1.3 Pupil dilation under irreducible uncertainty and surprise. (A) Pupillary 
dilation occurring between the presentation of the first and second cards was modulated 
by irreducible uncertainty. The pupil showed greater dilation if the outcome was certain 
(low uncertainty; first card was 1 or 10) than if there was high irreducible uncertainty 
about the outcome of the second card (high uncertainty; first card was 4, 5, 6 or 7). Pupils 
showed an intermediary dilatory response on trials with medium levels of irreducible 
uncertainty (first card was 2, 3, 8 or 9). (B) Significance of the difference between high 
and low uncertainty trials as presented in A. The horizontal line denotes an expected 
false discovery rate (FDR) of 5%. Times of significant difference fall above this line. (C) 
Pupil dilation after presentation of the second card was increased under high compared 
to low surprise about reward outcome. (D) Significance of the difference between high 
and low surprise trials according to C. Notation is the same as in B. Data in A and C are 
mean ± SEM. Figure adapted from Preuschoff et al., 2011.  
Assuming a relationship between NA and pupil dilation, the authors took the finding that 
post-outcome surprise (i.e., risk prediction error) modulated pupil diameter as indicative 
of a similar noradrenergic role for uncertainty as DA has for reward, namely the encoding 
of error signals. However, as I will address next, the finding that pupil dilation was 
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augmented under low (rather than high) irreducible uncertainty conflicts with the findings 
of alternative studies. 
In my work with de Berker et al., we demonstrated independent evidence to suggest that 
pupil diameter is modulated by both irreducible uncertainty and surprise (de Berker et 
al., 2016). In a volatile probabilistic learning task, participants were required to make 
predictions about binary aversive outcomes (electrical shock/no electrical shock) based 
on binary probabilistic visual cues (cue 1/cue 2). The true probabilistic relationship 
between cues and outcomes was fixed within a contextual block but changed discretely 
every 20-40 trials, with maximal irreducible uncertainty occurring under a 0.5/0.5 
cue:outcome probability. The HGF model was applied to the behavioural data to quantify 
individuals’ trial-wise estimates of uncertainty and surprise. Baseline pupil diameter (i.e., 
pupil diameter at the time immediately preceding cue onset) was found to increase with 
irreducible uncertainty about the current cue:outcome relationship (Figure 1.4A). In 
contrast to Preuschoff et al.’s finding, irreducible uncertainty was also shown to increase 
pupil diameter across the course of the trial (Figure 1.4B). An additional positive effect 
of surprise (here capturing sensory prediction error) occurred approximately two seconds 
after outcome presentation, mirroring Preuschoff et al.’s finding.  
 
Figure 1.4 Pupil diameter is modulated by estimates of irreducible uncertainty and 
surprise. (A) Baseline pupil diameter (i.e., pupil diameter immediately preceding cue 
onset) showed an inverted-U relationship with participants’ beliefs about the current 
cue:outcome probability, as reflected by their irreducible uncertainty. The relationship 
closely conformed to a Bernoulli distribution (grey dashed line), with peak baseline pupil 
diameter coinciding with maximal irreducible uncertainty (i.e., when the estimated 
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cue:outcome probability = 0.5/0.5). (B) Median splits, which separated trials according to 
whether they were high or low in irreducible uncertainty and high or low surprise, 
indicated that irreducible uncertainty increased pupil diameter throughout the trial. There 
was an additional positive effect of surprise approximately 2 seconds after outcome 
presentation. Data are mean ± SEM. Figure adapted from de Berker et al., 2016.  
There are some important differences in the approaches adopted by Preuschoff and de 
Berker, which might explain why different effects of irreducible uncertainty on pupil 
diameter were observed. For example, the relative time-points at which the impact of 
irreducible uncertainty on pupil diameter was assessed differs between the two studies. 
While Preuschoff examined the pupillary effect of irreducible uncertainty after 
presentation of a probabilistic cue, de Berker probed any effect both at baseline (i.e., 
before cue onset) and across the trial time-course (relative to outcome presentation). 
There was no motivation to assess baseline pupil diameter in Preuschoff’s study since 
pre-cue reward probability, and thus pre-cue irreducible uncertainty, were held constant 
(p=0.5). In contrast, in de Berker’s task, the probabilistic cue:outcome relationship 
changed over time. Since irreducible uncertainty on the current trial could be computed 
on the basis of trial history (Mathys et al., 2011), it was possible to investigate whether 
baseline pupil diameter was modulated by this quantity. 
Another difference between the two paradigms is that participants had to make 
predictions about different types of trial-wise outcomes (monetary reward/loss versus 
aversive/neutral stimuli), which may have evoked different neuromodulatory effects on 
pupil diameter. Further, these predictions were made at different time-points in the trial 
time-course. In de Berker’s task, participants were required to predict the trial’s outcome 
after the presentation of a probabilistic cue. In contrast, Preuschoff required participants 
to make a prediction about trial outcome before a probabilistic cue had been presented. 
As such, in Preuschoff’s task, there are two additional parameters that could have 
augmented the post-cue pupillary response. 
First, presentation of the cue would have conveyed a degree of post-decisional surprise. 
As mentioned previously, pre-cue irreducible uncertainty was constant in Presuchoff’s 
paradigm as reward probability was fixed at 0.5. Depending on the direction of the 
participant’s prediction and the value of the first (cue) card, trial-wise post-cue irreducible 
uncertainty would have increased or decreased at cue onset. For instance, if a participant 
had predicted that the second card would be lower than the first card, and the first card 
was then revealed to be a 2, they would have learned that there was a high likelihood 
that they had made a prediction error and that there was only moderate irreducible 
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uncertainty that the second card would be higher than the first. Post-decisional surprise 
would be highest when participants had made an incorrect prediction before the 
presentation of a cue card numbered 1 or 10 (i.e., on what Preuschoff et al. define as 
low irreducible uncertainty trials), possibly explaining the increased pupillary dilation on 
these trials. Second, given that low irreducible uncertainty in Preuschoff’s framework 
actually reflected post-cue certainty about whether a participant would win or lose a 
monetary bet, the associated increase in pupillary dilation may, at least in part, reflect 
outcome confirmation. Indeed, monetary rewards and losses have been shown to have 
a positive effect on pupil diameter (Seymour et al., 2007). 
In line with this suggestion, Satterthwaite et al. observed increased pupil dilation under 
high irreducible uncertainty when they utilised a similar version of Presuchoff’s gambling 
task (Satterthwaite et al., 2007; Figure 1.5A). As in Preuschoff’s paradigm, participants 
made predictions about the relative values of sequentially-presented pairs of cards, but 
here the prediction was made after presentation of the first (cue) card. This suggests 
that, when unconfounded by post-decisional surprise or outcome confirmation, 
irreducible uncertainty has a positive effect on pupil diameter. 
 
 
Figure 1.5 Pupil diameter tracks responses to uncertainty and surprise. (A) Pupil 
diameter during both the post-cue and post-outcome periods was greater on trials with 
high irreducible uncertainty than on certain trials. This finding is in line with that of de 
Berker et al., but opposes the effect observed by Preuschoff et al. (B) Following outcome 
presentation, losses evoked increased pupillary dilation compared to wins on uncertain 
trials. (C) This effect was even larger on probable trials when the loss was relatively 
unexpected, i.e. when there was a larger prediction error that conveyed increased 
surprise. Data are mean ± SEM. Figure adapted from Satterthwaite et al., 2007.  
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Moreover, pupillary dilation following presentation of the second (outcome) card, was 
augmented on trials on which participants had made a prediction error that led them to 
experience a monetary loss (Figure 1.5B). This effect was increased when the opposite 
outcome had been more likely (Figure 1.5C), echoing my hypothesised impact of post-
decisional surprise on low irreducible uncertainty trials in Preuschoff’s task. Nonetheless, 
it should be noted that, assuming participants made correct predictions on approximately 
50% of trials in Preuschoff’s task, any pupillary effect of post-decisional surprise may 
actually have been averaged out across trials. 
1.5.2.2 Evidence that pupil diameter is modulated by volatility 
Despite some differences in the precise results of these three studies, the observation 
that irreducible uncertainty and surprise modulate pupil diameter gives weight to the 
notion that pupil dilation offers an indirect measure of an individual’s perceptual 
estimates. Given that noradrenergic neurotransmission has been linked both to changes 
in pupil diameter and to learning under environmental volatility, one might expect that 
pupil diameter is also modulated by individuals’ volatility estimates. In the tasks 
implemented by Preuschoff et al. and Satterthwaite et al., a single probabilistic context 
was used, meaning there was no inherent volatility. As such, it was not possible to 
investigate any impact of volatility on pupil diameter. In de Berker et al.’s task, the 
probabilistic relationship between cues and outcomes was unstable. By applying the 
HGF model to individuals’ behavioural data, it was possible to capture their trial-wise 
volatility estimates and to isolate them from their estimates of surprise and uncertainty. 
However, any impact of volatility on pupil diameter was not the focus of the study and 
was therefore unaddressed.   
Nevertheless, pupillometric measures taken under alternative task paradigms have 
suggested that changes in pupil diameter are linked to estimates of volatility. In an 
experiment by Nassar et al., participants undertook an isoluminant predictive-inference 
task in which they were required to make trial-wise predictions about the next number in 
a series (Nassar et al., 2012). Numbers were drawn from a Gaussian distribution. The 
mean of the Gaussian distribution was stable within a particular context but changed 
unpredictably over time, introducing volatility. The standard deviation of the distribution 
introduced noise, i.e., random fluctuations in the data generated by an otherwise stable 
context. Over each block of trials, the standard deviation of the distribution was set to 
either 5 or 10, introducing low or high noise, respectively. 
Transient increases in pupil diameter (which the authors describe as pupil changes) were 
augmented under high surprise (i.e., high sensory prediction error) but low noise. Given 
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that larger prediction errors would be expected following a change in context, it was 
suggested that pupillary dilation might reflect perceived contextual instabilities arising at 
change-points (Figure 1.6A). Accordingly, transient increases in pupil diameter were 
found to predict change-point probability (Figure 1.6B), and coincided with an increase 
in learning rate that would be expected to accompany a contextual change. Together, 
these findings indicate that pupil diameter is sensitive to sensory changes that arise due 
to environmental volatility. 
 
 
 
Figure 1.6 Relationship between post-outcome pupil change, prediction error, 
noise and change-point probability. (A) Transient pupil change increased as a 
function of prediction error magnitude, scaled as a function of noise (black = low noise; 
grey = high noise). Pupil change was computed as the difference in mean (z-scored) 
pupil diameter measured late (time = 1-2 seconds) versus early (time = 0-1 seconds) 
post-outcome. (B) Increased pupillary dilation predicted a higher change-point 
probability, as estimated by a Bayesian learning model. Data are mean ± SEM. Figure 
adapted from Nassar et al., 2012.  
In addition, average pupil diameter during the outcome viewing period reflected the 
reliability with which recent trial history indicated the current contextual relationship 
(Figure 1.7), a parameter that the authors frame as relative uncertainty. Relative 
uncertainty encompasses my working definitions of irreducible and estimation 
uncertainty, reflecting both the unreliability with which a single sample can be predicted 
from a distribution with a known mean and the unreliability of an individual’s current 
estimate of that mean. It increases rapidly after a change-point and then decreases as 
more data are observed from the current distribution and an individual learns the rules 
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of the current context. The finding that average pupil diameter mirrored relative 
uncertainty, peaking after a change-point and then decreasing over subsequent trials 
(Figure 1.4), echoes, at least in part, our previous finding of increased pupil diameter 
under increased irreducible uncertainty (de Berker et al., 2016). 
 
Figure 1.7 Relationship between average pupil diameter and relative uncertainty. 
(A) Average pupil diameter as a function of trials pre- and post-change points. Pupil 
average is the mean (z-scored) pupil diameter across a 2 second outcome viewing 
period. The asterisk indicates that average pupil diameter on the trial immediately 
following the change-point was significantly greater than on all other trials. (B) An 
increase in average pupil diameter predicted an increase in relative uncertainty, as 
estimated by a Bayesian learning model. There was no relationship between relative 
uncertainty and transient pupil change. Data are mean ± SEM. Figure adapted from 
Nassar et al., 2012.  
Importantly, adaptive behaviour in dynamic probabilistic environments requires that the 
relative impact of incoming sensory information is modulated in line with different sources 
of uncertainty. When irreducible and estimation uncertainty (i.e., relative uncertainty) 
arise from noise, the average perceptual estimate over all historical sensory data is most 
predictive of future observations. In contrast, when volatility uncertainty arises from a 
change in probabilistic context, only the most recent observations are relevant. Thus, 
historical sensory data should be discounted and beliefs should be updated rapidly, in 
accordance with incoming sensory data, to maximise prediction accuracy. Nassar et al.’s 
finding that pupil diameter can predict both change-point probability and relative 
uncertainty suggests that the pupil might reflect the dynamics of the hypothesised 
noradrenergic processes that underlie learning in uncertain and volatile environments. 
Recently, Browning et al. conduced an explicit investigation into the relationship between 
pupil diameter and volatility (Browning et al., 2015). In an aversive probabilistic learning 
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task, participants were required to select one of two visual cues, each of which was 
probabilistically linked to a subsequent electrical shock of a magnitude defined by that 
cue. The probability that each cue predicted an electrical shock changed over time, 
introducing volatility. During a stable block, the cue:outcome probabilities were fixed for 
90 trials. During a volatile block, the cue:outcome probabilities switched every 20 trials. 
Pupillary dilation following outcome presentation was modulated by both surprise (Figure 
1.8A) and volatility (Figure 1.8B), as estimated by a Bayesian learning model.  
 
Figure 1.8 The effects of surprise and volatility on post-outcome pupil diameter 
during aversive probabilistic learning. (A) Pupil dilation was modulated by surprise 1-
3 seconds post-outcome and (B) by volatility 2-5 seconds post-outcome. Data are mean 
beta weights ± SEM. Figure adapted from Browning et al., 2015.  
Moreover, individuals with high trait anxiety demonstrated a reduced ability to adjust their 
learning rate following switches from stable to volatile blocks. Specifically, it seems that 
these individuals could not increase their learning rate under volatility, instead showing 
equivalent learning in both stable and volatile blocks. Elevated trait anxiety was also 
associated with a decreased mean pupillary response to volatility. There was no 
modulatory effect of trait anxiety on the mean pupil response to surprise. Given that 
anxiety has been linked to dysfunctional noradrenergic neurotransmission (Gorman et 
al., 2001), these results are compatible with the theorised functional relationship between 
noradrenergic neurotransmission, pupillary dynamics and learning under environmental 
volatility.  
In sum, varied behavioural and pupillometric evidence suggests that pupil diameter is 
modulated by an individual’s perceptual estimates under environmental uncertainty, with 
pupil dilation having been linked to uncertainty, surprise and volatility. Given the 
proposed role for NA in learning under volatility uncertainty, and the electrophysiological, 
pharmacological and neuroimaging data that suggest that pupil diameter is sensitive to 
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NA neurotransmission, the notion that pupil dilation can be used as a proxy for dynamic 
noradrenergic uncertainty computations is appealing. However, the foregoing 
investigations of pupillary responses to perceptual estimates have been heterogeneous: 
they have used different behavioural paradigms that exposed participants to different 
forms of uncertainty, and probed the impact of different combinations of perceptual 
beliefs on pupil diameter. As such, it is difficult to isolate the contribution of particular 
perceptual estimates to pupil diameter with confidence. Therefore, in Chapter 6, I 
combine a probabilistic learning task, pupillometry and a hierarchical Bayesian learning 
model to assess the impact of irreducible uncertainty, surprise and volatility on pupil 
diameter. Further, by utilising two pharmacological manipulations of NA, I causally 
assess whether any pupillary responses to these perceptual beliefs are under dynamic 
noradrenergic modulation. 
1.6 Thesis overview 
To summarise, this thesis addresses the neuromodulatory underpinnings of learning and 
action in uncertain environments. In a series of experiments, I seek to identify the relative 
contributions of NA, ACh and DA to perceptual belief updating and motor response 
modulation within a unified computational framework of irreducible, estimation and 
volatility uncertainty. Specifically, I hypothesised that: 
1. Pharmacologically manipulating NA would modulate learning under volatility 
uncertainty arising from environmental instability; 
2. Pharmacologically manipulating ACh would modulate learning under estimation 
uncertainty arising within probabilistic environmental contexts; 
3. Pharmacologically manipulating DA would modulate the sensitivity of motor 
responses to perceptual estimates of sensory prediction error; 
4. Inter-individual variations in COMT genotype would alter DA neurotransmission 
and thus the sensitivity of motor responses to perceptual estimates, echoing the 
effect of pharmacologically manipulating DA; 
5. Pharmacologically manipulating NA would modulate dynamic computations of 
uncertainty arising from environmental volatility, as reflected by pupil diameter. 
In Chapter 2, I introduce the methodological techniques implemented to interrogate the 
relative contributions of NA, ACh and DA to perceptual belief updating and response 
modulation under different forms of uncertainty. 
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In Chapter 3, I focus on the HGF model I apply to behavioural data in the following 
experimental chapters. I introduce the HGF as a generic Bayesian framework of 
individual learning under irreducible, estimation and volatility uncertainty. Further, I 
describe how I extended the original instantiation of the HGF so that it was possible to 
capture both individual learning and response modulation under these three forms of 
uncertainty. 
The empirical work of this thesis is presented in Chapters 4 to 6: 
In Chapter 4, I implement pharmacological interventions in 128 healthy human 
participants to characterise the influences of noradrenergic, cholinergic and 
dopaminergic receptor antagonism on individual computations of uncertainty during a 
probabilistic serial RT task. Using the novel instantiation of the HGF, I disentangle the 
effects of the neuromodulators on individual perceptual belief updating from any effects 
on the sensitivity of motor responses to perceptual estimates. 
In Chapter 5, I adopt a behavioural genetics approach to probe deeper into the role of 
DA in learning and response modulation under uncertainty. Specifically, I use the same 
serial probabilistic RT task and the same HGF model to assess the impact of COMT 
genotype on learning and action in 116 healthy human participants. As such, I aim to 
determine whether natural inter-individual variations in cortical dopaminergic 
neurotransmission modulate individual perceptual belief updating and/or the sensitivity 
of motor responses to perceptual estimates. 
In Chapter 6, I focus on the role of NA in learning under uncertainty. Combining 
pupillometry, the HGF model and two pharmacological manipulations of NA in 90 healthy 
human participants, I characterise dynamic noradrenergic responses to uncertainty, 
surprise and volatility during an auditory probabilistic learning task. 
Finally, in Chapter 7, I discuss the implications of this work, drawing together insights 
from the different lines of research presented in this thesis. 
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2 Methods 
In this chapter, I introduce the methodological techniques implemented in this thesis to 
investigate the neuromodulatory bases of learning and action in uncertain environments. 
I describe how the methods were developed and summarise the experimental 
considerations that were made. 
2.1 Behavioural paradigms to investigate learning and action 
under uncertainty 
In order to interrogate the roles of NA, ACh and DA in computing irreducible uncertainty, 
estimation uncertainty and volatility uncertainty, and in modulating motor responses to 
uncertainty, it was necessary to design behavioural paradigms that exposed participants 
to each quantity. For Chapters 4 and 5, I developed a novel probabilistic serial reaction 
time task that required participants to track these three forms of uncertainty to engender 
fast, accurate responses to visual stimuli. For Chapter 6, I adapted a previously 
documented probabilistic learning task (den Ouden et al., 2010; Iglesias et al., 2013; de 
Berker et al., 2016) that required participants to make accurate predictions about trial 
outcomes given uncertain cues whose reliability changed over time.  
2.1.1 Probabilistic serial reaction time task  
2.1.1.1 Task design 
The probabilistic serial reaction time task (PSRTT) required participants to respond to 
the trial-wise presentation of one of four visual stimuli by pressing an appropriate button 
as quickly as possible. At any given time, the trial sequence was generated by one of 
eight transition matrices (TMs), which changed every 50 trials. In each case, there were 
16 combinations that determined the probabilistic relationship between the stimuli 
presented on the current trial t, and the previous trial, t-1. In Chapter 4, three types of 
TM were utilised: 1st-order sequences, Alternating sequences, and 0th-order sequences 
(Figure 2.1). 
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Figure 2.1 Probabilistic structure of the PSRTT. (A) The eight TMs that determined 
the probabilistic relationship between the visual stimulus presented on the current trial, 
t, and that presented on the previous trial, t-1. (B) Example trial sequences generated 
from the eight TMs. TMs 1 and 2 generated 1st-order stimulus sequences in which there 
was a high probability of the sequences 1-2-3-4 and 4-3-2-1 occurring respectively. TMs 
3 and 4 resulted in a high probability of alternating between two stimuli. TMs 5-8 were 
0th-order sequences that led to one stimulus occurring with a high probability, one with a 
mid probability and two with a low probability. The TM switched to a different TM every 
50 trials. Over the course of the experiment, each TM occurred multiple times in a 
pseudorandom order, with no consecutive repeats of any one TM. The overall probability 
of each stimulus was equal across 1200 trials.  
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In Chapter 5, the task design was simplified slightly in that the Alternating TMs were 
replaced with two additional 1st-order sequences (Figure 2.2). All other TMs were 
identical to those used in Chapter 4.  
 
Figure 2.2 Alternative probabilistic contexts. (A) In Chapter 5, two additional 1st-order 
TMs replaced the Alternating TMs used in Chapter 4. (B) Example trial sequences 
indicate that TM 3 resulted in a high probability of the stimulus sequence 1-2-4-3 
occurring, and TM 4 a high probability of the stimulus sequence 1-4-2-3. In Chapter 5, 
TMs 1, 2, and 5-8 were identical to those defined in Figure 2.1.  
In both versions of the task, the order of the TMs was pseudorandom, with no 
consecutive repeats. This pseudorandom order of TMs was used to generate one 
stimulus sequence that was used for all participants to ensure comparable learning 
processes and model parameter estimates between individuals. Importantly, the overall 
probability of each stimulus was equal across the complete set of trials. 
The task design created transient contexts that participants could infer from stimulus 
observations, allowing them to reduce their uncertainty about events before they 
occurred (Harrison et al., 2006). Nonetheless, the probabilistic nature of these contexts 
also produced unexpected stimulus outcomes, i.e., a sensory prediction error (PE). For 
fast and accurate responses, participants had to track irreducible uncertainty arising from 
the inherent randomness of the probabilistic transitions between consecutive stimuli; 
estimation uncertainty arising from their imperfect knowledge of the probabilistic 
relationships governing stimulus transition contingencies within contexts; and volatility 
uncertainty maintained by the unsignalled contextual instability. 
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By implementing a hierarchical Bayesian learning model, with a response model adapted 
for this experimental paradigm (Chapter 3), it was possible to map an individual’s beliefs 
about stimulus transitions, transition contingencies, and volatility, and the respective 
irreducible, estimation and volatility uncertainty about these beliefs, onto his/her 
observed reaction time (RT) responses. In Chapter 4, the behavioural paradigm and 
computational modelling were combined with pharmacological manipulations of NA, ACh 
and DA in order to characterise the roles of the three neuromodulators in perceptual 
belief updating under these three forms of uncertainty, and in modulating motor 
responses to this uncertainty. In Chapter 5, genetic analyses of the Val158Met 
polymorphism in the COMT gene were used to probe the impact of inter-individual 
differences in dopaminergic neurotransmission on learning and action under uncertainty, 
thereby extending the findings of the pharmacological study. 
2.1.1.2 Training 
Each stimulus was associated with one particular button. Each participant acquired the 
stimulus-response mappings during a training block in which they received visual error 
feedback after each trial. The training session comprised at least 100 trials and did not 
finish until participants had reached a minimum performance criterion of 85% accuracy 
on the last 20 trials. This was to ensure that any learning during the task was related to 
the probabilistic relationships governing stimulus transitions, rather than the stimulus-
response mappings themselves. 
2.1.1.3 Button boxes  
Participants made their speeded responses via a custom-made button box. Four button 
boxes were used so that four participants could be tested in a multiple participant setup 
(see section 2.1.3). Two of the button boxes transmitted data to the testing computer via 
the serial port, and two via the parallel port. Button boxes, rather than computer 
keyboards, were used for improved precision of the logged RTs. Both the serial and 
parallel port button boxes had a temporal precision of 3-13ms, compared to a keyboard’s 
33ms.  
2.1.2 Probabilistic learning task 
2.1.2.1 Task design 
The probabilistic learning task (PLT) was closely modelled on a paradigm used in three 
recent studies (den Ouden et al., 2010; Iglesias et al., 2013; de Berker et al., 2016). On 
each trial, participants were presented with one of two auditory cues: a low pitch (450Hz) 
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or high-pitch (1000Hz) tone. They were required to make a prediction, signalled with a 
speeded button press, as to which auditory outcome (the word “cow” or the word “pig”) 
was likely to follow. A probabilistic mapping between stimulus and outcome exposed 
participants to estimation uncertainty about the current cue:outcome relationship. This 
probabilistic mapping shifted over the course of the experiment, introducing volatility 
uncertainty and requiring participants to constantly track the cue:outcome relationship 
over time. The task’s probabilistic nature also meant that unlikely outcomes were 
possible on any trial, giving rise to irreducible uncertainty. To make accurate predictions, 
participants therefore had to track three forms of uncertainty throughout. 
 
Figure 2.3 The instability of the PLT over time. The probabilities governing the 
cue:outcome relationships shifted unpredictably over time, producing fluctuations in 
uncertainty. The probabilities governing each block varied from heavily biased (0.9/0.1 
and 0.1/0.9), through moderately biased (0.7/0.3 and 0.3/0.7) to unbiased (0.5/0.5).  
2.1.2.2 Auditory stimuli 
Since the PLT was combined with pupillometry, the visual stimuli used in previous 
iterations of this task (den Ouden et al., 2010; Iglesias et al., 2013; de Berker et al., 2016) 
were replaced with auditory stimuli so as to eliminate any effects of luminance changes 
on pupil diameter. Moreover, to avoid any inter-stimulus difference in auditory saliency 
effects on the pupil, participants underwent an adaptive, two-alternative forced choice 
procedure before undertaking the behavioural task so as to match the subjective 
loudness of the auditory cues and outcomes. The two auditory cues and two auditory 
outcomes had the same durations (300ms and 600ms respectively). The auditory 
outcomes were neutral words that belonged to a single (animal) category and were easy 
to distinguish. 
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2.1.2.3 Training 
Participants were trained on the PLT before starting it. During four training blocks of five 
trials each, participants familiarised themselves with making predictions by button press 
on presentation of auditory cues. Participants were told at the start of each training block 
which cue and which outcome would be presented on each of the following five trials. 
After the outcome was presented, they were provided with visual error feedback. Each 
combination of cue and outcome was presented across the four training blocks. The 
order of the four training blocks (i.e., the pairings between each cue and each outcome) 
was counterbalanced across participants. To familiarise themselves with the timings of 
the PLT, participants then completed 12 practice trials without error feedback. On each 
trial there was a 50% probability that either cue would be followed by either outcome. 
2.1.3 Multiple participant setup 
For efficiency, I implemented multiple participant testing (Figure 2.4A). For the PSRTT, 
four participants were tested simultaneously. To ensure that they were not distracted 
while completing experimental tasks, participants wore ear defenders and sat in 
individual booths. For the PLT, which was combined with pupillometry, experimental 
sessions were staggered such that a second participant arrived once the first participant 
had received their drug or placebo and had entered the 1.5 hour waiting period that 
preceded commencement of the main behavioural task (see section 2.3.4 for details). 
To ensure that all participants received identical task instructions, they were provided in 
written form. 
 
Figure 2.4 Behavioural setup used during the PSRTT. (A) A multiple participant setup 
was employed for simultaneous testing of four participants. (B) Each participant sat 
fixating a central white cross presented on a black computer screen positioned 60cm 
away. They were instructed to place their left and right index and middle fingers on the 
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four buttons of a custom-made button box, and to maintain this position throughout the 
task. Following the trial-wise presentation of one of four visual stimuli, participants were 
required to make a speeded-button press response.  
2.2 Computational modelling of learning and action 
Computational modelling makes it possible to estimate the inferences made by 
participants during a behavioural task. Hierarchical Bayesian models have proven 
powerful for explaining the adaptation of behaviour to probabilistic contexts in dynamic 
environments (Behrens et al., 2007; den Ouden et al., 2010; Nassar et al., 2010; Wilson 
et al., 2013). In particular, the Hierarchical Gaussian Filter (HGF) model (Mathys et al., 
2011, 2014) has been successfully applied in several recent studies of probabilistic 
learning under volatility (Iglesias et al., 2013; Diaconescu et al., 2014, 2017; Hauser et 
al., 2014; Vossel et al., 2014a, 2014b, 2015; de Berker et al., 2016). 
The HGF models an individual’s learning across three levels: it tracks beliefs about 
environmental events (e.g. the presentation of a stimulus) at level 1, the probabilistic 
relationships linking different environmental events at level 2, and the volatility of these 
relationships at level 3. As such, it is possible to access the respective irreducible, 
estimation and volatility uncertainty about these beliefs, and to infer an individual’s beliefs 
about the causes of his/her sensory inputs. 
The HGF is hierarchical in that learning not only occurs simultaneously at multiple levels, 
but that belief updating at one level is constrained by beliefs at the level above. This 
provides a generic framework for implementing learning rates, which are crucial for 
learning in volatile environments (Behrens et al., 2007; den Ouden et al., 2010). 
Importantly, the HGF does not assume fixed “ideal” learning across individuals but rather 
contains participant-specific parameters that couple the hierarchical levels and allow for 
individual expression of (approximate) Bayes-optimal learning. 
The PLT used in Chapter 6 was compatible with a pre-existing instantiation of the HGF 
(Iglesias et al., 2013; de Berker et al., 2016). The PSRTT used in Chapters 4 and 5 
required the development of a novel instantiation of the HGF. This new version has two 
components: a three-level perceptual model of an agent’s mapping from environmental 
causes to sensory inputs, and a response model that maps those inferred environmental 
causes to observed RT responses. Full details are presented in Chapter 3. 
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2.3 Pharmacological manipulations of neuromodulatory function 
In Chapters 4 and 6, I employed pharmacological interventions that manipulate the 
noradrenergic, cholinergic and dopaminergic neuromodulatory systems in order to 
causally asses the roles of NA, ACh and DA in learning and response modulation under 
uncertainty. 
In Chapter 4, I utilised three antagonists for the different neuromodulators, and 
compared learning and action under each manipulation to placebo. Prazosin acts as a 
(nor)adrenergic antagonist. Specifically, the drug is an inverse agonist that binds to α1-
adrenoceptor but induces a pharmacological effect opposite to that of the receptor’s 
endogenous ligand, (nor)adrenaline (Zhu et al., 2000). Biperiden acts as an antagonist 
at cholinergic muscarinic M1-receptors. Since the drug has affinity, but no efficacy, for 
M1-receptors, it competes with ACh for receptor binding sites and dampens the effect of 
the natural cholinergic ligand. Similarly, when administered at a sufficient dose, 
haloperidol acts as a dopaminergic antagonist, competing with DA for D1- and D2-
receptor binding sites and dampening the pharmacological effect of DA. 
In Chapter 6, I probed dynamic noradrenergic responses to uncertainty by using two 
pharmacological agents that have bidirectional effects on the NA system. As in Chapter 
4, I used prazosin to antagonise NA. In addition, the selective NA reuptake inhibitor, 
reboxetine, was used to upregulate the NA system by blocking the action of the 
noradrenaline transporter (NET), which is responsible for the reuptake of extracellular 
NA. 
2.3.1 Between-subjects design 
For each pharmacological experiment (Chapters 4 and 6), I implemented a between-
subjects design. As such, each participant attended one experimental session during 
which they received either an active drug or a placebo. The principal reason for this was 
that my behavioural paradigms involved learning. Since each participant undertook the 
behavioural task only once, it was possible to eliminate any learning effects that may 
otherwise have been carried over from previous sessions. Moreover, a between-subjects 
design made it possible to use a single, pseudorandomly generated trial sequence for 
all participants undertaking the PSRTT (Chapters 4 and 5), ensuring comparable 
learning processes and model parameter estimates. A further benefit of a between-
subjects design was that participants were not required to attend multiple experimental 
sessions, minimising any problems caused by drop-outs. 
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2.3.2 Safety 
For safety purposes, it was necessary to screen participants to rule out intolerances or 
contraindications for the active drugs. To reduce the risk of side effects, I aimed to select 
relatively low drug doses that were nevertheless in line with previous studies showing 
clear behavioural and neurophysiological effects (Dostert et al., 1997; Ziemann et al., 
1997; Meintzschel and Ziemann, 2006; de Martino et al., 2007; Jepma et al., 2010; 
Korchounov and Ziemann, 2011; Bestmann et al., 2014). In addition, the following 
exclusion criteria applied: history of neurological or psychiatric disease, intake of 
medication (other than contraceptives), smoking, regular drug use, baseline blood 
pressure below 100/60, and current participation in other pharmacological studies. As an 
additional precaution, heart rate and blood pressure measurements were taken at three 
timepoints during the experimental session (see 2.3.3). A clinician was also available 
during each testing session in case of any medical queries or concerns.  
2.3.3 Physiological, psychometric and subjective control measures 
A between-subjects design meant that it was necessary to match the different drug-
groups for physiological, psychometric and subjective variables that could influence drug 
responses and behaviour during the experimental tasks. At recruitment, the study 
clinician pseudorandomly assigned participants to receive one of the active drugs or a 
placebo in order to ensure a balanced distribution of gender, age and body weight. 
Importantly, a double-blind design was achieved since both the experimenter (L.M.) and 
the participants were blind to the drug conditions. Since nicotine acts at cholinergic 
(nicotinic) receptors, smokers were excluded. 
Since participants’ working memory, impulsivity, risk-taking and distractibility could 
influence behaviour during the tasks, participants undertook computerised versions of 
the Digit Span test, Barratt Impulsiveness Scale (BIS-11) (Patton et al., 1995), Domain-
Specific Risk-Taking (DOSPERT) Scale (Blais and Weber, 2006) and Cognitive Failures 
Questionnaire (CFQ) (Broadbent et al., 1982) at baseline (i.e., before taking a drug). In 
both pharmacology experiments (Chapters 4 and 6), scores on these tests were 
established to be equivalent across drug-groups. 
2.3.3.1 Digit span 
Digit span is a common measure of working memory. Participants were instructed to 
memorise sets of digits that were presented to them via stereo headphones, and then to 
repeat those digits, in the order in which they had been read, by typing them via a 
computer keyboard. The first trial started with a set of three digits. Every two trials, the 
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set-length increased by one digit. For each set-length, participants were required to 
repeat at least one of the two sets correctly to progress to the next level. The task finished 
either when a participant incorrectly repeated two sets of the same length, or when they 
correctly repeated the maximum set-length of nine digits. After completing the forward 
digit span, participants undertook the backwards digit span. Here the rules were the 
same, except that participants had to repeat the digits that were presented to them in the 
reverse order. 
2.3.3.2 Barratt impulsiveness scale (BIS-11) 
The BIS-11 (Patton et al., 1995) consists of 30 items describing common impulsive, or 
non-impulsive (for reverse scored items), behaviours and preferences. It interrogates 
attentional, motor and non-planning impulsiveness. Participants used a 4-point scale to 
self-report whether they engaged in particular behaviours, or had particular preferences, 
“rarely/never”, “occasionally”, “often”, or “almost always/never”. The higher the summed 
score for all items, the higher the level of impulsiveness. 
2.3.3.3 Domain-specific risk-taking scale (DOSPERT) 
The DOSPERT is a validated scale (Blais and Weber, 2006) that assess an individual’s 
tendency for risk-taking behaviours, and their perceived-risk attitudes (defined as the 
willingness to engage in a risky activity as a function of its perceived riskiness) in five 
domains: ethical, financial, health/safety, social, and recreational decisions. It consists 
of 30 items. Participants self-reported the likelihood that they would engage in a 
described activity or behaviour, or how risky they considered a described behaviour to 
be, using a 7-point scale ranging from “extremely unlikely” to “extremely likely”, and from 
“not at all risky” to “extremely risky”, respectively. A higher total score indicates higher 
risk-taking behaviour. 
2.3.3.4 Cognitive failures questionnaire (CFQ) 
The CFQ (Broadbent et al., 1982) measures self-reported failures in perception, memory 
and motor function, and thus can be used to approximate an individual’s distractibility. It 
consists of 25 questions, such as “Do you read something and find you haven’t been 
thinking about it and must read it again?” Participants responded using a 5-point scale: 
“very often”, “quite often”, “occasionally”, “very rarely” and “never”. A higher score 
indicates a higher failure rate. 
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2.3.3.5 Controlling for subjective measures 
To assess any subjective drug effects, participants used sixteen visual analogue scales 
(VAS) to self-report their mood at baseline, before starting the main behavioural task 
(i.e., when the active drugs were at their most active) and after completing the 
behavioural task. For each VAS, two extreme moods, such as alert/drowsy and 
tense/relaxed were presented at either end of a 100-point scale and participants had to 
mark their current subjective feeling. The 16 measures were used to calculate scores for 
alertness, calmness and contentedness (Bond and Lader, 1974). Since there was a 
significant interaction between alertness and drug in both pharmacology studies, an 
alertness covariate was included in the analyses (see Chapters 4 and 6 for details). 
For completeness, heart rate and blood pressure measurements were taken at the same 
three timepoints as the VAS scores so as to monitor any physiological drug effects. 
2.3.4 Drug administration times 
Drug administration times were selected such that participants undertook the main 
experimental task when the active drug they had been administered was at its most 
active. Since average time-to-peak plasma concentrations varied across drugs, two 
different drug administration times were used. In the first pharmacology study (Chapter 
4), haloperidol was administered two hours before the main experimental session, while 
prazosin and biperiden were administered 1.5 hours in advance (Ziemann et al., 1997; 
Meintzschel and Ziemann, 2006; Korchounov and Ziemann, 2011). A random 50% of 
participants from the Placebo group were administered a placebo tablet at the first 
timepoint, and the other 50% at the second timepoint. 
In the second pharmacology experiment (Chapter 6), a minor modification was made to 
this approach so that all participants underwent an identical administration schedule. 
This time all participants were administered two tablets thirty minutes apart. Reboxetine 
was administered two hours before the main experimental task and prazosin 1.5 hours 
in advance (Dostert et al., 1997; de Martino et al., 2007; Jepma et al., 2010). At the 
timepoint at which participants in the Reboxetine and Prazosin groups did not receive an 
active drug, they were administered a placebo tablet. Participants in the Placebo group 
were administered a placebo tablet at both timepoints. This method ensured that, in 
multiple participant testing sessions, individuals would not infer any differences in how 
the different participants were being treated, and ensured that the experimenter (L.M.) 
remained blind to the drug conditions.   
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In both experiments, the study clinician administered the drug or placebo while the 
experimenter was away from the testing room. For comparable metabolism rates, 
participants were asked not to eat for at least one hour before the first drug administration 
time. 
2.4 Behavioural genetics 
An alternative approach to studying neuromodulatory systems is to interrogate genetic 
polymorphisms that introduce natural inter-individual variations in neuromodulatory 
function. A polymorphism of particular interest in the behavioural genetics literature is 
the Val158Met polymorphism in the COMT gene, which modulates activity of the COMT 
enzyme and thus DA neurotransmission. In Chapter 5, I combined the same PSRTT 
and novel instantiation of the HGF applied in Chapter 4 to assess individual perceptual 
belief updating and response modulation as a function of COMT genotype. As such, it 
was possible to probe whether inter-individual variations in DA neurotransmission were 
associated with altered learning and/or action under uncertainty. 
2.5 Pupillometry 
As discussed in the Introduction, the neuroscience literature has previously linked 
subjective uncertainty computations to changes in pupil diameter (Preuschoff et al., 
2011; Nassar et al., 2012; de Gee et al., 2014; de Berker et al., 2016), and pupil dilation 
to noradrenergic neuronal activity in the locus coeruleus (Aston-Jones and Cohen, 
2005a; Varazzani et al., 2015; Joshi et al., 2016). In Chapter 6, I combined 
pharmacological manipulations of NA with a behavioural paradigm and pupillometry to 
assess the neuromodulator’s causal impact on learning in dynamic environments and on 
pupillary responses to uncertainty. 
While participants undertook the PLT, the diameter of the left pupil was measured using 
an infrared ASL Eye-Trac 6 System (Applied Science Laboratories, USA), sampling at 
120Hz (Figure 2.5). In order to minimise movement, participants sat with their head 
supported in a forehead- and chin-rest. The viewing distance was fixed at 60cm. 
Participants were instructed to maintain fixation on a horizontally-centred fixation cross 
presented on an isoluminant, grey screen. The vertical position of the fixation cross was 
such that the participant’s line of vision was straight ahead. Auditory stimuli were 
presented via stereo headphones. 
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The eyetracker system calculates pupillary gaze by measuring the distance between the 
location of a participant’s pupil and corneal reflection (CR). For each participant, the 
eyetracker was calibrated to account for inter-participant differences in the relationship 
between the pupil and CR. The central calibration point was positioned at the location of 
the centre-point of the fixation cross used during the behavioural task. Calibration was 
repeated after each rest period to adjust for any subtle differences in head position. In 
order to align the pupil diameter time-course with experimental events occurring in the 
behavioural task (i.e., the precise timing of cue, response and outcome onsets) triggers 
were sent via the testing computer’s parallel port to the eyetracker system. 
 
Figure 2.5 Pupillometry setup used during the PLT. Participants sat in a darkened 
room with their head supported by a forehead- and chin-rest. During the experimental 
task, participants were instructed to maintain fixation on a black cross horizontally 
centred on a grey isoluminant display positioned 60cm ahead. The fixation cross was 
presented parallel with the participant’s line of vision. An infrared eyetracker was used 
to measure the diameter of the left pupil. Auditory stimuli were presented via stereo 
headphones. Participants were instructed to position their left and right index fingers on 
two marked keys on a computer keyboard, and to maintain this position throughout the 
experiment. On the presentation of each trial-wise auditory cue, participants were 
required to make a prediction via a speeded button-press as to which auditory outcome 
they thought would follow.  
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3 Modelling individual learning and action under 
uncertainty 
This chapter is based on work presented in Marshall L, Mathys C, Ruge D, de Berker 
AO, Dayan P, Stephan KE & Bestmann S. (2016) Pharmacological fingerprints of 
contextual uncertainty. PLOS Biology. 14(11): e1002575. 
3.1 Abstract 
A mechanistic understanding of perceptual belief updating and response modulation 
requires specification of the computational principles by which learning and action occur, 
and identification of their neurophysiological implementation in the brain. As such, the 
development of computational models is key to elucidating the neurophysiological bases 
of learning and action in uncertain environments. In 2011, Mathys et al. introduced the 
Hierarchical Gaussian Filter (HGF) model as a generic hierarchical Bayesian framework 
for individual learning under various forms of uncertainty inherent in the environment. In 
this chapter, I first provide a summary of the computational principles that inspired the 
HGF’s construction. Second, I describe how the original instantiation of the HGF is 
designed to capture individual learning under uncertainty. Third, I focus on a novel 
extension of the HGF model designed to link perceptual beliefs to action execution. 
Specifically, this new instantiation of the HGF characterises individual learning and 
response modulation during the serial probabilistic reaction time task (PSRTT) applied 
in Chapters 4 and 5. 
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3.2 Introduction   
Computational models offer a sophisticated means by which to probe the brain’s 
mechanisms of learning and adaptive behaviour in complex, uncertain environments. 
Such models commonly conceptualise the environment as a set of unobservable, hidden 
states whose temporal dynamics generate our observable, sensory input. Learning 
about the hidden states that define our present environmental context, and adapting to 
contextual changes, requires us to update our beliefs about the world by integrating our 
top-down, experience-driven expectations and our current bottom-up sensory evidence 
(Yu and Dayan, 2003). In so doing, we can exploit our past experience of the world while 
also taking into account the current state of the environment, thus improving our ability 
to predict future events and to prepare adaptive motor responses. One strategy for 
investigating human learning and action under uncertainty is to formulate the 
computational principles that underlie perceptual belief updating and response 
modulation, and identify the neurophysiological implementation of those computations in 
the brain (Daunizeau et al., 2010a). Indeed, combining formal models of learning and 
behaviour with the measurement of neural signals has brought significant advances to 
behavioural neuroscience in recent years (Daw et al., 2011; Takahashi et al., 2011; 
Iglesias et al., 2013). 
3.2.1 Capturing the computational principles that underlie learning and action 
Two classes of models that have been applied in an effort to infer the computational 
underpinnings of learning and action within the brain take inspiration from reinforcement 
learning and Bayesian learning principles. 
3.2.1.1 Reinforcement learning models 
Reinforcement learning (RL) models seek to capture how individuals learn to optimise 
their behaviour in a given environment by predicting the consequences of their actions 
(Sutton and Barto, 1998; Dayan and Niv, 2008). Inspired by classical conditioning 
(Peterson, 2004), RL rests upon the notion that humans and other animals learn when 
an event deviates from its expectations, i.e., it is surprising. As such, under RL models, 
learning (i.e., belief updating) is driven by prediction errors (PEs), which are formalised 
as the difference between predicted and actual outcomes. By computing PEs, individuals 
are proposed to use their experience of the environment to construct an internal model 
of the associations between stimuli, actions and rewards. Individuals select appropriate 
actions by searching this internal model space, thereby facilitating the execution of 
adaptive motor responses to environmental events. Within this framework, an individual 
3. Modelling individual learning and action under uncertainty 
71 
 
can learn to predict environmental outcomes based on sensory cues, and engender 
actions that will maximise their chance of gaining reward and minimise their chance of 
punishment. 
A particularly influential RL model has been that constructed by Rescorla and Wagner 
(Rescorla and Wagner, 1972). It prescribes that beliefs are updated in relation to an 
individual’s pre-existing belief and their current PE, weighted by a learning rate: 
𝜇𝑛 =  𝜇𝑛−1 + 𝛼(𝑥𝑛 −  𝜇𝑛−1), 
Equation 3.1 
where 𝜇𝑛 is the current belief, 𝜇𝑛−1  is the belief before making a new observation, 𝛼 is 
the learning rate, and (𝑥𝑛 −  𝜇𝑛−1) is the prediction error, i.e. the difference between the 
new observation, 𝑥𝑛 and the existing belief, 𝜇𝑛−1.  
The key advantages of the Rescorla-Wagner (RW) model are its conceptual simplicity 
and computational efficiency; it provides a capable account of how individuals build a 
primitive model of the world, associating environmental stimuli with their predictors. 
Moreover, because the learning rate determines the degree to which each PE influences 
existing beliefs, it modulates the relative influence of recent compared to past events on 
learning. 
However, a fixed learning rate means that individuals will only take into account a fixed 
number of previous observations when making new beliefs. Since the world is dynamic, 
and given that changes within different environmental contexts occur at different rates, 
individuals require a means by which to account for changes in environmental 
uncertainty. For instance, noisy but otherwise stable environments require low learning 
rates, which result in stable beliefs, whereas volatile environments necessitate higher 
learning rates and more flexible beliefs (Behrens et al., 2007; Nassar et al., 2010). There 
have been various efforts to extend the RW model by developing an adaptive learning 
rate that allows for flexible belief updating under varying degrees of environmental 
uncertainty (Kalman, 1960; Sutton, 1992; Nassar et al., 2010; Mathys et al., 2011; 
Payzan-LeNestour and Bossaerts, 2011; Wilson et al., 2013). Importantly, by allowing 
learning rates to vary across individuals and environmental contexts, a flexible RL 
framework can capture action selection that is adaptive to the changes inherent in 
dynamic environments. 
An alternative instantiation of RL is temporal difference (TD) learning. TD models extend 
the concept that PEs drive learning by incorporating an additional feature of learning 
commonly included in engineering algorithms, that of prediction (Sutton and Barto, 
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1981). Specifically, TD models utilise changes, or differences, in predictions over time to 
drive learning. This means that, whereas RW models describe the association between 
a predictor and an immediate outcome, TD learning assumes that individuals seek to 
find the earliest valid predictor of a variable of interest and continually adjust predictions 
in light of new evidence. A particular focus of TD learning has been capturing how 
individuals make optimal predictions so that they can select actions that will maximise 
their cumulative future reward (Sutton and Barto, 1998). 
Importantly, there is evidence to suggest that RL may be implemented neuronally. For 
instance, the signalling of PEs required for RL (Sutton, 1988) has been linked to the 
phasic activity of DA neurons (Montague et al., 1996). In particular, RL approaches have 
been central to postulates about electrophysiological and functional neuroimaging 
measures of brain activity during reward learning, with DA having been proposed to 
encode reward PE (Schultz et al., 1997; Montague et al., 2004; O’Doherty et al., 2004; 
Daw and Doya, 2006; D’Ardenne et al., 2008; Hart et al., 2014; Rutledge et al., 2014, 
2015). Alternative lines of research have linked DA to the signalling of sensory PE in the 
absence of reward, and to consequent influences on action selection (Friston et al., 2012; 
Galea et al., 2012; Bestmann et al., 2014). In both cases, RL has been influential in 
guiding hypotheses about behavioural and neural dynamics under different experimental 
learning paradigms.  
In sum, the major benefit of RL methods is their capacity to reduce a daunting problem 
to a series of simple update equations that are both intuitively appealing and 
computationally feasible. This approach, and its influence on fields ranging from 
electrophysiology through to cognitive neuroscience and artificial intelligence, has 
guided our understanding of learning. RL models also offer a useful computational 
framework for investigations of anticipatory action selection and adaptive behaviour 
(Killcross and Coutureau, 2003; Matsumoto and Tanaka, 2004; Balleine, 2005; Dolan, 
2007; Rushworth and Behrens, 2008), as well as the neuromodulatory contributions to 
these processes (Yu and Dayan, 2005; Pessiglione et al., 2006; Doya, 2008). Moreover, 
their non-normative, descriptive nature allows for modelling aberrant modes of learning 
that occur in disease states such as schizophrenia or depression (Smith et al., 2006; 
Frank, 2008; Murray et al., 2008; Dayan and Huys, 2009). 
Nonetheless, RL has its limitations. First, from a theoretical perspective, it is a heuristic 
approach that does not follow from the principles of probability theory that would be 
expected to support optimal learning. Second, at a practical level, RL often performs 
badly in real-world situations where environmental states and the outcomes of actions 
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are not known to the individual but must be inferred or learned. Third, RL models do not 
permit an explicit representation of uncertainty, which appears a shortcoming. Indeed, a 
strong line of argument from probability theory suggests that learning would be improved 
if the brain were to represent beliefs as probability distributions, whose variance 
inherently capture uncertainty, rather than single quantities (O’Reilly et al., 2012).  
To illustrate the advantage of capturing uncertainty for optimal belief updating, we can 
consider a coin toss. In this scenario, we know that the probability of observing heads on 
each toss is 0.5. If we bet that the outcome of an upcoming coin flip will be heads, at 
outcome we experience a (reward) PE, which is positive (+0.5) if the outcome is heads 
or negative (-0.5) if it is tails. Thus, even in situations where we have a pre-existing model 
of the environment and there is nothing left to learn, we experience PEs.  
If we start with the assumption that the coin is unbiased, this implies that after 100 coin 
flips, we have learned nothing. We are now very sure that the coin is unbiased but, 
because RL does not explicitly capture uncertainty, it does not offer a means to represent 
this confidence. This seems wasteful from a neurophysiological perspective; supposing 
DA signals the PE that follows each coin toss, the neuromodulator will be promoting 
neuronal plasticity in a situation where this is nothing to left to learn (Yu and Dayan, 
2005). Although suggestions have been made as to how RL models might be modified 
to account for this (Preuschoff and Bossaerts, 2007), it is generally thought that this is a 
limitation of this class of models (Daw and O’Doherty, 2013). To incorporate an explicit 
representation of uncertainty, and therefore improve models of learning and behaviour, 
researchers have turned to Bayesian statistics (Gershman and Niv, 2010). 
3.2.1.2 Bayesian learning 
The optimal method for learning from new information was first described by Laplace, 
who set out the laws of inductive inference (Laplace, 1774, 1812). Inductive reasoning 
is inherently uncertain; it concerns the degree to which a conclusion is credible according 
to a particular set of evidence. The mechanism by which conditional probabilities are 
updated in inductive inference was later formally described by Bayes’ theorem: 
𝑃(𝐴|𝐵) =  
𝑃(𝐵|𝐴)𝑃(𝐴)
𝑃(𝐵)
 
𝑃(𝐴|𝐵)  ∝ 𝑃(𝐵|𝐴)𝑃(𝐴) 
𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 ∝ 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑥 𝑝𝑟𝑖𝑜𝑟 
Equation 3.2 
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where A and B are events and P(B)≠0.  
As such, inductive inference has become more commonly known as Bayesian inference, 
or Bayesian learning. Bayesian inference prescribes that the statistically optimal strategy 
to learning in uncertain environments is to integrate the multiple sources of uncertain 
information with a weight inversely proportional to their uncertainty. It seems likely that 
this approach would require an individual’s beliefs to be represented as probability 
distributions (O’Reilly et al., 2012; Pouget et al., 2013). Assuming that these probability 
distributions are Gaussian, the mean of the distribution would capture an individual’s best 
guess at the value of a particular variable, i.e., its most probable value. The width, or 
variance, of the distribution would correspond to the uncertainty associated with the 
representation of that variable. The combination of multiple sources of information 
produces a probability density function with a variance smaller than that of either of the 
inputs (Figure 3.1) according to the following equation: 
𝜎𝑡𝑜𝑡𝑎𝑙 =  
𝜎1𝜎2
𝜎1 + 𝜎2
, 
Equation 3.3 
where 𝜎𝑥 is the variance associated with the probability distribution 𝑥. 
Importantly, there is convincing evidence that individuals combine sources of information 
in this manner. Indeed, in contrast to the aforementioned popularity of RL approaches in 
studies of reward learning, Bayesian strategies have been more widely applied in the 
field of sensorimotor control. For instance, researchers have demonstrated that 
Bayesian integration of this nature is a good predictor of individuals’ performance when 
estimating the height of a bar from noisy visual and haptic information (Ernst and Banks, 
2002), when estimating the position of a noise source from visual and auditory cues 
(Battaglia et al., 2003), and in guiding movements (Körding and Wolpert, 2004). 
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Figure 3.1 Integrating multiple sources of evidence. Under Bayesian inference, 
combining multiple sources of uncertain information produces a probability density 
function with a variance smaller than that of its inputs. For instance, in an experiment 
conducted by Ernst and Banks, individuals were required to estimate the height of a bar 
according to noisy visual and haptic information. Integrating these two sources of 
sensory evidence according to their uncertainty, here represented as the width of a 
probability density function (𝜎), produces a combined estimate with a lower variance than 
either of the two inputs (𝜎𝑐𝑜𝑚𝑏𝑖𝑛𝑒𝑑 < 𝜎𝑣𝑖𝑠𝑢𝑎𝑙 <  𝜎ℎ𝑎𝑝𝑡𝑖𝑐). A model implementing Bayesian 
integration of this nature was shown to be a good predictor of individuals’ performance 
of the task.  Figure adapted from Ernst and Banks, 2002.  
Bayesian inference does not only offer a means for combining multiple sources of 
uncertain sensory input. As set out in Equation 3.2, Bayes’ theorem also provides a way 
to optimally incorporate current sensory evidence with prior beliefs. To borrow a popular 
example from Körding and Wolpert, consider a tennis player preparing to return an 
approaching ball (Figure 3.2). Anticipatory preparation of an adaptive motor response to 
the ball hitting the ground requires an optimal prediction as to where the ball will bounce. 
To formulate this prediction, the player must consider both his bottom-up sensory input 
and his top-down experience-driven beliefs (Körding and Wolpert, 2004). Under ideal 
Bayesian learning, his posterior belief about where the ball is likely to bounce is 
determined by optimally integrating the likelihood of his sensory evidence (i.e., his 
current visual and auditory input) and his prior knowledge of the typical distribution of 
tennis shots:  
𝑃(𝑏𝑎𝑙𝑙 𝑎𝑡 𝑥|𝑝𝑒𝑟𝑐𝑒𝑝𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑎𝑙𝑙 𝑎𝑡 𝑥)  ∝ 𝑃(𝑝𝑒𝑟𝑐𝑒𝑝𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑎𝑙𝑙 𝑎𝑡 𝑥|𝑏𝑎𝑙𝑙 𝑎𝑡 𝑥)𝑃(𝑏𝑎𝑙𝑙 𝑎𝑡 𝑥) 
Equation 3.4 
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The posterior, prior and likelihood are represented as probability distributions, meaning 
they are inherently associated with an uncertainty. The prior and likelihood are integrated 
according to their relative uncertainties.  
 
 
 
Figure 3.2 Integrating priors and likelihoods over time. A Bayesian tennis player 
preparing to return an approaching ball can optimally predict the likely landing location 
of his opponent’s shot by combining the ball’s observed trajectory with the prior 
distribution of shot placement. (A) A schematic of a Kalman filter. At any point in time, 
the player holds a belief about the state of the world. This belief is updated with a model 
of the dynamics of the world to calculate the belief at the next point in time. The belief 
(prior; green patch) is then combined with new sensory information (likelihood; red patch) 
using Bayes’ rule to calculate the belief at the next point in time. (B) To predict the 
position at which the ball will hit the ground, the player continuously updates his belief in 
line with incoming sensory information. The posterior at the previous time point is the 
prior for the current time point. Figure adapted from Körding, 2007.  
Since Bayesian learners integrate their prior knowledge with new information optimally, 
they would be expected to make better predictions and thus have an evolutionary 
advantage over non-Bayesian learners. It therefore seems reasonable to hypothesise 
that the human brain has evolved such that it implements ideal Bayesian learning, i.e., 
inference on uncertain quantities according to the rules of probability theory (Geisler and 
Diehl, 2002). At least from a theoretical perspective, this conceptual framework seems 
well suited to describing information processing in the brain (Knill and Pouget, 2004; 
Tenenbaum et al., 2006; Körding, 2007). Further, there is considerable evidence from 
studies on various domains of learning and perception that human behaviour is better 
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described by Bayesian models than by other theories (Ernst and Banks, 2002; Battaglia 
et al., 2003; Körding and Wolpert, 2004; Bresciani et al., 2006; Yuille and Kersten, 2006; 
Behrens et al., 2007; Xu and Tenenbaum, 2007; Orbán et al., 2008; den Ouden et al., 
2010), and that human behaviour is close to Bayes optimal in tasks requiring multimodal 
cue integration and motor adaptation (Yu, 2007; Yu et al., 2009). 
Owing to the environment’s volatility, the reliability of a prior belief may change over time. 
In dynamic environments, old beliefs should be rapidly down-weighted relative to new 
evidence. In stable environments, old information is still valuable. Representing beliefs 
as probability distributions offers Bayesian learners a means by which to learn and adapt 
to environmental volatility, with higher uncertainty in dynamic environments reflected by 
a broader distribution over possible perceptual estimates. In line with this, Behrens et al. 
demonstrated that humans indeed track environmental volatility, thereby allowing them 
to learn quickly in dynamic environments, rapidly overwriting old beliefs, but to be more 
reliant on older information when the environment is stable (Behrens et al., 2007). 
Learning rates were found to vary systematically with the volatility of an environment’s 
underlying statistical structure, precisely as would be expected in a Bayesian learner. 
Indeed, comparing the ability of different models to account for individuals’ behaviour in 
volatile environments revealed that an optimal Bayesian learner model outperformed an 
RL model, despite the latter being tuned to fit the data via free parameters. 
However, developing computationally efficient, ecologically valid Bayesian learning 
models has proven challenging for several reasons. First, in most complex, real-world 
environmental settings, modelling Bayesian learning involves computationally-
demanding, high-dimensional integrals, making online belief updating difficult. An 
important consideration, therefore, is whether any evolutionary advantage conferred by 
optimal learning in humans might actually be outweighed by these computational costs. 
Related, we do not currently have a precise framework with which to precisely describe 
how ideal Bayesian learning, with its requirement for complex integrals, would be 
implemented neuronally, although there are ongoing efforts to establish underlying 
mechanisms, such as spiking neural networks (Deneve, 2007) and probabilistic 
population coding models (Sanger, 1996; Pouget et al., 2003; Ma et al., 2006; Yang and 
Shadlen, 2007; Beck et al., 2008; Ma and Jazayeri, 2014).  
In addition, despite evidence that humans and other animals demonstrate considerable 
inter-individual variability in learning and action, even under carefully controlled 
experimental conditions (Gluck et al., 2002; Daunizeau et al., 2010b), many Bayesian 
models are agnostic to inter-individual variability. There have been some attempts to 
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construct Bayesian models capable of capturing inter-individual variability (Steyvers et 
al., 2009; Nassar et al., 2010). Nonetheless, the failure of traditional Bayesian learning 
theory to account for these individual differences remains a key problem for 
understanding (mal)adaptive learning and action in humans. 
 Advantages Disadvantages 
Reinforcement 
learning 
models 
 Simple update equations are 
computationally feasible 
 Intuitive framework for 
investigations of learning 
and adaptive behaviour 
 Non-normative nature allows 
for modelling of aberrant 
modes of learning 
 Heuristic approach 
 Not grounded in probability 
theory 
 Often perform badly in real-
world situations where 
environmental states and 
outcomes are not known in 
advance 
 Do not capture uncertainty 
 
Bayesian 
learning 
models 
 Capture the optimal method 
for integrating multiple 
sources of new information 
and prior knowledge 
 Grounded in probability 
theory 
 Capture uncertainty of 
beliefs 
 Computationally 
demanding, making online 
learning difficult 
 Currently unclear how they 
would be implemented 
neuronally 
 Many models are agnostic 
to inter-individual variability 
 
Table 3.1 The advantages and disadvantages of different learning models.  
3.3 The Hierarchical Gaussian Filter 
In 2011, Mathys et al. developed the Hierarchical Gaussian Filter (HGF) model as a 
generic hierarchical Bayesian framework for individual learning under the various forms 
of uncertainty inherent in dynamic environments (Mathys et al., 2011, 2014). The HGF 
takes inspiration from RL schemes and aims to overcome the limitations of Bayesian 
approaches, namely their computational complexity and failure to capture differences in 
learning across individuals. It uses variational Bayes under mean-field approximation to 
derive trial-wise update equations that are analytical and efficient, allowing for real-time 
learning. A novel approximation to the conditional probabilities over unknown quantities 
replaces the conventional Laplace approximation used in Bayesian schemes. The form 
of the update equations is similar to those used in RW learning, meaning the HGF 
provides a Bayesian analogue to, and has a natural interpretation in terms of, RL. 
The HGF is an extension of a model proposed by Daunizeau et al., which quantifies the 
likelihood of an individual’s observed behaviour based on Bayes-optimal inferences in 
probabilistic environments (Daunizeau et al., 2010b). It also draws inspiration from the 
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aforementioned work by Behrens et al. so as to capture alterations in learning under 
environmental volatility (Behrens et al., 2007). Briefly, the original instantiation of the 
HGF comprises a perceptual model that tracks an individual’s learning of the underlying 
structure of the environment. The perceptual model has two components: a generative 
model and a recognition model. The generative model comprises a set of probabilistic 
assumptions that describe how sensory signals in the environment are generated. The 
recognition model captures the unobservable inference process made by an individual 
based on these sensory signals. It does this by performing (approximate) statistical 
inference on the observations of the actual sensory data and thus determining the 
probability distribution over variables in the generative model appropriate to those 
particular observations. 
3.3.1 Perceptual model 
The perceptual model makes it possible to quantify the inferences individuals make 
during an experimental learning task with known sensory signals, and to decompose the 
contributions of different forms of uncertainty to those inferences. In contradistinction to 
models that assume that individuals fashion the generative process to the task at hand 
(see the General Discussion for details), the HGF offers an inclusive scheme for 
explaining learning that generalises to a multitude of situations requiring inference about 
the state of the world.  
3.3.1.1 Generative model 
The HGF’s generative model describes how the hidden environmental states of the 
world, 𝑥, generate sensory inputs, 𝑢, across three hierarchical levels (Figure 3.3).  
Hierarchical Bayesian models have proven powerful for explaining learning in volatile 
probabilistic environments (Behrens et al., 2007; den Ouden et al., 2010; Nassar et al., 
2010; Wilson et al., 2013). In the case of the HGF, level 1 concerns trial-wise sensory 
outcomes, level 2 the probabilistic relationship between sensory outcomes and their 
predictive cues, and level 3 the volatility of this probabilistic relationship over time. 
The original instantiation of the HGF models an environment in which trial-wise sensory 
outcomes are of a binary form. Therefore, at level 1, the environmental state 𝑥1 at time 
t, denoted by 𝑥(𝑡) ∈ {0,1}, causes sensory input 𝑢(𝑡). This might capture whether a visual 
stimulus is black or white, an olfactory stimulus is present or not present, or, in the case 
of the probabilistic learning task used in Chapter 6, whether an auditory stimulus is a 
vocalisation of the word “cow” or the word “pig”. Accordingly, in what follows, the 
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likelihood model is assumed to take the following form (note that the time index t has 
been omitted here for simplicity): 
𝑝(𝑢|𝑥1) =  (𝑢)
𝑥1(1 − 𝑢)1−𝑥1 
Equation 3.5 
Thus, 𝑢 =  𝑥1 for both 𝑥1 = 1 and 𝑥1 = 0 (where 1 = stimulus type A; 0 = stimulus type 
B), and vice versa. As such, 𝑥1 captures the stimulus type. Knowing state 𝑥1 allows for 
an accurate prediction of input 𝑢. 𝑥1 is drawn from a Bernoulli distribution. The predicted 
probability of a particular sensory outcome is obtained by applying a sigmoid 
transformation to 𝑥2:   
𝑝(𝑥1|𝑥2) =  𝑠(𝑥2)
𝑥1(1 − 𝑠(𝑥2))
1−𝑥1 = Bernoulli(𝑥1; 𝑠(𝑥2)) 
Equation 3.6 
where 𝑠 is the logistic sigmoid function: 
     𝑠(𝑥) =  
1
1 + exp (−𝑥)
 
Equation 3.7 
Thus, 𝑥2 is mapped to the probability of 𝑥1 such that 𝑥2 = 0 means that 𝑥1 = 0 and 𝑥1 =
1 are equally probable. 
At level 2, 𝑥2 represents the probabilistic relationship between sensory cues and 
outcomes, in logit space. This could be, for instance, the conditional probability of an 
auditory outcome stimulus given an auditory cue (i.e., the cue:outcome contingency). It 
is an unbounded real parameter of the probability that 𝑥1 = 1: 
𝑝 (𝑥2
(𝑡)|𝑥2
(𝑡−1), 𝑥3
(𝑡)) =  Ν (𝑥2
(𝑡)
;  𝑥2
(𝑡−1)
, exp (𝑥3
(𝑡)
+ 𝜔)) 
Equation 3.8 
At level 3, 𝑥3 represents the (log-)volatility of the environment: 
𝑝 (𝑥3
(𝑡)|𝑥3
(𝑡−1), 𝜗) =  Ν (𝑥3
(𝑡)
;  𝑥3
(𝑡−1)
, 𝜗) 
Equation 3.9 
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Figure 3.3 A schematic representation of the HGF’s generative model. Left: 𝑥1
(𝑡)
,  
𝑥2
(𝑡)
 and 𝑥3
(𝑡)
 are hidden states of the environment at time t. 𝑥1
(𝑡)
represents the sensory 
outcome on the current trial, 𝑥2
(𝑡)
 the probability of that outcome given a preceding 
sensory cue, and 𝑥3
(𝑡)
 the volatility of the probabilistic relationship between cues and 
outcomes. The hidden states generate the sensory input at time t, 𝑢(𝑡).The hidden states 
at levels 2 and 3 are dependent on their immediately preceding values, 𝑥2
(𝑡−1)
 and 𝑥3
(𝑡−1)
, 
and two participant-specific parameters, ϑ and ω, that link the hierarchical levels. Right: 
The probability of the hidden state at each level is determined by the variables and 
parameters at the next highest level. At level 1, 𝑥1 determines the probability of the input 
𝑢. At levels 2 and 3, the hidden states evolve as Gaussian random walks, with 
participant-specific step sizes. At level 2, the step size of the Gaussian random walk is 
captured by the variance exp(𝑥3+ω) of the conditional probability. At level 3, the step size 
is captured by ϑ. Figure adapted from Mathys et al. 2011.  
At levels 2 and 3, the states evolve in time as Gaussian random walks, with each walk’s 
step size determined by the next highest level of the hierarchy. For the sake of generality, 
3. Modelling individual learning and action under uncertainty 
82 
 
the HGF makes no assumptions about the probabilities of 𝑥2
(𝑡)
 or 𝑥3
(𝑡)
, except that they 
may change over time as Gaussian random walks. This means that the values of 𝑥2
(𝑡)
 
and 𝑥3
(𝑡)
 will be normally distributed around their values at the preceding time point, 𝑥2
(𝑡−1)
 
and 𝑥3
(𝑡−1)
 respectively. Importantly, the HGF does not assume fixed “ideal” learning 
across individuals but rather contains participant-specific parameters that couple the 
hierarchical levels and allow for individual expression of (approximate) Bayes-optimal 
learning. 
Specifically, the dispersion of the random walk at level 2 (i.e., the variance exp(𝑥3+ω) of 
the conditional probability; Equation 3.8) is determined by both the participant-specific 
parameter ω and state 𝑥3 (c.f. Behrens et al., 2007, 2008). ω is a constant component 
of volatility that captures how rapidly an individual generally updates their beliefs about 
probabilistic relationships within the environment. As such, a higher ω would lead an 
individual to update their beliefs about environmental contingencies more rapidly, 
resulting in a faster tonic learning rate. 𝑥3 captures the environment’s phasic volatility, 
which can vary over time. Introducing ω therefore allows for a participant-specific tonic 
component of volatility that scales independently of state 𝑥3. The higher the volatility, the 
larger the step-size of the Gaussian walk at level 2. Note that the original instantiation of 
the HGF includes an additional participant-specific parameter, κ, which scales state 𝑥3, 
and hence modulates coupling between levels 2 and 3. In all applications of the HGF in 
this thesis, κ was held constant at 1 (Vossel et al., 2014a, 2014b, 2015; de Berker et al., 
2016). 
At level 3, the step-size of the Gaussian walk is determined by the participant-specific 
parameter ϑ, which captures the volatility of state 𝑥3 (Equation 3.9). ϑ therefore 
determines the speed of learning about volatility, i.e., the rate at which estimates of the 
environment’s phasic volatility are updated. As such, ϑ encapsulates metavolatility, i.e., 
the rate at which volatility changes, with higher values leading to a Gaussian random 
walk with a larger step-size, and implying a belief in a more unstable world, in turn leading 
to a more variable learning rate at level 2. It is possible to add additional levels to the 
HGF’s perceptual model, in which case the step-size of the Gaussian random walk would 
be determined by both ϑ and the state at level 4, 𝑥4. Mirroring previous studies that have 
utilised the HGF to investigate hierarchical learning (Iglesias et al., 2013; Diaconescu et 
al., 2014, 2017; Hauser et al., 2014; Vossel et al., 2014a, 2014b, 2015; de Berker et al., 
2016), a three-level perceptual model was applied in this thesis. 
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3.3.1.2 Recognition model 
Based on their observations, 𝑥1, individuals form and update beliefs about the true states 
represented at each level of the HGF. These beliefs are captured by a recognition model. 
Under this recognition model, individuals infer the approximate posterior distributions 
over the states at levels 2 and 3. More precisely, trial by trial, individuals update their 
beliefs about the true quantities at each level, which at levels 2 and 3 are modelled by 
Gaussian distributions with a mean (𝜇) and variance (σ), the latter reflecting the 
uncertainty of the estimate. The recognition model captures irreducible uncertainty 
arising from the inherent randomness of the probabilistic relationships between cues and 
outcomes at level 1, estimation uncertainty arising from an individual’s incomplete 
knowledge of these probabilistic relationships at level 2, and volatility uncertainty arising 
from the instability of these relationships at level 3. 
Sufficient statistics of the Gaussian approximations are computed at each time-point. 
The resulting update equations resemble RW learning (c.f. Equation 3.1) and take the 
form: 
prediction(t) = prediction(t-1) + learning rate x prediction error, 
where t is the current time-point. 
Given the aforementioned body of work suggesting that RL may be implemented 
neuronally, Mathys et al. postulate that this property means that the belief updates have 
an ecologically valid interpretation. Specifically, the HGF parameters that determine 
learning may relate to specific physiological processes, such as the neuromodulation of 
synaptic plasticity (Mathys et al., 2011). For instance, it has been hypothesised that 
dopamine, which regulates the plasticity of glutamatergic synapses (Gu, 2002), may 
encode the precision (i.e., the inverse variance, or inverse uncertainty) of PEs (Friston, 
2009). As I will describe later, precision-weighting of PEs occurs within the HGF’s 
computational framework. The HGF therefore offers a useful model-based approach to 
probing participant-specific computational and neurophysiological mechanisms of 
learning under uncertainty. Moreover, the dynamic learning rates that result from 
coupling the HGF’s different levels allow for the adaptation necessary in volatile 
environments (Behrens et al., 2007; den Ouden et al., 2010).  
Since the integrals arising in the recognition model are intractable, inference in the HGF 
is approximate. Variational Bayesian inversion determines the posterior distributions by 
maximising the log-model evidence, which corresponds to the negative surprise about 
the data, given a model. It is approximated by a lower bound, namely the negative free 
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energy (Beal, 2003; Friston and Stephan, 2007), building on the work of Friston et al. 
(Friston et al., 2006). 
3.3.2 Response model 
To link an individual’s posterior beliefs, as provided by the recognition model, to his/her 
actions, a response model that provides a complete mechanistic mapping from 
experimental stimuli to observed behavioural responses is required (Daunizeau et al., 
2010a, 2010b). This was a key focus of our novel instantiation of the HGF, which I 
describe in section 3.4. 
3.3.3 The merits and shortcomings of the HGF 
To summarise, the original instantiation HGF, with its constituent generative, recognition 
and response models, has the capacity to describe learning and action that is 
subjectively optimal in relation to an individual’s prior beliefs and sensory input. It is 
possible for this learning to be objectively maladaptive. Importantly, this means that the 
HGF can capture variations in learning across healthy individuals, as well as aberrant 
belief updating in individuals with conditions such as schizophrenia (Adams et al., 2016). 
Thus, the HGF’s approach to modelling learning and action may have potential clinical 
applications, including the development of diagnostic classifications of psychiatric 
spectrum disorders (Stephan et al., 2009a). The HGF has been successfully applied in 
several investigations of learning and action in volatile environments (Iglesias et al., 
2013; Diaconescu et al., 2014, 2017; Hauser et al., 2014; Vossel et al., 2014a, 2014b, 
2015; de Berker et al., 2016). In Chapter 6, I apply the original instantiation of the HGF 
to behavioural data recorded in individuals undertaking a probabilistic learning task with 
binary trial-wise outcomes. 
As mentioned above, the HGF was designed as an inclusive scheme for explaining 
learning that generalises to different situations requiring inference about the state of the 
world. However, modelling an environment in which all trial-wise sensory outcomes are 
of a binary form is clearly not representative of real-world scenarios. Further, the HGF’s 
perceptual model is not sufficient to elucidate the influence an individual’s perceptual 
beliefs has on action execution. 
As part of this thesis, I have worked on the development of a novel instantiation of the 
HGF. It features a perceptual model with the capacity to track an individual’s learning 
about multiple outcome types and a response model that quantifies the influence of that 
individual’s perceptual beliefs on their executed actions, specifically their RTs. Next, I 
describe how this novel instantiation of the HGF was applied to model individual learning 
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and action during the PSRTT utilised in Chapters 4 and 5. I also provide additional detail 
as to how individual learning and action is captured by the model. 
3.4 Developing a novel instantiation of the HGF 
To recap Chapter 2, the PSRTT required individuals to respond to the trial-wise 
presentation of one of four visual stimuli by pressing an appropriate button as quickly as 
possible. At any given time, the trial sequence was generated by one of eight transition 
matrices (TMs), which changed every 50 trials. In each case, there were 16 combinations 
that determined the probabilistic relationship between the stimuli presented on the 
current trial t, and the previous trial, t-1. The task design created contexts that 
participants could infer from their stimulus observations, allowing them to reduce their 
uncertainty about sensory events before they occurred  (Harrison et al., 2006). 
Nonetheless, the probabilistic nature of these contexts also produced unexpected 
stimulus outcomes, i.e., sensory PEs. For fast and accurate responses, participants had 
to track irreducible uncertainty arising from the inherent randomness of the probabilistic 
transitions between consecutive stimuli; estimation uncertainty arising from their 
imperfect knowledge of the probabilistic relationships governing stimulus transition 
contingencies within contexts; and volatility uncertainty maintained by the unsignalled 
contextual instability. 
The novel instantiation of the HGF has a focus on transition matrices and includes two 
components: a three-level perceptual model and a response model (Figure 3.4). The 
relevant Matlab code has been incorporated into the HGF Toolbox, which is available for 
download from http://www.translationalneuromodeling.org/tapas/. The perceptual model 
encompasses a generative model that describes how stimulus transitions were 
generated and a recognition model that captures an individual’s unobservable beliefs 
about these transitions. Since beliefs modulate behaviour, it is possible to reverse 
engineer an individual’s observed actions (here trial-wise log(RTs)) to infer their beliefs. 
A response model was developed to predict normally-distributed log(RTs) from 
parameters in the recognition model (Daunizeau et al., 2010a). 
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Figure 3.4 A novel instantiation of the HGF. The perceptual model tracks an 
individual’s learning of the PSRTT’s structure across three levels. State 𝒙1 represents 
trial-wise stimulus transitions from one stimulus to the next, 𝒙2 the transition 
contingencies, and 𝑥3 the phasic volatility of these contingencies, where t is the current 
trial number. Participants hold and update beliefs about the true quantities at each level, 
with a mean μ and a variance σ. ϑ and ω are participant-specific parameters that couple 
the levels and determine the respective speed of belief updating about phasic volatility 
and transition contingencies. The response model describes the mapping from a 
participant’s trial-wise beliefs onto their observed log(RT) responses.   
3.4.1 Perceptual model 
The perceptual model is a variant of the HGF as introduced by Mathys et al. (Mathys et 
al., 2011, 2014). It comprises a generative model and a recognition model, and thus 
tracks a participant’s learning of the task’s structure in a similar way to previous studies 
using the HGF (Iglesias et al., 2013; Diaconescu et al., 2014, 2017; Hauser et al., 2014; 
Vossel et al., 2014a, 2014b, 2015; de Berker et al., 2016). 
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3.4.1.1 Generative model  
Unlike previous applications of the HGF, in the novel instantiation the sensory data are 
observed transitions between stimuli that arise from a sequence of environmental states 
(𝒙1), where bold font is used to indicate a matrix. In the PSRTT (Figure 2.1), the jk
th 
element of 𝒙1 is the transition from stimulus k to stimulus j, the probability of which 
participants must learn to perform the task well. There are 16 possible transitions induced 
by the trial-wise presentation of one of four visual stimuli, meaning that 𝒙1 is a four-by-
four matrix. On each trial, an individual observes a sample from one column of the 
transition matrix. Therefore, the current transition in the corresponding column of 𝒙1 is 1, 
with all other elements in that column equal to zero. 
The generative model has two further levels above 𝒙1. Level 2 is a four-by-four matrix 𝒙2 
of real numbers governing the transition contingencies. These undergo random walks 
with increments that are independent of each other. At level 3, 𝑥3 sets the variance of 
those random walks, and so the rate of change (or volatility) of the elements of 𝒙2. Since 
all elements are assumed to experience the same volatility (c.f. Mathys et al. 2011; 
2014), 𝑥3 is a scalar. Collectively, 𝒙2 and 𝑥3 capture stimulus transitions and their 
changes over time (albeit represented heuristically as a continuous random walk in logit 
space with a bijective mapping to the probability of specific discrete changes). More 
specifically, a sample of 𝒙1 is generated by applying a logistic sigmoid transformation to 
the column of 𝒙2 associated with the stimulus that was previously shown to generate a 
probability distribution over the four possible next stimuli. A sample is then drawn from 
that distribution. 
Thus, level 1 of the HGF represents a sequence of environmental states 𝒙1 (here the 
presentation of one of four stimuli). Level 2 represents the transition contingency 𝒙2 (i.e., 
the conditional probability, in logit space, of the stimulus on trial t given the stimulus 
presented on trial t-1). 𝑥3 represents the phasic volatility. The hidden states at levels 2 
and 3 are assumed to evolve as a Gaussian random walk, such that their variance 
depends on the state at the level above: 
𝑝(𝑥1,𝑗𝑘|𝑥2,𝑗𝑘) =  𝑠(𝑥2,𝑗𝑘)
𝑥1,𝑗𝑘 (1 − 𝑠(𝑥2,𝑗𝑘))
1−𝑥1,𝑗𝑘
= Bernoulli (𝑥1,𝑗𝑘; 𝑠(𝑥2,𝑗𝑘)) 
Equation 3.10 
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𝑝 (𝑥2,𝑗𝑘
(𝑡) |𝑥2,𝑗𝑘
(𝑡−1), 𝑥3
(𝑡)) =  Ν (𝑥2,𝑗𝑘
(𝑡)
;  𝑥2,𝑗𝑘
(𝑡−1)
, exp (𝑥3
(𝑡)
+ 𝜔)) 
Equation 3.11 
𝑝 (𝑥3
(𝑡)|𝑥3
(𝑡−1), 𝜗) =  Ν (𝑥3
(𝑡)
;  𝑥3
(𝑡−1)
, 𝜗) 
Equation 3.12 
where 𝑥1,𝑗𝑘 and 𝑥2,𝑗𝑘 (with j,k=1,…,4) are the elements of the level 1 transition matrix 𝒙1 
and of the level 2 matrix 𝒙2 respectively, and 𝑠 is the logistic sigmoid function previously 
defined in Equation 3.7.  
3.4.1.2 Recognition model 
The recognition model takes observations of 𝒙1 and infers approximate posterior 
distributions over the values of 𝒙2 and 𝑥3. This amounts to a variant of predictive coding 
in which beliefs are dynamically updated across the levels via PEs that are weighted by 
their salience, or expected precision (equivalent to inverse variance, or uncertainty). 
Estimates of stimulus transition contingencies correspond to the posterior distribution 
over 𝒙2 and are updated by PEs about stimulus occurrences. Estimates of environmental 
volatility, i.e., the posterior distribution over 𝑥3, are updated in proportion to PEs about 
the transition contingencies. Thus, the effective learning rate is influenced by uncertainty 
about current beliefs and environmental instability. 
As in the original instantiation of the HGF, trial by trial, participants update their beliefs 
about the true quantities at each level, which at levels 2 and 3 are modelled by Gaussian 
distributions with a mean (𝜇) and variance (σ), the latter reflecting the uncertainty of the 
estimate. Precision (?̂?) of the prediction is equal to the inverse variance (1/?̂?), where the 
hat denotes the participant’s predicted estimate before seeing the stimulus outcome on 
each trial. At level 1, when the elements of 𝒙2 are each transformed by the logistic 
sigmoid to produce probabilities ?̂?1, there is irreducible uncertainty (the participant’s 
estimate of which is captured by ?̂?1). Irreducible uncertainty, which gets its name since 
it is undiminished by learning (Payzan-LeNestour and Bossaerts, 2011), arises from any 
probabilistic relationship, and is closely related to entropy, with an inverted-U relationship 
to probability that peaks at p=0.5. The quantity gives rise to sensory PE (𝜹1) following 
the presentation of an unexpected, or surprising, stimulus that would require a participant 
to respond against their expectation: 
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    𝛿1,𝑗𝑘
(𝑡) =  𝜇1,𝑗𝑘
(𝑡) − ?̂?1,𝑗𝑘
(𝑡)
 
Equation 3.13 
where the prediction ?̂?1
(𝑡)
 about stimulus outcome results from a sigmoidal transformation 
of the previous belief about the stimulus transition contingency 𝝁2
(𝑡−1)
: 
    ?̂?1,𝑗𝑘
(𝑡) = 𝑠(𝜇2,𝑗𝑘
(𝑡−1)
) 
Equation 3.14 
Note that column-wise normalisation of ?̂?1 is not enforced (i.e., the columns do not 
necessarily add up to one, as they would have to in order to represent a probability 
distribution over mutually exclusive events). Ensuring that the probabilities sum to one 
would arguably require a sort of certainty about the stimuli that participants do not 
necessarily have when performing the behavioural task; for instance, it would require 
precise a priori knowledge that each and every trial will present exactly one of four stimuli 
and that there is no possibility of novel stimuli occurring during the experiment. In 
practice, the statistics governing the sensory events that occur in the PSRTT ensure that 
column sums of participants’ ?̂?1 estimates never stray far from unity. 
At level 2, 𝝈2 which is informational in origin, represents estimation uncertainty about the 
true probabilistic relationships governing stimulus transitions, giving rise to a more 
abstract contingency PE (𝜹2). At level 3, volatility uncertainty arises from the 
environment’s volatility, i.e. how quickly the transition contingencies are changing. This 
is in contrast to 𝜎3, which represents the uncertainty about the volatility. 
Generally, at any level 𝑖 of the hierarchy, the update of the belief on trial t (i.e., posterior 
mean  𝜇𝑖
(𝑡)
 of the state 𝑥𝑖) is proportional to the precision-weighted PE, 𝜀𝑖
(𝑡)
. This weighted 
PE is the product of the upward-propagating PE, 𝛿𝑖−1
(𝑡)
, and a precision ratio, 𝜓𝑖
(𝑡)
, 
capturing the uncertainty about input from the level below relative to the uncertainty 
about the state of the level being updated (Iglesias et al., 2013). A general and 
didactically useful form of this precision-weighted PE (with subtle differences below level 
3; see Mathys et al. 2014) is: 
Δ𝜇𝑖
(𝑡) ∝ 𝜀𝑖
(𝑡) = 𝜓𝑖
(𝑡) 𝛿𝑖−1
(𝑡)
 
Equation 3.15 
where        
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𝜓𝑖
(𝑡)
 =
?̂?𝑖−1
(𝑡)
𝜋𝑖
(𝑡)
 
Equation 3.16 
Thus, precision-weighted sensory PE (𝜺2) about stimulus outcome is weighted by 
uncertainty at levels 1 and 2 and serves to update the belief about 𝒙2 (the stimulus 
transition contingency in logit space):  
    𝜇2,𝑗𝑘
(𝑡) −  𝜇2,𝑗𝑘
(𝑡−1) =  𝜓2,𝑗𝑘
(𝑡) 𝛿1,𝑗𝑘
(𝑡)
 
                      =  𝜀2,𝑗𝑘
(𝑡)
 
Equation 3.17  
At level 3, the update of the belief about 𝑥3 (phasic environmental (log-)volatility) is 
proportional to the precision-weighted contingency PE 𝜺3, which captures uncertainty at 
levels 2 and 3: 
    𝜇3
(𝑡) −  𝜇3
(𝑡−1) ∝  𝜓3,𝑗𝑘
(𝑡) 𝛿2,𝑗𝑘
(𝑡)
 
                             =  
?̂?2,𝑗𝑘
(𝑡)
𝜋3
(𝑡)
𝛿2,𝑗𝑘
(𝑡)
 
                   =  𝜀3,𝑗𝑘
(𝑡)
 
Equation 3.18 
Here, the PE concerns the volatility of the stimulus transition contingency, or more 
precisely, the variance ratio of its estimates (in logit space) after and before observing 
the sensory input, respectively: 
    𝛿2,𝑗𝑘
(𝑡)
=  
𝜎2,𝑗𝑘
(𝑡)
+ (𝜇2,𝑗𝑘
(𝑡) −  𝜇2,𝑗𝑘
(𝑡−1)
)2
𝜎2,𝑗𝑘
(𝑡−1)
+  𝑒𝜇3
(𝑡−1)+𝜔
 − 1 
Equation 3.19 
Importantly, like the original instantiation, the novel perceptual model includes two 
participant-specific parameters that couple the hierarchical levels and allow for individual 
expression of approximate Bayes-optimal learning (Figure 3.4). The first of these 
parameters is ϑ, which determines the speed of learning about the volatility of the 
environment, i.e. the rate at which estimates of trial-wise phasic volatility (𝜇3) are updated 
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(Equation 3.12). The second, ω, is a constant component of the learning rate at level 2 
that captures a tonic learning rate about the stimulus transition contingencies (Equation 
3.11).  
The punctate change-points contained in the true generative process are detected 
implicitly by the HGF via spikes in the precision weights. At levels 2 and 3, 𝛼𝑖
(𝑡)
 is 
proportional to the precision ratio, 𝜓𝑖
(𝑡)
, defined in Equation 3.16. At level 1, the learning 
rate 𝜶1 is simply defined as the update divided by the prediction error: 
𝜶1
(𝑡)
∝  
𝝁𝟐
(𝑡)
− ?̂?𝟏
(𝑡)
𝜹1
(𝑡)
 
Equation 3.20                                                                                 
As I will demonstrate in Chapter 4, the HGF implicitly captures punctate change-points 
in the PSRTT’s generative process as an increase in learning rate, 𝛼1, following a true 
change in context (Figure 3.5). 
 
Figure 3.5 Example learning rate (𝜶𝟏) trajectory. Increases in 𝛼1 are observed 
following a true change in context. As such, learning rate at level 1 of the HGF implicitly 
captures punctate change-points contained in the PSRTT’s generative process. Data are 
mean 𝛼1 for trials undertaken by Placebo participants in Chapter 4. For further details, 
see Figure 4.5.  
3.4.2 Response model  
As described above, in addition to the perceptual (generative + recognition) model, the 
novel instantiation of the HGF features a response model. Its purpose is to link estimates 
from the recognition component of the perceptual model to an individual’s actions during 
the PSRTT. A response model offers an important extension to the perceptual model by 
linking modulations of action execution to perceptual beliefs. Alternative response 
models have been added to the HGF previously (Vossel et al., 2014a, 2014b, 2015). The 
response model developed and applied in the present work describes the mapping from 
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a participant’s trial-wise beliefs, as provided by the perceptual model, onto his/her 
observed responses, log(RTs). 
I reasoned that there are several variables that could influence this mapping, and thus 
trial-wise log(RT). Therefore, I constructed and formally compared a range of response 
models using random effects Bayesian model selection (Stephan et al., 2009; Rigoux et 
al., 2014) and associated techniques for assessing differences in model frequencies 
across groups, as implemented in the VBA toolbox (Daunizeau et al., 2014). Further 
details of this model comparison are provided in Chapter 4. 
As we will see in Chapter 4, the winning response model (Equation 3.21) was a linear 
function prescribing that trial-wise log(RT) is determined by a constant component of RT 
(β0) and estimates arising from each level of the perceptual model: sensory PE (𝛿1) 
arising at level 1, precision-weighted contingency PE (𝜀3) arising at level 2, and trial-wise 
phasic volatility (𝜇3) arising at level 3. Additionally, as observed in previous work using 
similar RT tasks (Rabbitt, 1966; Botvinick et al., 2001; Gehring and Fencsik, 2001; 
Cavanagh et al., 2014), there was evidence of post-error slowing in the PSRTT, i.e., 
participants were slower to respond on a trial that followed an incorrect response. ζ is a 
noise term. 
log(RT)(t) =  β0 +  β1(δ1
(t)
)  +  β2(ε3
(t)
)  +  β3(μ3
(t)
)  +  β4(PostError
(t))  +  ζ(t) 
Equation 3.21 
While the perceptual model assumes that participants update their beliefs according to 
the stimulus presented on each trial, the response model incorporates correct trials only.             
3.4.3 Model fitting 
For each participant, individual maximum a posteriori estimates for perceptual and 
response model parameters were jointly obtained using the Broyden-Fletcher-Goldfarb-
Shanno algorithm as implemented in the HGF Toolbox. Where priors were required, they 
were defined by inverting the perceptual model in isolation, given the known stimulus 
sequence (using the function ‘tapas_bayes_optimal_whatworld_config’ contained in the 
TAPAS Toolbox), under suitably uninformative priors. The resulting posterior estimates 
were then used to define the priors for the subsequent inversion of the full model given 
the behavioural data. In other words, the prior means in the empirical data analysis 
corresponded to those parameter values for which the stimulus sequence would 
generate minimal surprise (in an observer with the aforementioned uninformative priors). 
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4 Pharmacological fingerprints of uncertainty 
This chapter is based on work presented in Marshall L, Mathys C, Ruge D, de Berker 
AO, Dayan P, Stephan KE & Bestmann S. (2016) Pharmacological fingerprints of 
contextual uncertainty. PLOS Biology. 14(11): e1002575. 
4.1 Abstract 
Successful interaction with the environment requires flexible updating of our beliefs about 
the world. By estimating the likelihood of future events, it is possible to prepare 
appropriate actions in advance and execute fast, accurate motor responses. According 
to theoretical proposals, individuals track the variability arising from changing 
environments by computing various forms of uncertainty. Several neuromodulators have 
been linked to uncertainty signalling, but comprehensive empirical characterisation of 
their relative contributions to perceptual belief updating, and to the selection of motor 
responses, is lacking. In this chapter, I assess the roles of noradrenaline (NA), 
acetylcholine (ACh) and dopamine (DA) within a single, unified computational framework 
of uncertainty. Using pharmacological interventions in a sample of 128 healthy human 
participants and a hierarchical Bayesian learning model, I characterise the influences of 
noradrenergic, cholinergic and dopaminergic receptor antagonism on individual 
computations of uncertainty during a probabilistic serial reaction time task. I propose that 
NA influences learning of uncertain events arising from unexpected changes in the 
environment, while ACh balances attribution of uncertainty to chance fluctuations within 
environmental contexts or to gross environmental violations following a contextual 
switch. In contrast, DA supports the use of uncertainty representations to engender fast, 
adaptive motor responses. 
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4.2 Introduction 
Adaptive performance in dynamic environments depends on our ability to represent and 
manipulate internal estimates of the world’s statistical structure (Conant and Ashby, 
1970; Körding and Wolpert, 2004; Yu and Dayan, 2005; Behrens et al., 2007). By 
tracking the environment’s underlying regularities, an individual can learn the causes of 
their sensory input and thus the likelihood that a particular event will occur. In turn, this 
permits anticipatory action preparation and the rapid execution of responses (Bestmann 
et al., 2008).  
However, the environment’s richly complicated sources of noise and latent structure 
present us with various forms of uncertainty. In Chapter 1, I introduced three distinct 
forms. First, irreducible uncertainty captures the randomness inherent in any complex 
environment and is undiminished by learning. Second, estimation uncertainty arises from 
an individual’s incomplete knowledge of the probabilistic relationships within the current 
environmental context. Third, volatility uncertainty arises from our beliefs about the 
stability of the environment, and thus how quickly probabilistic relationships are changing 
between contexts. Optimal learning, prediction and anticipatory action preparation 
require that these sources of uncertainty are taken into account (Ma and Jazayeri, 2014; 
Meyniel et al., 2015; Pouget et al., 2016). 
4.2.1 The brain computes different forms of uncertainty 
To recap Chapter 1, multiple lines of theoretical, behavioural and neurobiological 
evidence suggest that the brain indeed computes estimates of uncertainty relating to the 
environment’s sensory events, contextual associations and their changes over time 
(Averbeck et al., 2006; Ma et al., 2006; Behrens et al., 2007; den Ouden et al., 2010; 
Fiser et al., 2010; Mathys et al., 2011, 2014; Payzan-LeNestour and Bossaerts, 2011; 
Bach and Dolan, 2012; Bland and Schaefer, 2012; Friston et al., 2012; Iglesias et al., 
2013; Payzan-LeNestour et al., 2013; Vossel et al., 2014a, 2014b; de Berker et al., 2016; 
Diaconescu et al., 2017). It has been proposed that, with their broad distribution and 
extensive connectivity, the brain’s neuromodulatory networks are well-placed to facilitate 
the widespread changes in neuronal gain required to modulate the relative impact of top-
down prior expectations and bottom-up sensory evidence in light of uncertainty (Berridge 
and Waterhouse, 2003; Warren et al., 2016). In accordance with this notion, ACh and 
NA are known to enhance bottom-up, feedforward thalamocortical transmission of 
sensory information relative to top-down, intracortical and feedback processing 
(Hasselmo et al., 1996; Gil et al., 1997; Kimura et al., 1999; Kobayashi et al., 2000; Yu 
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and Dayan, 2002, 2005; Hasselmo and McGaughy, 2004; Sarter et al., 2005; Dayan and 
Yu, 2006a; Deco and Thiele, 2011; Moran et al., 2013), in turn promoting learning about 
the current environmental context (Yu and Dayan, 2003). 
4.2.1.1 A proposed role for acetylcholine under estimation uncertainty 
The application of two types of behavioural paradigm has offered more detailed insight 
into the relative roles played by NA and ACh in learning under uncertainty. Accordingly, 
ACh is thought to support learning within stable environmental contexts defined by 
particular rules. Here uncertainty arises from ignorance about, and the unreliability of, 
probabilistic relationships within the environment that predict upcoming sensory events. 
The learning of these relationships is modulated by pharmacological (Witte et al., 1997; 
Phillips et al., 2000a), surgical (Voytko et al., 1994; Chiba et al., 1999), and 
neurodegenerative (Parasuraman et al., 1992) manipulations of ACh. Moreover, activity 
in the human cholinergic basal forebrain has been shown to reflect an individual’s 
estimation uncertainty about contextual probabilistic relationships (Iglesias et al., 2013; 
Diaconescu et al., 2017), while pharmacological cholinergic stimulation under the drug 
galantamine increases the rate at which humans learn probabilistic relationships under 
estimation uncertainty (Vossel et al., 2014a). Together, these findings support the notion 
that ACh enhances learning accorded to stimuli with uncertain predictive consequences 
(Bucci et al., 1998) by boosting the contribution of bottom-up sensory processing relative 
to top-down prior expectations (Yu and Dayan, 2005). 
4.2.1.2 A proposed role for noradrenaline under environmental volatility 
While NA plays no consistent role in probabilistic learning within contexts (Clark et al., 
1989; Witte and Marrocco, 1997), it is thought to offer an interrupt signal when volatility 
uncertainty arises between contexts (Clark et al., 1989; Arnsten and Contant, 1992; 
Smith et al., 1992; Coull et al., 1995; Witte and Marrocco, 1997; Bouret and Sara, 2005; 
Dayan and Yu, 2006b). Learning to make accurate predictions from the strongly 
unexpected observations that follow a contextual switch necessitates heightened 
sensory vigilance and a disregard for outdated top-down expectations. NA, with its broad 
neural network capable of triggering multiple, simultaneous changes across the brain 
(Bouret and Sara, 2004), is well-placed to rapidly coordinate this process. Indeed, 
neurons in the locus coeruleus (LC), the primary source of cortical NA, show strong 
responses to unexpected environmental changes (Sara and Segal, 1991; Aston-Jones 
et al., 1997). Pharmacologically upregulating NA accelerates the detection of 
unexpected switches in the predictive properties of sensory stimuli (Devauges and Sara, 
1990), while noradrenergic deafferentation of rat medial frontal cortex impairs 
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behavioural adaptation to contextual switches (McGaughy et al., 2008). Moreover, BOLD 
activity in the human LC has been shown to dynamically track volatility uncertainty 
(Payzan-LeNestour et al., 2013). Furthermore, pupil dilation – which is influenced by 
(nor)adrenergic afferents (Joshi et al., 2016) – correlates with unexpected changes in 
probabilistic context (Preuschoff et al., 2011; Nassar et al., 2012). 
4.2.2 Motor responses are sensitive to uncertainty 
Thus, uncertainty representations existing both within and between environmental 
contexts are crucial for optimal predictions about the probability of future events. While 
good predictions facilitate anticipatory preparation of appropriate motor responses 
(Bestmann et al., 2008), they are not sufficient for adaptive performance in dynamic 
environments. An additional mechanism is required to modify action selection based on 
one’s own beliefs about the latent changes in the environment and/or the occurrence of 
unexpected events. Indeed, when an unexpected event occurs, humans are capable of 
engaging resources to inhibit a prepared response and replace it with an alternative 
(Hikosaka and Isoda, 2010; Isoda and Hikosaka, 2011), albeit at the expense of a 
prolonged reaction time (RT) (Galea et al., 2012; Bestmann et al., 2014). 
4.2.2.1 A proposed role for dopamine in response modulation 
There is considerable evidence linking DA to flexible behaviour (Cools et al., 2001a, 
2009; Stelzel et al., 2010, 2013; van Holstein et al., 2011). Dopaminergic deficits due to 
Parkinson’s disease are associated with specific flexibility impairments in both motor 
(Cools et al., 1984; Galea et al., 2012) and cognitive domains (Beatty and Monson, 1990; 
Cools et al., 2001a), with performance restored by dopaminergic medication (Cools et 
al., 2001b; Galea et al., 2012). In healthy individuals, pharmacological DA depletions 
impair adaptive reactions to unexpected events occurring within a broadly predictable 
context (Bestmann et al., 2014). However, it remains unclear whether DA supports 
accurate response selection by facilitating perceptual belief updating (Iglesias et al., 
2013), or by modulating the sensitivity of response selection to perceptual beliefs. 
4.2.3 A unified framework of uncertainty 
In sum, while physiological, pharmacological, behavioural and theoretical work has 
suggested separable neuromodulatory involvement in different uncertainty 
computations, attempts to characterise the relative roles of NA, ACh and DA within a 
single computational scheme are lacking. Of note, since the conception of the work 
reported in this thesis, Varazzani et al. have contrasted the roles of NA and DA in 
motivation (Varazzani et al., 2015) and Brown et al. have assessed the impact of 
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pharmacological NA and ACh manipulations on orienting responses to novel stimuli 
(Brown et al., 2015). Nonetheless, there has been no direct investigation of the relative 
contributions of NA, ACh and DA to human learning and response modulation within a 
unified computational framework of uncertainty.  
In this chapter, I employ the probabilistic serial RT task (PSRTT) introduced in Chapter 
2 and the novel instantiation of the Hierarchical Gaussian Filter (HGF) model (Mathys et 
al., 2011, 2014) developed in Chapter 3 to characterise human learning and response 
modulation in dynamic, probabilistic environments and under pharmacological NA, ACh 
and DA interventions. To recap, the HGF’s three-level perceptual model captures an 
individual’s mapping from environmental causes to sensory inputs, while the response 
model maps those inferred environmental causes to observed RT responses (Daunizeau 
et al., 2010a). Thus, I sought to disentangle the effects of the three pharmacological 
manipulations on participant-specific perceptual belief updating under irreducible, 
estimation and volatility uncertainty from those effects on the sensitivity of motor 
responses to perceptual estimates. 
4.3 Methods 
4.3.1 Participants 
128 healthy participants (56 male, aged 18-38 years, 119 right-handed) with normal or 
corrected-to-normal vision took part in this study after giving written informed consent. 
The experimental protocol was approved by the UCL Research Ethics Committee. The 
following exclusion criteria applied: history of neurological or psychiatric disease, intake 
of medication (other than contraceptives), self-reported smoking, self-reported 
recreational drug use, and current participation in other pharmacological studies. 
Following a screening interview to rule out intolerances or contraindications, the study 
clinician assigned participants pseudorandomly (i.e., ensuring a balanced distribution of 
gender, age and body weight) to receive a NA, ACh or DA antagonist, or a placebo. The 
experimenter (L.M.) was blind to the drug conditions. 
4.3.2 General procedure 
A double-blind, between-subjects design was employed. Each participant attended one 
experimental session during which they received a single, oral dose of one of the 
following: 1mg prazosin (α1-arenoceptor antagonist; NA- group), 6mg biperiden (M1-
receptor antagonist; ACh- group), 2.5mg haloperidol (D1/D2-receptor antagonist; DA- 
group), or a placebo. Doses were selected in line with previous studies showing clear 
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behavioural and neurophysiological effects (Ziemann et al., 1997; Meintzschel and 
Ziemann, 2006; Korchounov and Ziemann, 2011; Bestmann et al., 2014). On arrival, 
participants completed computerised versions of the Digit Span test, Barratt 
Impulsiveness Scale (BIS-11) (Patton et al., 1995), Doman-Specific Risk-Taking 
(DOSPERT) Scale (Blais and Weber, 2006) and Cognitive Failures Questionnaire (CFQ) 
(Broadbent et al., 1982). Participants also self-reported their baseline mood (alertness, 
calmness and contentedness) with visual analogue scales (VAS) (Bond and Lader, 
1974), and had their baseline heart rate (HR) and blood pressure (BP) measured. To 
assess any subjective and/or physiological drug effects, the VAS, HR and BP 
measurements were repeated before participants started the PSRTT and again once 
they completed it. Please refer to Chapter 2 (section 2.3.3) for details about the 
psychometric and subjective measures. 
Two different drug administration times were used to match peak plasma concentration 
across drugs, based on previous pharmacokinetic data. To ensure that participants 
undertook the RT task when the drug was at its most active, haloperidol was 
administered two hours in advance (Time A; Figure 4.1A), while prazosin and biperiden 
were administered 1.5 hours before the main experimental session (Ziemann et al., 
1997; Meintzschel and Ziemann, 2006; Korchounov and Ziemann, 2011). A random 50% 
of participants from the Placebo group were administered a placebo tablet at the first 
timepoint, and the other 50% at the second timepoint. The study clinician administered 
the drug or placebo while the experimenter was away from the testing room. Participants 
were asked not to eat for at least one hour before the first drug administration time. 
4.3.3 Probabilistic serial reaction time task 
Participants sat facing a computer screen positioned approximately 60cm away. They 
were instructed to rest their left and right index and middle fingers on the four buttons of 
a custom-made button box placed in front of them, and to maintain this position 
throughout the task. On each trial, participants were required to respond to the 
presentation of one of four visual stimuli by making a speeded button-press before the 
end of a 1200ms intertrial interval (ITI) (Figure 4.1B). Each stimulus was associated with 
one particular button. The stimulus-response mappings remained consistent within an 
experimental session but were counterbalanced across participants. 
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Figure 4.1 Task design. (A) Timeline for each experimental session. At baseline, 
participants had their heart rate (HR) and blood pressure (BP) measured, self-reported 
their alertness, contentedness and calmness via visual analogue scales (VAS) (Bond 
and Lader, 1974), and undertook a battery of psychometric tests to assess working 
memory, impulsivity, risk-taking and distractibility. HR, BP and VAS measures were 
repeated before and after completing the behavioural task. Due to different times-to-peak 
plasma concentration across drugs, two different drug administration times (Time A and 
Time B) were used so that participants undertook the behavioural task when the drugs 
were at their most active. 50% of participants in the Placebo group received a placebo 
tablet at Time A and the other 50% at Time B. (B) Trial sequence. A trial began with the 
presentation of a central white fixation cross against a black background. After an initial 
delay of 1500ms at the start of each block, one of four visual stimuli was presented for 
200ms. Participants were required to make a speeded button-press response before the 
end of a 1200ms intertrial interval (ITI). (C) Stimulus transitions were generated by one 
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of eight different transition matrices (TMs), which changed every 50 trials without explicit 
indication to the participant. These TMs comprised two different 1st-order sequences, two 
alternating sequences, and four 0th-order sequences, each of which occurred three times 
in a pseudorandom order across 1200 trials. The overall probability of each stimulus was 
equal across the 1200 trials. For full details, see Figure 2.1. (D) Example trial sequences 
generated from the three example TMs in B. (E) By tracking the transition probabilities, 
subjects could learn to predict high probability events and prepare to make the correct 
button-press accordingly. Faster responses were observed for predictable stimuli 
compared to unexpected stimuli. Here Placebo group log(RTs) (mean ± SEM) are 
depicted for each of the 16 possible combinations between consecutive stimuli for the 
1st-order sequence shown in C. Grey boxes indicate stimulus combinations with a high 
transition probability. (F) Indeed, across all types of TM, responses were faster for stimuli 
with higher transition probabilities (mean ± SEM).  
4.3.3.1 Training 
Each participant acquired the stimulus-response mappings for their session during a 
training block in which they received visual error feedback after each trial. The training 
session comprised at least 100 trials and did not finish until the participant had reached 
a minimum performance criterion of 85% accuracy on the last 20 trials. Participants were 
then given 40 practice trials, in which the stimuli were presented in a random order and 
without error feedback, to familiarise them with the timings of the main experiment. An 
additional refresher block, consisting of at least 26 trials with error feedback, was 
completed immediately before the main experiment. Again, participants had to achieve 
85% accuracy in the last 20 trials to proceed. On average, participants reached this 
criterion in 28.1 ± 1.1 trials, indicating adequate learning and retention of the mappings. 
There was no difference in the number of refresher trials required between groups 
(F3,120=1.17, p=0.324). 
4.3.3.2 Task design 
Each participant performed 1200 trials of the probabilistic RT task. Figure 4.1B shows 
an example trial sequence. Anticipatory responses (<80ms RT) were recorded as 
incorrect. At any given time, the trial sequence was generated by one of eight transition 
matrices (TMs), which changed every 50 trials without explicit indication to the 
participant. In each TM, there were 16 combinations that determined the probabilistic 
relationship between the stimulus presented on the current trial, t, and the stimulus 
presented on the previous trial, t-1. Three types of TM were utilised: two 1st-order 
sequences, two Alternating sequences, and four 0th-order sequences (see Figure 4.1C 
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and Figure 2.1 for further details). Trials were drawn from each TM three times. The 
order of TMs was pseudorandom, with no consecutive repeats. Importantly, the overall 
probability of each stimulus was equal across the 1200 trials. 
The different TMs created contexts that the participants could infer from stimulus 
observations, allowing them to reduce their uncertainty about events before they 
occurred (Harrison et al., 2006). Nonetheless, the probabilistic nature of these contexts 
also produced unexpected stimulus outcomes, i.e. a sensory prediction error (PE). For 
fast and accurate responses, participants had to track three forms of uncertainty: 
irreducible uncertainty arising from the inherent randomness of the probabilistic 
transitions between consecutive stimuli; estimation uncertainty arising from their 
imperfect knowledge of the probabilistic relationships governing stimulus transition 
contingencies within contexts; and volatility uncertainty maintained by the unsignalled 
contextual instability. 
The pseudorandom order of TMs was used to generate one stimulus sequence that was 
used for all participants to ensure comparable learning processes and model parameter 
estimates. Rest periods occurred every 185 trials, orthogonal to TM switches. The 
importance of fast responses was stressed. Participants were told that by paying 
attention to any patterns in the order in which stimuli were presented, and to any switches 
in these patterns, it may be possible to respond faster. No further information about the 
nature of the experiment was provided. 
Combining the behavioural paradigm with three pharmacological manipulations 
permitted direct assessment of any separable roles for NA, ACh and DA in belief 
updating under irreducible uncertainty, estimation uncertainty and volatility uncertainty, 
and in sensitising the motor system to participants’ individual perceptual beliefs. At the 
end of the experimental session, participants were debriefed, indicated whether they 
thought they had taken an active drug or placebo, and reported the quality and quantity 
of their sleep on the previous night (Ellis et al., 1980). 
4.3.4 Model-agnostic analyses 
Trial-wise RT was calculated as the time between stimulus onset and the subsequent 
button press. The RT data were log-transformed (Bestmann et al., 2014). A series of 
conventional, model-agnostic analyses of behaviour were first conducted to assess 
whether participants learned about the underlying stimulus transition contingencies, and 
whether learning was influenced by the pharmacological interventions. To assess the 
interaction between stimulus transition probability and drug, trials were binned according 
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to three probability levels corresponding to the presented stimuli’s true transition 
probabilities as existed in the TMs (High: 0.85 and 0.70; Mid: 0.25 and 0.20; Low: 0.05) 
(Galea et al., 2012; Bestmann et al., 2014). A repeated-measures analysis of variance 
(RM-ANOVA) was used to compare mean log(RTs) for correct responses across these 
three probability levels and between drug-groups. 
To obtain a model-agnostic indication of learning across the course of the probabilistic 
contexts, a median split was performed on each 50-trial contextual block. A RM-ANOVA 
was used to compare mean log(RTs) on correct Early (1-25) and Late (26-50) trials at 
each probability level, and between drug-groups. To assess any learning in more detail, 
RTs on correct, high probability Early trials were examined after having been baseline-
corrected by subtracting the mean RT on the last three correct, high probability trials of 
the previous context. 
In many behavioural response time tasks, participants typically demonstrate post-error 
slowing, i.e., slower responses on trials following those on which they made an error 
(Rabbitt, 1966; Botvinick et al., 2001; Gehring and Fencsik, 2001; Cavanagh et al., 
2014). To identify any evidence of post-error slowing during the PSRTT, a RM-ANOVA 
was used to compare log(RTs) on correct trials that immediately followed both correct 
and erroneous responses. A further RM-ANOVA compared log(RTs) on correct, post-
infrequent trials (i.e., trials following those with a true transition probability of 0.05) and 
correct trials following trials with a true transition probability >0.05. 
4.3.5 Model-based analyses 
While model-agnostic analyses offer a heuristic indication of learning and possible drug 
effects, a model-based approach permits quantification of participants’ (approximate) 
inferences and subjective expectations about the transitions, which are driven by data-
limited observations. A novel instantiation of the HGF model, consisting of a three-level 
perceptual model and a response model (see Chapter 3 and Figure 4.2), was therefore 
applied to the data. Thus, it was possible to map each individual’s estimated perceptual 
beliefs about stimulus transitions, transition contingencies and volatility, and the 
respective irreducible, estimation and volatility uncertainty about these beliefs, onto 
his/her observed log(RT) responses. The model was implemented using the 
‘tapas_logrt_linear_whatworld’ code contained in the HGF Toolbox 
(http://www.translationalneuromodeling.org/tapas/). 
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Figure 4.2 The Hierarchical Gaussian Filter (HGF). (A) The perceptual model tracks 
an individual’s learning of the task’s structure across three levels. State 𝒙1 represents 
trial-wise transitions from one stimulus to the next, 𝒙2 the transition contingencies, and 
𝑥3 the phasic volatility, where t is the current trial number and bold font is used to indicate 
a matrix. Participants hold and update beliefs about the true quantities at each level, with 
a mean μ and a variance σ. ϑ and ω are participant-specific parameters that couple the 
levels and determine the respective speed of belief updating about phasic volatility and 
transition contingencies. The response model describes the mapping from a participant’s 
trial-wise beliefs onto their observed log(RT) responses. (B) Example of the trial-wise 
dynamics at level 3 for Placebo Participant 2. 𝜇3 reflects the participant’s belief about the 
true phasic volatility (𝑥3). Vertical dashed lines indicate true context switches. 𝜇3 tends 
to increase following a context change and then decreases over the course of a context 
as the participant learns the new contextual rule and thus perceives the environment to 
be increasingly stable. √ϑ is a variance determining the step-size of 𝜇3 and therefore how 
quickly the participant updates their phasic volatility estimates. (C) As in B, but for 
precision-weighted contingency PE (𝜺3) at level 2. This estimate results from weighting 
the contingency PE (𝜹2) by a precision ratio that captures uncertainty about input from 
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the level below relative to the level above. The higher the precision at level 2, the more 
meaningful a deviation from the predicted stimulus transition contingency. This in turn 
increases the impact on phasic volatility belief updating at level 3. For simplicity, the 
depicted 𝜀3 trajectory is for true transition changes only. (D) As in B and C, but for sensory 
PE (𝜹1) at level 1. This estimate arises from irreducible uncertainty about stimulus 
transitions. Trial-wise values are equivalent to 1-𝑥1, where 𝑥1 is equal to the probability 
of the predicted transition. Again, for simplicity only 𝛿1 values for truly occurring 
transitions are shown here. (E) Mean β values for the Placebo group indicate that 
increases in sensory PE (β1), precision-weighted contingency PE (β2), and phasic 
volatility estimates (β3) slowed participants’ trial-wise log(RTs). There was also evidence 
of post-error slowing (β4). Results are mean ± SEM. *** p<0.001.  
4.3.5.1 Perceptual model 
The perceptual model tracks an individual’s learning of the task’s structure: the trial-wise 
stimulus transitions at level 1, the probability of the transitions (i.e., transition 
contingencies) at level 2, and the volatility of transition contingencies at level 3 (Figure 
4.2A). It is hierarchical in that learning not only occurs simultaneously at multiple levels, 
but belief updating at one level is constrained by beliefs at the level above. This provides 
a generic framework for implementing dynamic learning rates, which are crucial for 
learning in volatile environments (Behrens et al., 2007; den Ouden et al., 2010). 
Trial-wise trajectories of a participant’s perceptual estimates at each level evolve 
according to the predictions made and outcomes experienced by that individual (Figure 
4.2B-D). At levels 2 and 3, these estimates are modelled by Gaussian distributions with 
a mean (μ) and a variance (σ), the latter reflecting the uncertainty of the estimate. 
Precision (π) of the estimate is equal to inverse variance (1/σ). Irreducible uncertainty at 
level 1 gives rise to sensory PE, 𝜹1. Estimation uncertainty at level 2 gives rise to 
contingency PE, 𝜹2. PEs can be weighted according to their precision (inverse 
uncertainty). At level 1, this gives us precision-weighted sensory PE, 𝜺2, and at level 2 
precision-weighted contingency PE, 𝜺3. Volatility uncertainty arises from phasic volatility 
beliefs, 𝜇3, at level 3. Please refer to Chapter 3 for full details.  
Importantly, the HGF does not assume fixed learning across the population but rather 
contains participant-specific parameters that couple the hierarchical levels and allow for 
individual expression of approximate Bayes-optimal learning. ϑ determines the speed of 
learning about volatility, i.e., the rate at which estimates of phasic volatility (𝜇3) are 
updated. As such, ϑ encapsulates metavolatility, i.e., the rate at which volatility changes, 
with higher values implying a belief in a more unstable world and leading to a more 
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variable learning rate (as expressed in phasic volatility belief updating). By contrast, ω is 
a constant component of the volatility and captures how rapidly individuals generally 
update their beliefs about transition contingencies at level 2. Changes in ω therefore lead 
to a tonic alteration of the learning rate. By comparing ϑ and ω estimates for each of the 
drug-groups to the Placebo group, it was possible to interrogate the effects of NA, ACh 
and DA antagonism on perceptual belief updating. 
4.3.5.2 Response model  
The response model describes the mapping from a participant’s trial-wise beliefs, as 
provided by the perceptual model, onto his/her observed responses, log(RTs). I 
reasoned that there are several variables that could influence trial-wise log(RT). 
Therefore, three response models were constructed and compared using random effects 
Bayesian model selection (Stephan et al., 2009; Rigoux et al., 2014) and associated 
techniques for assessing differences in model frequencies across groups as 
implemented in the VBA toolbox (Daunizeau et al., 2014). Random effects Bayesian 
model selection allows for heterogeneity in the population; the best model for each 
individual is allowed to vary, producing an estimate of model frequency in the population 
(i.e., for how many participants that model is the best model), and an exceedance 
probability that the model is the most frequently utilised in the population. This is a more 
conservative approach than conventional fixed-effects analyses, which assume that data 
from all participants are best explained by a single model. 
Each response model proposed that log(RT) on any given trial is a linear function of a 
constant component of log(RT) and several other factors. Since there is evidence, both 
from earlier work (Rabbitt, 1966; Botvinick et al., 2001; Gehring and Fencsik, 2001; 
Cavanagh et al., 2014) and the present study, that participants’ RTs increase on a trial 
following an incorrect response, post-error slowing was included in each response 
model. While the perceptual model assumed that participants updated their beliefs 
according to the stimulus presented on each trial, the response model incorporated 
correct trials only. 
The extra factors in the different models came from quantities at each level of the HGF 
that might influence log(RT). The first response model contained the following 
parameters: 𝛿1 (sensory PE), due to evidence that DA sensitises motor responses to 
low-level PE (Galea et al., 2012; Bestmann et al., 2014), 𝜀3 (precision-weighted 
contingency PE), which has been shown to correlate with activity in the cholinergic basal 
forebrain (Diaconescu et al., 2017), and 𝜇3 (estimated phasic volatility), which is relevant 
to switching tasks for which there is a proposed role for DA (Cools et al., 2001a, 2001b). 
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For each parameter, the quantity relates to the true stimulus transition on each trial. ζ is 
Gaussian noise. 
Response Model 1:  
log(RT)(t) =  β0 +  β1(δ1
(t)
)  +  β2(ε3
(t)
)  +  β3(μ3
(t)
)  +  β4(PostError
(t))  +  ζ(t) 
Equation 4.1                      
Alternative research has indicated that activity in the dopaminergic midbrain correlates 
with the precision-weighted form of sensory PE, 𝜀2 (Iglesias et al., 2013; Diaconescu et 
al., 2017). To disambiguate whether motor responses are modulated according to raw 
sensory PE or the confidence one has in their sensory predictions, the second response 
model contained 𝜀2 instead of 𝛿1. 
Response Model 2:   
log(RT)(t) =  β0 + β1(ε2
(t)
)  +  β2(ε3
(t)
)  +  β3(μ3
(t)
)  +  β4(PostError
(t))  +  ζ(t) 
Equation 4.2        
Since 𝛿1 and 𝜀2 are highly correlated, a third response model containing both parameters 
was constructed to ascertain whether one had a higher degree of explanatory power in 
terms of determining log(RT). 
Response Model 3:  
log(RT)(t) =  β0 + β1(δ1
(t)
)  + β2(ε2
(t)
)  + β3(ε3
(t)
)  +  β4(μ3
(t)
)  +  β5(PostError
(t))  +  ζ(t) 
Equation 4.3 
4.3.5.3 Model fitting 
For each participant, individual maximum a posteriori estimates for perceptual and 
response model parameters were jointly obtained using the Broyden-Fletcher-Goldfarb-
Shanno algorithm as implemented in the HGF Toolbox. Where priors were required, they 
were defined by inverting the perceptual model in isolation, given the known stimulus 
sequence (using the function ‘tapas_bayes_optimal_whatworld_config’), under suitably 
uninformative priors. The resulting posterior estimates were then used to define the 
priors for the subsequent inversion of the full model given the behavioural data (see 
Table 4.1). In other words, the prior means in the empirical data analysis corresponded 
to those parameter values for which the stimulus sequence would generate minimal 
surprise (in an observer with the aforementioned uninformative priors). 
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Table 4.1 A summary of HGF parameters and priors. 
 All priors are specified in the space in which they are estimated. For an account of how 
this relates to the native space of that parameter, please refer to Chapter 3 and to the 
original description of the model (Mathys et al., 2011).  
Parameter Notes Prior 
 
Perceptual Model 
 
ϑ  Metavolatility belief parameter; controls the 
step size of the Gaussian random walk at 
level 3. Estimated in logit space. 
Mean 
Variance 
Upper bound 
0 
2 
0.01 
ω  Tonic volatility belief parameter; a constant 
component of the learning rate at level 2. 
Mean 
Variance 
-6 
25 
Stimulus 
Transitions 
(𝒙1) 
4x4 matrix; the predictions are a sigmoid 
transformation of the probabilities 
represented in 𝒙2, and so do not have a 
starting prior value. 
𝝁1: 
Mean 
Variance 
 
NaN 
NaN 
𝝈1: 
Mean 
Variance 
 
NaN 
NaN 
Stimulus 
Transition 
Contingencies  
(𝒙2) 
4x4 matrix; estimated conditional 
probabilities for the 16 possible stimulus 
transitions are updated on each trial. At 
level 2, estimates are made in logit space   
(-1.0986 is equivalent to a 0.25 probability). 
𝝁2: 
Mean 
Variance 
 
-1.0986 
0 
 
𝝈2: 
Mean 
Variance 
 
0 
log(1) 
Volatility 
(𝑥3) 
Scalar; one trial-wise volatility estimate is 
updated after each stimulus transition. 
𝜇3: 
Mean 
Variance 
 
1 
0.1 
𝜎3: 
Mean 
Variance 
 
log(0.1) 
1 
 
Response Model  
 
β0 log(RT) constant Mean 
Variance 
log(500) 
3 
β1 Sensory PE (𝛿1) 
 
Mean 
Variance 
0 
4 
β2 Precision-weighted contingency PE (𝜀3) Mean 
Variance 
0 
4 
β3 Volatility estimate (𝜇3) Mean 
Variance 
0 
4 
β4 Post-error Mean 
Variance 
0 
3 
ζ Noise Mean 
Variance 
-3 
1e-3 
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4.3.5.4 Parameters of interest 
Since the HGF separates the relatively complex and interacting factors that influence 
RTs in a computationally limpid way, the individual effects of the three pharmacological 
manipulations on perceptual belief updating and response modulation could be probed. 
By comparing participant-specific perceptual parameters (ϑ and ω) in each drug-group 
to Placebo, it was possible to characterise learning under pharmacological NA, ACh and 
DA manipulations. Moreover, any neuromodulatory effects on perceptual belief updating 
could be distinguished from those on the sensitivity of motor responses (as reflected by 
the response model β estimates) to perceptual beliefs. 
4.3.6 Statistical analyses 
In reporting statistical differences, a significance threshold of =0.05 was used. Where 
assumptions of sphericity were violated (Mauchly’s test p<0.05), the Greenhouse-
Geisser correction was applied. Since a significant time x drug interaction on self-
reported alertness was identified (see section 4.4.5.1 for details), the participant-specific 
difference in alertness between baseline and the time corresponding to peak drug 
concentration, Δalertness, was used as a covariate in all analyses to control for any inter-
participant variability in subjective drug effect. 
For comparisons across the four drug-groups, partial eta-squared (ηp2) is reported as the 
effect size. The key experimental question pertained how different neuromodulators 
influence learning and response modulation compared to placebo. Therefore, planned 
comparisons were made between each of the three active drug-groups (NA-, ACh- and 
DA-) and the Placebo group by fitting a linear model separately for each participant-
specific model parameter (ϑ, ω and each β). Here a Benjamini-Hochberg correction for 
three pairwise comparisons was applied to account for the false discovery rate (FDR) 
(Benjamini and Hochberg, 1995). For pairwise comparisons, Cohen’s d is reported as 
the effect size. 
4.3.7 Control analyses 
4.3.7.1 Permutation tests 
In addition to the linear models used to assess the effects of the three drug manipulations 
on the HGF model parameters, permutation tests randomising drug assignment over 
participants were conducted to make distribution-free comparisons. 10,000 permutations 
were run per parameter of interest. For each parameter and each permutation, the 
difference between the mean for each permuted drug and the mean for the permuted 
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Placebo was calculated. The permutation values were then tested by calculating the 
fraction of the permutation points with larger absolute differences than, but in the same 
direction as, those differences observed in the empirical data. 
4.3.7.2 Exhaustive response model comparison 
To further verify that a response model that offered the best means by which to explain 
trial-wise log(RT) had been identified, a more exhaustive set of models containing 
different combinations of parameters from the HGF was compared for the Placebo group. 
A family-wise model comparison was first run on models containing every combination 
of the parameters 𝛿1, 𝜀2, 𝜀3 and 𝜇3 (Family 1) versus models containing every 
combination of predicted uncertainty estimates from each level of the HGF, ?̂?1, ?̂?2 and ?̂? 
(Family 2). All models contained an additional parameter for post-error slowing. Once 
the winning family was identified, random effects Bayesian model selection was run on 
all models in that family. See section 4.4.5.3 for details. 
4.3.7.3 Model parameter correlations 
To demonstrate that the HGF provided a good fit to the behavioural data, the correlations 
between the Bayesian parameter averages (BPAs) for model parameters in each drug-
group were assessed. 
4.3.7.4 Residuals 
For further verification that the HGF model provided a good fit to the behavioural data, 
the residuals between the observed log(RTs) and those predicted by the model were 
assessed for each drug-group. To confirm that the HGF did not systematically under- or 
over-estimate log(RTs) at true contextual change-points, autocorrelations between 
residuals for participants in each drug-group were calculated.  
4.3.7.5 Simulations 
To demonstrate that the HGF can capture the effects reported in the results, and to 
illustrate the implications of different model parameters further, the HGF was used to 
generate simulated log(RT) data. First, 100 simulations were run for each set of posterior 
parameter values obtained for each participant in the Placebo group, generating 1200 
log(RTs) for each run. The simulated log(RTs) on high (p=0.85 or p=0.70), mid (p=0.25 
or p=0.20) and low (p=0.05) probability trials were then averaged, i.e., to mirror the 
model-agnostic analyses. For each of a series of further simulations, the same parameter 
settings were taken, but particular parameters of interest, identified based on the 
empirical observations, were modified. For these parameters of interest, the estimated 
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parameters for each Placebo participant were shifted by the difference between the 
Placebo group average and the relevant drug-group average for that parameter. All 
averaging was performed in the space in which the parameters were estimated. Again, 
100 runs for each “computationally drugged” participant were run and the simulated 
log(RTs) were averaged across three probability levels. Thus, it was possible to assess 
the impact of different model parameters on log(RT), and to compare simulated log(RTs) 
to empirical data in each drug-group. 
4.4 Results 
Data from 124 participants are reported. Four participants were excluded from analyses: 
three due to high missed response rates (≥11%) and one because behavioural model 
parameter estimation (using the Broyden-Fletcher-Goldfarb-Shanno algorithm) did not 
converge. The four drug-groups were matched for gender (Kruskal-Wallis test: H3=0.53, 
p=0.912), age (one-way ANOVA: F3,120=0.46, p=0.714), body weight (F3,120=2.24, 
p=0.087), education level (H3=1.31, p=0.727), and all baseline psychometric measures 
taken (Table 4.2). 
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4.4.1 Model-agnostic results 
On average, 90.3 ± 0.8% (±SEM), 88.4 ± 1.2%, 87.7 ± 1.3% and 89.2 ± 0.91% of trials 
were correct in the Placebo, NA-, ACh- and DA- groups respectively. The percentages 
of correct responses did not differ between groups (F3,123=1.12, p=0.345).  
First, a RM-ANOVA was conducted on the log(RTs) for correct responses on trials 
binned according to the five true conditional probabilities that existed in each of the TMs, 
grouped into High (0.85 and 0.70), Mid (0.25 and 0.20), and Low (0.05) transition 
probabilities, with drug as a between-subjects factor (Figure 4.3A). This revealed a 
significant decrease in log(RTs) with increasing transition probability (main effect of 
probability: F1.27,151.36=483.50, p<0.001, effect size ηp2=0.80), which was modulated by 
drug-type (probability x drug interaction: F3.82,151.36=12.37, p<0.001, ηp2=0.24), but not by 
Δalertness (p=0.909). 
Table 4.2 Participant details for each experimental group.  
Between-groups comparisons revealed no significant differences (ns = non-significant) 
for gender, age, body weight, education level, baseline working memory (Digit Span), 
impulsivity (Barratt Impulsiveness Scale; BIS-11), risk-taking (Domain-Specific Risk-
Taking Scale; DOSPERT), distractibility (Cognitive Failures Questionnaire; CFQ), fatigue 
during the task, or sleep quality or quantity on the previous night. For continuous data, 
one-way ANOVAs were used to test for any between-group differences. For discrete 
data (#), Kruskal-Wallis tests were applied. Education Level refers to the highest attained 
from the following: 1 = compulsory education (≤ 12 years); 2 = further education (13-14 
years); 3 = undergraduate degree (15-17 years); 4 = one postgraduate degree (≥ 18 
years); 5 = multiple postgraduate degrees. Age data are mean ± SD. Remaining data 
are mean ± SEM.  Active drug refers to the percentage of participants within each group 
who reported at the end of the experiment that they believed they had received an active 
drug.  
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Figure 4.3 Model-agnostic results. Changes in log(RT) indicate that participants 
learned to predict the stimulus transitions. (A) In all four groups, log(RT) increased as a 
stimulus’ true transition probability decreased. (B) A median split on each 50-trial 
contextual block was used to compare mean log(RTs) on Early (1-25) and Late (25-50) 
trials at each probability level. Over the course of a context, participants became faster 
at responding to High and Mid probability stimuli, and slower at responding to Low 
probability stimuli. Raw RTs are plotted here to simplify interpretation of ΔRT, but 
statistics were run on log(RTs). (C) Across drug-groups, participants showed evidence 
of post-error slowing on correct trials that followed an erroneous response compared to 
those following correct responses. (D) Participants also showed evidence of slowing on 
correct trials that followed an infrequent stimulus transition. Results are mean ± SEM, 
corrected for Δalertness. Results shown in A, B and D were modulated by drug-group.  
Moreover, across the course of a contextual block (Figure 4.3B), participants became 
faster at responding to High and Mid probability stimuli and slower at responding to Low 
probability stimuli (significant main effects of probability: F1.28,152.70=476.88, p<0.001, 
ηp2=0.80 and time: F1,119=12.01, p<0.001, ηp2=0.34; probability x time interaction: 
F2,238=113.73, p<0.001, ηp2=0.49). The effect was modulated by drug-type (probability x 
time x drug interaction: F6,238=3.10, p=0.006, ηp2=0.07), but again not systematically 
related to differences in Δalertness (all p>0.06). Post-hoc (FDR-corrected) pairwise 
comparisons indicated that the impact of drug was driven by the ACh- group, which 
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showed significant log(RT) slowing compared to Placebo (t58=3.06, p=0.009, effect size 
Cohen’s d=0.80). Together, these results indicate that participants learned about the true 
stimulus transition contingencies, and that this learning was modulated by the 
pharmacological manipulations.  
Participants showed evidence of post-error slowing on correct trials following those on 
which they made an error (F1,119=108.25, p<0.001, ηp2=0.48; Figure 4.3C). This effect 
was not modulated by drug-group (trial-type x drug interaction: p=0.957), or by 
Δalertness (p=0.608). Participants also demonstrated significant log(RT) slowing on 
correct, post-infrequent trials (true transition probability = 0.05) compared to all other 
correct trials (F1,119=441.12, p<0.001, ηp2=0.79; Figure 4.3D), which was modulated by 
drug-group (F3,119=4.47, p=0.005, ηp2=0.10) but not by Δalertness (p=0.652). This effect 
was driven by the ACh- group, with (FDR-corrected) pairwise comparisons revealing 
significant slowing compared to Placebo (t58=3.44, p=0.003 d=0.90). Error rates 
significantly decreased with increasing transition probability (main effect of probability: 
F1.54,183.50=143.60, p<0.001, ηp2=0.55). The effect was again modulated by drug-type 
(probability x drug interaction: F4.63,183.50=5.21, p<0.001, ηp2=0.12), but not by Δalertness 
(p=0.283). There was no between-subjects effect of drug-group (p=0.776). 
4.4.2 Model-based results 
4.4.2.1 Perceptual model 
Overall, the HGF tracked the true stimulus transitions well (Figure 4.4). Note that the 
model is uninformed about the true stimulus transition probabilities, but rather bases its 
estimates on the observed stimulus transitions only.  
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Figure 4.4 Estimated transition contingencies for two example participants. (A) 
Transitions between pairs of stimuli, from trial t-1 to trial t, were defined by transition 
matrices. Every 50 trials the transition matrix switched to a different matrix. (B) Each 
panel corresponds to one of 16 possible transitions between stimuli across 1200 trials. 
The black lines indicate the true transition contingencies. The blue lines reflect the 
participant’s inferred estimates (i.e., the posterior expectation of these contingencies, ?̂?1) 
before seeing the stimulus outcome on each trial. The model tracked the true underlying 
contingencies and detected change-points. Here, in a representative participant from the 
Placebo group, the model tracked the true transition contingencies closely, whereas a 
participant from the ACh- group showed a greater discrepancy in the tracking of the true 
transition contingencies. This is reflected in the participants’ ω estimates: Placebo 
Participant 2 showed a higher transition contingency learning rate (ω=-3.27) than ACh- 
Participant 16 (ω=-5.84).  
The punctate change-points contained in the true generative process were detected 
implicitly by the HGF as an increase in learning rate (𝛼1; Figure 4.5), which reflects the 
influence of increased uncertainty and formally corresponds to a reduced contribution of 
belief precision (denominator in Equation 3.16) to the weighting of PE. 
 
Figure 4.5 Learning rate (α1) trajectories for the Placebo group. Increases in α1 are 
observed following a true change in context. This α1 increase is amplified for a more 
obvious switch from one easy-to-detect 0th-order context to a different 0th-order context. 
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In contrast, a switch to an Alternating context, which is trickier to detect, is accompanied 
by a modest, more gradual increase in α1. Data are mean ± SEM for truly occurring 
transitions.  
Importantly, when trials were categorised according to participants’ trial-wise estimates 
of transition contingencies, as provided by model parameter ?̂?1 (five bins: 0.8-1, 0.6-0.8, 
0.4-0.6, 0.2-0.4, 0-0.2), the same decrease in log(RT) with increasing transition 
probability found in the model-agnostic results was observed (c.f. Figure 4.6 with Figure 
4.3A; significant effect of ?̂?1: F1.68,188.02=297.92, p<0.001, ηp
2=0.73). As in the model-
agnostic results, this was modulated by drug-group (significant ?̂?1 x drug interaction: 
F5.04,188.02=9.52, p<0.001, ηp2=0.20), but not by Δalertness (p=0.112). 
 
Figure 4.6 Model-based changes in log(RT) mirror the model-agnostic results. In 
all four groups, faster responses were observed as participants’ estimates of the true 
transition contingencies increased, demonstrating that the HGF captured the same 
behavioural effect identified in the model-agnostic analyses, i.e., that participants learned 
to predict the stimulus transitions and prepared motor responses to high probability 
transitions (c.f. Figure 4.3A). Results are mean ± SEM, corrected for Δalertness.  
4.4.2.2 Response model 
Random effects Bayesian model selection established that Response Model 1 
(containing parameters 𝛿1, 𝜀3 and 𝜇3) was superior in all four pharmacological groups by 
a considerable margin. For the Placebo, NA-, ACh- and DA- groups respectively, the 
posterior model probabilities were 0.911, 0.828, 0.636 and 0.829; protected exceedance 
probabilities (i.e., the probability that Response Model 1 is more likely than any other 
model in the comparison set) were 1.000, 1.000, 0.963, 1.000 (Figure 4.7). Moreover, no 
significant difference in model frequencies between the Placebo group and any of the 
drug-groups was identified (NA- vs Placebo: p=0.958, ACh- vs Placebo: p=0.560, DA- 
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vs Placebo: p=0.955). Therefore, Response Model 1 was used for all subsequent 
analyses. 
 
Figure 4.7 Random effects Bayesian model selection results. Response Model 1 
was found to be superior in all four groups. Posterior probabilities quantify the likelihood 
of each model given the data. Protected exceedance probabilities quantify how likely it 
is that any given model is more frequently utilised by individuals than all other models in 
the comparison set, while also protecting against the possibility that the observed 
variability in (log-) model evidences could be due to chance. The dotted line indicates 
the threshold for chance-level posterior probabilities (p=0.33).  
All regression coefficients for the Placebo group were significantly greater than 0 (Figure 
4.2E), meaning that sensory PE (β1(𝛿1): t30=7.90, p<0.001, effect size d=1.41), precision-
weighted contingency PE (β2(𝜀3): t30=6.33, p<0.001, d=1.13) and phasic volatility 
estimates (β3(𝜇3): t30=5.49, p<0.001, d=0.98) all had slowing influences on log(RT), and 
that there was evidence of post-error slowing (β4(PostError): t30=5.85, p<0.001, d=1.05). 
Each of the drug-groups showed equivalent post-error slowing to the Placebo group (all 
p>0.54; Figure 4.9F), mirroring the model-agnostic result. The lack of a difference in the 
noise parameter ζ between the Placebo group and any of the drug-groups (all p>0.34; 
Figure 4.9A) indicates that the model’s ability to predict log(RT) was unaltered under the 
drug manipulations.  
4.4.3 The influence of noradrenaline and acetylcholine in perceptual 
uncertainty computations  
4.4.3.1 Noradrenaline antagonism increased phasic volatility learning rate  
The noradrenergic (α1-adrenoceptor) antagonist prazosin increased the rate at which 
individuals updated their volatility estimates, as reflected by an increase in ϑ (linear 
model: t60=2.32, p=0.033, effect size Cohen’s d=0.60; Figure 4.8A). A higher ϑ leads to 
greater fluctuations in participants’ phasic volatility estimates, 𝜇3, resulting in a more 
variable phasic learning rate. By contrast, there was no effect on ω (p=0.388; Figure 
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4.8B), indicating that the tonic learning rate about the probabilistic contexts remained 
unchanged. 
 
Figure 4.8 Perceptual model parameter results. (A-B) Compared to the Placebo 
group, NA and ACh antagonism modulated participants’ perceptual belief updating. NA- 
increased the rate at which participants updated their phasic volatility estimates 
(increased ϑ). ACh- decreased the rate at which participants learned about stimulus 
transition contingencies (decreased ω), and increased the rate at which participants 
updated their phasic volatility estimates (increased ϑ). Results are (mean Drug) – (mean 
Placebo), ± the standard error of the difference (SED) between the means of the two 
samples, and corrected for Δalertness. * p<0.05 following an FDR correction for three 
multiple comparisons. See Table 4.3 for Placebo group means.  
4.4.3.2 Acetylcholine antagonism slowed learning about stimulus transition 
contingencies   
Muscarinic cholinergic (M1-receptor) antagonism under biperiden had more widespread 
perceptual effects. While ϑ was again significantly increased compared to Placebo 
(t58=2.95, p=0.012 d=0.81; Figure 4.8A), ω estimates in the ACh- group were significantly 
reduced (t58=-2.68, p=0.025, d=-0.74; Figure 4.8B). The lower estimate of ω indicates 
that participants were slower to update their transition contingency estimates under 
biperiden and thus slower to adapt to the probabilistic contexts. 
4.4.3.3 Dopamine antagonism had no effect on learning about task structure 
The D1/D2 dopamine receptor antagonist haloperidol did not influence the rate at which 
participants learned about the task’s volatility or contextual transition contingencies 
compared to Placebo (ϑ and ω: both p>0.23). 
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To summarise, both NA and ACh antagonism altered learning of uncertain events arising 
from unexpected contextual changes in the environment. Only ACh antagonism 
disrupted learning of transition contingencies within probabilistic contexts. 
4.4.4 Neuromodulatory effects on response modulation  
4.4.4.1 Noradrenaline antagonism had no influence on responses 
The response model output revealed no significant effects of NA antagonism on 
participants’ capacity to modulate their motor responses according to their perceptual 
estimates of uncertainty (all p>0.09; Figure 4.9C-E). 
4.4.4.2 Acetylcholine antagonism reduced response sensitivity to perceptual 
beliefs 
Compared to Placebo, ACh antagonism reduced the sensitivity of participants’ motor 
responses to sensory PE (β1: t58=-3.27, p=0.004, d=-0.90), precision-weighted 
contingency PE (β2: t58=-2.67, p=0.026, d=-0.74) and phasic volatility estimates (β3: t58=-
3.95, p<0.001, d=-1.09) (Figure 4.9C-E). 
4.4.4.3 Dopamine antagonism reduced response sensitivity to phasic volatility 
Compared to Placebo, DA antagonism led to a decrease in the influence of phasic 
volatility estimates on log(RT) (β3: t61=-2.69, p=0.012, d=-0.67; Figure 4.9E). This 
indicates that DA antagonism suppressed the sensitivity of motor responses to higher-
level inference. There was no significant effect of DA antagonism on the sensitivity of 
motor responses to sensory PE or precision-weighted contingency PE (all p≥0.14). 
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Figure 4.9 Response model results. DA- antagonism decreased the sensitivity of 
participants’ trial-wise responses to their phasic volatility estimates (β3). DA- and ACh- 
antagonism also caused some general response slowing (β0). The three drug-groups 
and the Placebo group showed equivalent post-error slowing (β4) and Gaussian noise 
(ζ). Results are (mean Drug) – (mean Placebo), ± SED and corrected for Δalertness. * 
p<0.05, ** p<0.01, *** p<0.001 following an FDR correction for multiple comparisons. 
See 
Table 4.3 for Placebo group means.  
In addition to the effects reported above, the log(RT) constant output indicated that 
suppressing DA and ACh also led to some general log(RT) slowing (β0: t61=2.54, p=0.019 
d=0.64; t58=4.85, p<0.001, d=1.34 respectively; Figure 4.9B). Subjective Δalertness 
systematically modulated the effects observed on ϑ (t119=2.54, p=0.013, d=0.02), 
sensory PE (β1: t119=2.53, p=0.013, d=0.02) and precision-weighted contingency PE (β2: 
t119=-3.09, p=0.002, d=-0.02). 
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Parameter Mean SEM t-value p-value 
ϑ 0.0034 0.0035 - - 
ω -3.5849 0.1880 - - 
β0 5.7079 0.0992 57.567 <0.001 
β1(δ1) 0.1996 0.0253 7.9020 <0.001 
β2(ε3) 0.2256 0.0357 6.3260 <0.001 
β3(μ3) 0.5208 0.0949 5.4900 <0.001 
β4(Post-Error) 0.0620 0.0106 5.8520 <0.001 
ζ 0.0536 0.0013 - - 
 
Table 4.3 Average perceptual and response model parameters for the Placebo 
group. β0 reflects a constant component of log(RT). β1-4 reflect the influence of sensory 
PE (𝛿1), precision-weighted contingency PE (𝜀3), phasic volatility estimates (𝜇3) and 
post-error trials on log(RT). All β values were significantly greater than zero (all p<0.001), 
indicating that these parameters slowed log(RT). All data are corrected for Δalertness.  
4.4.5 Control analyses 
4.4.5.1 Physiological and subjective control measures 
Self-reported ratings for alertness, calmness and contentedness all changed significantly 
over the course of the experiment (F1.79,214.39=71.60, p<0.001, ηp2=0.37; F1.88,225.25=5.96, 
p=0.004, ηp2=0.05 and F2,240=25.65, p<0.001, ηp2=0.18 respectively), but only alertness 
ratings showed a significant time x drug interaction (F5.36,214.39=6.40, p<0.001, ηp2=0.14). 
On average, alertness decreased within-participants over the course of the experiment 
in all four groups. A one-way ANOVA with drug as a between-subjects factor revealed 
that the degree to which alertness decreased between Baseline (Figure 4.1A) and the 
time corresponding to peak drug concentration (Post-Drug) varied between groups 
(F3,120=7.92, p<0.001, ηp2=0.17). More specifically, compared to Placebo, the alertness-
decrease was significantly more pronounced in the ACh- and NA- groups (t59=-4.31, 
p<0.001, d=-1.11 and t61=-2.76, p=0.007, d=-0.70 respectively). 
Heart rate (HR) varied significantly with time (F1.89, 226.71=129.25, p<0.001, ηp2=0.52) and 
this effect was modulated by drug-group (F5.67,226.71=5.40, p<0.001, ηp2=0.12). On 
average, all groups showed participant-specific HR decreases between Baseline and 
Post-Drug. The magnitude of HR deceleration differed between groups (F3,120=6.65, 
p<0.001, ηp2=0.14), but only in the ACh- group was HR deceleration more pronounced 
than Placebo (t59=-3.14, p=0.002, d=-0.81). While systolic blood pressure (BP) varied 
with time (F2,240=7.12, p=0.001, ηp2=0.06), there was no time x drug interaction 
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(F6,240=1.55, p=0.16). Diastolic BP showed no main effect of time (F2,240=0.37, p=0.695), 
but there was a significant time x drug interaction (F6,240=3.52, p=0.002, ηp2=0.08). More 
precisely, participant-specific differences in diastolic BP between Baseline and Post-
Drug varied significantly between groups (F3,120=5.11, p=0.002, ηp2=0.11) due to a 
significant decrease in diastolic BP in the NA- group compared to the Placebo group 
(t61=-3.49, p<0.001, d=-0.88). This is unsurprising given that the NA- drug administered 
(prazosin) is used clinically as an anti-hypertensive. A summary of the subjective and 
physiological measures is reported in Table 4.4. 
  Placebo NA- ACh- DA- 
A
le
rt
-
n
e
s
s
 
Baseline 
Post-Drug 
Post-Task 
64.4 ± 2.8 
60.7 ± 2.3 
59.5 ± 2.8 
64.7 ± 2.5 
52.5 ± 2.6 
48.7 ± 2.8 
65.2 ± 2.5 
48.0 ± 2.3 
49.9 ± 2.4 
65.1 ± 2.3 
59.6 ± 3.0 
52.8 ± 3.6 
C
a
lm
-
n
e
s
s
 
Baseline 
Post-Drug 
Post-Task 
66.9 ± 2.9 
70.6 ± 2.6 
60.8 ± 2.9 
68.9 ± 3.2 
68.5 ± 2.9 
66.4 ± 2.8 
66.4 ± 2.6 
62.9 ± 2.6 
60.2 ± 2.7 
61.5 ± 3.0 
67.3 ± 2.4 
63.5 ± 2.5 
C
o
n
te
n
t-
e
d
n
e
s
s
 Baseline 
Post-Drug 
Post-Task 
71.2 ± 2.3 
69.7 ± 2.2 
65.9 ± 2.4 
70.2 ± 2.6 
67.2 ± 2.5 
66.7 ± 2.4 
69.4 ± 2.1 
63.5 ± 2.1 
59.5 ± 2.1 
69.5 ± 2.3 
67.7 ± 2.3 
64.9 ± 2.2 
H
R
 
Baseline 
Post-Drug 
Post-Task 
69.8 ± 1.9 
61.2 ± 1.7 
62.8 ± 1.6 
78.7 ± 2.4 
72.7 ± 2.3 
73.1 ± 2.0 
71.0 ± 1.8 
55.8 ± 1.7 
56.6 ± 1.5 
74.8 ± 2.1 
65.3 ± 1.7 
66.7 ± 1.8 
S
y
s
to
lic
 
B
P
 
Baseline 
Post-Drug 
Post-Task 
110.8 ± 1.9 
109.5 ± 1.5 
110.1 ± 1.5  
121.7 ± 2.2 
117.5 ± 2.1 
121.6 ± 2.1 
111.5 ± 2.0 
109.8 ± 2.1 
116.3 ± 2.8 
117.6 ± 2.6 
114.5 ± 2.0 
116.4 ± 2.2 
D
ia
s
to
lic
 
B
P
 
Baseline 
Post-Drug 
Post-Task 
68.8 ± 1.3 
70.5 ± 1.4 
71.7 ± 1.4 
73.4 ± 1.1 
69.0 ± 1.5 
69.7 ± 1.3 
69.1 ± 1.4 
68.7 ± 1.5 
70.6 ± 1.9 
69.6 ± 1.7 
70.9 ± 1.4 
69.3 ± 1.8 
 
Table 4.4 Subjective and physiological measures for each experimental group. 
Readings were taken at baseline, immediately before participants started the PSRTT 
(i.e., when the drugs were at their most active; Post-Drug), and after completing the 
PSRTT (Post-Task). Data are mean ± SEM.  
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4.4.5.2 Permutation tests 
Aside from the effect of ACh- on β2, all significant effects observed in the multiple 
comparisons reported above (c.f. Figure 4.8 and Figure 4.9) were mirrored in the results 
of the permutation tests. 
 Comparison 
(drug vs Placebo) 
Direction of effect 
(for drug vs Placebo) 
p-value Significant? 
ϑ NA- vs Placebo ↑ 0.040 * 
ACh- vs Placebo ↑ 0.016 * 
DA- vs Placebo - 0.147 ns 
ω NA- vs Placebo - 0.203 ns 
ACh- vs Placebo ↓ 0.002 ** 
DA- vs Placebo - 00106 ns 
β0 NA- vs Placebo - 0.322 ns 
ACh- vs Placebo ↑ <0.001 *** 
DA- vs Placebo ↑ 0.011 * 
β1 NA- vs Placebo - 0.568 ns 
ACh- vs Placebo ↓ <0.001 *** 
DA- vs Placebo - 0.392 ns 
β2 NA- vs Placebo - 0.130 ns 
ACh- vs Placebo - 0.057 ns 
DA- vs Placebo - 0.104 ns 
β3 NA- vs Placebo - 0.122 ns 
ACh- vs Placebo ↓ <0.001 *** 
DA- vs Placebo ↓ 0.006 ** 
β4 NA- vs Placebo - 0.554 ns 
ACh- vs Placebo - 0.542 ns 
DA- vs Placebo - 0.711 ns 
ζ NA- vs Placebo - 0.571 ns 
ACh- vs Placebo - 0.098 ns 
DA- vs Placebo - 0.505 ns 
 
Table 4.5 Permutation test results. 10,000 permutations were run for each of the HGF 
model parameters, randomising drug assignment over participants. Aside from the effect 
of ACh- on β2, all significant effects observed in the multiple comparisons reported above 
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(c.f. Figure 4.8 and Figure 4.9) were mirrored in the results of the permutation tests. * 
p<0.05, ** p<0.01, *** p<0.001; ns = non-significant.  
4.4.5.3 Exhaustive response model comparison 
A family-wise model comparison established that Family 1 (containing models with 
different combinations of the parameters 𝛿1, 𝜀2, 𝜀3 and 𝜇3) was superior to Family 2 
(containing models with different combinations of the parameters ?̂?1, ?̂?2 and ?̂?3) (posterior 
probability: 0.700; exceedance probability: 0.999; Table 4.6). Mirroring the model 
comparison results reported above (section 4.4.2.2), random effects Bayesian model 
comparison on all models in Family 1 identified Response Model 1 as superior (posterior 
probability: 0.270, protected exceedance probability: 0.844; Table 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.6 Results of family-wise Bayesian model comparison. To further verify that 
 Model 
Parameters 
Posterior 
Probability 
Exceedance 
Probability 
F
a
m
il
y
 1
 
𝛿1, 𝜀3, 𝜇3, PostError, 𝜁 
𝜀2, 𝜀3, 𝜇3, PostError, 𝜁 
𝛿1, 𝜀2, 𝜀3, 𝜇3, PostError, 𝜁 
𝛿1, PostError, 𝜁 
𝛿1, 𝜀2, PostError, 𝜁 
𝛿1, 𝜀2, 𝜀3, PostError, 𝜁 
𝛿1, 𝜀2, 𝜇3, PostError, 𝜁 
𝛿1, 𝜀3, PostError, 𝜁 
𝛿1, 𝜇3, PostError, 𝜁 
𝜀2, PostError, 𝜁 
𝜀2, 𝜀3, PostError, 𝜁 
𝜀2, 𝜇3, PostError, 𝜁 
𝜀3, PostError, 𝜁 
𝜀3, 𝜇3, PostError, 𝜁 
𝜇3, PostError, 𝜁 
 
 
 
 
 
 
 
 
 
 
0.700 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.999 
F
a
m
il
y
 2
 
?̂?1, PostError, 𝜁 
?̂?2, PostError, 𝜁 
?̂?3, PostError, 𝜁 
?̂?1, ?̂?2, PostError, 𝜁 
?̂?2, ?̂?3, PostError, 𝜁 
?̂?1, ?̂?2, ?̂?3, PostError, 𝜁 
 
 
 
 
0.300 
 
 
 
 
0.001 
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Response Model 1 offered the best means by which to explain trial-wise log(RT), a more 
exhaustive set of linear response models containing different combinations of 
parameters from the HGF were compared for the Placebo group. A family-wise model 
comparison was first run on models containing every combination of the parameters 𝛿1, 
𝜀2, 𝜀3 and 𝜇3 (Family 1) versus models containing every combination of ?̂?1, ?̂?2 and ?̂?3 
(Family 2). Note that the quantities corresponded to the true transition that occurred on 
each trial. All models included post-error slowing. Family 1 was found to be superior 
(posterior probability: 0.700; exceedance probability: 0.999).  
 
Table 4.7 Bayesian model comparison results for Family 1. Each model contained a 
combination of the parameters 𝛿1, 𝜀2, 𝜀3 and 𝜇3, and a parameter for post-error slowing. 
Response Model 1 was again found to be superior (posterior probability: 0.270; protected 
exceedance probability: 0.844).  
4.4.5.4 Model parameter correlations 
Aside from two exceptions, Bayesian parameter averages (BPAs) for the different model 
parameters were only moderately correlated across groups (all absolute r≤0.660; Figure 
Model 
Number 
Model 
Parameters 
Posterior 
Probability 
Protected 
Exceedance 
Probability 
1 𝛿1, 𝜀3, 𝜇3, PostError, 𝜁 0.270 0.844 
2 𝜀2, 𝜀3, 𝜇3, PostError, 𝜁 0.023 0.000 
3 𝛿1, 𝜀2, 𝜀3, 𝜇3, PostError, 𝜁 0.024 0.000 
4 𝛿1, PostError, 𝜁 0.115 0.026 
5 𝛿1, 𝜀2, PostError, 𝜁 0.023 0.000 
6 𝛿1, 𝜀2, 𝜀3, PostError, 𝜁 0.022 0.000 
7 𝛿1, 𝜀2, 𝜇3, PostError, 𝜁 0.022 0.000 
8 𝛿1, 𝜀3, PostError, 𝜁 0.024 0.000 
9 𝛿1, 𝜇3, PostError, 𝜁 0.144 0.068 
10 𝜀2, PostError, 𝜁 0.023 0.000 
11 𝜀2, 𝜀3, PostError, 𝜁 0.038 0.000 
12 𝜀2, 𝜇3, PostError, 𝜁 0.021 0.000 
13 𝜀3, PostError, 𝜁 0.097 0.013 
14 𝜀3, 𝜇3, PostError, 𝜁 0.133 0.049 
15 𝜇3, PostError, 𝜁 0.021 0.000 
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4.10). Higher correlations existed between BPAs for ω (transition contingency learning 
rate) and 𝜇3_0 (the initial phasic volatility estimate) (r=-0.948, -0.764, -0.771, -0.983 for 
Placebo, NA-, ACh- and DA- respectively). This is to be expected on theoretical grounds 
because the two parameters perform very similar functions in the generative model. Note 
that the initial value of 𝜇3 was estimated as 𝜇3 was used as a predictor of log(RT) in the 
response model. However, when 𝜇3_0 was fixed there were no changes to any of the 
reported main effects. 
 
Figure 4.10 Model parameter correlations for the Bayesian parameter averages 
(BPAs). Note that 𝜇3_0 and 𝜎3_0 are the initial values of 𝜇3 (the phasic volatility estimate) 
and 𝜎3 (the uncertainty about the phasic volatility estimate) respectively.  
Higher correlations also occurred between BPAs for β0 (log(RT) constant) and β3(𝜇3) (the 
sensitivity of log(RTs) to phasic volatility estimates) (r=-0.877, -0.736, -0.630 and -0.880). 
Here the negative correlation indicates that both the constant component of log(RT) and 
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phasic volatility estimates had a similar slowing effect on log(RT). This reflects the fact 
that, while including 𝜇3 as a predictor of log(RT) significantly improves model evidence, 
it is much less variable than the other predictors because volatility inevitably changes at 
a slower time scale than transition contingencies. 
4.4.5.5 Residuals 
The distribution of residuals between the observed log(RTs) and those predicted by the 
HGF suggests that the model captured the patterns in the data well, and thus provided 
a good fit to the behavioural data (Figure 4.11). The mean (± SEM) correlations between 
observed log(RTs) and predicted log(RTs) were 0.38 ± 0.02, 0.36 ± 0.02, 0.26 ± 0.01 
and 0.36 ± 0.02 for Placebo, NA-, ACh- and DA- respectively.  
 
Figure 4.11 Residuals between observed and predicted log(RTs). The distribution of 
residuals between observed log(RTs) and those predicted by the HGF suggests that, 
across drug-groups, the model captured any patterns in the data well. Data are mean ± 
SEM.  
Moreover, autocorrelations between residuals for participants in each drug-group 
indicate that the model did not systematically under- or over-estimate log(RTs) at true 
contextual change-points (Figure 4.12).  
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Figure 4.12 Autocorrelations between residuals across trials. Across groups, the 
HGF did not systematically under- or overestimate log(RTs) at true change-points. Data 
are mean ± SEM.  
4.4.5.6 Simulations 
Simulated log(RT) data generated using the posteriors for each participant in the Placebo 
group as model parameters faithfully reflected the increase in log(RT) with decreasing 
stimulus transition probability that was observed in the Placebo group’s empirical data 
(Figure 4.13). Shifting the parameters significantly altered by the different drug 
manipulations by the difference between the Placebo group mean for those parameters 
and the relevant drug-group mean simulated log(RT) data comparable to the empirical 
data observed in each drug-group. Indeed, simulating NA antagonism by increasing ϑ 
generated log(RTs) comparable to those for the NA- group. The same was true when 
DA antagonism was simulated by simultaneously increasing β0 and decreasing β3. 
Similarly, simulating ACh antagonism by increasing ϑ and β0, and decreasing ω, β1, β2 
and β3 produced slower simulated log(RTs) that faithfully reflected the empirical ACh- 
log(RT) data. Note that, unlike the empirical data, there is no additional slowing caused 
by post-error effects in the simulated data. 
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Figure 4.13 Empirical and simulated log(RTs). Empirical data (filled bars) indicated 
that log(RT) increased as a stimulus’ true transition probability decreased. Simulated 
data (unfilled bars) generated for the Placebo group and for three “computationally 
drugged” groups faithfully reflected the empirical log(RTs) in each drug-group. Note that 
there are no post-error slowing effects in the simulated data. Data are mean ± SEM.  
The simulated data was also able to capture the increase in RT observed in the empirical 
data following true contextual change-points, as well as the learning that occurred across 
trials within a stable context. (Figure 4.14). The model-agnostic data shown in Figure 
4.14A is for mean (±SEM) ΔRT (collapsed across TM-types) for high-probability trials 
(p>=0.70, as defined in the relevant TM) on which participants made a correct response, 
following true change-points for each of the drug-groups. The trial-wise ΔRT measure is 
the difference between RT on each post-change trial and the average of the last three 
high probability, correct trials in the previous context. RTs increased on the trial following 
a true change-point across drug-groups (one-way ANOVA with Δalertness covariate: 
F4,119=6.52, p<0.001, ηp2=0.18), with an additional between-subjects effect of drug-group 
(F4,119=7.50, p<0.001, ηp2=0.16). Post-hoc comparisons (FDR-corrected) demonstrated 
that this RT increase was significantly attenuated in the ACh- group compared to the 
Placebo (t58=-4.14, p<0.001, d=-1.09) group. This is in line with the earlier assessment 
that individuals in the ACh- group showed poorer learning of the contextual transition 
contingencies. 
Moreover, over the course of the context, there was a decrease in RT for high-probability 
trials, reflecting learning of the new context. Applying an ANOVA, with a Δalertness 
covariate, to compare the lines of best fit for each participant’s ΔRTs, demonstrated 
learning across the course of the contexts (reflected by the negative slopes; effect of 
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slope: F4,119=6.52, p<0.001, ηp2=0.18) and modulation by drug-group (effect of drug: 
F3,118=6.31, p=0.001, ηp2=0.14). Again, corrected post-hoc comparisons indicated slower 
learning in the ACh- group compared to the Placebo group (t58=4.05, p<0.001, d=1.06) 
group, in line with the finding of a reduced transition contingency learning rate (as 
reflected by model parameter ω) following ACh antagonism. 
Figure 4.14B indicates that the simulated data echoes the model-agnostic results: there 
are equivalent between-group differences, most notably a dampened RT increase 
following a true contextual switch, as well as a reduced learning rate, for the ACh- group.  
 
Figure 4.14 Empirical and simulated responses following true change-points. (A) 
Mean baseline-corrected RTs for the first 25 (high probability) trials in each context, 
where the baseline is the mean RT of the last three high probability trials in the previous 
context. RTs increase following a true contextual change-point, but fall as participants 
learn the new contextual rule. (B) As in A, but for simulated RTs. The model neatly 
captures the increase in RTs following true change-points, the reduction in RT that 
occurs with learning across the course of the new context, and the suppressed effects 
of change-points and learning on RTs in the ACh- group. Data are mean ± SEM. Raw 
RTs have been used here to simplify interpretation of ΔRT.  
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4.5 Discussion 
By implementing a novel PSRTT in conjunction with three pharmacological 
manipulations and placebo, it was possible to characterise the roles of three 
neuromodulatory systems during perceptual belief updating and response selection. 
Leveraging a hierarchical Bayesian learning model to decompose hierarchically-related 
forms of uncertainty meant that particular processes could be linked to NA, ACh and DA. 
While manipulating NA and ACh modulated perceptual uncertainty computations, DA 
receptor antagonism reduced the sensitivity of the motor system to perceptual estimates. 
A key benefit of the pharmacological approach used in the present study is that it 
permitted direct manipulation of the function of three different neuromodulatory systems 
and comparison of the resulting psychopharmacological effects to a placebo condition. 
This is relevant given likely functional overlap between the different neuromodulatory 
systems, as observed here. Indeed, manipulation of a single neuromodulatory system, 
or use of a single drug, would be agnostic to such an overlap and could make any one 
effect appear more relevant and specific than it is. The pharmacological approach also 
meant that it was possible to extend the interpretations of earlier neuroimaging studies 
(Iglesias et al., 2013; Payzan-LeNestour et al., 2013), from which it is not possible to 
infer with certainty that activations in particular brain regions, with inhomogeneous 
cellular compositions, reflect the activity of specific neuromodulatory neurons.  
4.5.1 Overlapping, but dissociable, noradrenergic and cholinergic influences 
on perceptual belief updating 
Considerable overlap in the influence of NA and ACh antagonism on perceptual belief 
updating was identified, but there were also quantitative differences between the drug 
conditions. While part-synergistic, part-antagonistic interactions between the two 
neuromodulators during uncertainty processing have been theorised previously (Yu and 
Dayan, 2005), to my knowledge this is the first study to directly assess these putative 
computational roles, and to distinguish them from dopaminergic effects, under three 
pharmacological manipulations and within the same computational framework. I propose 
that ACh guides probabilistic learning within environmental contexts, while NA has a 
more circumscribed role in modulating the rate at which an agent learns about the 
volatility latent in the environment.  
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4.5.1.1 Noradrenaline influences beliefs about unexpected environmental 
changes 
The present results suggest that NA antagonism under prazosin altered the rate at which 
individuals updated their volatility beliefs, as indicated by an increase in the model 
parameter ϑ. An influence of NA- on ϑ fits with the theorised role for NA in computing 
uncertainty arising from changes in environmental context (Yu and Dayan, 2005). 
Numerous studies have offered evidence that the NA system is sensitive to highly 
unexpected events that arise from a hidden contextual change. Noradrenergic neurons 
in the rat and nonhuman primate LC are responsive to environmental novelty and 
unexpected changes in reward contingencies (Sara and Segal, 1991; Vankov et al., 
1995; Aston-Jones et al., 1997; Bouret and Sara, 2004). Additionally, changes in pupil 
diameter, attributed at least in part to noradrenergic LC activity (Murphy et al., 2014; 
Varazzani et al., 2015; Joshi et al., 2016), have been shown to correlate with unexpected 
outcomes (Preuschoff et al., 2011; Nassar et al., 2012; Browning et al., 2015). I will return 
to this concept in Chapter 6. 
More specifically, in the present study, faster volatility belief updating was observed 
following NA antagonism. In the HGF model, ϑ represents the volatility of the volatility, 
and thus the results suggest that NA stabilises an agent’s estimate of environmental 
volatility. This is compatible with the notion that the volatility estimate has a relatively low 
baseline level, to which it returns after being pushed away. In a volatile environment, this 
is not an adaptive feature. Rather, the volatility estimate should remain high to enable 
revision of one’s beliefs. It is possible that NA prevents the volatility estimate from falling 
by reducing an agent’s ϑ estimate.  
The neurophysiological literature has distinguished two functional modes of LC 
noradrenergic release (Aston-Jones and Cohen, 2005b; Bouret and Sara, 2005). A 
phasic mode, characterised by a relatively low baseline firing rate and high phasic 
responsiveness to task relevant stimuli, has been linked to enhanced task engagement, 
and a tonic mode to increased distractibility, attention-shifting and exploratory behaviour 
(Aston-Jones et al., 1994; Usher et al., 1999; Aston-Jones and Cohen, 2005b, but see 
Jepma et al., 2010). More recently, BOLD activity in the human LC was demonstrated to 
correlate with “unexpected uncertainty” induced by a switch in reward probabilities 
associated with familiar stimuli (Payzan-LeNestour et al., 2013), although the negative 
sign of this correlation still seems to lack explanation. In both my task and that used by 
Payzan-LeNestour et al., contextual switches required participants to identify discrete 
changes in underlying transitions between familiar stimuli. To continue making accurate 
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predictions in light of new transition probabilities, participants had to increase their 
attentional engagement to facilitate an augmented learning rate. It is likely that in both 
cases a phasic LC activity mode was recruited, and that this would be recognised as a 
decrease in BOLD activity at a neuronal population level. Speculatively, it also suggests 
that the pharmacological NA manipulation in my study may have enabled more phasic 
NA responsiveness to emerge under suppression of tonic NA firing. Future investigations 
of the impact of noradrenergic drugs on LC activity profiles are needed to validate this 
theory. 
4.5.1.2 Acetylcholine balances the attribution of uncertainty within and between 
environmental contexts 
Muscarinic ACh receptor antagonism by biperiden led to slower updating of beliefs about 
stimulus transition contingencies, and so slower adaptation to the probabilistic contexts, 
as reflected by a decrease in the model parameter ω. I argue that this slowed adaptation 
also had knock-on effects higher up in the inferential hierarchy. Specifically, I propose 
that participants attributed perceived violations of their expectations to gross contextual 
switches as opposed to chance fluctuations in stimulus outcomes, which would be 
expressed as an increase in ϑ. In light of previous work, which I discuss next, it seems 
reasonable to suggest that by setting the rate at which an agent learns probabilistic 
associations, ACh facilitates the appropriate attribution of violated expectations to 
chance fluctuations in an environment’s statistical regularities, or to gross switches in 
environmental context. 
According to the structure of the HGF, a reduction in ω maps onto a reduced precision-
weighting of perceptual belief updates at level 2 (compare Equation 3.15 and Equation 
3.11). The present findings indicate that under biperiden less weight was given to 
sensory evidence, and updates of probability estimates became more reliant on current 
beliefs. This supports proposed roles for ACh in regulating the relative influences of 
stimulus-driven versus expectation-guided processing (McGaughy et al., 2008; Bentley 
et al., 2011) and attentional deployment (Bucci et al., 1998; Chiba et al., 1999). For 
instance, it has been shown that pharmacologically stimulating ACh augments bottom-
up sensory signalling in human primary auditory cortex in response to auditory stimuli, 
possibly by enhancing the gain of superficial pyramidal cells, to bias inference towards 
sensory data (Moran et al., 2013). 
In a recent study, Vossel et al. examined perceptual belief updating during a probabilistic 
attentional cueing paradigm. By applying a similar instantiation of the HGF to saccadic 
reaction times, the authors demonstrated faster learning about contextual probabilities 
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following administration of galantamine, an acetylcholinesterase inhibitor which 
increases the synaptic availability of ACh, as indicated by an increase in model 
parameter ω (Vossel et al., 2014a). In the present study, the opposite behavioural effect 
was observed with the opposite pharmacological manipulation (ACh receptor 
antagonism), offering independent evidence that ACh signalling guides belief updating 
about probabilistic associations within environmental contexts.  
The present results also indicate that ACh antagonism led individuals to update their 
volatility estimates more rapidly, reflected by an increase in the model parameter ϑ. This 
is consistent with the notion that ACh- participants’ impaired ability to learn transition 
contingencies led them to infer that contexts changed at a faster rate. Notably, in their 
theoretical framework, Yu and Dayan predicted that ACh depletions should cause an 
agent to underestimate the amount of randomness in a given context. In turn, this causes 
chance events occurring within a context to seem more significant than they are, 
meaning they are more likely to be incorrectly taken as indicative of a context change 
(see Figure 6D in Yu and Dayan, 2005). My experimental observations support this 
hypothesis and are compatible with data indicating that cholinergic antagonists increase 
distractibility (Jones and Higgins, 1995) while agonists suppress it (Prendergast et al., 
1998; Terry et al., 2002; O’Neill et al., 2003). 
It should be noted that, although the perceptual quantities used in this current work are 
not identical to those previously introduced by Yu and Dayan (Yu and Dayan, 2005), the 
HGF does embody versions of the same forms of uncertainty. The highest level of 
uncertainty in the Yu and Dayan (YD) framework was induced by abrupt, discrete, 
changes in contingencies, which induced what YD call “unexpected uncertainty” (and 
ascribed to NA). By contrast, the highest level of uncertainty in the HGF is the overall 
instability of the world, i.e., the rate at which volatility changes. It is this that I found to be 
modulated by the NA antagonist. Conversely, YD’s notion of “expected uncertainty” 
(ascribed to ACh) suggests that it arises from the known unreliability of predictive 
relationships within a familiar environmental context. Amongst other effects, the lower 
the expected uncertainty, the slower the learning – consistent with the effect of parameter 
ω in the HGF, which was found to decrease under cholinergic antagonism. Along with 
YD, I also argue that this change in learning has further knock-on effects for what 
participants perceive to be a chance random event, or a change of context (and hence 
unexpected uncertainty). 
In sum, my findings offer empirical support for the theoretical proposal that ACh and NA 
interact to construct appropriate cortical representations of volatile contexts, which 
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facilitates optimal inferences about the current environment (Yu and Dayan, 2005). By 
regulating high-level uncertainty representations, the two neuromodulators contribute to 
the updating of an individual’s perceptual beliefs, both within and between environmental 
contexts, an idea that is broadly supported by recent neuroimaging (Iglesias et al., 2013; 
Payzan-LeNestour et al., 2013; Diaconescu et al., 2017) and pharmacological (Vossel 
et al., 2014a) evidence.  
4.5.2 Dopamine sensitises motor responses to environmental volatility 
As per its construction, the present instantiation of the HGF allowed me not only to 
characterise perceptual belief updating under three pharmacological manipulations, but 
also to assess how each intervention influenced the deployment of motor responses in 
in light of individual estimates of uncertainty. Pharmacologically manipulating DA and 
ACh altered the degree to which participants’ perceptual beliefs modulated the 
preparation of their speeded responses to uncertain stimuli. In contrast, NA antagonism 
had no significant impact on the sensitivity of participants’ motor responses to their 
current perceptual beliefs, relative to placebo. 
I had originally predicted that an individual’s capacity to modulate response selection 
following a sensory PE would be dependent on DA. Indeed, it has previously been shown 
that pharmacological DA depletion impedes adaptive reactions to unexpected events 
occurring within predictable contexts (Bestmann et al., 2014). However, in the present 
study, there was no evidence to suggest that DA receptor antagonism influenced 
participants’ reactions to low-level sensory PE (𝛿1). Rather, suppressing DA significantly 
reduced β3, which I interpret as a reduction in the sensitivity of participants’ motor 
responses to their higher-level phasic volatility estimates (𝜇3).  
It is important to note that some key differences distinguish the present experimental 
design from previous paradigms. In earlier work, participants were pre-trained to respond 
to stimuli presented within one predictable context, defined by one transition matrix. 
Furthermore, switches from predictable to unpredictable contexts, consisting of random 
presentations of stimuli, were explicitly signalled (Bestmann et al., 2014). Therefore, any 
probabilistic learning and higher-level perceptual uncertainty was removed. In this earlier 
setting, dopaminergic antagonism under haloperidol selectively impaired participants’ 
reactions to unexpected events that elicited large sensory PEs. 
In contrast, the present task created a more complex, and arguably more ecologically 
valid, scenario in which individuals had to infer the current context for themselves and 
adapt to any contextual changes. Here, uncertainty representations had to be acquired 
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through direct sampling from a distribution of observations. To my knowledge, the current 
study is the first attempt to interrogate the impact of NA, ACh and DA on non-rewarded 
probabilistic learning within a single behavioural paradigm and a unified Bayesian 
framework. By estimating beliefs about various forms of uncertainty, I sought to identify 
neuromodulatory contributions specifically related to particular forms of uncertainty, as 
opposed to any confounding variables. 
Related to this point, a large body of literature examining the role of DA in the context of 
PE has focused on reward, rather than sensory, PE. Specifically, it is widely thought that 
phasic activity of dopaminergic neurons in the midbrain signals the discrepancy between 
the predicted and experienced reward of a particular event (Schultz et al., 1997; 
Hollerman and Schultz, 1998; O’Doherty et al., 2003; Nakahara et al., 2004; Bayer and 
Glimcher, 2005; Abler et al., 2006; Daw and Doya, 2006; Pessiglione et al., 2006; 
D’Ardenne et al., 2008; Hare et al., 2008; Matsumoto and Hikosaka, 2009; Zaghloul et 
al., 2009; Diederen et al., 2017). The fact that probabilistic learning was unrewarded in 
the present experiment is one possible reason why no dopaminergic effects on motor 
responses to low-level sensory PE were observed. 
Nonetheless, there have been reports of a role for DA in PE signalling outside the 
framework of reward (Redgrave et al., 1999; den Ouden et al., 2012; Friston et al., 2012; 
Galea et al., 2012; Bestmann et al., 2014; Tomassini et al., 2015). Further, it should be 
noted that the HGF’s perceptual model only outputs participant-specific (constant) 
parameters at the higher levels. As such, in the present study, it was not possible to 
compare the effects of DA antagonism on sensory PE to Placebo using the approach 
adopted to examine the effects of NA and ACh on parameters ϑ and ω. Within the 
framework of the current instantiation of the HGF, it would have been possible to identify 
an altered effect of sensory PE on motor responses (parameter β1) under DA 
antagonism, but not a general effect on the perception of sensory PE. Using fMRI, 
Iglesias et al. observed that activity in the dopaminergic midbrain correlated with 
precision-weighted sensory PE (parameter 𝜀2) during an alternative probabilistic learning 
task (Iglesias et al., 2013), providing a further indication that DA is involved in updating 
beliefs in light of low-level sensory PE. Indeed, the authors identified this correlation both 
when learning was orthogonal to monetary reward and when reward was omitted from 
the behavioural task entirely. Future work combining neuroimaging and pharmacological 
manipulations of DA will help to pinpoint the neuromodulator’s precise role in perceptual 
belief updating and response modulation. 
4. Pharmacological fingerprints of uncertainty 
138 
 
The finding that haloperidol reduced the sensitivity of participants’ responses to their 
phasic volatility estimates does sit well with an alternative line of work highlighting the 
importance of DA in behavioural switching (Cools et al., 2009; van Holstein et al., 2011). 
For instance, Parkinson’s disease patients with DA dysfunction have an impaired 
capacity to switch from naming digits to letters when both types of stimuli are presented 
simultaneously, even when the task-shift is explicitly cued (Cools et al., 2001a). In 
summary, I propose that DA antagonism suppressed response modulation by impeding 
switching following complex contextual rule changes.   
Muscarinic ACh receptor antagonism under biperiden also led to decreased response 
modulation by parameters at all three hierarchical levels, sensory PE (𝛿1), precision-
weighted contingency PE (𝜀3) and phasic volatility estimates (𝜇3), compared to Placebo. 
I propose that ACh receptor antagonism impeded participants’ abilities to learn the 
statistical structure of the behavioural task, which in turn impaired their capacities to 
respond accordingly. Although both ACh and DA had effects on response modulation, in 
light of previous work, I suggest that DA’s role is to modulate motor responses according 
to the widespread perceptual effects of ACh. 
4.5.3 Limitations and future work 
One of the main constraints of the study is that although prazosin, biperiden and 
haloperidol are rather selective for NA, ACh and DA receptors respectively, there are 
complex interactions and dependencies between noradrenergic, cholinergic and 
dopaminergic systems. Such interactions are a main reason why direct quantitative 
comparison between drug groups would not have provided direct comparisons between 
the action of different neuromodulators, and therefore why the current study was 
designed to detect changes relative to placebo instead. While the results highlight 
qualitative differences in how NA, ACh and DA influence perceptual belief updating, 
future work will have to conduct direct quantitative comparisons of their roles. 
Further, it is the receptors rather than the neuromodulators themselves that bring about 
psychophysiological effects, and there are dissociable roles of different receptor sub-
types. For instance, the functions of nicotinic versus muscarinic cholinergic receptors in 
uncertainty signalling have yet to be directly compared. Distinctions have also been 
made between D1 and D2 dopaminergic receptor sub-types in regulating adaptive 
responses to unexpected stimuli (Bestmann et al., 2014). Thus, future work could 
usefully be extended with a range of selective agonists and antagonists for different 
receptor sub-types. In Chapter 5, I adopt an alternative behavioural genetics approach 
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to investigate the effects of natural inter-individual variations in DA neurotransmission on 
perceptual belief updating and response modulation. 
Finally, it is likely that all the neuromodulators operate over multiple timescales - for 
instance, separate, even competing, tonic and phasic effects have been a special target 
of investigation for NA (Aston-Jones and Cohen, 2005a). Teasing these timescales apart 
more fully is an ambition for the future, requiring a temporally richer design. 
Nevertheless, the current findings emphasise the necessity of studying the NA, ACh and 
DA systems conjointly, as tasks associated with uncertainty will tend to involve them all. 
4.5.4 Conclusion 
In summary, these results offer novel and direct insight into the complex and intricate 
effects of NA, ACh and DA during a PSRTT. Employing a hierarchical Bayesian learning 
model to interrogate various forms of uncertainty and PE, provided interventional 
evidence linking ACh and NA to uncertainty computations within and between 
behavioural contexts. In contrast, DA appears to be involved in sensitising motor 
responses to perceptual volatility estimates. While pharmacological manipulations do not 
selectively target particular neuromodulatory systems, the results offer a fresh 
perspective on the effects of noradrenergic, cholinergic and dopaminergic 
neurotransmission on the computational mechanics of perceptual belief updating 
according to Bayesian principles. Future studies will verify the generality of the observed 
effects to different behavioural paradigms with and without learning, reward, prediction 
and action. By characterising uncertainty computations and response modulation, the 
methodology reported here could also be used to offer fresh insight into the numerous 
neurological and psychiatric disorders in which there is dysregulation of processes 
dependent on NA, ACh and DA. 
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5 Genetic fingerprints of uncertainty 
5.1 Abstract 
Behavioural genetics offers an alternative means by which to investigate the relative 
contribution of different neuromodulators to human learning and action under 
uncertainty. A range of proteins, from receptors to transporters and degradative 
enzymes, regulate dopaminergic, noradrenergic and cholinergic neurotransmission. 
Polymorphisms in the genes that encode these proteins give rise to natural inter-
individual variations in neuromodulatory function and to alterations in behaviour. The 
Val158Met polymorphism in the COMT gene has received particular attention within the 
behaviour genetics literature, with an array of studies having identified variations in 
dopaminergic neurotransmission and behavioural flexibility as a function of COMT 
genotype. In this chapter, I employ the same probabilistic serial reaction time task 
(PSRTT) and the same instantiation of the Hierarchical Gaussian Filter (HGF) model 
used in Chapter 4 to study individual computations of uncertainty and motor response 
modulation in a naïve sample of 116 healthy human volunteers. I first replicate the 
behaviour displayed by the Placebo participants in Chapter 4, and verify the capacity of 
the HGF to capture individual perceptual belief updating and response modulation within 
a single computational framework of irreducible, estimation and volatility uncertainty. 
Next, I examine the impact of dopaminergic neurotransmission on these processes by 
assessing perceptual belief updating and response modulation as a function of COMT 
genotype. The participant sample size is shown to be insufficient to ascertain whether 
COMT genotype has any impact on dopamine-specific learning or action under 
uncertainty. I discuss how future behavioural genetics approaches could offer fresh 
insight into the relative roles of dopamine (DA), noradrenaline (NA) and acetylcholine 
(ACh) to learning and action in dynamic probabilistic environments.  
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5.2 Introduction 
Pharmacological manipulations offer one methodological tool with which to assess the 
neuromodulatory underpinnings of learning and action in uncertain environments. 
However, as discussed in Chapter 4, the technique does have its caveats. There are 
complex interactions and dependencies between different neuromodulatory systems, 
and different pharmacological agents have different specificities for different receptor 
sub-types. An alternative approach is to examine learning and action under the natural 
variations in neuromodulatory function that occur due to polymorphisms in the genes 
encoding neuromodulatory receptors, transporters and degradative enzymes (Frank et 
al., 2007, 2009; Tan et al., 2007a, 2007b; Green et al., 2008; Ullsperger, 2010; den 
Ouden et al., 2013; Doll et al., 2016). 
As discusses in Chapter 1, in the context of probing the relative contributions of NA, ACh 
and DA to learning and action under uncertainty, polymorphisms in the genes that 
encode the dopamine transporter (DAT), the noradrenaline transporter (NET), the 
degradative enzymes catechol-O-methyltransferase (COMT) and acetylcholinesterase 
(ACHE), and the dopaminergic D2-receptor are of particular interest.  A summary of the 
functions of these five proteins, known polymorphisms in the genes that encode them, 
and any established impact on neuromodulatory phenotype is provided in Table 5.1. For 
additional details, please refer back to Chapter 1. 
Gene Function Polymorphism Phenotype 
COMT Encodes the COMT 
enzyme, which catalyses 
the degradation of 
catecholamines, 
including DA, especially 
in the prefrontal cortex 
Val158Met single 
nucleotide 
polymorphism (SNP) at 
rs4680, resulting in Val 
and Met alleles 
Met allele is associated 
with decreased COMT 
activity and increased 
DA neurotransmission 
DAT1 Encodes the DAT, which 
mediates the reuptake of 
DA from the synaptic 
cleft, especially in the 
striatum 
Variable number 
tandem repeat (VNTR) 
at  rs28363170 (the 3’ 
untranslated region), 
commonly resulting in 
9- (9R) and 10-repeat 
(10R) alleles 
9R allele has been 
associated with altered 
DAT availability and a 
putative change in DA 
neurotransmission, but 
the precise functional 
impact is speculative 
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DRD2 Encodes the DA D2-
receptor, of which there 
is a particularly high 
striatal density 
SNP at rs1800497, 
resulting in A1 and A2 
alleles 
A2 allele associated 
with increased DA D2-
receptor expression 
NET Encodes the NET, which 
mediates the reuptake of 
NA from the synaptic 
cleft 
SNP at rs2242446, 
resulting in C and T 
alleles 
Any functional impact 
on NA 
neurotransmission is 
unclear 
ACHE Encodes the ACHE 
enzyme, which catalyses 
the degradation of ACh 
SNP at rs2571598, 
resulting in A and G 
alleles 
Any functional impact 
on ACh 
neurotransmission is 
unclear 
 
Table 5.1 Summary of genetic polymorphisms that modulate neuromodulatory 
function. The Val158Met SNP in the COMT gene is one of the best studied 
polymorphisms in the behavioural genetics literature, with effects on COMT activity and 
DA neurotransmission being relatively well established. Polymorphisms in the DAT1 and 
DRD2 genes are also thought to impact on DA neurotransmission, but their precise 
functional effects are speculative. Any functional impact of the NET and ACHE 
polymorphisms on neuromodulatory transmission is also currently unclear.  
Behavioural genetics has several methodological advantages. First, it permits the effects 
of different neuromodulatory systems to be assessed within individuals and in a single 
experimental session. Second, it offers a means by which to investigate the relative 
contribution of neuromodulators to learning and action without any confounding effects 
of pharmacological interventions. For instance, pharmacological agents are often not 
wholly specific for particular receptor sub-types and they likely modify the baseline 
dynamics, interactions and compensatory mechanisms of different functionally-coupled 
neuromodulatory systems. Third, identifying the functional consequences of 
polymorphisms in the genes that encode different neuromodulatory receptors and 
transporters, with different relative distributions throughout the brain, holds the potential 
to better elucidate the contributions of different neuromodulatory signalling pathways to 
learning and action under uncertainty. 
This chapter was motivated by the possibility to characterise the effects of COMT, DAT1, 
DRD2, NET and ACHE genotypes on learning and response modulation within 
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individuals undertaking the same PSRTT applied in Chapter 4. To recap, the PSRTT 
exposes participants to three distinct forms of uncertainty: irreducible uncertainty arising 
from the inherent randomness of the probabilistic transitions between consecutive 
stimuli, estimation uncertainty arising from an individual’s imperfect knowledge of the 
probabilistic relationships governing stimulus transition contingencies within contexts, 
and volatility uncertainty arising from contextual instability. By applying the novel 
instantiation of the HGF model to the behavioural data, the original aim was to 
characterise the impact of dopaminergic, noradrenergic and cholinergic genotypes on 
perceptual belief updating and response modulation in dynamic probabilistic 
environments. 
While the influence of COMT genotype on cortical dopaminergic neurotransmission is 
relatively well established (Gogos et al., 1998; Männistö and Kaakkola, 1999; Akil et al., 
2003; Chen et al., 2004; Tunbridge et al., 2004; Yavich et al., 2007), investigations of 
learning and action as a function of DAT1, DRD2, and particularly NET and ACHE, 
genotypes would have been more exploratory. Indeed, the functional impact of the latter 
four genes on dopaminergic, noradrenergic and cholinergic neurotransmission is 
currently more elusive. Nevertheless, behavioural investigations of polymorphisms in the 
COMT, DAT1, DRD2, NET and ACHE genes hold the potential to extend the 
pharmacological results in Chapter 4 by further elucidating the roles of DA, NA and ACh 
in learning and response modulation under uncertainty. In particular, in light of the finding 
that pharmacological DA antagonism reduced the sensitivity of motor responses to 
phasic volatility estimates but not to sensory prediction error (PE), a key motivation for 
investigating any impact of COMT and DAT1 genotypes on response modulation within 
the same computational framework was the possibility to identify separable cognitive 
(cortical) and motoric (striatal) DA-mediated processes underlying flexible behaviour, 
respectively.  
Unfortunately, careful scrutiny of the genetic data revealed that the laboratory that 
undertook the genotyping analyses had not provided reliable genotypic summaries for 
all five genes in the first cohort of individuals from whom genetic data was collected. As 
such, participant recruitment was halted early. One gene for which I do have reliable 
genotypic data from 116 participants is COMT. Therefore, in the following, I focus on 
assessing the effects of three dopaminergic COMT genotypes on perceptual belief 
updating and response modulation during the PSRTT. This approach complemented the 
methodology employed in Chapter 4 by facilitating an alternative examination of 
dopaminergic contributions to learning and action in uncertain environments, focusing 
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on cortical DA neurotransmission and free from potentially confounding effects of 
pharmacological DA manipulations. 
5.2.1 The Val158Met COMT polymorphism 
To reiterate Chapter 1, the COMT gene encodes the COMT enzyme which catalyses the 
degradation of catecholamines, particularly cortical DA (Gogos et al., 1998; Akil et al., 
2003; Tunbridge et al., 2004; Yavich et al., 2007). A single nucleotide polymorphism 
(SNP) at rs4680 results in an amino acid switch from valine (Val) to methionine (Met), at 
codon 158. The Met isoform has reduced thermostability at body temperature, resulting 
in a 3-4 fold decrease in COMT enzymatic activity compared to the Val isoform, and so 
higher synaptic DA concentrations (Männistö and Kaakkola, 1999; Chen et al., 2004). In 
contrast, the Val allele is associated with higher enzymatic activity and so lower synaptic 
DA availability. 
5.2.2 Probing a role for dopamine in perceptual belief updating and response 
modulation 
In Chapter 4, dopaminergic antagonism under haloperidol was found to decrease the 
sensitivity of participants’ motor responses to their beliefs about the environment’s 
volatility. In contrast, no effects of DA antagonism were observed on the rate at which 
participants learned about contextual transition contingencies or the volatility of these 
contingencies over time. As discussed in Chapter 4, I had originally predicted that DA 
would modulate an individual’s capacity to modulate response selection following a low-
level sensory PE owing to previous work demonstrating that pharmacological DA 
depletion impedes adaptive reactions to unexpected events occurring within predictable 
contexts (Bestmann et al., 2014). While the absence of an effect of DA on response 
modulation by sensory PE can be explained by differences in experimental paradigms, 
and while the finding that DA sensitises motor responses to phasic volatility estimates 
sits well with a hypothesised role for DA in behavioural switching (Cools et al., 2001a, 
2009; van Holstein et al., 2011), in the present experiment I sought to extend these 
findings beyond a pharmacological approach. 
5.2.2.1 Replication of learning and action during the PSRTT 
In particular, employing the same PSRTT and novel instantiation of the HGF applied in 
Chapter 4, I tracked human learning and response modulation in a dynamic probabilistic 
environment that gave rise to irreducible, estimation and volatility uncertainty. It was 
therefore possible to investigate whether the learning and behaviour observed in Chapter 
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4’s Placebo group could be replicated in a naïve cohort of healthy individuals, and 
whether the HGF model would perform as well as it had done in its first application.   
5.2.2.2 Replication of dopaminergic effects on learning and action 
Next, since the HGF captures an individual’s learning of the task’s structure and maps 
their beliefs onto their observed reaction time (RT) responses, participant-specific 
perceptual belief updating could be disentangled from the sensitivity of motor response 
to perceptual estimates. Further, it was possible to assess belief updating and response 
modulation as a function of COMT genotype. Given that COMT regulates DA 
neurotransmission, I aimed to: 
1. Replicate the finding that DA sensitises an individual’s motor responses to their 
phasic volatility estimates. Given that Met carriers show lower COMT activity 
and thus higher DA neurotransmission than Val/Val homozygotes, I 
hypothesised that motor responses in Val/Met and Met/Met individuals would 
show increased sensitivity to phasic volatility estimates (Figure 5.1E). 
2. Probe whether the sensitivity of an individual’s motor responses to their sensory 
PE varies as a function of COMT genotype, suggesting a modulatory role for 
DA. Based on previous work (Bestmann et al., 2014), I hypothesised that motor 
responses in Met carriers might show increased sensitivity to sensory PE 
(Figure 5.1D). However, the results of Chapter 4 would predict no effect of DA 
on this parameter.  
3. Replicate the finding from Chapter 4 that reduced DA neurotransmission leads 
to general RT slowing, echoing bradykinesia in Parkinson’s disease, a disorder 
characterised by DA depletion in the substantia nigra (Berardelli et al., 2001). I 
hypothesised that the constant component of RT would be increased in Val/Val 
homozygotes (Figure 5.1C).  
4. Replicate the finding that DA neurotransmission does not modulate the speed 
at which individuals update their beliefs about phasic volatility (Figure 5.1A) or 
contextual transition contingencies (Figure 5.1B). 
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Figure 5.1 Predicted effects of COMT genotype on perceptual belief updating and 
response modulation. (A-B) Based on the pharmacological DA results of Chapter 4, 
increasing DA neurotransmission in Met carriers would be expected to have no effects 
on perceptual belief updating (i.e., on parameters ϑ and ω). (C-E) The pharmacological 
findings predict motor response modulation would vary between Met carriers and Val/Val 
homozygotes. Specifically, increased DA neurotransmission in Met carriers would be 
expected to decrease the constant component of log(RT) responses (β0) and increase 
the sensitivity of motor responses to phasic volatility estimates (β3). The pharmacological 
results would predict no effect of COMT genotype on the sensitivity of motor responses 
to sensory PE (β1) (D; dashed line) but, given previous work demonstrating that DA 
depletion is associated with impaired reactions to unexpected events occurring in 
predictable contexts, I hypothesised that motor responses in Met carriers would show 
increased sensitivity to sensory PE (D; solid line). 
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5.3 Methods 
5.3.1 Participants 
116 healthy participants (18 male, aged 18-31 years, 73 Caucasian) with normal or 
corrected-to-normal vision took part in this study after giving written informed consent. 
The experiment was run in collaboration with the University of Birmingham. The 
experimental protocol was approved by the University of Birmingham Research Ethics 
Committee. 
5.3.2 Probabilistic serial reaction time task 
The experimental setup and PSRTT used were based on those described in Chapter 4. 
In brief, participants sat facing a computer screen positioned approximately 60cm away. 
They were instructed to rest their left and right index and middle fingers on four marked 
keys on a computer keyboard, and to maintain this position throughout the task. On each 
trial, participants were required to respond to the presentation of one of four visual stimuli 
by making a speeded button-press before the end of a 1200ms intertrial interval (ITI). 
Each stimulus was associated with one particular button. The stimulus-response 
mappings remained consistent within an experimental session but were counterbalanced 
across participants. 
5.3.2.1 Training 
Each participant acquired the stimulus-response mappings for their session during a 
training block in which they received visual error feedback after each trial. The training 
session comprised at least 100 trials and did not finish until the participant had reached 
a minimum performance criterion of 85% accuracy on the last 20 trials. Participants were 
then given 15 practice trials, in which the stimuli were presented in a random order and 
without error feedback, to familiarise them with the timings of the main experiment. On 
average, participants responded correctly on 90.4 ± 1.1% (± SEM) of the practice trials, 
indicating adequate learning and retention of the mappings. 
5.3.2.2 Task design 
Each participant performed 800 trials of the PSRTT. At any given time, there was an 
underlying probabilistic rule, defined by one of eight transition matrices (TMs), which 
determined the probabilistic relationship between the stimulus presented on trial, t, and 
the stimulus presented on the previous trial, t-1. The TM switched every 50 trials without 
explicit indication to the participant. The TMs comprised the two 1st-order and four 0th-
order TMs used in Chapter 4 (Figure 2.1), as well as two additional 1st-order TMs (Figure 
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2.2). Trials were drawn from each TM twice. The order of TMs was pseudorandom, with 
no consecutive repeats. The overall probability of each stimulus was equal across the 
800 trials.  
As in Chapter 4, the different TMs created contexts that the participants could infer from 
stimulus observations. For fast and accurate responses, participants had to track 
irreducible uncertainty arising from the inherent randomness of the probabilistic 
transitions between consecutive stimuli; estimation uncertainty arising from their 
imperfect knowledge of the probabilistic relationships governing stimulus transition 
contingencies within contexts; and volatility uncertainty arising from the unsignalled 
contextual instability. 
The pseudorandom order of TMs was used to generate one stimulus sequence that was 
used for all participants to ensure comparable learning processes and model parameter 
estimates. Rest periods occurred every 215 trials, orthogonal to TM switches. The 
importance of fast responses was stressed. Participants were told that by paying 
attention to any patterns in the order in which stimuli were presented, and to any switches 
in these patterns, it may be possible to respond faster. No further information about the 
nature of the experiment was provided. Anticipatory responses (<80ms) were recorded 
as incorrect. 
5.3.3 General procedure 
Participants were recruited from the University of Birmingham Undergraduate 
Psychology Student cohort. To ascertain the effects of DA neurotransmission on learning 
and action in uncertain environments, any differences in perceptual belief updating and 
response modulation during the PSRTT were assessed as a function of COMT genotype.  
5.3.4 Genotyping 
Genomic DNA was extracted from saliva samples collected from each participant using 
the Oragene OG-500 self-collection kit (Oragene, DNA Genotek Inc., Canada) according 
to the manufacturer’s recommendations. Molecular genetic analyses were performed at 
the West Midlands Genetic Laboratory at Birmingham Women’s Hospital. Next 
generation sequencing was conducted to genotype the SNP at rs4680 within the COMT 
gene. 
Salivary DNA was extracted according to standardised protocols and quantified using 
Qubit fluoriometry. Genotyping was carried out by multiplex polymerase chain reaction 
(PCR) amplicon resequencing. In brief, PCR amplicons flanking the SNP of interest were 
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designed via identification of their position in the UCSC hg19 reference genome. 
Reference sequences for +/- 200 base pairs flanking the SNP were retrieved and a 
sequencing amplicon was designed using Primer 3 (Untergasser et al., 2012) set for an 
annealing temperature of 60oC and with design conditions as recommended for Fluidigm 
Access Array primer design. Primers were validated using gradient PCR. 20ng of 
genomic DNA collected from participants was pooled and barcoded. Multiplex amplicon 
PCR was carried out using the Fluidigm Access Array system using standard conditions. 
The multiplexed library was diluted to a loading concentration of 4pM and sequenced on 
an Illumina MiSeq using a v2 500 cycle kit. Each amplicon was sequenced to a minimum 
read depth of 2000x. FASTQ files were exported from the sequencing instrument, quality 
trimmed with Trimgalore and aligned to the hg19 reference genome using Bowtie2 
(Langmead and Salzberg, 2012). SNP variants were called using FreeBayes (Garrison 
and Marth, 2012) and annotated using ANNOVAR (Yang and Wang, 2015). Variant QC 
was carried out by visual inspection of 10% of amplicon calls for 10% of samples using 
the UCSC genome browser. 
PCR primers were designed to flank the SNP, producing a 249 base pair amplification 
product (Table 5.2). 
 Forward primer Reverse primer 
COMT CGAGGCTCATCACCATCGAG GGGAGGACAAAGTGCGCAT 
 
Table 5.2 Sequence primers for the COMT SNP (rs4680).  
5.3.5 Model-agnostic analyses 
Trial-wise RT was calculated as the time between stimulus onset and the subsequent 
button press. The RT data were log-transformed (Bestmann et al., 2014; Marshall et al., 
2016). A series of conventional, model-agnostic analyses of behaviour were first 
conducted to assess whether participants learned about the underlying stimulus 
transition contingencies, whether the behavioural data replicated that observed in the 
Placebo group in Chapter 4, and whether learning was modulated by COMT genotype. 
To assess the interaction between stimulus transition probability and drug, trials were 
binned according to three probability levels corresponding to the presented stimuli’s true 
transition probabilities as existed in the TMs (High: 0.85 and 0.70; Mid: 0.20; Low: 0.05) 
(Galea et al., 2012; Bestmann et al., 2014; Marshall et al., 2016). A repeated-measures 
analysis of variance (RM-ANOVA) was used to compare mean log(RTs) for correct 
responses across these three probability levels. 
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To obtain a model-agnostic indication of learning across the course of the probabilistic 
contexts, a median split was performed on each 50-trial contextual block. A RM-ANOVA 
was used to compare mean Δlog(RTs) on correct Early (1-25) vs Late (26-50) trials at 
each probability level. 
To identify any evidence of post-error slowing during the PSRTT, i.e. slower responses 
on trials following those on which participants made an error (Rabbitt, 1966; Botvinick et 
al., 2001; Gehring and Fencsik, 2001; Cavanagh et al., 2014; Marshall et al., 2016), a 
RM-ANOVA was used to compare log(RTs) on correct trials that immediately followed 
correct and erroneous responses. A further RM-ANOVA compared log(RTs) on correct, 
post-infrequent trials, i.e., trials following those with a true transition probability of 0.05, 
and correct trials following trials with a true transition probability >0.05. 
5.3.6 Model-based analyses 
The same instantiation of the HGF used in Chapter 4 (see Figure 3.4, Figure 4.2 and 
Figure 5.2) was applied to the behavioural data. To recap, this version comprises a three-
level perceptual model and a response model. 
5.3.6.1 Perceptual model 
The perceptual model tracks each participant’s estimated beliefs about the PSRTT’s trial-
wise stimulus transitions, transition contingencies, the volatility of the transition 
contingencies, and the respective irreducible, estimation and volatility uncertainty about 
these beliefs. The participant-specific parameters ϑ and ω capture the respective rates 
at which an individual updates their beliefs about phasic volatility and transition 
contingencies, and allows for individual expression of approximate Bayes-optimal 
learning. 
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Figure 5.2 The Hierarchical Gaussian Filter (HGF). The perceptual model tracks an 
individual’s learning across three levels. State 𝒙1 represents trial-wise stimulus 
transitions from one stimulus to the next, 𝒙2 the transition contingencies, and 𝑥3 the 
phasic volatility, where t is the current trial number and bold font is used to indicate a 
matrix. Participants hold and update beliefs about the true quantities at each level, with 
a mean μ and a variance σ. ϑ and ω are participant-specific parameters that couple the 
levels and determine the respective speed of belief updating about phasic volatility and 
transition contingencies. The response model describes the mapping from a participant’s 
trial-wise beliefs onto their observed log(RT) responses.  
5.3.6.2 Response model 
The response model provides a mapping from each participant’s trial-wise beliefs, as 
provided by the perceptual model, onto his/her observed log(RT) responses. To verify 
that the response model applied in Chapter 4 was equally applicable in the present study, 
three response models were constructed and compared using random effects Bayesian 
model selection (Stephan et al., 2009; Rigoux et al., 2014). The three response models 
were identical to those compared in Chapter 4 (see section 4.3.5.2). To recap, the first 
specified that trial-wise log(RT) was a linear function of a constant component of log(RT), 
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sensory PE (𝛿1), precision-weighted contingency PE (𝜀3), estimated phasic volatility (𝜇3), 
post-error slowing, and Gaussian noise (ζ). 
Response Model 1: 
log(RT)(t) =  β0 +  β1(δ1
(t)
)  +  β2(ε3
(t)
)  +  β3(μ3
(t)
)  +  β4(PostError
(t))  +  ζ(t) 
Equation 5.1 
The second contained the precision-weighted form of sensory PE (𝜀2) instead of 𝛿1. 
Response Model 2: 
log(RT)(t) =  β0 + β1(ε2
(t)
)  +  β2(ε3
(t)
)  +  β3(μ3
(t)
)  +  β4(PostError
(t))  +  ζ(t) 
Equation 5.2        
Since 𝛿1 and 𝜀2 are highly correlated, a third response model containing both parameters 
was constructed. 
Response Model 3: 
log(RT)(t) =  β0 + β1(δ1
(t)
)  + β2(ε2
(t)
)  + β3(ε3
(t)
)  +  β4(μ3
(t)
)  +  β5(PostError
(t))  +  ζ(t) 
Equation 5.3 
5.3.6.3  Model fitting 
The perceptual and response model priors were identical to those used in Chapter 4 (see 
Table 4.1). As in Chapter 4, the perceptual model assumed that participants updated 
their beliefs according to the stimulus presented on each trial, while the response model 
incorporated correct trials only. 
5.3.6.4 Parameters of interest 
To probe any dopaminergic effects on perceptual belief updating, the participant-specific 
phasic volatility learning rate (ϑ) and transition contingency learning rate (ω) were 
assessed as a function of COMT genotype. Similarly, to identify any dopaminergic effects 
on response modulation, the sensitivity of participants’ log(RTs) to their sensory PE (β1) 
and phasic volatility estimates (β3) were compared across COMT genotypes, as was the 
constant component of log(RT) (β0). 
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5.3.7 Statistical analyses 
In reporting statistical differences, a significance threshold of =0.05 was used. Where 
assumptions of sphericity were violated (Mauchly’s test p<0.05), the Greenhouse-
Geisser correction was applied. 
For comparisons across repeated-measures and across the three COMT genotypes 
(Val/Val, Val/Met and Met/Met), partial eta-squared (ηp2) is reported as the effect size. 
For analyses of the perceptual and response model parameters of interest, one-way 
ANOVAs were first conducted to assess any impact of the three COMT genotypes. Due 
to the different sample sizes across genotypes (Table 5.4), further exploratory analyses 
were conducted. Here individuals with a Val/Met or Met/Met genotype were grouped to 
form a single set of 37 Met carriers. Independent t-tests were then applied to compare 
Met carriers to Val/Val homozygotes. To recap, the Met isoform produces a less active 
form of COMT, resulting in higher dopaminergic neurotransmission due to reduced 
catecholamine degradation. Before conducting each independent t-test, Levene’s test 
was used to verify that there was no significant difference in the variances of the 
populations from which the data samples had been drawn. For independent t-tests, 
Cohen’s d is reported as the effect size. 
5.3.8 Control analyses 
5.3.8.1 Model parameter correlations 
To demonstrate that the HGF provided a good fit to the behavioural data, the correlations 
between the Bayesian parameter averages (BPAs) for the model parameters were 
assessed. 
5.4 Results 
Data from 116 participants are reported. A summary of demographics is provided in 
Table 5.3. 
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 Participants 
(n = 116) 
Gender 
(number male) 
(number female) 
 
18 
98 
Age 
(years) 
19.6 ± 2.1 
Education Level 
(1-5) 
2.2 ± 0.1 
Ethnicity (%) 
Caucasian 
Asian 
African 
Mixed Race 
Other 
 
62.9 
23.3 
6.0 
6.0 
1.7 
 
Table 5.3 Summary details for all 116 participants. Education Level refers to the 
highest attained from the following: 1 = compulsory education (≤ 12 years); 2 = further 
education (13-14 years); 3 = undergraduate degree (15-17 years); 4 = one postgraduate 
degree (≥ 18 years); 5 = multiple postgraduate degrees. Age data are mean ± SD. 
Education data are mean ± SEM.  
5.4.1 Model-agnostic results 
On average, participants made correct responses on 88.5 ± 0.5% (± SEM) of trials, which 
was equivalent to the Placebo group’s mean correct response rate (90.3 ± 0.8% of trials) 
in Chapter 4 (t146=1.65, p=0.101). Note that Levene’s test indicated that that there was 
no significant difference in the variances of the populations from which the genetic and 
Placebo data samples were drawn (F=2.88, p=0.092). 
A 3 probability RM-ANOVA conducted on the log(RTs) for correct trials binned according 
to the four true conditional probabilities that existed in each of the transition matrices, 
grouped into High (0.85 and 0.70), Mid (0.20) and Low (0.05) transition probabilities, 
indicated that there was a significant increase in log(RTs) with decreasing transition 
probability (main effect of probability: F1.63,187.06=567.72, p<0.001, effect size ηp2=0.83; 
Figure 5.3A).  
Moreover, a RM-ANOVA on Δlog(RTs) for Late vs Early trials indicated that, across the 
course of a contextual block (Figure 5.3B), participants became faster at responding to 
High and Mid probability and slower at responding to Low probability stimuli 
(F1.89,217.30=132.45, p<0.001, ηp2=0.54). Together, these results demonstrate that 
participants showed learning of the true stimulus transition contingencies. 
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Figure 5.3 Model-agnostic results. Changes in log(RT) indicate that participants 
learned to predict the stimulus transitions, echoing the results for the Placebo group in 
Chapter 4. (A) An increase in log(RT) occurred as a stimulus’ true transition probability 
decreased. (B) A median split on each 50-trial contextual block was used to compare 
mean log(RTs) on Early (1-25) and Late (26-50) trials at each probability level. Over the 
course of a context, participants became faster at responding to High and Mid probability 
stimuli, and slower at responding to Low probability stimuli. Raw RTs are plotted here to 
simplify interpretation of ΔRT, but statistics were conducted on log(RTs). (C) Across 
drug-groups, participants showed evidence of post-error slowing on correct trials that 
followed an erroneous response compared to those that followed correct responses. (D) 
Participants also showed evidence of slowing on correct trials that followed an infrequent 
stimulus transition. Results are mean ± SEM. *** p<0.001.  
Participants in the genetics cohort also showed evidence of post-error slowing on correct 
trials that followed those on which they made an error (F1,115=119.14, p<0.001, ηp2=0.51; 
Figure 5.3C). Participants also demonstrated significant log(RT) slowing on correct, post-
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infrequent trials (true transition probability = 0.05) compared to all other correct trials 
(F1,115=952.43, p<0.001, ηp2=0.89; Figure 5.3D). 
These four findings replicate the results for the Placebo group in Chapter 4. Indeed, 
repeating the analyses with group (i.e., Genetics cohort or Placebo cohort) as a between-
subjects factor revealed no significant between-subjects effect of group on log(RTs) (all 
p≥0.14). 
Repeating each of the analyses with COMT genotype (Val/Val, Val/Met, Met/Met) as a 
between-subjects factor revealed no significant effects of genotype on log(RTs) across 
true transition probability levels (p=0.680), across the course of contextual blocks 
(p=0.167), on post-error trials (p=0.082) or on post-infrequent trials (p=0.494).  
5.4.2 Model-based results 
5.4.2.1 Perceptual model 
Overall, the HGF tracked the true stimulus transitions well (Figure 5.4). Note again that 
the model is uninformed of the true stimulus transition probabilities, but rather bases its 
estimates on the observed stimulus transitions only. 
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Figure 5.4 Estimated transition contingencies for an example participant. (A) 
Transitions between pairs of stimuli, from trial t-1 to trial t, were defined by transition 
matrices. Every 50 trials the transition matrix switched to a different matrix. (B) Each 
panel corresponds to one of the 16 possible transitions between stimuli across 800 trials. 
The black lines indicate the true transition contingencies. The blue lines reflect the 
participant’s inferred estimates (i.e., their posterior expectation of these contingencies, 
?̂?1) before seeing the stimulus outcome on each trial. The model tracked the true 
underlying contingencies and detected change-points. Here, in a representational 
participant from the Genetics cohort, the model tracked the true transition contingencies 
closely.  
Again, as demonstrated in Chapter 4, when trials were categorised according to 
participants’ trial-wise estimates of transition contingencies, as provided by model 
parameter ?̂?1 (five bins: 0.8-1, 0.6-0.8, 0.4-0.6, 0.2-0.4, 0-0.2), the same increase in 
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log(RT) with decreasing transition probability found in the model-agnostic results was 
observed (c.f. Figure 5.5 with Figure 5.3A); significant effect of ?̂?1: F2.04,175.53=269.14, 
p<0.001, ηp2=0.76). 
 
Figure 5.5 Model-based changes in log(RT) mirror the model-agnostic results. 
Faster responses were observed as participants’ estimates of the true transition 
contingencies increased, demonstrating that the HGF captured the same behavioural 
effect identified in the model-agnostic analyses, i.e., that participants learned to predict 
the stimulus transitions and prepared motor responses to high probability transitions (c.f. 
Figure 5.3A). Results are mean ± SEM. *** p<0.001.  
5.4.2.2 Response model 
Random effects Bayesian model selection established that Response Model 1 
(containing parameters 𝛿1, 𝜀3 and 𝜇3) was superior by a considerable margin (posterior 
probability: 0.5643; protected exceedance probability, i.e., the probability that Response 
Model 1 is more likely than any other model in the comparison set: 0.9493; Figure 5.6A). 
This replicates the finding in Chapter 4 that Response Model 1 was superior. Moreover, 
no significant difference was found in the noise parameter ζ between the Genetics and 
Placebo cohorts (t146=1.46, p=0.146; Figure 5.6B), indicating that Response Model 1’s 
ability to predict log(RTs) was unaltered across the two experiments. Note that Levene’s 
test established that there was no difference in the variances of the populations from 
which the Genetics and Placebo ζ samples were drawn (F=1.783, p=0.184). 
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Figure 5.6 Model comparison results. (A) Random effects Bayesian model selection 
indicated that Response Model 1 was superior. Posterior probabilities quantify the 
likelihood of each model given the data. Protected exceedance probabilities quantify how 
likely it is that any given model is more frequent than all other models in the comparison 
set while also protecting against the possibility that the observed variability in (log-) 
model evidence could be due to chance. The dotted line indicates the threshold for 
chance-level posterior probabilities (p=0.33). (B) The lack of a difference in the noise 
parameter ζ between the Genetics cohort and the Placebo cohort (p=0.146) indicates 
that the model’s ability to predict log(RT) was unaltered across groups.  
5.4.3 Assessment of the effects of COMT genotype on perceptual belief 
updating and response modulation 
The number of participants with each COMT genotype is summarised in Table 5.4.  
Polymorphism Genotype Participants 
COMT Val/Val 79 
(rs4680) Val/Met 24 
 Met/Met 13 
 
Table 5.4 Number of participants with each COMT genotype.  
5.4.3.2 No identifiable effects of COMT genotype on perceptual belief updating 
The rate at which individuals updated their volatility estimates, as reflected by parameter 
ϑ, was equivalent across the three COMT genotypes (F2,113=0.76, p=0.471; Figure 5.7A). 
Similarly, the rate at which individuals updated their transition contingency estimates and 
thus adapted to the probabilistic contexts, as reflected by parameter ω, was unaltered 
5. Genetic fingerprints of uncertainty 
161 
 
by COMT genotype (F2,113=1.40 p=0.251; Figure 5.7B). These results echo the finding in 
Chapter 4 that D1/D2 receptor antagonism under haloperidol did not influence the rate 
at which participants learned about the task’s volatility or contextual transition 
contingencies compared to Placebo. 
Similarly, comparing these two perceptual model parameters in Val/Val homozygotes 
and in individuals with higher DA neurotransmission (Met carriers) also indicated no 
effect of COMT genotype on ϑ (t114=0.50, p=0.618) or ω (t114=-0.84, p=0.404). Note that 
Levene’s test confirmed equality of variances across groups for both ϑ (F=0.72, p=0.397) 
and ω (F=1.80, p=0.182). 
 
Figure 5.7 Perceptual and response model parameter results. (A-E) No significant 
effects of COMT genotype on participants’ perceptual belief updating, or on the 
sensitivity of participants’ motor responses to their beliefs, were identified. Data are mean 
± SEM.  
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5.4.3.3 No identifiable effects of COMT genotype on response modulation 
The response model output revealed no significant effects of the three COMT genotypes 
on participants’ capacity to modulate their motor responses according to their perceptual 
estimates of sensory PE (β1: F2,113=1.72, p=0.183; Figure 5.7D) or phasic volatility (β3: 
F2,113=0.72, p=0.487; Figure 5.7E). The three COMT genotypes also had no significant 
impact on participants’ general log(RTs) (β0: F2,113=0.57, p=0.568; Figure 5.7C).   
Similarly, comparing these response model parameters in Val/Val homozygotes and in 
individuals with higher DA neurotransmission (Met carriers) also indicated no effect of 
COMT genotype on the sensitivity of participants’ motor responses to their sensory PE 
(β1: t114=1.57, p=0.118) or phasic volatility estimates (β3: t114=-1.17, p=0.244), or on 
general log(RTs) (β0: t114=1.06, p=0.292). Again, Levene’s test confirmed equality of 
variances across groups for β1 (F=1.12, p=0.293), β3 (F=2.25, p=0.137) and β0 (F=2.41, 
p=0.123). 
For completeness, any effects of the three COMT genotypes on the sensitivity of 
participants’ motor responses to their precision-weighted contingency PE were probed. 
No significant effects were identified (β2: F2,113=1.88, p=0.157). There was also no 
significant difference in the degree of post-error slowing demonstrated by individuals with 
each COMT genotype (β4: F2,113=2.89, p=0.060). 
5.4.4 Control analyses 
5.4.4.1 Model parameter correlations 
Aside from two exceptions, Bayesian parameter averages (BPAs) for the different model 
parameters were only moderately correlated across groups (all absolute r≤0.352; Figure 
5.8). As in Chapter 4, a higher correlation existed between the BPAs for β0 (log(RT) 
constant) and β3(𝜇3) (the sensitivity of log(RTs) to phasic volatility estimates): r=-0.885. 
This negative correlation indicates that both the constant component of log(RT) and 
phasic volatility estimates had a similar effect on log(RTs). As mentioned in Chapter 4, 
this reflects the fact that, while including 𝜇3 as a predictor of log(RT) significantly 
improves model evidence, it is much less variable than the other predictors because 
volatility inevitably changes at a slower timescale than stimulus contingencies. In 
addition, a higher correlation existed between the BPAs for β1(𝛿1) (sensory PE) and 
β2(𝜀3) (precision-weighted contingency PE): r=-0.7139. Again this reflects the similar 
effect the two parameters had on log(RTs). 
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Figure 5.8 Model parameter correlations for Bayesian parameter averages (BPAs). 
Note that 𝜇3_0 and 𝜎3_0 are the initial values of 𝜇3 (the phasic volatility estimate) and 𝜎3 
(the uncertainty about the phasic volatility estimate) respectively.  
5.4.4.2 Sample size analysis 
Since the effects of different genotypes on behavioural parameters are typically small, 
we had originally planned to recruit at least 400 participants to this experiment, in line 
with previous work (den Ouden et al., 2013). However, due to inconsistent data reporting 
by the genetics laboratory that assessed the DNA samples, testing had to be stopped 
prematurely. Nonetheless, for exploratory purposes, I used the data collected from the 
116 tested participants to calculate the sample size (online materials: 
http://powerandsamplesize.com/Calculators/Compare-2-Means/2-Sample-Equality) that 
would be necessary to determine whether the sensitivity of motor responses to sensory 
PE (β1) and to phasic volatility estimates (β3) was altered by COMT genotype (Table 5.5). 
For simplicity, I computed the sample sizes that would be necessary to observe a 
significant effect of increased DA neurotransmission on these two response model 
parameters by comparing Met carriers to Val/Val homozygotes. A total of 374 
participants would be required to observe an effect of COMT genotype on β1 and 669 
participants would be required to observe an effect on β3, assuming a type I error rate 
(α) of 0.05 and a power (1-β, where β = type II error rate) of 0.8. 
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Parameter of interest β1 (sensory PE) β3 (precision-weighted 
contingency PE) 
Observed mean (Val/Val); n=79 0.2162 -0.0726 
Observed mean (Met carriers); n=37 0.1560 0.0637 
Observed total standard deviation 0.1929 0.5856 
Sampling ratio 2.14 2.14 
Required sample size (Val/Val) 255 456 
Required sample size (Met carriers) 119 213 
Required total sample size 374 669 
 
Table 5.5 Sample sizes required to observe an effect of COMT genotype on 
behaviour. The calculations assume a comparison between two means (Group 1: 
Val/Val homozygotes; Group 2 = Met carriers). Note that type I (α) error rate is assumed 
to be 0.05 and power (1-β, where β = type II error rate) is set to 0.8.  
5.5 Discussion 
Investigating learning and action during the PSRTT in a naïve cohort of 116 healthy 
human participants meant that the replicability of the results observed in Chapter 4’s 
Placebo cohort could be assessed. Further, by using the novel instantiation of the HGF 
to probe individual perceptual belief updating and response modulation as a function of 
COMT genotype, it was possible to examine any effects of natural inter-individual 
variations in cortical DA neurotransmission on learning and action under uncertainty.     
5.5.1 Replication of learning and response modulation under irreducible, 
estimation and volatility uncertainty 
The naïve cohort of 116 healthy human participants who undertook the PSRTT in the 
present experiment showed learning and behaviour comparable to that displayed by the 
Placebo participants in Chapter 4’s pharmacological study. Specifically, faster log(RTs) 
on trials with a high transition probability, which became even faster over the course of 
a contextual block, suggest that participants learned to predict the stimulus transitions, 
and to prepare appropriate motor responses, in the same way as the Placebo 
participants had in Chapter 4. In addition, findings of increased log(RTs) on post-error 
and post-infrequent trials were also replicated in the novel participant cohort.   
As in Chapter 4, the HGF’s perceptual model was found to track the true transition 
contingencies occurring in the PSRTT closely. Moreover, the same response model, 
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which captures trial-wise log(RT) as a function of a constant component of log(RT), 
sensory PE, precision-weighted contingency PE, phasic volatility estimate and post-error 
slowing, was found to be superior to alternatives. Together, these findings suggest that 
the PSRTT reliably evokes particular learning and behavioural processes in healthy 
individuals, which can be reliably captured by the novel instantiation of the HGF 
developed in Chapter 3 and applied in Chapter 4.  
5.5.2 No identified effects of COMT genotype on perceptual belief updating or 
response modulation 
In the present study, there was no evidence to suggest that COMT genotype, and hence 
the associated natural variations in cortical DA neurotransmission, had any effect on 
perceptual belief updating or motor response modulation between individuals. Indeed, 
no effects on learning and action were identified when the HGF’s perceptual and 
response model parameters were compared across individuals with a Val/Val, Val/Met 
and Met/Met genotype, or when Val/Val homozygotes were compared to Met carriers. 
5.5.3 Interpretation is limited by an insufficient sample size 
However, interpretation of the behavioural genetics results in the present study is limited 
by an insufficient sample size. Genotypic effects on behavioural parameters are typically 
small, meaning that large sample sizes are commonly required to detect a behavioural 
effect (den Ouden et al., 2013). For this reason, I had originally planned to recruit at least 
400 healthy participants. An additional complication is that distributions of different 
genotypes tend to be uneven across populations, as was indeed observed for the COMT 
genotype in the present experiment. This has the effect of reducing the statistical power 
to detect a behavioural effect as a function of genotype, further increasing the required 
sample size. Data collected from the 116 tested participants could be used to calculate 
the sample sizes needed to determine whether COMT genotype is associated with 
altered motor response sensitivity to sensory PE and phasic volatility estimates (the 
samples being 374 and 669, respectively). Therefore, while there is no evidence to 
suggest that COMT genotype modulated learning or behaviour in the present dataset, 
the experiment is not sufficiently powered to rule out the possibility that the Val158Met 
polymorphism does influence response modulation in uncertain environments. 
5.5.4 Limitations of a behavioural genetics approach 
While the behavioural genetics approach applied in the present experiment does hold 
the potential to identify inter-individual variations in DA-dependent learning and response 
modulation in a larger cohort of healthy individuals, there are several methodological 
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limitations. First, since the COMT enzyme actually degrades both DA and NA, any 
observed effect of COMT genotype on learning or action would have to be interpreted 
with caution. However, COMT’s effect on NA levels is thought to be minor, at least in the 
PFC (Tunbridge et al., 2006), meaning that any confounding noradrenergic influences 
are likely to be minor. Indeed, COMT knockout mice show increased baseline frontal DA 
levels, with no effect on NA (Gogos et al., 1998). Moreover, administration of the COMT 
inhibitor tolcapone increases extracellular DA, but has no impact on NA, in the rat medial 
PFC following induction of neuronal catecholamine release (Tunbridge et al., 2004).   
Second, categorising individuals according to genotype can often lead to unbalanced 
distributions of gender and ethnicity, as occurred in the present experiment. This means 
that confounding effects arising from distributional biases in genetic polymorphisms are 
possible. Indeed, an effect of gender on COMT activity has been identified in animal 
models (Gogos et al., 1998). Although statistical methods that account for the systematic 
differences that arise between experimental populations can help to address this issue, 
caution must be taken when basing conclusions on genetic polymorphisms that are rare 
and/or known to vary widely in frequency across males and females, or across different 
ethnic groups (Montana and Pritchard, 2004). 
Third, the function and regulation of the neuromodulatory systems is intricate. A multitude 
of proteins, from receptors to transporters to degradative enzymes, mediate 
neurotransmission. As such, the individual genes that encode these proteins function in 
complex networks, and polymorphisms in each of them can influence neuromodulatory 
function. Therefore, while the Val158Met polymorphism in the COMT gene might predict 
DA-mediated response modulation in volatile environments given a sufficient sample 
size, investigating the relative contributions of additional dopaminergic, noradrenergic 
and cholinergic genes could offer further insights. Indeed, there is evidence to suggest 
that the functional effects of the COMT polymorphism can be modulated by other 
dopaminergic polymorphisms, such as those in the DAT1 and DRD2 genes (Meyer-
Lindenberg et al., 2006; Nackley et al., 2006; Diaz-Asper et al., 2008).  
5.5.5 Future investigations of genotypic effects on learning and action under 
uncertainty 
5.5.5.1 Alternative genetic targets 
As discussed previously, the original aim of the present experiment was to assess the 
impact of COMT, DAT1, DRD2, NET and ACHE genotypes on perceptual belief updating 
and response modulation in uncertain environments. While it was only possible to probe 
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the effects of COMT here, the remaining genes remain sensible targets for future 
investigations. For instance, a VNTR in the DAT1 gene, linked to altered expression of 
the DAT and thus altered striatal DA neurotransmission (Caron, 1996; Heinz et al., 2000; 
Lewis et al., 2001; Mill et al., 2002; van Dyck et al., 2005; van de Giessen et al., 2009; 
Frank and Fossella, 2011; Spencer et al., 2013), could offer a means by which to garner 
further insight into the contributions of DA to learning and action under uncertainty. In 
particular, contrasting any impact of COMT and DAT1 genotypes on learning and 
response modulation during the PSRTT might enable cortical DA-mediated behavioural 
switching under volatility to be distinguished from striatal DA-mediated motoric 
responses to sensory PE. This would be of interest given the findings in Chapter 4 that 
pharmacological DA antagonism decreased the sensitivity of individuals’ motor 
responses to their phasic volatility estimates, possibly due to impaired behavioural 
switching, but had no impact on responses to sensory PE. The latter result was surprising 
given previous literature demonstrating impaired reactions to unexpected events 
occurring in predictable contexts following both pharmacological and pathological DA 
depletions (Galea et al., 2012; Bestmann et al., 2014). Analysing behaviour in the PSRTT 
as a function of DAT1 genotype would offer an alternative methodology with which to 
probe any DA-mediated motor responses to sensory PE. 
Behavioural switching also varies with levels of striatal DA D2-receptor expression 
(Stelzel et al., 2010, 2013; van Holstein et al., 2011). A SNP in the DRD2 gene is known 
to modify D2-receptor expression, particularly in the striatum (Noble, 2003). As such, 
investigating learning and action in the PSRTT as a function of DRD2 genotype might 
offer still more intricate insight into the underlying dopaminergic processes. Given the 
proposed contributions of NA and ACh to learning under volatility and estimation 
uncertainty, genes that regulate noradrenergic and cholinergic neurotransmission also 
make sensible targets for future investigations. Indeed, while it is currently unclear 
exactly how two known polymorphisms in the NET and ACHE genes modulate 
neuromodulatory function, they may offer a means by which to speculatively study inter-
individual differences in NA- and ACh-mediated learning, respectively. 
5.5.5.2 Gene scoring 
As mentioned above, the complexities of the neuromodulatory systems mean that a 
multitude of genetic polymorphisms can influence their function. For example, an 
individual might be a Met carrier for the COMT gene, a 10R carrier for the DAT1 gene 
and an A2 carrier for the DRD2 gene. As such, they might be expected to display 
relatively high cortical DA neurotransmission, low striatal DA neurotransmission and 
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increased DA D2-receptor expression. Further, it is possible that the relative levels of DA 
neurotransmission in particular brain regions might influence DA signalling in other brain 
regions, in addition to the function of the NA and ACh systems. This highlights the 
importance of considering the relative contributions of the various genes that modify 
neuromodulatory function when characterising the relative contributions of DA, NA and 
ACh to learning and action under uncertainty.  Nevertheless, researchers must consider 
the statistical constraint of correcting for multiple comparisons when designing studies 
that aim to address the behavioural impact of multiple genotypes. 
One possible way to address this is to adopt a gene scoring approach. Indeed, in their 
investigation of genetic variations in DA-mediated motor learning, Pearson-Fuhrhop et 
al. calculated a gene score that represented the additive effects of several 
polymorphisms with established effects on DA neurotransmission (Pearson-Fuhrhop et 
al., 2013). Genotypes thought to increase DA neurotransmission added 1 to the score 
while genotypes that decrease transmission added 0. As such, a higher DA polygene 
score corresponded to higher DA neurotransmission. A similar approach could be 
applied to assess whether the net effect of COMT, DAT1 and DRD2 polymorphisms on 
DA neurotransmission is associated with altered learning and response modulation 
during the PSRTT.  
It should be noted that subtle insights into the relative cortical and striatal processes 
supporting these functions would be lost using such a method, unless the gene score 
weighted the contributions of different genes appropriately. Moreover, each of these 
genes is likely to only subtly alter the net function of an entire neuromodulatory circuit, 
meaning that elucidating how various genetic factors interact with each other is inherently 
difficult. Nonetheless, hypothesis-driven investigations of the functional impact of target 
genes and genetic interactions is likely the best approach. Given the multitude of 
potential genes that could influence learning and behaviour, unconstrained exploratory 
analyses of genetic interactions would require prohibitively large sample sizes to counter 
multiple comparisons and type I errors (i.e., false positives) (Purcell et al., 2009; Shi et 
al., 2009; Stefansson et al., 2009).    
5.5.5.3 Combining genetics, pharmacological and neuroimaging approaches 
A behavioural genetics approach to studying neuromodulatory contributions to learning 
and response modulation provides an important extension to insights offered by 
pharmacological manipulations. Indeed, the precise effects of pharmacological 
manipulations of neuromodulatory function can be unclear. For example, evidence from 
the animal literature suggests that DA D2-receptor antagonists such as haloperidol, the 
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drug utilised in Chapter 4, may actually exert their effects primarily via presynaptic 
autoreceptors  (Richfield et al., 1989; Starke et al., 1989; Grace, 1995; Schoemaker et 
al., 1997; Schmitz et al., 2003; Frank and Fossella, 2011). Suppression of DA 
autoreceptor-mediated inhibitory feedback may actually increase phasic DA release, 
particularly in the basal ganglia where D2-receptors are highly expressed (Moghaddam 
and Bunney, 1990; Wu et al., 2002; Garris et al., 2003; Chen et al., 2005). It seems 
unlikely that this was the principal effect of haloperidol in Chapter 4 since the 
manipulation caused a general increase in RTs, echoing bradykinesia observed due to 
nigrostriatal DA depletions in Parkinson’s disease (Galea et al., 2012). Nonetheless, the 
intricacies of the neuromodulatory effects caused by pharmacological interventions, and 
the compensatory mechanisms they may trigger, highlight the need to combine insights 
from pharmacology with alternative methodologies, such as behavioural genetics. 
The correlational nature of behavioural genetics studies is another reason to combine 
them with insights offered by other methodologies. Indeed, corroboratory evidence 
acquired by adopting complementary methodologies will help to inspire confidence in the 
proposed contributions of different neuromodulatory systems to particular functions. For 
instance, Diaconescu et al. recently combined fMRI and behavioural genetics to 
demonstrate that low-level sensory PEs activate the dopaminergic midbrain and that 
these activations are influenced by the Val158Met polymorphism in the COMT gene, 
offering further weight to the notion that DA is implicated in signalling sensory PEs 
(Diaconescu et al., 2017).  Together, behavioural genetics, psychopharmacological and 
neuroimaging studies, both in healthy individuals and in patients with known 
neuromodulatory dysfunction, can help to elucidate the neuromodulatory contributions 
of DA, NA and ACh to learning and action in uncertain environments. 
A further reason to combine behavioural genetics and psychopharmacology is that 
individual behavioural responses to pharmacological manipulations can depend strongly 
on baseline levels of DA, NA and ACh neurotransmission (Kimberg et al., 1997; Mehta 
et al., 2004a; Roesch-Ely et al., 2005; Frank and O’Reilly, 2006; Cools et al., 2007b; 
Clatworthy et al., 2009). For example, pharmacological DA D2-receptor stimulation 
generally improves task performance in individuals with low baseline working memory 
span (Kimberg et al., 1997; Frank and O’Reilly, 2006), high impulsivity (Cools et al., 
2007b) or low baseline DA synthesis (Cools et al., 2009), but impairs performance in 
those showing the opposite baseline trait. Since multiple genes are thought to modulate 
baseline neuromodulatory function, there is strong reason to predict that individual 
differences in dopaminergic, noradrenergic and cholinergic drug effects are, at least in 
part, genetic. Indeed, DRD2 genotype has been shown to predict the direction of an 
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individual’s neural and behavioural responses to pharmacological DA D2-receptor 
stimulation (Cohen et al., 2007). I will return to this concept in Chapter 7. 
5.5.6 Conclusion 
In conclusion, by employing the PSRTT to interrogate learning and action in a naïve 
cohort of healthy participants exposed to dynamic, probabilistic environments, it was 
possible to replicate the behaviour displayed by the Placebo participants in Chapter 4. 
Moreover, the novel instantiation of the HGF showed a verifiable capacity to capture 
individual perceptual belief updating and response modulation within a unified 
computational framework of irreducible, estimation and volatility uncertainty. As such, 
the PSRTT and HGF appear to offer a robust means by which to investigate learning 
and response modulation in uncertain environments. While previous literature linking 
cortical DA neurotransmission and behavioural flexibility suggests that it is reasonable 
to predict that COMT genotype might modify the modulation of motor responses by 
phasic volatility estimates, future work will need to confirm whether this effect can be 
detected using the PSRTT in a larger participant cohort. Additional genetic, 
pharmacological and neuroimaging investigations of dopaminergic, noradrenergic and 
cholinergic neurotransmission will verify the generality of any behavioural effects to 
different behavioural tasks with and without learning, reward, prediction and action. 
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6 Dynamic noradrenergic computations of 
uncertainty 
This chapter was, in part, motivated by work presented in de Berker AO, Rutledge RB, 
Mathys C, Marshall L, Cross GF, Dolan RF & Bestmann S. (2016) Computations of 
uncertainty mediate acute stress responses in humans. Nature Communications. 
7:10996. 
6.1 Abstract 
Noradrenaline (NA) has been proposed to play an important role in learning under the 
uncertainty that arises from environmental volatility. Parallel lines of work have linked 
subjective uncertainty computations, and noradrenergic activity in the locus coeruleus 
(LC), to changes in pupil diameter. In this chapter, I combine a probabilistic learning task, 
pupillometry, pharmacological manipulations and the Hierarchical Gaussian Filter (HGF) 
model to characterise the impact of subjective beliefs and NA on pupillary dynamics in 
90 healthy human participants. Baseline pupil diameter was found to reflect an 
individual’s belief about the current relationship between environmental events. Dynamic 
pupillary dilation tracked both uncertainty and surprise arising from the probabilistic 
relationship between environmental events. Pharmacological manipulations of NA 
modulated pupillary responses to uncertainty and volatility estimates. Collectively, the 
results provide empirical support for the notion that pupil diameter offers an indirect 
measure of individual dynamic noradrenergic computations of uncertainty and volatility. 
Importantly, they also highlight the need for unified behavioural and computational 
frameworks in characterising the relative contributions of subjective beliefs and 
neuromodulatory dynamics to pupil dilation. 
 
  
6. Dynamic noradrenergic computations of uncertainty 
172 
 
6.2 Introduction 
For several decades, pupil dilation at constant luminance has been considered a marker 
of central arousal (Hess and Polt, 1964; Kahneman and Beatty, 1966; Bradshaw, 1967; 
Kahneman et al., 1967; Beatty, 1982). More recently, it has been proposed that pupil 
diameter might offer an indirect measure of noradrenergic neuronal activity in the LC 
(Rajkowski et al., 1993; Phillips et al., 2000b; Aston-Jones and Cohen, 2005a; Murphy 
et al., 2014; Varazzani et al., 2015; Joshi et al., 2016). Further, as we saw in Chapter 4, 
NA has been linked to learning under volatility uncertainty (Yu and Dayan, 2005; Payzan-
LeNestour et al., 2013; Marshall et al., 2016). Inspired by these findings, researchers 
have started to probe whether transient changes in pupil diameter can be used as a 
proxy for physiological autonomic processes that occur during behavioural tasks, 
including those requiring NA-mediated learning under environmental uncertainty (Siegle 
et al., 2003; Aston-Jones and Cohen, 2005a; Critchley, 2005; Satterthwaite et al., 2007; 
Einhäuser et al., 2008; Hupé et al., 2009; Einhauser et al., 2010; Gilzenrat et al., 2010; 
Privitera et al., 2010; Jepma and Nieuwenhuis, 2011; Preuschoff et al., 2011; Fiedler and 
Glöckner, 2012; Nassar et al., 2012; Wierda et al., 2012; Eldar et al., 2013; de Gee et 
al., 2014; Browning et al., 2015; de Berker et al., 2016; Korn et al., 2016; van den Brink 
et al., 2016; Urai et al., 2017). The sensitivity of the pupil to such processes means that 
pupillometry might offer a simple, non-invasive and cost-effective tool with which to 
measure individual noradrenergic computations of uncertainty, without the need for 
pharmacological interventions or behavioural genetics analyses.    
6.2.1 Pupil diameter as an indirect measure of noradrenergic 
neurotransmission 
As discussed in detail in Chapter 1, converging bodies of electrophysiological (Rajkowski 
et al., 1993; Aston-Jones and Cohen, 2005a; Varazzani et al., 2015; Joshi et al., 2016), 
pharmacological (Phillips et al., 2000c) and human neuroimaging (Samuels and 
Szabadi, 2008; Murphy et al., 2014) evidence suggest a relationship between NA and 
pupil dilation under constant luminance. 
6.2.2 A proposed link between pupil diameter and perceptual beliefs 
A parallel line of work has sought to establish whether pupil diameter reflects an 
individual’s perceptual estimates by integrating pupillometry into studies of human 
learning and behaviour (Gilzenrat et al., 2010; Jepma and Nieuwenhuis, 2011). In 
particular, during the last five years, researchers have focused on developing 
quantitative models to formally test the hypothesised association between human pupil 
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dilation and the perceptual estimates underlying learning and behaviour in uncertain 
environments. Indeed, a range of studies has investigated the modulation of pupil 
diameter by perceptual quantities such as uncertainty, prediction error (which the pupil 
literature commonly conceptualises as surprise), and volatility (Preuschoff et al., 2011; 
Nassar et al., 2012; de Gee et al., 2014; Browning et al., 2015; de Berker et al., 2016). 
The results of these studies have offered varying evidence to suggest that pupil dilation 
is associated with each of these perceptual estimates. 
6.2.3 Pupil diameter as a proxy for dynamic noradrenergic uncertainty 
computations  
Given my finding in Chapter 4 that NA modulates learning under the uncertainty arising 
from environmental volatility, the notion that pupil dilation can be used as a proxy for 
dynamic noradrenergic uncertainty computations is appealing. However, the previous 
investigations of pupillary responses to perceptual estimates have been heterogeneous: 
they used different behavioural paradigms that exposed participants to different forms of 
environmental uncertainty, and the investigators probed the impact of different 
combinations of perceptual beliefs on pupil diameter. As such, it is difficult to isolate the 
contribution of particular perceptual estimates to pupil diameter with confidence. 
Therefore, in this chapter, I combine a probabilistic learning task, pupillometry and the 
HGF model to assess the impact of irreducible uncertainty, surprise and volatility on pupil 
diameter. Further, by utilising two pharmacological manipulations of NA, I causally 
assess whether any pupillary responses to these perceptual beliefs are under dynamic 
noradrenergic modulation. 
6.3 Methods 
6.3.1 Participants 
90 healthy participants (39 male, aged 19-38 years, 83 right-handed) with normal hearing 
and normal or corrected-to-normal vision took part in this study after giving written 
informed consent. The experimental protocol was approved by the UCL Research Ethics 
Committee. The following exclusion criteria applied: history of neurological or psychiatric 
disorder, baseline blood pressure below 100/60, intake of medication (other than 
contraceptives), self-reported regular smoking, self-reported recreational drug use, and 
current participation in other pharmacological studies. Following a screening interview to 
rule out intolerances or contraindications, the study clinician assigned participants 
pseudorandomly (i.e., ensuring a balanced distribution of gender, age and body weight) 
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to receive a NA antagonist, a NA reuptake inhibitor or a placebo. The experimenter (L.M.) 
was blind to the drug conditions. 
6.3.2 General procedure 
A double-blind, between-subjects design was employed. Each participant attended one 
experimental session during which they received a single, oral dose of one of the 
following: 4mg reboxetine (selective NA reuptake inhibitor; NA+ group), 1mg prazosin 
(α1-adrenoceptor antagonist; NA- group), or a placebo. Doses were selected in line with 
previous studies showing clear behavioural and neurophysiological effects (Dostert et 
al., 1997; Meintzschel and Ziemann, 2006; de Martino et al., 2007; Jepma et al., 2010; 
Korchounov and Ziemann, 2011; Marshall et al., 2016). On arrival, participants 
completed computerised versions of the Digit Span test, Barratt Impulsiveness Scale 
(BIS-11) (Patton et al., 1995), Domain-Specific Risk-Taking (DOSPERT) Scale (Blais 
and Weber, 2006) and Cognitive Failures Questionnaire (CFQ) (Broadbent et al., 1982). 
Participants also self-reported their baseline mood (alertness, calmness and 
contentedness) with 16 visual analogue scales (VAS) (Bond and Lader, 1974), and had 
their baseline heart rate (HR) and blood pressure (BP) measured. To assess any 
subjective and/or physiological drug effects, the VAS, HR and BP measurements were 
repeated before participants started the behavioural task and again once they completed 
it. 
All participants were administered two tablets thirty minutes apart. Two different active 
drug administration times were used, based on previous pharmacokinetic data, so that 
participants undertook the behavioural task when the drug was at its most active (Dostert 
et al., 1997; de Martino et al., 2007; Jepma et al., 2010). Reboxetine was administered 
two hours before the main behavioural task (Time A; Figure 6.1A), and prazosin 1.5 
hours in advance (Time B). Participants in the NA+ (reboxetine) group received a 
placebo at Time B, while participants in the NA- (prazosin) group received a placebo at 
Time A. Participants in the Placebo group received a placebo tablet at Time A and at 
Time B. Participants were told that they would receive either two placebo tablets, or one 
active drug and one placebo tablet. An independent clinician administered the drug or 
placebo while the experimenter was away from the testing room. For comparable drug 
absorption rates, participants were asked not to eat for at least one hour before Time A. 
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Figure 6.1 Task design. (A) Timeline for each experimental session. At baseline, heart 
rate (HR) and blood pressure (BP) measurements were taken, and participants self-
reported their alertness, contentedness and calmness via visual analogue scales (VAS) 
(Bond and Lader, 1974), and undertook a battery of psychometric tests to assess 
working memory, impulsivity, risk-taking and distractibility. HR, BP and VAS measures 
were repeated before and after completing the behavioural task. Due to different times-
to-peak plasma concentration across drugs, two different drug administration times 
(Time A and Time B) were used so that participants undertook the behavioural task when 
the drugs were at their most active. Participants in the active drug-groups received a 
placebo tablet at the administration time at which they did not receive an active drug. 
Placebo participants received two placebo tablets: one at Time A and one at Time B. (B) 
Trial sequence. Throughout the task, an isoluminant grey screen was displayed with a 
central black fixation cross and the words “Cow” and “Pig” on each side. On each trial, 
an auditory low-pitch (450Hz) or high-pitch (1000Hz) cue was presented for 300ms. 
Participants were required to make a speeded button-press response within a 1200 ± 
200ms window to indicate their prediction about which auditory outcome would follow. 
The auditory outcome was either the word “cow” or the word “pig”, presented for 600ms. 
This was followed by an intertrial interval (ITI) lasting 3200 ± 500ms. (C) The probabilities 
governing cue:outcome relationships shifted unpredictably over time, introducing 
volatility and thus producing fluctuations in uncertainty.   
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6.3.3 Probabilistic learning task 
Participants sat in a darkened room facing an isoluminant computer screen. They were 
instructed to rest their left and right index fingers on two response buttons, and to 
maintain this position throughout the task. Participants were asked to maintain fixation 
on a black fixation cross presented in the centre of a grey screen at a viewing distance 
of 60cm. During the probabilistic learning task (PLT), the diameter of the left pupil was 
measured using an infrared ASL Eye-Trac 6 System (Applied Science Laboratories, 
USA), sampled at 120Hz. To minimise movement, participants sat with their head 
supported by a forehead- and chin-rest (Figure 2.5). 
The PLT was closely modelled on a task used in three recent studies (den Ouden et al., 
2010; Iglesias et al., 2013; de Berker et al., 2016), but used auditory rather than visual 
stimuli so as to eliminate any effects of luminance changes on pupil diameter. Each 
participant completed a set of 320 trials. On each trial, participants were presented, via 
stereo headphones, with one of two auditory cues: a low-pitch (450Hz) or high-pitch 
(1000Hz) tone. The cue was presented for 300ms before participants were asked to 
make a prediction, signalled with a speeded button-press response, as to which auditory 
outcome (the word “cow” or the word “pig”) would follow (Figure 6.1B). This decision was 
made under time pressure, with a timeout period averaging 1200ms (± 200ms). The 
auditory outcome was followed by an intertrial interval (ITI) averaging 3200ms (± 500ms). 
The durations of the decision period and the ITI were jittered on each trial so that the 
pupil responses could be maximally divorced from different events. Jitter was 
implemented using a uniform distribution, discretised into chunks of a size determined 
according to the size of the interval in question. 
The probabilistic mapping between cue and outcome shifted over the course of the 
experiment (Figure 6.1C), requiring participants to constantly track the cue:outcome 
relationship over time in order to maximise their proportion of correct predictions. This 
resulted in fluctuations in the level of uncertainty about the outcome, given the cue. Each 
session of 320 trials was divided into 10 blocks of different cue:outcome probabilities, 
and of lengths that varied between 26 and 38 trials. The transitions between these blocks 
were not made explicit to the participant. The probabilities governing each block varied 
from highly biased (0.9/0.1), through moderately biased (0.7/0.3) to unbiased (0.5/0.5), 
allowing the effect of predictability (Iglesias et al., 2013) on pupil diameter (de Berker et 
al., 2016) to be examined. Each of the biased probability blocks was repeated four times 
(two for each bias direction, i.e. 0.7/0.3 and 0.3/0.7) and the unbiased blocks were 
repeated twice. 
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Participants were told that the cue:outcome probabilities would shift unpredictably over 
time and might sometimes be completely random, but they were uninformed as to the 
frequency of switches. The task therefore required participants to track the same three 
forms of uncertainty we have encountered in previous chapters: irreducible uncertainty 
arising from the inherent randomness of the probabilistic relationships between cues and 
outcomes, estimation uncertainty arising from incomplete knowledge of those 
probabilistic relationships within each block, and volatility uncertainty maintained by the 
unsignalled instability of the relationships over time  (Behrens et al., 2007; Mathys et al., 
2011, 2014; Payzan-LeNestour and Bossaerts, 2011; Iglesias et al., 2013; Payzan-
LeNestour et al., 2013; Hauser et al., 2014; Vossel et al., 2014a, 2014b, 2015; de Berker 
et al., 2016; Diaconescu et al., 2017). 
The visual display remained stable throughout, with the word “cow” displayed to the left 
of the fixation cross and the word “pig” to the right. Rest periods lasting 90 seconds 
occurred every 65 trials, orthogonal to cue:outcome probability switches.  Before starting 
the PLT, participants underwent a volume matching procedure to ensure that they 
perceived the different auditory cues and outcomes as equally loud, and a training block 
to familiarise themselves with making button-press predictions in response to auditory 
cues (see sections 6.3.5 and 2.1.2.3 for details).  
To encourage task engagement, participants were paid a base rate of £25 and informed 
that they would receive an extra £5 if they could make correct predictions on more than 
68% of trials. This threshold was based on the average number of correct predictions 
made by participants who undertook a similar experiment conducted in my work with de 
Berker et al. (de Berker et al., 2016). It was not explicitly signalled to the participant 
whether each outcome reflected a correct or incorrect prediction on their part. 
6.3.4 Control task 
After completing the PLT, participants undertook an additional control task (CT) 
consisting of two blocks of 30 trials each. The CT was identical to the PLT except that 
this time there was no uncertainty about which auditory outcome would follow which 
auditory cue. Rather, participants were explicitly told at the beginning of each block which 
cue and which outcome would occur on each of the next 30 trials. One cue was paired 
with one outcome for the first block, and the other cue was paired with the other outcome 
for the second block. On hearing the auditory cue at the start of each trial, participants 
were required to make a speeded button-press response to indicate their “prediction” as 
to which outcome they knew would follow. Timings for the CT were identical to those 
used in the probabilistic task. The exact pairings between cues and outcomes, and their 
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assignment to the first or second block of the CT were counterbalanced across 
participants. As before, the diameter of the left pupil was recorded online at 120Hz. As 
one would expect, participants were highly accurate during the CT: the mean percentage 
of correct “predictions” was 100% for participants in the NA- and NA+ groups, and 98.3% 
for those in the Placebo group. 
6.3.5 Volume matching 
Before undertaking the behavioural task, participants underwent an adaptive, two-
alternative forced choice procedure in order to match the subjective loudness of the two 
cues and the two outcomes used in the PLT. On each trial, participants were played the 
two cues or the two outcomes in succession and asked to report whether the second 
sound was louder or quieter than the first. The volumes of the low-pitch cue and the 
outcome “cow” were kept constant throughout. The level of the high-pitch cue and the 
outcome “pig” were varied according to a maximum likelihood procedure (Green, 1993; 
Soranzo and Grassi, 2014) to obtain estimates of the attenuation required for subjective 
volume equality. For the two cues and the two outcomes, three adaptive runs of 10 trials 
were performed. The average final attenuation values for the cues and outcomes were 
used in the PLT and CT. 
6.3.6 Training 
Participants were trained on the PLT before starting it. During four training blocks of five 
trials each, participants familiarised themselves with making predictions by button press 
following the presentation of auditory cues. Participants were told at the start of each 
training block which cue and which outcome would be presented on each of the following 
five trials. After the outcome was presented, they were provided with visual error 
feedback. Each combination of cue and outcome was presented across the four training 
blocks. The order of the four training blocks (i.e., the pairings between each cue and 
each outcome) was counterbalanced across participants. To familiarise themselves with 
the timings of the PLT, participants then completed 12 practice trials without error 
feedback. On each trial there was a 50% probability that either cue would be followed by 
either outcome. 
6.3.7 Pupillometry 
The ASL Eye-Trac system calculates pupillary gaze by measuring the distance between 
the location of a participant’s pupil and corneal reflection (CR). For each participant, the 
eyetracker was calibrated to account for inter-participant differences in the relationship 
between the pupil and CR. Each participant was instructed to sequentially fixate nine 
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calibration points arranged in a 3x3 square on the computer screen ahead of them. The 
central calibration point was positioned at the location of the centre-point of the fixation 
cross used during the PLT, which was horizontally centred on the computer screen and 
in line with the participant’s line of vision when looking straight ahead. During the PLT 
and CT, calibration was repeated after each rest period to adjust for any subtle 
differences in head position. In order to align the pupil diameter timecourse with 
experimental events occurring in the PLT and CT (i.e., the precise timing of cue, 
response and outcome onsets), triggers were sent via the testing computer’s parallel port 
to the eyetracker system. Pupil diameter was sampled at 120Hz. 
6.3.8 Model-agnostic analyses 
A series of conventional, model-agnostic analyses of behaviour were first conducted to 
assess whether participants showed evidence of learning the underlying cue:outcome 
relationships during the PLT, and whether learning was influenced by the 
pharmacological interventions. 
6.3.8.1 Accuracy and decision time 
Accuracy was defined as the percentage of correct responses. Decision time was 
calculated as the time between cue onset and the subsequent button-press response 
made to indicate the predicted outcome. 
First, accuracy and decision times during the unbiased (0.5/0.5) blocks were assessed 
to verify that they were equivalent across drug-groups. Here no probabilistic advantage 
arose from the cue:outcome relationship, meaning that any participant who fully 
understood the task requirements and was actively engaged in the PLT would be 
expected to perform at close to chance level. Indeed, any drug effect would indicate a 
non-specific effect on behaviour rather than an effect specific to altered uncertainty 
computations. 
To obtain a model-agnostic indication of learning across the course of the probabilistic 
blocks, a median split was performed on each block. A 3 bias (high/moderate/none) x 2 
time (Early/Late) x 3 drug repeated-measures analysis of variance (RM-ANOVA) was 
used to compare accuracy on Early (first half of each block) and Late (second half of 
each block) trials at each bias level, and between drug-groups. As two bias directions 
had been used for each bias level, I collapsed across highly biased blocks (0.9/0.1 and 
0.1/0.9), and across moderately biased blocks (0.7/0.3 and 0.3/0.7). A second bias x 
time x drug RM-ANOVA was applied to assess decision times in the same way. 
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6.3.8.2 Performance score 
Since improved performance on the PLT is reflected by a higher accuracy rate and lower 
decision times (Volkmann, 1934; Yeung et al., 2004; Fetsch et al., 2014), a performance 
score that captured these two components was calculated as follows: 
𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 𝑆𝑐𝑜𝑟𝑒 =
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦
𝐷𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑇𝑖𝑚𝑒
 
A higher performance score reflects improved performance owing to an increased 
accuracy and/or decreased decision time. RM-ANOVAs were applied to compare mean 
performance scores across the three bias levels, Early and Late Trials, and across drug-
groups. 
6.3.9 Model-based analyses 
A three-level instantiation of the HGF model was applied to the behavioural data to 
quantify participants’ (approximate) inferences and subjective expectations about trial-
wise auditory stimulus outcomes.  
To recap Chapter 3, the original instantiation of the HGF applied here consists of a 
perceptual model (i.e., a generative and recognition model) that tracks an individual’s 
learning of the PLT’s structure: the trial-wise auditory stimulus outcomes at level 1, the 
probabilistic relationship between cue and outcome at level 2, and the volatility of the 
cue:outcome relationship at level 3. Trial-wise trajectories of a participant’s estimates at 
each level evolve according to the predictions made and outcomes experienced by that 
individual (Figure 6.2). At levels 2 and 3, these beliefs are represented as Gaussian 
distributions characterised by a mean (μ) and a variance (σ). This framework naturally 
captures irreducible uncertainty resulting from the probabilistic relationships between 
cues and outcomes, estimation uncertainty resulting from imperfect knowledge of these 
probabilistic relationships, and volatility uncertainty reflecting the instability of these 
relationships over time. 
Importantly, the model does not assume fixed learning across participants but rather 
contains participant-specific parameters that couple the hierarchical levels and allow for 
individual expression of approximate Bayes-optimal learning. ϑ determines the speed of 
learning about phasic volatility, and ω captures how rapidly individuals update their 
beliefs about the cue:outcome relationship. 
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Figure 6.2 The Hierarchical Gaussian Filter (HGF). (A) The model tracks an 
individual’s learning of the task’s structure across three levels. State 𝑥1 represents trial-
wise auditory stimulus outcomes, 𝑥2 the probabilistic relationship between cue and 
outcome, and 𝑥3 the phasic volatility of this relationship, where t is the current trial 
number. Participants hold and update beliefs about the true quantities at each level. (B-
E) Examples of the trial-wise dynamics at levels 1 and 3 for Placebo Participant 2. At 
level 1, irreducible uncertainty (?̂?1) results from a sigmoid transformation of the estimated 
probabilities (𝜇2) represented at level 2. As such, 𝜇1
(𝑡)
 reflects the participant’s current 
belief about the true cue:outcome probabilities (𝑥2; grey line in D), which the participant 
tracks closely. Irreducible uncertainty gives rise to trial-wise estimates of surprise, which 
is mathematically equivalent to sensory prediction error (|𝛿1|; E). At level 3, 𝜇3 reflects 
the participant’s belief about the true phasic volatility (𝑥3). 𝜇3 tends to increase following 
the true switches in cue:outcome probability (marked by grey dashed lines in C), and 
decreases over the course of the highly biased blocks as the participant learns the new 
cue:outcome relationship and thus perceives the environment as increasingly stable. An 
individual’s uncertainty about their predicted phasic volatility estimate is captured by ?̂?3 
(B).  
6.3.9.1 Parameters of interest 
To probe dynamic noradrenergic responses to uncertainty, four key parameters from the 
HGF were assessed. In my previous work with de Berker et al., we found evidence to 
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suggest that decision times are modulated by low-level irreducible uncertainty and that 
pupil diameter appears to track both irreducible uncertainty and surprise (de Berker et 
al., 2016). Therefore, the effect of irreducible uncertainty and surprise on behaviour and 
pupil diameter was also assessed in the current study. Irreducible uncertainty (?̂?1) arises 
from the inherent randomness of the probabilistic cue:outcome relationships. It is a 
quantity closely related to entropy, with an inverted-U relationship to probability that 
peaks at p=0.5. Trial-wise values are equivalent to 1-𝑥1, where 𝑥1 is the probability of the 
predicted outcome. Irreducible uncertainty gives rise to sensory prediction error (|𝛿1|), 
which the pupil literature commonly describes as surprise. 
In Chapter 4, I found evidence to suggest that NA influences learning of uncertain events 
arising from unexpected changes in the environment, a finding in line with previous 
literature linking NA to uncertainty arising from environmental volatility (Yu and Dayan, 
2005; Payzan-LeNestour et al., 2013; Marshall et al., 2016). In a parallel line of research, 
it has been proposed that pupil dilation reflects an individual’s subjective volatility 
estimates (Browning et al., 2015). Moreover, pupil dilation has been suggested to offer 
an indirect measure of NA activity (Murphy et al., 2014; Varazzani et al., 2015; Joshi et 
al., 2016). Therefore, I also assessed the impact of two further parameters from level 3 
of the HGF on pupil diameter. First, the trial-wise estimate of phasic volatility (𝜇3), and 
second the uncertainty about phasic volatility beliefs (?̂?3). 
Inspired by literature linking volatility estimates to learning rate (Behrens et al., 2007; den 
Ouden et al., 2010; Browning et al., 2015; Jepma et al., 2016), I also assessed learning 
rates (𝛼1) at level 1 across drug-groups. 
6.3.9.2 Model fitting 
The HGF model was implemented using the ‘tapas_hgf_binary’ code contained in the 
HGF Toolbox (http://www.translationalneuromodeling.org/tapas/). Where priors were 
required, they were generated by running a Bayes optimal version of the model (using 
the function ‘tapas_bayes_optimal_binary_config’), under suitably uninformative priors. 
The resulting posterior estimates were then used to define the priors for the subsequent 
inversion of the full model given the behavioural data (see Table 6.1). In other words, the 
prior means in the empirical data analysis corresponded to those parameter values for 
which the stimulus sequence would generate minimal surprise (in an observer with the 
aforementioned uninformative priors). Note that these priors are in line with those used 
in our previous study using a visual version of the PLT (de Berker et al., 2016). 
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6.3.9.3 Decision times according to beliefs 
To verify the HGF’s capacity to capture participants’ beliefs about the true cue:outcome 
probabilities, trials were binned according to 10 evenly-spaced irreducible uncertainty 
belief levels (model parameter ?̂?1) ranging from 0/1 to 1/0. Since two bias directions had 
been used in the PLT, the data were symmetrical. Therefore, I next collapsed across 
equivalent beliefs in each bias direction to create five bias categories (i.e., 0-0.1/0.9-1, 
0.1-0.2/0.8-0.9. 0.2-0.3/0.7-0.8, 0.3-0.4/0.6-0.7, 0.4-0.5/0.5-0.6). A 5 bias x 3 drug RM-
ANOVA was used to compare mean decision times across these five belief levels and 
between drug-groups. Since the model is informed of participants’ trial-wise predictions, 
but not their decision times, an increase in decision time as irreducible uncertainty, and 
hence the belief about cue:outcome probabilities, approach 0.5/0.5 would indicate that 
the HGF had captured participants’ beliefs well, assuming participants showed typical 
Parameter Notes Prior 
ϑ  Metavolatility belief parameter; controls the 
step size of the Gaussian random walk at 
level 3. Estimated in logit space. 
Mean 
Variance 
 
0 
16 
 
ω  Tonic volatility belief parameter; a constant 
component of the learning rate at level 2. 
Mean 
Variance 
-3 
16 
Stimuli 
(𝑥1) 
The stimulus predictions are a sigmoid 
transformation of the probabilities 
represented in 𝑥2, and so do not have a 
starting value. 
𝜇1: 
Mean 
Variance 
 
NaN 
NaN 
𝜎1: 
Mean 
Variance 
 
NaN 
NaN 
Probabilities 
(𝑥2) 
A starting value of 0 implies neutrality 
between outcomes. 
𝜇2: 
Mean 
Variance 
 
0 
0 
𝜎2: 
Mean 
Variance 
 
log(0.1) 
log(1) 
Volatility 
(𝑥3) 
The absolute starting value of 𝑥3 is arbitrary 
as changes in fitted parameters affect 
scaling. 
𝜇3: 
Mean 
Variance 
 
1 
0.1 
𝜎3: 
Mean 
Variance 
 
log(1) 
0 
Table 6.1 A summary of HGF parameters and priors. 
All priors are specified in the space in which they are estimated. For an account of how 
this relates to the native space of that parameter, please refer to Chapter 3 and to the 
original description of the model (Mathys et al., 2011).  
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decision time slowing with increasing uncertainty (Volkmann, 1934; Yeung et al., 2004; 
Fetsch et al., 2014). 
6.3.9.4 Learning rate 
As in Chapter 4, I examined the learning rate (model parameter 𝛼1), across the course 
of the PLT and at true context change-points, i.e., following a switch in cue:outcome 
probability. Where differences in learning rate at change-points were calculated, the 
mean 𝛼1 for the last three trials of the previous context were subtracted from the mean 
𝛼1 for the first two trials of the next context. ANOVAs were applied to assess whether 
learning rates differed across drug-groups, and whether the noradrenergic manipulations 
modulated how learning rates changed at context change-points.   
6.3.10 Statistical analyses of behavioural data 
In reporting statistical differences, a significance threshold of =0.05 was used. Where 
assumptions of sphericity were violated (Mauchly’s test p<0.05), the Greenhouse-
Geisser correction was applied. Since a significant time x drug interaction on self-
reported alertness was identified (see section 4.4.5.1 for details), the participant-specific 
difference in alertness between baseline and the time corresponding to peak drug 
concentration, Δalertness, was used as a covariate in all analyses to control for any inter-
participant variability in subjective drug effect. 
For comparisons across the three drug-groups, partial eta-squared (ηp2) is reported as 
the effect size. The key experimental question pertained how noradrenergic 
manipulations influence behaviour, and pupillary responses to uncertainty estimates, 
compared to placebo. Therefore, for behavioural data, planned comparisons were made 
between the two active drug-groups (NA- and NA+) and the Placebo group. Here a 
Benjamini-Hochberg correction for two pairwise comparisons was applied to account for 
the false discovery rate (FDR) (Benjamini and Hochberg, 1995). For pairwise 
comparisons, Cohen’s d is reported as the effect size. 
6.3.11 Analysis of pupil diameter 
For the purpose of analysis, pupil data were exported using ASL software and then 
imported into Matlab (MathWorks, USA). Blinks (defined as pupil losses lasting ≤300ms) 
were detected using a custom-made algorithm and removed by linear interpolation of 
samples 50ms either side of the blink. Additional artefacts (<50ms) were identified in the 
data by taking the first derivative of the pupil series to detect rapid (sample-wise) 
changes in pupil diameter measuring >10% of the maximum pupil diameter. These 
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artefacts were removed by the same linear interpolation method. Pupil losses lasting 
longer than 300ms were removed by NaN padding. The interpolated pupil time series 
were low-pass filtered (4Hz, 3rd order Butterworth) (de Gee et al., 2014; de Berker et al., 
2016), detrended, and z-scored. In line with Browning et al., 2015, trials in which more 
than 50% of the eyetracking data were interpolated or lost were not used in subsequent 
analyses (mean ± SEM: 2.8 ± 0.8% of trials for NA-, 1.4 ± 0.6% for Placebo, and 2.5 ± 
1.1% for NA+).  
6.3.11.1 Event-related analysis of pupil diameter 
To gain insight into the role played by uncertainty, the pupillary response was epoched 
by trial (i.e., from -200ms from cue onset on trial t to -200ms from cue onset on trial t+1). 
Each epoch was baseline-corrected by subtracting the mean of all pre-trial pupil diameter 
values in the window from -200 to 0ms from cue onset from the pupil diameter trajectory 
for that trial. Each trial-wise, baseline-corrected pupil diameter trajectory was separated 
into three epochs: 1) -0.2 to 0.3s from cue onset, 2) -0.2 to 1s from response onset (i.e., 
the button-press that indicated a participant’s decision), and 3) -0.2 to 3s from outcome 
onset. Any trials on which participants failed to indicate a decision by button-press before 
outcome presentation was excluded. The percentage of missed button-press responses 
was very low across drug-groups (mean ± SEM: 0.55 ± 0.17% of trials for NA-, 0.34 ± 
0.09% for Placebo, and 0.76 ± 0.29% for NA+). 
A one-way ANOVA was applied to assess peak pupil diameter during the post-response 
and post-outcome periods across drug-groups. For the post-response period, the peak 
pupil was calculated as the mean of a 100ms window spanning the time of the average 
peak pupil measurement. For the outcome period, a 250ms window was used. Trial-wise 
pupillary responses during the PLT were contrasted with trial-wise pupillary responses 
during the CT, which was identical in structure to the PLT but gave rise to no uncertainty 
about the cue:outcome relationship. Again, the percentage of (excluded) missed button-
press responses was very low in the CT across drug-groups (mean ± SEM: 0.33 ± 0.04% 
of trials for NA-, 0.05 ± 0.02% for Placebo, and 0.10 ± 0.05% for NA+). 
6.3.11.2 Pupil diameter at baseline 
Within the framework of the HGF model, information about irreducible uncertainty on the 
current trial is available to participants before the trial begins since it is computed on the 
basis of trial history (Mathys et al., 2011). Therefore, in line with my previous work (de 
Berker et al., 2016), baseline pupil diameter, computed as the mean of all pre-trial values 
in the window from -200ms to 0ms from cue onset, was interrogated in order to determine 
6. Dynamic noradrenergic computations of uncertainty 
186 
 
whether it reflected participants’ current beliefs, and whether this relationship differed 
across drug-groups. As with the decision time data, trials were first binned according to 
10 evenly-spaced belief levels (model parameter ?̂?1) ranging from 0/1 to 1/0. For 
statistical comparisons, I collapsed across equivalent probability beliefs in each bias 
direction to create five bias categories (i.e., 0-0.1/0.9-1, 0.1-0.2/0.8-0.9. 0.2-0.3/0.7-0.8, 
0.3-0.4/0.6-0.7, 0.4-0.5/0.5-0.6). A 5 bias x 3 drug RM-ANOVA was used to compare 
mean baseline pupil diameter across these five belief levels and between drug-groups. 
6.3.11.3 Pupil diameter modulation by predictions and beliefs 
For an initial model-agnostic assessment of pupil diameter modulation across post-
response and post-outcome periods, trials were binned according to whether participants 
had made a correct or incorrect prediction about outcome type. In my previous work with 
de Berker et al., it was possible to show that pupil responsivity to probabilistic outcomes 
is influenced by participants’ beliefs about surprise and irreducible uncertainty (de Berker 
et al., 2016). Therefore, I next implemented median splits to separate trials according to 
whether they were high or low in participant-specific surprise (model parameter |𝛿1|) and 
irreducible uncertainty (?̂?1). 
Note that ?̂?1 reflects participants’ estimated beliefs of the current cue:outcome 
probabilities. These estimates lie between 0 and 1 and encapsulate two bias directions, 
e.g., a ?̂?1 estimate of 0.1 indicates an equivalent bias magnitude as a ?̂?1 estimate of 0.9, 
but in the opposite bias direction. Maximal irreducible uncertainty occurs at p=0.5. Since 
?̂?1 showed a symmetrical inverted-U relationship with baseline pupil diameter (see 
section 6.4.3.1), the median splits were conducted using a ?̂?1 parameter that had been 
adjusted to scale between 0 and 0.5. As such, any raw ?̂?1 values between 0 and 0.5 
remained unchanged, while those between 0.5 and 1 were transformed as follows: 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 ?̂?1 =  −?̂?1 + 1 
Equation 6.1 
In accordance with the prediction that NA would influence phasic volatility estimates (𝜇3) 
and/or phasic volatility uncertainty (?̂?3), I also performed additional median splits on high 
and low 𝜇3 and ?̂?3. Note that ?̂?3 captures an individual’s uncertainty about their current 
phasic volatility estimate, in contrast to volatility uncertainty which is the uncertainty that 
arises due to environmental instability. 
RM-ANOVAs were applied to assess peak pupil diameter during the post-response and 
post-outcome periods for these different trial-types and across drug-groups. Peak pupil 
6. Dynamic noradrenergic computations of uncertainty 
187 
 
responses were calculated according to the method described in section 6.3.11.1. Where 
significant drug effects were identified, additional exploratory analyses were conducted 
on the individual drug-groups to further characterise the effect of beliefs on pupil 
diameter. A Benjamini-Hochberg correction was applied to each of these additional 
analyses to control for FDR. No analyses were conducted on the post-cue period as it 
was fixed at 300ms to minimise overlap with the timing of the button-press responses 
(Table 6.4). 
6.3.11.4 Regression analyses 
To extend these analyses by pinpointing the specific effects of participants’ beliefs on 
pupil diameter, and assessing the impact of the noradrenergic manipulations on these 
pupil responses, a regression approach implemented by Browning et al. was adopted 
(Browning et al., 2015). Specifically, regression analyses were conducted to examine the 
effects of trial-wise estimates of surprise, irreducible uncertainty, phasic volatility, and 
phasic volatility uncertainty on pupil dilation during the post-response and post-outcome 
periods. For the Placebo group, pupil diameter during the post-response period (0 to 1s 
from response onset) was sampled using 120 8.3ms bins (i.e., 1s/sample rate). Pupil 
diameter during the post-outcome period (0 to 3.3s from outcome onset) was sampled 
using 396 8.3ms bins. The total duration of the post-outcome period entered into the 
regression analyses was the minimum that could occur on any given trial. 
Regression analyses were conducted for each of these bins, with surprise (|𝛿1|), 
irreducible uncertainty (?̂?1), phasic volatility estimate (𝜇3), and phasic volatility 
uncertainty (?̂?3) entered as regressors of interest. As in section 6.3.11.3, the adjusted 
irreducible uncertainty measure, which peaks at p=0.5 (see Equation 6.1), was used in 
all regression analyses. 
Cue type (-1 for low-pitch tone, 1 for high-pitch tone), response type (-1 for left button-
press, 1 for right button-press), and outcome type (-1 for “cow”, 1 for “pig”) were entered 
into the analysis as control regressors. 
For each participant in each of the active drug-groups, the mean Placebo regression 
beta weights across the post-response and post-outcome periods were subtracted from 
the time-series of beta weights for that participant. 
The resulting time-series of beta weights (for the Placebo group) and Δbeta-weights (for 
the active drug-groups) for the constant component of pupil diameter, surprise, 
irreducible uncertainty, phasic volatility estimate, and phasic volatility uncertainty were 
down-sampled to give mean beta weight estimates of the effects of each factor on pupil 
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dilation for 6 sequential 166.7ms bins across the post-response period and 19 sequential 
167.7ms bins across the post-outcome period.  
For the Placebo group, t-tests were used to determine whether each down-sampled 
beta-weight bin differed significantly from zero. Each active drug-group was compared 
to Placebo by using t-tests to determine whether each down-sampled Δbeta-weight bin 
differed significantly from zero. Since 6 comparisons were made across the post-
response period, 19 comparisons were made across the post-outcome period, and these 
comparisons were made across three drug-groups, a Benjamini-Hochberg correction 
was applied to correct for the FDR arising from the total of 75 comparisons. 
6.3.12 Behaviour vs pupil responses 
To assess whether the pupillary responses to participants’ beliefs were associated with 
altered behaviour during the PLT, correlation analyses were conducted. Specifically, for 
each of the three drug-groups, a Pearson’s correlation was used to compare the mean 
volatility beta weight from 0-1.7s post-outcome, and the mean irreducible uncertainty 
beta weight from 0.7-1.7s post-outcome, to participants’ mean learning rate and mean 
performance score. 
6.3.13 Control analyses 
6.3.13.1 Model parameter correlations 
To verify that the output of the regression analyses was not complicated by high 
correlations between the model parameters entered as regressors, correlations between 
|𝛿1|, ?̂?1, 𝜇3 and ?̂?3 were assessed. 
6.4 Results 
Behavioural data for 90 participants are reported. The three groups were matched for 
gender (Kruskal-Wallis test: H2=0.00, p=1.000), age (one-way ANOVA: F2,89=1.29, 
p=0.281), body weight (F2,89=0.082, p=0.921), education level (H2=4.79, p=0.091), and 
all other baseline psychometric measures taken (Table 6.2). Pupil data for one 
participant from the NA+ group is missing due to a technical problem with the eyetracker 
at the time of recording. 
6.4.1 Model-agnostic results 
On average, 45.9 ± 1.28% (±SEM), 47.9 ±1.28% and 46.5 ± 1.28% of predictions made 
during the unbiased (0.5/0.5) blocks were correct in the NA-, Placebo and NA+ groups 
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respectively, indicating that participants were performing close to chance level when 
there was no cue:outcome bias (Figure 6.3A). A one-way ANOVA indicated that 
accuracy (i.e., the percentage of correct responses) in the unbiased blocks did not differ 
between drug-groups (F2,86=0.55, p=0.581). Similarly, decision times during unbiased 
blocks were equivalent across drug-groups (F2,86=0.36, p=0.697; Figure 6.4A), indicating 
that the drug manipulations did not merely modulate participants’ ability to respond 
quickly. Neither effect was modulated by Δalertness (both p≥0.74). 
 Placebo 
(n = 30) 
NA- 
(n = 30) 
NA+ 
(n = 30) 
Between-
groups 
difference? 
Gender 
(number male)# 
13 13 13 
ns 
p = 1.000 
Age 
(years) 
24.1 ± 4.2 26.0 ± 5.9 24.8 ± 3.9 
ns 
p = 0.281 
Weight 
(kg) 
69.5 ± 2.8 68.3 ± 2.2 68.5 ± 1.8 
ns 
p = 0.921 
Education Level 
(1-5)# 
2.8 ± 0.2 3.1 ± 0.1 3.4 ± 0.2 
ns 
p = 0.091 
Digit Span 
(forwards + backwards)# 
12.8 ± 0.5 12.8 ± 0.4 13.4 ± 0.4 
ns 
p = 0.334 
Impulsivity: 
BIS-11 
64.4 ± 2.0 61.5 ± 1.4 61.4 ± 1.4 
ns 
p = 0.337 
Risk-taking: 
DOSPERT (total) 
113.1 ± 3.6 104.3 ± 4.0 108.2 ± 3.8 
ns 
p = 0.699 
Distractibility: 
CFQ 
39.5 ± 2.0 41.4 ± 2.6 40.0 ± 2.2 
ns 
p = 0.833 
Sleep quantity on the 
previous night (hours)# 
7.0 ± 0.2 7.6 ± 0.3 7.1 ± 0.2 
ns 
p = 0.107 
Sleep quality on the 
previous night (1-8)# 
5.2 ± 0.2 5.4 ± 0.2 5.5 ± 0.3 
ns 
p = 0.615 
Fatigue during task 
(0 – 100) 
45.4 ± 3.9 44.7 ± 3.8 46.6 ± 4.1 
ns 
p = 0.941 
Active drug 
(%)# 
37 57 73 p = 0.017 
 
Table 6.2 Summary details for participants in each experimental group. Between-
groups comparisons revealed no significant differences (ns = non-significant) for gender, 
age, body weight, education level, baseline working memory (Digit Span), impulsivity 
(Barratt Impulsiveness Scale; BIS-11), risk-taking (Domain-Specific Risk-Taking Scale; 
DOSPERT), distractibility (Cognitive Failures Questionnaire; CFQ), fatigue during the 
task, or sleep quality or quantity on the previous night. For continuous data, one-way 
ANOVAs were used to test for any between-group differences. For discrete data (#), 
Kruskal-Wallis tests were applied. Education Level refers to the highest attained from the 
following: 1 = compulsory education (≤ 12 years); 2 = further education (13-14 years); 3 
= undergraduate degree (15-17 years); 4 = one postgraduate degree (≥ 18 years); 5 = 
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multiple postgraduate degrees. Age data are mean ± SD. Remaining data are mean ± 
SEM. Active drug refers to the percentage of participants within each group who reported 
at the end of the experiment that they believed they had received an active drug.  
6.4.1.1 Accuracy increases with increasing cue:outcome bias 
A 3 bias (high/moderate/none) x 2 time (Early/Late trials) x 3 drug RM-ANOVA revealed 
that accuracy increased significantly as the true cue:outcome bias increased (effect of 
bias: F1.70,146.55=337.45, p<0.001, ηp2=0.80; Figure 6.3B). Additional (FDR-corrected) 
exploratory analyses revealed that the effect of bias existed in all three drug-groups (NA-
: F1.58,44.17=155.68, p<0.001, ηp2=0.85; Placebo: F1.66,46.44=118.37, p<0.001, ηp2=0.81; 
NA+: F2,56=81.65, p<0.001, ηp2=0.75). Together with the significant increase in accuracy 
over the course of a contextual block (effect of time F1,86=20.58, p<0.001, ηp2=0.19), this 
indicates that participants learned to estimate the true cue:outcome probabilities. The 3 
bias x 2 time x 3 drug RM-ANOVA indicated a significant bias x time interaction 
(F1.83,157.39=7.80, p=0.001, ηp2=0.08), but none of the main effects were modulated by 
drug (all p>0.21) or Δalertness (all p>0.13). 
Since learning would not be expected over the course of an unbiased block, I examined 
whether the bias x time interaction was driven by an increase in accuracy during the 
biased, but not the unbiased, blocks. A 2 time x 3 drug RM-ANOVA on the percentage 
correct responses in the unbiased blocks indeed revealed no effect of time (p=0.604) 
and no modulation by drug (p=0.808) or Δalertness (p=0.940). In contrast, a 2 bias x 2 
time x 3 drug RM-ANOVA on the highly and moderately biased blocks revealed 
significant effects of bias (F1,86=437.97, p<0.001, ηp2=0.84) and time (F1,86=41.20, 
p<0.001, ηp2=0.32), and no modulation by drug (all p>22) or Δalertness (all p>0.09). The 
increase in accuracy over time was equivalent across highly and moderately biased 
blocks (no probability x time interaction: p=0.168). 
Further (FDR-corrected) exploratory analyses indicated that accuracy increased across 
the course of the highly biased blocks in all three drug-groups (NA-: F1,28=9.94, p=0.004, 
ηp2=0.26; Placebo: F1,28=36.87, p<0.001, ηp2=0.57; NA+: F1,28=5.76, p=0.023, ηp2=0.17), 
and across the course of the moderately biased blocks in the NA- (F1,28=5.85, p=0.022, 
ηp2=0.17) and Placebo groups (F1,28=10.281, p=0.003, ηp2=0.27). NA+ group accuracy 
remained unchanged across the course of the moderately biased blocks (p=0.627). 
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Figure 6.3 Model-agnostic analysis of accuracy. Participants in all three drug-groups 
demonstrated learning of the underlying the cue:outcome relationships. (A) Across 
groups, participants made correct predictions on a higher percentage of trials as the true 
cue:outcome bias increased. (B) This learning was observed over the course of the 
biased contextual blocks, with participants in all three drug-groups achieving a higher 
accuracy on trials in the second half of the highly biased blocks. Accuracy rates in the 
NA- and Placebo groups also increased over the course of the moderately biased blocks. 
Accuracy remained unchanged over the course of the unbiased blocks in all three drug-
groups. Results are mean ± SEM, corrected for Δalertness. * p<0.05, ** p<0.01, *** 
p<0.001, after an FDR correction for three multiple comparisons.  
6.4.1.2 Decision times decrease with increasing cue:outcome bias 
A 3 bias (high/moderate/none) x 2 time (Early/Late trials) x 3 drug RM-ANOVA indicated 
that participants’ decision times decreased significantly as the true cue:outcome bias 
increased (effect of bias: F2,172=17.96, p<0.001, ηp2=0.17; Figure 6.4B), again indicative 
of learning of the true cue:outcome probabilities. Additional (FDR-corrected) exploratory 
analyses revealed that the effect of bias existed in the NA- (F2,56=11.50, p<0.001, 
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ηp2=0.29) and Placebo (F2,56=5.58, p=0.006, ηp2=0.17) groups, and there was a trend-
level effect in the NA+ group (F2,56=3.15, p=0.051, ηp2=0.10). However, there was no 
significant change in decision time over the course of the contextual blocks (no effect of 
time: p=0.164). The 3 bias x 2 time x 3 drug RM-ANOVA indicated that the effect of bias 
was not modulated by drug (p=0.173) or Δalertness (p=0.708). However, there was a 
significant time x drug interaction (F2,86=4.24, p=0.018, ηp2=0.09).  
Again, since there was a bias x time interaction (F2,72=6.64, p=0.002, ηp2=0.07), and 
because a decrease in decision time would not necessarily be expected across the 
course of the unbiased blocks, a 2 time x 3 drug RM-ANOVA was conducted on the 
decision times in the unbiased blocks. This indeed revealed no significant effect of time 
(p=0.155), and no modulation by drug (p=0.127) or Δalertness (p=0.183). In contrast, a 
2 bias x 2 time x 3 drug RM-ANOVA on the highly and moderately biased blocks revealed 
significant effects of bias (F1,86=27.63, p<0.001, ηp2=0.24) and time (F1,86=16.09, 
p<0.001, ηp2=0.16), and a significant time x drug interaction (F2,86=3.18, p=0.047, 
ηp2=0.07). Post-hoc (FDR-corrected) pairwise comparisons between the active drug-
groups and Placebo indicated that the time x drug interaction was driven by the NA+ 
group, with participant-specific differences in decision times on Late vs Early trials 
demonstrating less speeding across biased blocks compared to Placebo (t56=2.52, 
p=0.014, Cohen’s d=0.67). There was a trend-level bias x drug interaction (F2,86=3.05, 
p=0.053, ηp2=0.07), but none of the effects were modulated by Δalertness (all p>0.41). 
Further (FDR-corrected) exploratory analyses indicated that decision time decreased 
across the course of the highly biased blocks in the NA- (F1,28=12.139, p=0.002, 
ηp2=0.30) and Placebo (F1,28=16.304, p<0.001, ηp2=0.37) groups, but not in the NA+ 
group (p=0.693). Uncorrected analyses indicated that Placebo group decision times also 
decreased over the course of the moderately biased blocks (F1,28=5.93, p=0.022, 
ηp2=0.18), but the result did not survive an FDR correction for multiple comparisons. No 
change in decision times across the course of the moderately biased blocks was 
observed in the NA- or NA+ groups (both p>0.88). 
In summary, the increasing accuracy and decreasing decision time that accompanied an 
increase in cue:outcome bias, and continued over the course of the biased blocks, 
indicates that participants in all three drug-groups demonstrated learning of the task’s 
underlying probabilistic structure. Moreover, the smaller decrease in decision times 
across biased blocks in the NA+ group compared to Placebo is indicative of a modulation 
of learning by reboxetine.  
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Figure 6.4 Model-agnostic analysis of decision times. (A) Decision times decreased 
as the true cue:outcome bias increased, further demonstrating learning of the task’s 
structure in the three drug-groups. (B) Learning was observed over the course of the 
biased contextual blocks, with participants in the NA- and Placebo groups showing 
decreased decision times on trials in the second half of the highly biased blocks. A trend-
level decrease in decision time was also observed across the course of the moderately 
biased blocks in the Placebo group. Decision times remained unchanged over the course 
of the unbiased blocks in all three drug-groups. Results are mean ± SEM, corrected for 
Δalertness. * p<0.05, ** p<0.01, *** p<0.001, # trend, after an FDR correction for three 
multiple comparisons.  
6.4.1.3 Task performance is modulated by cue:outcome bias and noradrenaline 
Next, accuracy and decision time were combined to calculate a performance score 
(Figure 6.5). A 3 bias x 2 time x 3 drug RM-ANOVA on performance scores demonstrated 
that performance improved significantly as the true cue:outcome bias increased (effect 
of probability: F1.66,142.92=252.41, p<0.001, ηp2=0.75) and as a contextual block 
progressed (effect of time: F2,86=23.73, p<0.001, ηp2=0.22). There was a significant bias 
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x time interaction (F2,172=15.50, p<0.001, ηp2=0.153) and a trend-level time x drug 
interaction (F2,86=3.08, p=0.051, ηp2=0.07). Post-hoc pairwise (FDR-corrected) 
comparisons on the participant-specific differences in performance scores on Late vs 
Early trials demonstrated that this interaction was driven by the NA+ group (Figure 6.5C). 
Indeed, performance was poorer in the NA+ group compared to Placebo (t56=2.67, 
p=0.016, d=0.71). In the 3 bias x 2 time x 3 drug RM-ANOVA, neither the effect of bias 
nor the bias x time interaction was modulated by drug (both p>0.52). None of the effects 
were modulated by Δalertness (all p>0.09). 
 
Figure 6.5 Model-agnostic analysis of performance scores. In each case, a higher 
score indicates better performance since it reflects a higher accuracy and/or faster 
decision time. (A)  Performance improved significantly in each drug-group as the true 
cue:outcome probability increased. (B) Performance also improved across the course of 
the contextual blocks with subjects achieving higher performance scores on Late trials 
(i.e., those in the second half of the contextual blocks) compared to Early trials (i.e., those 
in the first half of the contextual blocks). Here the data have been collapsed across the 
three bias levels. (C) Assessment of the participant-specific differences in performance 
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scores on Late vs Early trials across the three bias levels indicates that performance was 
poorer in the NA+ group compared to Placebo. Data are mean ± SEM, corrected for 
Δalertness. * p<0.05, ** p<0.01, *** p<0.001. 
6.4.2 Model-based results  
6.4.2.1 Decision times are modulated by irreducible uncertainty 
Participants’ estimated beliefs about the current cue:outcome probabilities, and hence 
their current irreducible uncertainty (model parameter ?̂?1), predicted their decision times 
(Figure 6.6A). Indeed, a curve describing the variance of a Bernoulli distribution 
representing beliefs about probabilities, which is the formulation of irreducible uncertainty 
?̂?1 used here, predicts mean decision times across the three drug-groups (Pearson’s 
correlations for NA: r=0.942, p<0.001; Placebo: r=0.902, p<0.001; NA+: r=0.931, 
p<0.001), replicating my previous work with de Berker et al. (de Berker et al., 2016) 
A 5 bias x 3 drug RM-ANOVA indicated that participants’ decision times increased 
significantly as their estimates of cue:outcome bias decreased, and thus as their 
estimated irreducible uncertainty increased (effect of bias: F2.38,188.25=60.69, p<0.001, 
ηp2=0.43; Figure 6.6B). Additional (FDR-corrected) exploratory analyses revealed that 
the effect of bias existed in all three drug-groups (NA-: F1.88,48.75=19.48, p<0.001, 
ηp2=0.43; Placebo: F2.50,64.98=36.69, p<0.001, ηp2=0.59; NA+: F2.89,72.22=13.97, p<0.001, 
ηp2=0.36). Indeed, the effect of estimated bias on decision times was not modulated by 
drug (p=0.723), or by Δalertness (p=0.310). 
Since the HGF is informed of participants’ trial-wise predictions, but not their decision 
times, this increase in decision time with decreasing bias and increasing irreducible 
uncertainty (i.e., as beliefs approach p=0.5) indicates that the model captured 
participants’ beliefs well. Indeed, the relationship between decision time and probability 
is clearer when trials are categorised according to participants’ estimated beliefs about 
the current cue:outcome probability compared to when trials are categorised according 
to the true cue:outcome probabilities, which were hidden from participants (c.f. Figure 
6.4). 
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Figure 6.6 Decision times according to participants’ cue:outcome probability 
beliefs. (A) Participants’ estimated beliefs about cue:outcome probabilities (and their 
beliefs about irreducible uncertainty) lay between 0 and 1. Across drug-groups, the 
distribution of decision times across these estimates conformed closely to a Bernoulli 
distribution (grey dashed line), with decision times peaking with maximal irreducible 
uncertainty (?̂?1=0.5). (B) For statistical analysis of the effect of irreducible uncertainty on 
decision times, bins showing an equivalent bias magnitude (but in opposite directions) 
were collapsed, to create 5 bias bins spanning 0/1 to 0.5/0.5. Across the three drug-
groups, decision time increased significantly as irreducible uncertainty about the 
cue:outcome relationships increased. Since the HGF is uninformed of participants’ 
decision times, this relationship with estimated irreducible uncertainty indicates that the 
model captured participants’ beliefs well. Data are mean ± SEM, corrected for 
Δalertness. *** p<0.001, after an FDR correction for three comparisons.  
6. Dynamic noradrenergic computations of uncertainty 
197 
 
6.4.3 Pupil analyses 
6.4.3.1 Baseline pupil diameter is modulated by irreducible uncertainty 
Baseline pupil diameter on each trial displayed a clear inverted-U relationship with belief 
about the current cue:outcome probabilities, and thus with estimates of irreducible 
uncertainty, as reflected by model parameter ?̂?1 (Figure 6.7A). This recapitulates the 
relationship between decision times and irreducible uncertainty, and replicates my 
previous work with de Berker et al. (de Berker et al., 2016). A curve describing the 
variance of a Bernoulli distribution representing beliefs about cue:outcome probabilities 
predicts mean baseline pupil diameter extremely well across the three drug-groups 
(Pearson’s correlations for NA: r=0.886, p<0.001; Placebo: r=0.921, p<0.001; NA+: 
r=0.938, p<0.001).  
A 5 bias x 3 drug RM-ANOVA indicated that participants’ baseline pupil diameter 
increased significantly as their estimates of cue:outcome bias decreased and therefore 
as their estimated irreducible uncertainty increased (effect of bias: F1.91,149.25=16.98, 
p<0.001, ηp2=0.18; Figure 6.7B). Additional (FDR-corrected) exploratory analyses 
revealed that the effect of bias existed in all three drug-groups (NA-: F1.98,51.49=5.68, 
p<0.001, ηp2=0.18; Placebo: F1.83,47.49=6.17, p<0.001, ηp2=0.19; NA+: F1.86,44.59=9.83, 
p<0.001, ηp2=0.29). Indeed, the effect of estimated bias on baseline pupil diameter was 
not modulated by drug (p=0.613), or by Δalertness (p=0.564). 
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Figure 6.7 Baseline pupil diameter according to participants’ cue:outcome 
probability beliefs. (A) Across drug-groups, the relationship between pupil diameter 
and beliefs about cue:outcome probabilities (and thus irreducible uncertainty) closely 
conformed to a Bernoulli distribution (grey dashed line), with pupil diameters peaking 
with maximal irreducible uncertainty (?̂?1=0.5). (B) For statistical analysis of the effect of 
irreducible uncertainty on pupil diameter, bins showing an equivalent bias magnitude (but 
in opposite directions) were collapsed to create 5 bias bins spanning 0/1 to 0.5/0.5. 
Across the three drug-groups, pupil diameter increased significantly as irreducible 
uncertainty about the cue:outcome relationships increased. Data are mean ± SEM, 
corrected for Δalertness. *** p<0.001, after an FDR correction for three comparisons.  
6.4.3.2 Event-related analysis of pupil diameter 
By epoching pupil diameter during the PLT by trial, and then according to cue, response 
and outcome onset within each trial, it was possible to characterise pupil diameter 
modulations during the post-response and post-outcome periods (Figure 6.8). Across 
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drug-groups, pupil diameter started to increase after cue onset, and continued to 
increase following the button-press response participants made to indicate their 
prediction about which outcome would follow. Following outcome onset, pupils showed 
a positive evoked response. The peak post-response increase in pupil diameter was 
identical across drug-groups (p=0.802). Compared to Placebo, the peak post-outcome 
increase in pupil diameter tended to be augmented in the NA+ group and suppressed in 
the NA- group. However, a one-way ANOVA on the post-outcome pupillary peak 
revealed no significant modulation by drug-group (p=0.202). No reported effects were 
modulated by Δalertness (p≥0.37). 
 
Figure 6.8 Trial-wise pupil diameter during the probabilistic learning task (PLT). 
Data have been baseline-corrected and epoched according to (1) cue, (2) response and 
(3) outcome onset. Across the three drug-groups, pupil diameter begins to increase after 
cue onset, continues to increase following the button-press response participants make 
to indicate their prediction about which outcome will follow, and then shows a positive 
evoked response following outcome onset. Compared to Placebo, there was a tendency 
for the post-outcome increase in pupil diameter to be augmented in the NA+ group and 
suppressed in the NA- group. Data are mean pupil diameter across participants. Error 
bars indicate the maximum SEM for each drug-group.  
Applying the same epoching approach to the control data, pupil diameter was again 
found to start increasing after cue onset, and to continue increasing following the 
participants’ button-press response (Figure 6.9). Unlike during the PLT, there was no 
positive evoked response following outcome presentation in any of the drug-groups. 
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Figure 6.9 Trial-wise pupil diameter during the control task (CT). Data have been 
baseline-corrected and epoched according to (1) cue, (2) response and (3) outcome 
onset. Across the three drug-groups, pupil diameter begins to increase after cue onset, 
and continues to increase following the button-press response participants make to 
indicate their “prediction” about which outcome will follow. Unlike during the PLT, there 
is no positive evoked response following outcome presentation. Data are mean pupil 
diameter across participants. Error bars indicate the maximum SEM for each drug-group.  
The key difference between the PLT and the CT was that the latter was free from 
uncertainty about which outcome would follow the cue on any given trial. Therefore, the 
fact that no increase in pupil diameter was observed post-outcome in the CT suggests 
that the evoked response observed during the PLT was indeed due to uncertainty and/or 
surprise about trial-wise outcome presentation. 
In both the PLT and CT, an increase in pupil diameter was observed following the button-
press response participants made to indicate their prediction about which outcome would 
follow. Given that this pupillary response was observed under both conditions of 
uncertainty and conditions of no uncertainty about outcome type, this suggests that the 
increase in pupil diameter at this stage in the trial is linked to the act of making a decision 
by button-press. Moreover, across drug-groups, the maximum pupil diameter during the 
post-response period was greater during the PLT (mean for NA-: 0.445; Placebo: 0.416; 
NA+: 0.427) than the CT (mean for NA-: 0.299; Placebo: 0.253; NA+: 0.263), and was 
sustained for longer, suggesting that uncertainty during the PLT may have had an 
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additional dilatory effect on pupils over and above the effect of making a button-press 
response. 
6.4.3.3 Model-agnostic analyses of pupil diameter modulation across post-
response and post-outcome periods 
A RM-ANOVA indicated that the peak increase in pupil diameter following outcome 
presentation was greater on trials on which participants had made an incorrect prediction 
about outcome type compared to when they had made a correct prediction (F1,85=29.91, 
p<0.001, ηp2=0.26; Figure 6.10). However, this effect was modulated by drug-group 
(F2,85=29.91, p=0.002, ηp2=0.14). Indeed, additional exploratory analyses demonstrated 
that this increased pupillary response on incorrect trials existed in the NA- (F1,28=11.17, 
p=0.003, ηp2=0.29) and NA+ (F1,27=18.22, p<0.001, ηp2=0.40) groups, but not in the 
Placebo group (p=0.348). None of these effects were modulated by Δalertness (p>0.34). 
In contrast, there was no effect of drug on post-response pupillary dilation (p=0.224).  
 
Figure 6.10 Pupil diameter on trials with correctly and incorrectly predicted 
outcomes. An incorrect prediction augmented the post-outcome dilatory pupillary 
response in the NA- and NA+ groups. Data are mean pupil diameter across participants. 
Error bars indicate the maximum SEM for each trial-type.  
6.4.3.4 Model-based analyses of pupil diameter modulation across post-
response and post-outcome periods 
Using estimates of participants’ trial-wise beliefs, as provided by the HGF, to categorise 
trials indicated that high surprise (|𝛿1|) and high irreducible uncertainty (?̂?1) were 
associated with an increase in the pupillary response observed in the post-outcome 
period compared to low surprise (F1,85=45.52, p<0.001, ηp2=0.35; Figure 6.11A) and low 
irreducible uncertainty (F1,85=45.15, p<0.001, ηp2=0.35; Figure 6.11B), respectively.  The 
positive effect of surprise on post-outcome pupil diameter is reassuring given the positive 
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effect of incorrect responses observed previously (Figure 6.10), and given that the 
surprise quantity estimated by the HGF is correlated with correct/incorrect predictions 
(NA-: mean r=0.589 ± 0.03 (± SEM); Placebo: r=0.611 ± 0.03; NA+: r=0.562 ± 0.04). 
These effects were equivalent across drug-groups (all p>0.50). There was also a 
significant effect of high irreducible uncertainty during the post-response period 
(F1,85=7.05, p=0.009, ηp2=0.08), but this effect was not significant within the individual 
NA- (p=0.465), Placebo (p=0.465) or NA+ (p=0.054) groups. 
A RM-ANOVA with drug-group as a between-subjects factor indicated that high phasic 
volatility estimates (𝜇3) were associated with an increased post-outcome pupillary 
response (F1,85=11.89, p=0.001, ηp2=0.12; Figure 6.11C). Additional exploratory 
analyses indicated that this effect was driven by the NA- group (F1,28=11.49, p=0.006, 
ηp2=0.29), but not the Placebo (p=0.110) or NA+ (p=0.433) groups. Similarly, high phasic 
volatility uncertainty estimates (?̂?3) were associated with an increased post-outcome 
pupillary response when drug-group was included in a RM-ANOVA as a between-
subjects factor (F1,85=6.81, p=0.011, ηp2=0.07; Figure 6.11D), but additional analyses on 
the individual drug-groups demonstrated that this effect was not significant within the NA- 
(p=0.033), Placebo (p=0.259) or NA+ (p=0.141) groups. There was also a significant 
effect of high phasic volatility uncertainty during the post-response period (F1,85=5.98, 
p=0.021, ηp2=0.18), but again this effect was not significant within the individual drug-
groups (all p≥0.058). None of the reported effects were modulated by Δalertness (all 
p>0.09). 
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Figure 6.11 Model-based analysis of pupil diameter. Median splits indicated that, 
across drug-groups, high surprise (|𝛿1|; A) and high irreducible uncertainty (?̂?1; B) were 
associated with an increased pupil diameter in the post-outcome period compared to low 
surprise and low irreducible uncertainty. High phasic volatility estimates (𝜇3; C) were 
associated with increased post-outcome pupillary dilation in the NA- group only. There 
was a tendency for high phasic volatility uncertainty (?̂?3; D) to be associated with 
increased post-outcome pupil diameter, but the effect was not significant within individual 
drug-groups. There was also a tendency for high irreducible uncertainty and high 
volatility uncertainty to increase pupil diameter in the post-response period across drug-
groups. Data are mean pupil diameter across participants. Error bars indicate the 
maximum SEM for each trial-type.  
6.4.3.5 Regression analyses: Placebo data 
Regression analyses enabled the specific pupillary effects of participants’ estimates of 
surprise, irreducible uncertainty, phasic volatility, and phasic volatility uncertainty during 
the post-response and post-outcome periods to be identified. Reassuringly, the 
regression analysis of the Placebo group pupil data identified a constant component of 
pupil diameter (Figure 6.12A) with a trial-wise trajectory strikingly similar to the mean 
pupil diameter trajectory shown in Figure 6.8. FDR-corrected t-tests indicated that pupil 
diameter was significantly greater than baseline during the 0-1s post-response period 
(all FDR-corrected p<0.001), and from 0-1.5s post-outcome (all p≤0.001). Pupil diameter 
then decreased below baseline levels from 2.3-3.2s post-outcome (all p≤0.03). 
Surprise significantly increased pupil diameter from 1.2-2.3 and 2.7-3.2s post-outcome 
(all p≤0.04); Figure 6.12B). Again, this result is reassuring given the positive effect of 
surprise and incorrect predictions on pupil diameter observed previously (Figure 6.11A). 
Irreducible uncertainty had a tendency to increase pupil diameter 0-1s post-response (all 
uncorrected p≤0.03), but this result did not survive correction for multiple comparisons. 
Irreducible uncertainty did significantly increase pupil diameter 0-1.s post-outcome (all 
FDR-corrected p≤0.04; Figure 6.12C). 
Phasic volatility estimates showed a tendency to decrease pupil diameter 0.8-1s post-
response (uncorrected p=0.038), but this result did not survive correction for multiple 
comparisons (Figure 6.12D). No significant effects of phasic volatility uncertainty on pupil 
diameter were observed (Figure 6.12E). 
6. Dynamic noradrenergic computations of uncertainty 
205 
 
In summary, pupil diameter tracked both surprise and irreducible uncertainty. Additional 
control regressors for cue type, response type and outcome type were included in the 
analysis but had no significant influence on pupil diameter (all FDR-corrected p>0.09). 
 
Figure 6.12 Regression analyses on Placebo pupil data. The output indicates the 
effects of Placebo participants’ beliefs on pupil diameter. The constant component of 
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pupil diameter strongly reflects the mean pupil diameter trajectory (see Figure 6.8).  Data 
are mean ± SEM. * p<0.05 (FDR-corrected), + p<0.05 (uncorrected).  
6.4.3.6 Regression analyses: Noradrenergic manipulations 
Next the output of the regression analyses for each of the active drug-groups was 
compared to the output of the regression analysis for the Placebo group (Figure 6.13). 
Compared to Placebo, individuals in the NA+ group showed a general tendency towards 
an increased pupil diameter in the post-outcome period, indicated by an augmented 
constant component of pupil diameter 0.7-1.3s and 1.7-2.3s post-outcome (all p≤0.04; 
Figure 6.13A). However, these results did not survive FDR-correction for multiple 
comparisons. While the NA- group showed a numerical decrease in the constant 
component of post-outcome pupil diameter compared to Placebo approximately 0.7-1.3s 
post-outcome, this decrease was not statistically significant (all uncorrected p≥0.12). 
Compared to Placebo, surprise tended to have a reduced influence on pupil diameter in 
the NA- group 0-1s post-response (all uncorrected p≤0.05), and in the NA+ group 1.5-
2.3s post-outcome (all uncorrected p≤0.05). However, these results did not survive 
correction for multiple comparisons (Figure 6.13B). 
Irreducible uncertainty estimates had a significantly reduced effect on pupil diameter in 
the NA- group 0.5-1s post-response (all FDR-corrected p≤0.05; Figure 6.13C) and 0-
1.8s post-outcome (all p≤0.05). In the NA+ group, a reduced effect of irreducible 
uncertainty on pupil diameter was only observed after outcome onset, specifically 0.7-1s 
and 1.3-1.7s post-outcome (all p≤0.05). 
Compared to Placebo, phasic volatility estimates significantly increased pupil diameter 
in both drug-groups (Figure 6.13C). In both the NA- and NA+ groups, volatility increased 
pupil diameter 0.5-1s post-response (all FDR-corrected p≤0.02). For the post-outcome 
period, volatility increased pupil diameter 0-1.2s post-outcome in the NA- group, and 0-
2s post-outcome in the NA+ group (all FDR-corrected p≤0.03). 
Phasic volatility uncertainty estimates tended to decrease pupil diameter during the 0.2-
0.5s post-response in the NA+ group compared to Placebo (all uncorrected p≤0.05; 
Figure 6.13D), but this result did not survive FDR-correction for multiple comparisons. 
There was no effect of NA- on pupil diameter modulation by phasic volatility uncertainty.  
In summary, noradrenergic antagonism (NA-) modulated the pupil response to volatility 
and irreducible uncertainty. Boosting noradrenergic function (NA+) had the tendency to 
increase the general responsivity of the pupil, and also modulated the pupil response to 
volatility and irreducible uncertainty. 
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Figure 6.13 Regression analyses on NA- and NA+ pupil data. The output indicates 
noradrenergic manipulations of participants’ beliefs on pupil diameter. Data are Drug – 
mean Placebo, ± the standard error of the difference (SED). * p<0.05 (FDR-corrected), 
+ p<0.05 (uncorrected).  
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6.4.4 Learning rate 
As in Chapter 4, the punctate change-points contained in the PLT’s true generative 
process are detected implicitly as an increase in learning rate (α1; Figure 6.14A). This 
implies that, as one would expect, higher learning rates following a true change-point 
reflect behaviour that is strongly controlled by recent outcomes. 
 
Figure 6.14 Mean learning rates across drug-groups. (A) An increase in mean 
learning rate was identified following true context change-points. Error bars indicate the 
maximum SEM for each drug-group. (B) Mean learning rates across the PLT. (C) Mean 
difference in learning rate at all context change-points. For B and C, data are mean ± 
SEM.  
A one-way ANOVA demonstrated that mean learning rates across the PLT were 
equivalent across drug-groups (F2,86=0.07, p=0.928; Figure 6.14B) and that there was 
no modulation by Δalertness (F1,86=0.42, p=0.520). Moreover, the drug manipulations did 
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not alter the mean difference in learning rate across all types of context switch 
(F2,86=0.61, p=0.547; Figure 6.14C). However, across the three drug-groups, there were 
differences in the degree to which learning rates changed across different types of 
context switch (Figure 6.15). Indeed, an 8 context switch-type x 3 drug RM-ANOVA 
indicated that the type of context switch significantly altered the difference in learning 
rate (F2.80,25.15=3.99, p=0.021, ηp2=0.31). There was a trend-level modulatory effect of 
drug-group (F5.59,25.15=2.02, p=0.105, ηp2=0.31, and no modulation by Δalertness 
(p=0.742). 
 
Figure 6.15 Mean learning rates at all types of context change-point. Augmented 
increases in learning rate were observed for more obvious context switches (e.g., from 
a highly biased context to a context highly biased in the opposite direction, or from a 
highly biased to a moderately biased context) than for less obvious context switches 
(e.g., from a moderately biased to an unbiased context). Error bars indicate the maximum 
SEM for each drug-group.  
For exploratory purposes, I next assessed whether the drug manipulations altered the 
degree to which learning rates changed following the three most obvious context 
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changes (i.e., switches from a highly biased context to either a different highly biased, 
moderately biased or unbiased context) using three individual (FDR-corrected) one-way 
ANOVAs (Figure 6.16). No significant effect of drug was observed at switches to highly 
biased (p=0.974), moderately biased (p=0.792) or unbiased contexts (p=0.276). Note 
that the uncorrected comparisons were also non-significant (p=0.974, p=0.528 and 
p=0.092, respectively). 
 
Figure 6.16 Mean learning rate differences at context change-points. No significant 
effects of drug on the difference in learning rate were identified following a switch from a 
highly biased block to a different highly, moderately or unbiased block. Data are mean ± 
SEM, corrected for Δalertness.  
6.4.5 Behaviour vs pupil data 
To ascertain whether the effect of participants’ beliefs on pupil diameter was associated 
with behavioural changes during the PLT, correlational analyses were conducted on the 
volatility and irreducible uncertainty pupil beta weights, mean learning rates and mean 
performance scores.  
The influence of volatility estimates on pupil diameter was negatively correlated with 
mean learning rate in the NA+ group (Pearson’s r=-0.418, p=0.024; Figure 6.17A) but 
not in the NA- (r=0.021, p=0.911) or Placebo (r=-0.215, p=0.254) groups. Volatility’s 
effect on pupil diameter was not correlated with mean performance score in any of the 
drug-groups (NA-: r=-0.218, p=0.247; Placebo: r=-0.156, p=0.411; NA+: r=-0.123, 
p=0.524; Figure 6.17B). 
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Figure 6.17 The effect of phasic volatility estimates on pupil diameter compared to 
behaviour. The influence of phasic volatility estimates on pupil diameter was negatively 
correlated with mean learning rate in the NA+ group. No other significant correlations 
were identified.  
The influence of irreducible uncertainty estimates on pupil diameter were not correlated 
with mean learning rate in any of the drug-groups (NA-: r=-0.016, p=0.935; Placebo: r=-
0.160, p=0.412; NA+: r=0.217, p=0.259; Figure 6.18A). Irreducible uncertainty’s effect 
on pupil diameter was positively correlated with mean performance score in the NA+ 
group (r=0.0374, p=0.045; Figure 6.18B), but not in the NA- (r=0.106, p=0.579) or 
Placebo (r=0.006, p=0.976) groups. 
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Figure 6.18 The effect of irreducible uncertainty on pupil diameter compared to 
behaviour. The influence of irreducible uncertainty estimates on pupil diameter were 
positively correlated with mean performance score in the NA+ group. No other significant 
correlations were identified.  
6.4.6 Control analyses 
6.4.6.1 Physiological and subjective control measures 
Self-reported ratings for alertness and contentedness changed significantly over the 
course of the experiment (F1.74,151.73=42.63, p<0.001, ηp2=0.33; F1.71,148.93=12.84, 
p<0.001, ηp2=0.13 respectively); calmness ratings remained unchanged (F2,174=0.88, 
p=0.42). Alertness ratings showed a significant time x drug interaction (F3.48,151.73=3.34, 
p=0.016, ηp2=0.07). A one-way ANOVA with drug as a between-subjects factor revealed 
that the degree to which alertness decreased between Baseline (Figure 6.1A) and the 
time corresponding to peak drug concentration (Post-Drug) varied between groups 
(F2,87=6.56, p=0.002, ηp2=0.13). More specifically, (FDR-corrected) pairwise 
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comparisons indicated that, compared to Placebo, the alertness-decrease was 
significantly more pronounced in the NA+ group (t58=-3.59, p=0.002, d=-0.94). 
Heart rate (HR) varied significantly with time (F2,174=13.11, p<0.001, ηp2=0.13) and this 
effect was modulated by drug-group (F4,174=4.22, p=0.003, ηp2=0.09). On average, all 
groups showed mild participant-specific HR decreases between Baseline and Post-Drug. 
The magnitude of HR deceleration differed between groups (F2,87=5.13, p=0.008, 
ηp2=0.11), with the deceleration being less pronounced in the NA- (t58=2.24, p=0.027, 
d=0.59) and NA+ (t58=3.10, p=0.006, d=0.81) groups compared to Placebo. Systolic 
blood pressure (BP) did not change significantly over time (p=0.783) and there was no 
modulation by drug-group (p=0.088). Diastolic BP did vary significantly with time 
(F2,174=3.30, p=0.039, ηp2=0.04) and this effect was modulated by drug-group 
(F4,174=5.81, p<0.001, ηp2=0.12). Indeed, in line with the known effect of NA on BP, an 
effect of drug-group on the participant-specific difference in diastolic BP between 
Baseline and Post-Drug (F2,87=13.42, p<0.001, ηp2=0.24) was driven by a significant 
increase in BP in the NA+ group compared to Placebo (t58=3.22, p=0.004, d=0.85) and 
a trend-wise decrease in BP in the NA- group (t58=-1.90, p=0.061, d=-0.50). A summary 
table of the subjective and physiological measures is reported in (Table 6.3). 
6.4.6.2 Parameter correlations 
The parameters entered into the pupil regression analyses were not highly correlated 
(Figure 6.19). The highest correlation existed between surprise (|𝛿1|) and phasic volatility 
estimates (𝜇3) (mean for NA-: r=0.534; Placebo: r=0.536; NA+: r=0.498). The absolute 
mean for all other correlations was r≤0.055 for NA-, r≤0.134 for Placebo, and r≤0.056 for 
NA+.  
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  NA- Placebo NA+ 
A
le
rt
-
n
e
s
s
 
Baseline 
Post-Drug 
Post-Task 
70.9 ± 2.8  
61.8 ± 3.5  
56.6 ± 3.2  
68.9 ± 2.9  
64.7 ± 3.0  
60.4 ± 2.9 
69.3 ± 2.8  
52.2 ± 3.6  
49.9 ± 3.8 
C
a
lm
-
n
e
s
s
 
Baseline 
Post-Drug 
Post-Task 
72.2 ± 3.2 
67.2 ± 4.2  
64.4 ± 3.8 
67.6 ± 2.7  
72.4 ± 2.8  
67.0 ± 2.9 
61.5 ± 2.8  
64.9 ± 3.0  
66.0 ± 2.6 
C
o
n
te
n
t-
e
d
n
e
s
s
 Baseline 
Post-Drug 
Post-Task 
72.9 ± 2.6 
69.4 ± 2.6  
65.7 ± 2.4 
78.0 ± 2.5 
75.5 ± 2.2  
73.2 ± 2.6 
71.4 ± 2.5  
64.6 ± 2.9  
62.1 ± 3.9 
H
R
 
Baseline 
Post-Drug 
Post-Task 
73.9 ± 2.1  
71.1 ± 2.1  
68.3 ± 1.8 
71.8 ± 1.6  
64.1 ± 1.6  
64.1 ± 1.6 
69.2 ± 2.3  
68.2 ± 2.2  
69.3 ± 2.2 
S
y
s
to
lic
 
B
P
 
Baseline 
Post-Drug 
Post-Task 
121.6 ± 2.8  
117.5 ± 2.6  
120.3 ± 2.7 
 118.6 ± 2.4  
116.7 ± 2.4  
118.7 ± 2.8 
120.1 ± 2.6  
124.2 ± 2.9  
121.9 ± 2.3 
D
ia
s
to
lic
 
B
P
 
Baseline 
Post-Drug 
Post-Task 
75.2 ± 1.6  
71.4 ± 1.5  
73.5 ± 2.4 
74.3 ± 1.5 
74.1 ± 1.5  
77.3 ± 1.5 
74.1 ± 1.6  
80.1 ± 2.0  
79.4 ± 2.2 
 
Table 6.3 Subjective and physiological measures for each experimental group. 
Readings were taken at baseline, immediately before participants started the PLT (i.e., 
when the drugs were at their most active; Post-Drug), and after completing the PLT and 
CT (Post-Task). Data are mean ± SEM.  
 
Figure 6.19 Model parameter correlations. The parameters used in the regression 
analyses were not highly correlated with each other (all mean absolute r≤0.534 for NA-, 
r≤0.536 for Placebo, and r≤0.498 for NA+).   
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6.4.6.3 Decision times during the PLT and CT 
On average, mean and minimum decision times during the CT tended to be faster than 
during the PLT across drug-groups (Table 6.4). This is to be expected given that 
participants knew with certainty which cue and which outcome would be presented on 
each trial. 
 NA- Placebo NA+ 
PLT Mean Decision 
time (ms) 
651.6 ± 20.7  661.7 ± 22.0 676.5 ± 20.5 
Mean Minimum 
Decision time (ms) 
300.3 ± 14.9 315.1 ± 14.2  327.6 ± 14.1 
CT Mean Decision 
time (ms) 
392.3 ± 21.2  422.1 ± 23.4 428.8 ± 21.4 
Mean Minimum 
Decision time (ms) 
232.0 ± 12.2 234.8 ± 11.6 242.0 ± 14.0 
 
Table 6.4 Mean and minimum decision times during the PLT and CT. Data are mean 
± SEM. 
6.5 Discussion 
By combining a probabilistic learning task with pharmacological manipulations, 
pupillometry and a hierarchical Bayesian learning model, it was possible to characterise 
the impact of NA and dynamic uncertainty computations on changes in pupil diameter. 
Implementing a unified framework of hierarchically-related forms of uncertainty meant 
that I could assess the degree to which individuals’ computations of irreducible 
uncertainty, surprise, phasic volatility and phasic volatility uncertainty were reflected by 
the pupil, and compare the effects of two drugs, with different effects on NA 
neurotransmission, on individuals’ subjective beliefs, behaviour and pupillary responses.  
6.5.1 Baseline pupil diameter reflects individual irreducible uncertainty 
The finding that baseline pupil diameter increases with increasing irreducible uncertainty 
replicates our previous finding with a visual version of the PLT (de Berker et al., 2016). 
It also echoes a finding by Nassar et al. that baseline pupil diameter reflects the reliability 
with which recent event history indicates the current probabilistic relationship between 
environmental events during predictive inference (Nassar et al., 2012). Strikingly, the 
inverted-U relationship observed between pupil diameter and irreducible uncertainty in 
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the present study was strongly reflected in the relationship between irreducible 
uncertainty and decision time, indicative of a tight link between irreducible uncertainty 
computations, baseline pupil diameter and behaviour. However, these relationships do 
not appear to be dependent on NA. Indeed, neither downregulating NA 
neurotransmission with prazosin nor upregulating NA neurotransmission with reboxetine 
appeared to alter the relationships between irreducible uncertainty, baseline pupil 
diameter and decision time. 
6.5.2 Pupil diameter tracks irreducible uncertainty and surprise 
Using median splits to compare peak pupil diameter on trials high in subjective surprise 
and irreducible uncertainty suggested that each of the perceptual quantities had a 
positive effect on pupil diameter in the Placebo group, replicating our previous work (de 
Berker et al., 2016). Estimates of phasic volatility and phasic volatility uncertainty did not 
appear to modulate pupil diameter. However, this method of analysis only offers a 
relatively crude way of repeatedly categorising trials according to subjective beliefs. 
Importantly, in the present study, regression analyses were implemented to pinpoint the 
relative contributions of individuals’ subjective beliefs on pupil diameter during the post-
response and post-outcome periods. The Placebo group showed increases in pupil 
diameter during the post-outcome period that were dependent on subjective estimates 
of irreducible uncertainty and surprise, echoing the median split analyses used both here 
and in previous work (de Berker et al., 2016). Pupillary dilation due to post-outcome 
surprise has also been observed by other research groups (Preuschoff et al., 2011; 
Browning et al., 2015), albeit with subtly different quantifications of surprise. In particular, 
my finding of a positive effect of surprise on pupil diameter 1.2-3.2s post-outcome 
replicates Browning et al.’s observation that surprise increases pupil diameter in a 1-3s 
post-outcome window during probabilistic learning (Browning et al., 2015; c.f. Figure 
6.12B and Figure 6.20A). 
As anticipated by the median split method, regression analyses did not reveal a 
significant effect of individuals’ estimates of phasic volatility or phasic volatility 
uncertainty on pupil diameter. The lack of an effect of volatility estimates on pupil dilation 
contradicts a finding by Browning et al. that volatility increases post-outcome pupil 
diameter (Browning et al., 2015; c.f. Figure 6.12C and Figure 6.20B). However, the 
authors observed the pupil diameter increase 2-5s post-outcome, a window that lay 
outside the limits of the minimum ITI used in the current task. Therefore, it is possible 
that the post-outcome period used in the present experiment was not long enough to 
capture this effect. 
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Figure 6.20 The effects of surprise and volatility on post-outcome pupil diameter 
during aversive probabilistic learning observed by Browning et al. (A) The post-
outcome pupillary response to surprise is strikingly similar to that observed in the present 
study (c.f. Figure 6.12B). (B) Browning et al. also identified a positive effect of 
environmental volatility on pupil diameter post-outcome, which I did not replicate (c.f. 
Figure 6.12C). Figure adapted from Browning et al., 2015.  
Another notable difference between Browning et al.’s study and the experiment 
conducted here is the behavioural paradigm used to generate volatility. Browning et al. 
manipulated the volatility of trials in a block-wise manner so that participants had to learn 
one probabilistic relationship during a stable block of 90 trials (i.e., approximately three 
times the block-length used in the present study) or track multiple changes in a 
probabilistic relationship during a volatile block of 90 trials. This method may have offered 
a superior means by which to manipulate individuals’ volatility estimates and may thus 
have produced larger effects on pupil diameter. However, since Browning et al.’s 
outcome stimuli were electric shocks rather than auditory stimuli, the possibility that the 
effect of volatility estimates on pupil diameter was increased under exposure to aversive 
stimuli cannot be ruled out. Indeed, our previous work has highlighted the relevance of 
pupillary dilation as an acute stress response during learning under uncertain threat of 
aversive stimuli (de Berker et al., 2016). Nonetheless, it would certainly be interesting to 
adopt Browning et al.’s method of manipulating the volatility of a probabilistic relationship 
between auditory cues and auditory outcomes. As such, it would be possible to 
determine whether this paradigm has a superior ability to capture a post-outcome effect 
of volatility estimates on pupil diameter in the absence of aversive stimuli. 
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6.5.3 Noradrenaline influences pupillary responses to trial outcome, volatility 
and irreducible uncertainty 
6.5.3.1 Noradrenaline modulates the constant component of pupil diameter 
The opposing noradrenergic manipulations tended to have opposite effects on the 
constant component of pupil diameter. Upregulating NA neurotransmission with 
reboxetine resulted in a trend-wise increase in post-outcome pupil diameter, whereas 
NA antagonism under prazosin tended to decrease the post-outcome pupil diameter. 
While these results should be interpreted with caution since they did not survive 
correction for multiple comparisons, they do fit well with previous literature that has 
assessed the impact of noradrenergic agents on pupillary dynamics. Indeed, α2-
adrenoceptor agonists, such as clonidine, which decease the activity of central 
noradrenergic neurons (and thus have a similar effect to α1-adrenoceptor antagonists 
such as prazosin), have been shown to decrease baseline pupil diameter and increase 
spontaneous pupillary fluctuations. In contrast, α2-adrenoceptor antagonists, such as 
yohimbine, which have the opposite effect on central NA, have been shown to have the 
opposite effect on pupils, i.e., an increase in baseline pupil diameter and decreased 
pupillary fluctuations (Phillips et al., 2000b). Moreover, the fact that these noradrenergic 
effects on the constant component of pupil diameter are observed post-outcome, but not 
post-cue or post-response, suggests that they are event-specific. 
6.5.3.2 Noradrenaline modulates pupillary responses to volatility 
Both noradrenergic manipulations increased the effect of subjective volatility on post-
response and post-outcome pupil dilation. This interaction between NA, volatility and 
pupil diameter sits well with the finding in Chapter 4 that NA plays an important role in 
learning under uncertainty that arises from environmental volatility (Yu and Dayan, 2005; 
Payzan-LeNestour et al., 2013; Marshall et al., 2016) and with suggestions that pupil 
diameter offers an indirect measure of noradrenergic neuronal activity in the LC (Aston-
Jones and Cohen, 2005a; Varazzani et al., 2015; Joshi et al., 2016). 
Nonetheless, the fact that the direction of the effect on pupil diameter was identical under 
two drugs with supposedly opposing effects on NA neurotransmission is puzzling. This 
likely speaks to the complexities and subtleties of the neuromodulatory systems with 
which the pharmacological agents interacted. Prazosin acts as an antagonist at α1-
adrenoceptors, a high density of which exist in the LC, at least in rats (Jones et al., 1985; 
Stone et al., 2004), and in the human neocortex (Zilles et al., 1993). As such, one would 
expect it to have reduced LC-NA neurotransmission to the cortex. In contrast, reboxetine 
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is a selective NA reuptake inhibitor (SNRI) that works by blocking the action of the NA 
transporter (NET), thereby slowing the rate at which NA is cleared from the synaptic cleft. 
Since reboxetine increases extracellular NA concentrations, it is thought to increase NA 
neurotransmission. 
However, it has been proposed that, while SNRIs primarily increase NA levels due to 
reuptake inhibition, secondary indirect activation of inhibitory presynaptic α2-
autoreceptors reduces noradrenergic activity in areas such as the LC (Invernizzi and 
Garattini, 2004). It is therefore possible that reboxetine may have actually reduced 
noradrenergic firing in the LC in some individuals. However, given the observation of a 
trend-wise increase in the constant component of pupil diameter under reboxetine, in line 
with previous accounts that upregulating NA results in pupillary dilation (Phillips et al., 
2000b), this seems unlikely in the present study, at least on average. It has also been 
proposed that the net effect of a SNRI’s two actions likely depends on dosage and on an 
individual’s baseline NA activity (Coull, 2001; de Rover et al., 2012). Future studies will 
need to determine whether any polymorphisms in the NET gene are associated with 
inter-individual differences in baseline NA activity and, if so, whether these 
polymorphisms are linked to altered responses to SNRIs and altered pupillary responses 
to volatility estimates.    
Furthermore, the extent to which pharmacological manipulations of NA modulate phasic 
and tonic modes of NA activity is currently unclear. As discussed in Chapter 4, the 
neurophysiological literature has described two functional modes of NA 
neurotransmission in the LC (Aston-Jones and Cohen, 2005b; Bouret and Sara, 2005). 
A phasic mode, characterised by a relatively low baseline firing rate and high phasic 
responsiveness to task relevant stimuli, has been linked to enhanced task engagement. 
A tonic mode (lacking phasic activity) has been linked to increased distractibility, 
attention-shifting and exploratory behaviour (Aston-Jones et al., 1994; Usher et al., 1999; 
Aston-Jones and Cohen, 2005b, but see Jepma et al., 2010). Some pharmacological 
manipulations of NA have been shown to shift the balance between phasic and tonic 
noradrenergic activity. 
In Chapter 4, I discussed the possibility that prazosin may have enabled more phasic NA 
responsiveness to emerge under suppression of tonic NA firing. Related to this point, a 
recent study in rats found that the NET-blocker atomoxetine reduces baseline LC activity 
while preserving the stimulus-evoked phasic LC response, leading to an increase in 
phasic relative to tonic LC activity (Bari and Aston-Jones, 2013). It is therefore possible 
that drugs that block NET, including reboxetine, enhance neural responses to stimuli that 
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evoke large LC responses. However, it should be noted that atomoxetine also blocks the 
serotonin transporter (SERT) and dopamine transporter (DAT), meaning that its effects 
on phasic and tonic NA activity may not be NET-specific. Further investigations utilising 
electrophysiological recordings in animals are required to characterise the relative 
impact of other noradrenergic drugs on phasic and tonic NA activity. 
In summary, the fact that the two noradrenergic manipulations used in the present study 
modulated the pupillary response to volatility provides weight to the notion that pupil 
diameter reflects, in part, noradrenergic volatility computations. However, to determine 
the precise neurophysiological bases of these responses, future work and continued 
cross-talk between human and animal research are required to pinpoint the effects of 
different pharmacological manipulations on NA neurotransmission. 
6.5.3.3 Noradrenaline modulates pupillary responses to irreducible uncertainty 
Both noradrenergic manipulations decreased the effect of subjective irreducible 
uncertainty on post-outcome pupil dilation. NA antagonism under prazosin also 
decreased the post-response effect of irreducible uncertainty on pupil diameter. Again, 
the fact that the effect was negative in both drug groups is surprising, but the same 
considerations regarding the complex effects of pharmacological manipulations on 
intricate neuromodulatory systems discussed in the previous section apply here.  
Importantly, the finding of an interaction between NA, irreducible uncertainty and pupil 
diameter highlights the need to consider the impact of multiple parameters when using 
pupil diameter as a proxy for subjective uncertainty computations. As is apparent in the 
present experiment, the pupil does not reflect a single belief but is rather modulated by 
estimates of irreducible uncertainty, surprise and volatility. Thus, unified frameworks of 
uncertainty, such as that offered by the HGF, are an important tool for pinpointing the 
relative contributions of individuals’ subjective estimates on pupil diameter. 
6.5.4 Pupil dilation follows a motor response indicating a decision 
In addition to the post-outcome pupillary responses observed in the present study, pupil 
dilation also occurred following the button-press response participants made to indicate 
their prediction as to the trial’s outcome. Since post-response pupillary dilation occurred 
during both the PLT, where there was always a degree of uncertainty about whether the 
decision was correct, and during the CT, where participants were certain of the outcome 
that would follow each cue, it appears that this pupillary response is, at least in part, 
driven by the motor response used to report the choice. Moreover, the fact that post-
response pupillary dilation was augmented and sustained under conditions of uncertainty 
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during the PLT, compared to certainty during the CT, is indicative of an additional dilatory 
effect of post-decisional uncertainty about whether the predicted outcome was correct or 
incorrect. Indeed, in line with this, the regression analysis on the Placebo pupil data 
indicated a tendency for irreducible uncertainty to increase pupil diameter during the 
post-response period.  
In accordance with this interpretation, it has been previously proposed that pupil-linked 
neuromodulatory systems are activated by the termination of decision processes and 
consequently that these systems affect the post-decisional brain state. Indeed, pupil 
dilation has been linked to the final choice terminating a decision process (Einhäuser et 
al., 2008; Hupé et al., 2009; Einhauser et al., 2010). Some research groups have 
suggested that decision-related noradrenergic brainstem activity, and thus  pupil dilation, 
is driven by an individual’s final commitment to a choice (Aston-Jones and Cohen, 2005a; 
Einhäuser et al., 2008), and others that it is driven by the motor response used to report 
that choice (Hupé et al., 2009). The present results are compatible with the notion that 
post-response pupillary dilation is modulated by both factors. 
In contrast, de Gee et al. have argued that pupil dilation is actually primarily driven during 
the course of making a decision, rather than once a decision has been made (de Gee et 
al., 2014). Specifically, sustained pupil dilation has been shown to coincide with the 
course of decision formation during an isoluminant visual detection task in which 
participants were required to decide whether or not a visual contrast signal was 
embedded in dynamic noise. Moreover, the magnitude of this intra-decisional pupil 
dilation was found to be greater than the transient increase in pupil diameter that 
occurred following a decision indicated by button-press. The noradrenergic intra-
decisional computations of uncertainty that this pupillary dilation may reflect are 
notionally sensible since estimating uncertainty before choice commitment would allow 
for anticipatory behavioural adaptation. Indeed, Urai et al. recently demonstrated that 
pupil dilation occurring after a perceptual choice but before feedback not only reflects 
decision uncertainty (i.e., the probability that a choice was correct given the sensory 
evidence) but also predicts subsequent behavioural biases (Urai et al., 2017). 
Unfortunately, it is not possible to determine with confidence whether decision-making 
during the PLT used in the present experiment had a dilatory effect on pupils, or whether 
any dilatory effect was modulated NA, because the importance of decision speed was 
stressed to participants, meaning the time period between cue and response was often 
short. However, pupil diameter did appear to start increasing from cue-onset (Figure 6.8), 
suggesting a potential influence of an intra-decisional component on pupil diameter. 
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Nevertheless, since pupil diameter also tends to increase from cue-onset during the CT 
(Figure 6.9), this component does not seem specific to uncertainty modulations. 
It should also be noted that, in contrast to de Gee’s study, the design of the present task 
meant that irreducible uncertainty could be computed on the basis of trial history, and 
therefore that participants could estimate its current magnitude before a new trial began. 
Indeed, this was reflected by an increase in baseline pupil diameter with increasing 
irreducible uncertainty estimates (Figure 6.7). As such, an intra-decisional increase in 
pupil diameter, possibly reflecting an uncertainty computation, would not necessarily be 
comparable in this instance. In sum, while a potential additional influence of intra-
decisional processes on pupil diameter cannot be ruled out, the present results do 
suggest that the act of making a motor response to indicate a decision does have a 
dilatory effect on pupils. 
6.5.5 The link between behaviour and pupillary responses to subjective beliefs 
is unclear 
The effects of the noradrenergic manipulations on behaviour during the PLT were subtle, 
with boosted NA neurotransmission under reboxetine leading to a smaller improvement 
in (model-agnostic) task performance across the course of biased blocks compared to 
Placebo. There was no difference in (model-based) learning rates across drug-groups. 
Any associations between the effect of participants’ beliefs on pupil diameter and 
behavioural changes during the PLT were also subtle. Indeed, correlations between 
pupillary responses and behaviour only existed in the NA+ group. Here, the influence of 
volatility and irreducible uncertainty estimates on post-outcome pupil diameter were 
negatively correlated with mean learning rate, and positively correlated with mean task 
performance score, respectively. 
As such, how pupillary responses to subjective beliefs are linked to behaviour is unclear. 
This is likely to be, at least in part, due to the fact that performance was very good across 
all three drug-groups, with very little behavioural difference under the noradrenergic 
manipulations. Jepma et al. have recently offered alternative evidence that atomoxetine, 
which upregulates NA, modulates learning rate following an environmental switch. 
Critically, the direction of this effect was found to be dependent on an individual’s 
baseline learning rate under placebo (Jepma et al., 2016). Due to the between-subjects 
design of the current experiment, it is not possible to replicate this analysis. Nonetheless, 
it would be fruitful to repeat the present experiment with a within-subjects placebo 
session to determine whether baseline-corrected learning rates correlate with the 
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pupillary response to volatility estimates, and thus whether there is any association 
between pupillary and behavioural responses to volatility. 
6.5.6 A unified computational framework of uncertainty will facilitate future 
comparisons between different drugs and neuromodulatory systems 
While the notion that pupil diameter offers an indirect measure of noradrenergic neural 
activity in the LC has received particular attention (Aston-Jones and Cohen, 2005a; 
Varazzani et al., 2015; Joshi et al., 2016), activity in the cholinergic basal forebrain has 
also been suggested to modulate pupil dilation (Yu, 2012). Pupil dilation is controlled by 
two muscles: the sphincter for contraction and the dilator for dilation. These two muscles 
are innervated by ACh and NA respectively. Both the muscarinic ACh antagonist 
scopolamine and the nicotinic ACh antagonist mecamylamine have been shown to 
increase pupil diameter in healthy elderly individuals (Little et al., 1998). Moreover, 
Alzheimer’s disease patients, who have a severe and specific cholinergic deficit, have 
been found to have larger pupil diameters than healthy control individuals, both tonically 
and in reflexive response to light. Administering these patients an acetylcholinesterase 
inhibitor, which increases extracellular ACh concentrations, leads to pupillary responses 
reminiscent of those in healthy individuals (Fotiou et al., 2009). Furthermore, it has 
recently been demonstrated that pupillary fluctuations are highly correlated with activity 
of both NA and ACh projections to the cortex (Reimer et al., 2016). 
Further work is needed to determine whether cognitive control of pupil diameter is under 
both ACh and NA influence, as opposed to NA alone, and to elucidate how these two 
neuromodulatory systems interact. In particular, there is a need for continued cross-talk 
between animal and human research so that electrophysiological recordings of 
neuromodulatory neurons can be linked to pupillary fluctuations in animals (Joshi et al., 
2016) and to the effects of different pharmacological manipulations on behaviour and 
pupil dilation in humans. A unified computational framework of uncertainty, such as that 
applied in the present study, offers an ideal tool with which to make comparisons 
between the effects of different drugs and different neuromodulatory systems on dynamic 
uncertainty computations and their impact on pupil diameter. 
It should also be noted that NET, the transporter targeted by reboxetine, can also 
reuptake extracellular dopamine (DA) (Bymaster et al., 2002; Swanson et al., 2006; Koda 
et al., 2010). Due to the extensive connectivity of its neuromodulatory network, DA, like 
NA, holds the potential to modulate synaptic transmission across the brain. Moreover, 
LC activity can trigger co-release of DA from noradrenergic terminals, at least in rats 
(Devoto and Flore, 2006), and there are bidirectional projections between the 
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dopaminergic ventral tegmental area and the noradrenergic LC (Sara, 2009). The 
neurocognitive literature has established that DA neurons respond to novel and 
unexpected stimuli, and that individuals with Parkinson’s disease, and thus DA 
dysfunction, have an impaired capacity to switch between task-specific behaviours 
(Cools et al., 2001a; Cools and Robbins, 2004; Wise, 2004). As such, DA appears well-
placed to support behavioural switching, which is an adaptive process under 
environmental volatility. Furthermore, in Chapter 4, DA was found to sensitise motor 
responses to subjective estimates of phasic volatility. Therefore, at present, additional 
dopaminergic modulation of the pupillary response to volatility cannot be ruled out. 
Again, pharmacological manipulations of the dopamine network within the same 
behavioural and computational framework would help to address this. 
6.5.7 Conclusion 
In summary, the results presented in this chapter offer novel insight into the relative 
contributions of uncertainty, surprise, volatility and noradrenaline to dynamic changes in 
behaviour and pupil diameter. Baseline pupil diameter strongly reflects an individual’s 
belief about the current relationship between environmental events, as reflected by their 
irreducible uncertainty estimates. Dynamic pupillary dilation tracks both subjective 
irreducible uncertainty and surprise. NA modulates pupillary responses to irreducible 
uncertainty and volatility estimates. Pupillometry may therefore offer a useful proxy for 
computations of uncertainty, surprise and volatility, which appear to be, at least in part, 
dependent on NA. Importantly, changes in pupil diameter reflect dynamic beliefs about 
several perceptual parameters. This means that, while pupillometry offers a cheap and 
simple adjunct to behavioural paradigms, it should be used with suitable caution. Indeed, 
unified computational frameworks of uncertainty, such as the HGF, are required to fully 
capture the relative contributions of uncertainty, surprise and volatility to pupillary 
dilation. Future work utilising consistent behavioural and computational frameworks to 
contrast the impact of different pharmacological agents will help to elucidate the 
complexities of noradrenergic (and possible cholinergic and dopaminergic) modulations 
of behaviour and pupil diameter during learning. 
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7 General discussion 
Learning the world’s underlying statistical structure enables individuals to predict the 
likelihood of future environmental events, facilitating anticipatory action preparation and 
the execution of fast, accurate motor responses. In this thesis I have shed light upon the 
neuromodulatory processes that contribute to learning and response modulation in 
dynamic, probabilistic environments by examining the impact of pharmacological 
manipulations of noradrenaline (NA), acetylcholine (ACh) and dopamine (DA) (Chapters 
4 and 6), and genetic variations in DA neurotransmission (Chapter 5), within a unified 
computational framework of uncertainty (Chapter 3). I have demonstrated that NA and 
ACh modulate learning under uncertainty. Specifically, NA influences learning of 
uncertain events that arise due to the environment’s volatility. Further, dynamic 
noradrenergic computations of uncertainty and volatility can be measured indirectly 
using pupillometry. ACh balances the attribution of uncertainty to chance fluctuations 
within environmental contexts or to gross environmental violations following a contextual 
switch. In contrast, DA supports the use of perceptual estimates, namely volatility 
representations, to engender adaptive motor responses. Since each experimental 
chapter contains a relatively extensive discussion of the issues pertinent to that study, in 
this summary I draw together some common threads between the experiments, discuss 
the implications and limitations of this body of work, and formulate suggestions for future 
extensions to the field. 
7.1 Benefits and limitations of the behavioural paradigms 
7.1.1 The probabilistic serial reaction time task 
A key benefit of the novel probabilistic serial reaction time task (PSRTT) implemented in 
Chapters 4 and 5, is the scope to characterise learning and response modulation under 
irreducible, estimation and volatility uncertainty. Its design created a more complex, and 
arguably more ecologically valid, scenario than earlier paradigms that explicitly signalled 
contextual rules and switches (Galea et al., 2012; Bestmann et al., 2014). Instead, 
individuals were required to infer a current environmental context for themselves and 
adapt to contextual changes. Within the framework of a novel instantiation of the 
Hierarchical Gaussian Filter (HGF) model, it was possible to interrogate the relative 
contributions of NA, ACh and DA to learning of the task’s contextual probabilistic rules 
and to motor response modulation in light of individuals’ beliefs about those rules 
(Marshall et al., 2016). 
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However, despite offering a paradigmatic advance, one should be mindful of the fact that 
the PSRTT is not fully representative of real-world learning and response modulation. 
Indeed, future work employing alternative task designs will be needed to verify the 
generality of the effects reported in Chapter 4 to alternative behavioural paradigms with 
and without learning, reward, prediction and action. For instance, while using a paradigm 
that combined learning and action has the aforementioned merits, one could argue that 
indirectly inferring participants’ predictions from their reaction times (RTs) is not the 
cleanest approach for investigating learning under different sources of environmental 
uncertainty. Indeed, contrasting the impacts of pharmacological manipulations of NA and 
ACh within a volatile predictive learning paradigm would offer a useful means by which 
to validate my finding that NA and ACh play respective roles in mediating learning 
between and within environmental contexts, in the absence of motor response 
modulation. Moreover, by introducing reward to the PSRTT, it might be possible to 
identify dopaminergic contributions to motor response modulation under reward 
prediction error (PE) rather than sensory PE. 
In addition, while the use of speeded button-press responses and a novel response 
model enabled me to quantify the modulation of an individual’s RTs by their perceptual 
beliefs, the approach offers little insight into how uncertainty modulates the quality of 
executed actions. The predominant approach to studying behavioural adaptation to 
perceptual estimates has been to examine when individuals initiate an action (Beierholm 
et al., 2013; Guitart-Masip et al., 2014; Vossel et al., 2014a, 2014b, 2015; Marshall et 
al., 2016). However, this only captures part of the picture. Environmental sources of 
uncertainty also influence how individuals execute actions (Bays and Wolpert, 2007). A 
simple yet fruitful extension to the work in this thesis would be to have individuals use a 
force button-box to complete the PSRTT. By requiring individuals to respond to the 
presentation of trial-wise stimuli by pressing an appropriate button quickly and within a 
required force range, it would be possible to investigate how irreducible, estimation and 
volatility uncertainty influenced the quality of action execution, here force generation, as 
well as the speed of action selection. 
7.1.2 The probabilistic learning task 
The major advantage of adopting the probabilistic learning task (PLT) (den Ouden et al., 
2010) in Chapter 6 was that it enabled direct comparisons to be made to our previous 
study that had used the same fundamental paradigm (de Berker et al., 2016). 
Importantly, by applying the same HGF model to a novel dataset acquired from 
participants that received a noradrenergic drug or placebo, it was possible to replicate 
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our earlier finding that baseline pupil diameter reflects irreducible uncertainty, and to 
extend previous results by establishing that pupil dilation is modulated by surprise and 
noradrenergic computations of volatility in a quantitatively rigorous fashion. My review of 
the previous pupillometric literature in Chapter 1 highlighted the diversity of paradigmatic 
approaches implemented to study changes in pupil diameter under different 
combinations of uncertainty, surprise and volatility. A key rhetoric of this thesis is the 
need for researchers to adopt unified frameworks of uncertainty, surprise and volatility, 
such as that offered by the HGF, in order to develop comparable tasks powered to isolate 
the relative contributions of different neuromodulators to learning under different 
perceptual quantities. 
In Chapter 6, I noted that no post-outcome pupillary response to volatility was observed 
under placebo. This finding contrasts with Browning et al.’s observation of post-outcome 
pupillary dilation in response to both surprise and volatility (Browning et al., 2015), and 
is likely due to the fact that volatility was not explicitly manipulated in the PLT. A fruitful 
extension to the current work would therefore be to investigate the impact of 
pharmacological manipulations of NA on pupillary responses to perceptual estimates 
within a modified version of the PLT that manipulated volatility over time. I would 
anticipate that, by modulating individuals’ volatility estimates, this approach would 
produce larger effects on pupil diameter, thus making it possible to observe pupillary 
responses to volatility under placebo. I would also expect to replicate my finding that 
noradrenergic manipulations modulate the influence of volatility estimates on pupil 
diameter. 
7.2 Benefits and limitations of the HGF model 
The HGF is a general-purpose, heuristic Bayesian inference model. Taking inspiration 
from reinforcement learning schemes, the HGF seeks to overcome the computational 
complexity of traditional Bayesian approaches, and offers a means by which to capture 
differences in learning across individuals. A key advantage of the HGF is that it provides 
a generic hierarchical framework for individual learning that can be applied to a diverse 
set of behavioural paradigms (Iglesias et al., 2013; Diaconescu et al., 2014, 2017; 
Hauser et al., 2014; Vossel et al., 2014a, 2014b, 2015; de Berker et al., 2016; Marshall 
et al., 2016). Given that the brain would likely benefit from a flexible mechanism by which 
to modify learning and action, and therefore facilitate adaptation to novel environments 
characterised by unfamiliar contextual rules, this is arguably a sensible computational 
strategy. 
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7.2.1 A unified computational framework of uncertainty  
In this thesis I have verified the HGF as a useful tool with which to model individual 
learning and behaviour under various forms of uncertainty inherent in the environment. 
In Chapter 6, I presented confirmatory evidence of the HGF’s ability to capture individual 
learning under irreducible, estimation and volatility uncertainty. Furthermore, Chapters 
4 and 5 demonstrated that the novel instantiation of the HGF developed in Chapter 3 
could capture separable influences of uncertainty on learning and motor response 
modulation (Marshall et al., 2016). Importantly, the generalisable nature of the HGF 
means it can be used to probe learning and action across different behavioural 
paradigms, but within a unified computational framework of uncertainty.  
7.2.2 Alternative models of learning and action 
Nevertheless, a heuristic framework is not the only viable approach to modelling 
individual learning and action under uncertainty. An alternative strategy is to develop 
task-specific models. 
7.2.2.1 The Forgetful Observer Model 
In an ongoing collaboration with Franziska Bröker and Peter Dayan, we are seeking to 
test whether individual behaviour during the PSRTT might be captured more faithfully by 
a simpler, task-specific model. Specifically, a Forgetful Observer Model (FOM) has been 
built to reflect the properties of the PSRTT more closely by taking additional task-relevant 
information into account (Bröker, 2016). Like the HGF, the FOM features a perceptual 
model that captures individual learning and a response model that predicts participants’ 
behaviour based on their perceptual beliefs. However, while the HGF is initially minimally 
adapted to a given behavioural task, such as the PSRTT, the FOM assumes that 
individuals make use of their prior knowledge of the task’s structure. As such, the HGF 
assumes that individuals’ beliefs about the transition probabilities between successive 
stimuli evolve independently of each other in the PSRTT, whereas the FOM implements 
a generative model that closely resembles the PSRTT’s true generative process. On one 
hand, a task-specific model seems reasonable given that participants were informed 
before starting the task that one of four possible stimuli would be presented on each trial, 
meaning that the state space was constrained. Nonetheless, one could argue that the 
brain is not afforded the luxury of a constrained state space in real-world scenarios, 
instead requiring sufficient computational flexibility to account for unexpected events.  
Another feature of the FOM is that it applies an exponential forgetting process to prior 
expectations. The forgetting rate weights past experience exponentially. As such, it offers 
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a heuristic means by which more recent transitions can have a greater impact on current 
probability estimates. The forgetting rate is conceptually related to the transition 
contingency learning rate, ω, in the HGF and allows the model to learn the transition 
probabilities within the different transition matrices implemented in the PSRTT. 
Preliminary data suggest that, compared to the HGF, the FOM is superior at capturing 
individual learning and action in the PSRTT (Bröker, 2016). This is not necessarily 
surprising; one would expect a task-specific model to be more accurate, at least during 
initial learning. Further, a simpler model is not penalised by complexity. Whether the 
brain facilitates behavioural adaptation by constructing a multitude of task-specific 
models, and indeed whether the mechanisms underlying the FOM map onto 
neurophysiological processes, is another matter. In terms of physiological and 
behavioural relevance, both the HGF and the FOM have appealing properties. A 
heuristic, general-purpose model like the HGF would provide the brain with a flexible 
mechanism by which to adapt to any environmental context (Kumaran and Duzel, 2008; 
Shohamy and Wagner, 2008), but it is also possible that evolutionary experience has led 
the brain to fine-tune an array of environmentally valid, context-specific models of the 
world. In the latter case, an individual might learn the underlying rules of a novel 
environment by retrieving a similar pre-existing contextual model (Heckers et al., 2004) 
and adapting it to the current environmental parameters. An interesting avenue for future 
research would be to determine if and how individuals switch between different 
perceptual and response models when exposed to different environmental contexts 
(Boorman and Rushworth, 2009; Kumaran et al., 2009; Daw et al., 2011), perhaps via a 
hippocampal mechanism (Eichenbaum, 2000; Preston et al., 2004).   
7.2.2.2 Modelling changes in volatility and metavolatility 
It should also be noted that although the FOM features an heuristic forgetting rate that 
allows the model to learn the transition probabilities within the PSRTT’s different 
transition matrices, it does not explicitly capture volatility uncertainty arising from 
contextual instability. Rather, it assumes a fixed, optimal learning process. This is in 
contrast to the HGF whose metavolatility parameter, ϑ, captures the rate at which 
volatility changes, with higher values implying a belief in a more unstable world and 
leading to a more variable learning rate. Given the relevance of volatility estimates to 
learning and action demonstrated in this thesis, it is important that future models 
incorporate a means by which to track volatility uncertainty since changes in this 
perceptual estimate indicate when and how learning rate should be adapted, with 
consequences for belief updating and response modulation. 
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A useful extension to both the HGF and the FOM would be an additional hierarchical 
level that allows estimates of metavolatility to change over time. Indeed, it seems 
reasonable that an individual’s phasic volatility learning rate would vary across different 
environments with different degrees of volatility that change over different timescales. 
7.2.2.3 Modelling change-points under environmental volatility 
In both the PSRTT and PLT, participants were exposed to volatile environments 
characterised by discrete switches in probabilistic context. Neither the HGF nor the FOM 
acknowledges these punctate change-points directly. This contrasts with an alternative 
class of models that capture learning under volatility by modelling change-points 
explicitly (Adams and MacKay, 2007; Fearnhead and Liu, 2007; Nassar et al., 2010; 
Wilson et al., 2010, 2013). Early attempts to identify change-points using Bayesian 
inference relied on pre-specification of the rate at which they occur, i.e., the hazard rate. 
These models were limited practically by requiring the unrealistic assumption that the 
hazard rate was fixed and known in advance (Adams and MacKay, 2007; Fearnhead 
and Liu, 2007). Robert Wilson, Matthew Nassar and Joshua Gold offered an important 
methodological advancement by developing a hierarchical extension to earlier models 
that allowed the hazard rate itself to be inferred from the data, in turn facilitating 
identification of change-points (Wilson et al., 2010). Further developments permitted 
efficient Bayesian inference in volatile environments to be approximated by a 
computationally simple mixture of error-driven “delta” rules (Wilson et al., 2013). While 
the HGF does not explicitly model the change-points contained in the true generative 
process underlying the PSRTT and the PLT, I have demonstrated that true change-
points are detected implicitly by the model as an increase in learning rate. In so doing, 
the HGF offers a flexible means of tracking individual learning in dynamic environments. 
To summarise, in this thesis, I have validated the HGF as a useful tool with which to 
model individual learning and response modulation under various forms of environmental 
uncertainty. I have verified the capacity of the HGF’s original instantiation to capture 
individual learning under irreducible, estimation and volatility uncertainty, and I have 
developed a novel instantiation of the HGF that is capable of capturing separable 
influences of uncertainty, prediction error and volatility on learning and action (Marshall 
et al., 2016). The heuristic computational framework offered by the HGF offers an 
important tool with which to probe the neuromodulatory mechanisms implemented by the 
brain to support learning and adaptive motor behaviour. The suggested extensions to 
the model may help to elucidate these mechanisms more precisely.      
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7.2.3 Relevance for machine learning 
It is also worth noting that, compared to contemporary machine learning methods, 
humans are exceptionally good at inferring hidden probabilistic and causal relationships 
from limited experience. Indeed, as demonstrated in Chapters 4, 5 and 6, individuals 
can closely track the probabilistic associations within a given environment and rapidly 
adapt to changes in contextual rules. Refining models of human learning and behaviour 
under uncertainty holds the potential to better elucidate the strategies employed by the 
brain to make these inferences. Since the brain offers seemingly efficient and effective 
solutions to the computational and implementational challenges of probabilistic 
inference, this approach might inspire new methodologies in machine learning and 
artificial intelligence. Nevertheless, the vast parameter space of heuristic models such 
as the HGF does present challenges. Different parameters relate to a variety of variables 
and testing the impact of each of them on learning, behaviour and/or pupil diameter 
presents a multiple comparisons problem. It is therefore important that all future 
computational analyses are hypothesis-driven. Indeed, this highlights an excellent case 
for the pre-registration of research studies, whereby researchers commit to their 
research predictions and methods before starting their experiments.   
7.3 Combining pharmacology and neuroimaging 
A number of key papers that inspired the work presented in this thesis used human 
functional magnetic resonance imaging (fMRI) to link the noradrenergic, cholinergic and 
dopaminergic systems to computations of different forms of environmental uncertainty. 
Indeed, blood-oxygenation-level-dependent (BOLD) activity in the noradrenergic locus 
coeruleus (LC) has been shown to dynamically track volatility uncertainty (Payzan-
LeNestour et al., 2013), BOLD activity in the cholinergic basal forebrain reflects an 
individual’s estimation uncertainty (specifically, their precision-weighted contingency 
PE), and BOLD activity in the dopaminergic midbrain correlates with individual estimates 
of precision-weighted sensory PE (Iglesias et al., 2013; Diaconescu et al., 2017). It is not 
possible to infer with certainty that activations in particular brain regions, with 
inhomogeneous cellular compositions, reflect the activity of specific neuromodulatory 
neurons. Adopting a pharmacological approach in Chapters 4 and 6 made it possible to 
corroborate and extend the interpretations of these neuroimaging studies. 
A recommendation for future investigations of the neuromodulatory bases of learning 
and/or behaviour under uncertainty would be to combine pharmacology and 
neuroimaging approaches (Mattay et al., 2000; Coull et al., 2001; Thiel et al., 2001, 2002; 
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Bentley et al., 2011; Chowdhury et al., 2013; Crockett et al., 2013). Taking advantage of 
the two complementary methodologies will enable researchers to pinpoint the 
contributions of NA, ACh and DA to different neurophysiological processes occurring in 
different brain regions. Future work will also be required to characterise the physiological 
roles of the different neuromodulators acting at different receptor sub-types and over 
multiple timescales. Related, continued cross-talk between human and animal research 
will facilitate the isolation of neuromodulatory contributions to these processes. By 
developing behavioural tasks and computational learning models that can be translated 
to different species, it will be possible to utilise a wide repertoire of methodologies, 
including more invasive techniques such as neuronal lesions, electrophysiological 
recordings and optogenetics, to characterise the specific neuromodulatory 
underpinnings of learning and action in uncertain environments. As recently set out by 
Krakauer et al., human behavioural neuroscience is well-placed to elucidate an 
understanding of learning and action under uncertainty through careful experimental 
decomposition of behaviour which, with associated pharmacological, behavioural 
genetics and neuroimaging approaches, can be linked to different neuromodulatory 
systems and brain regions. In turn, this sets the stage to causally test the precise neural 
implementation of behaviour using invasive interventions in animals (Krakauer et al., 
2017). Nonetheless, as argued throughout this thesis, critical to this approach will be the 
use of unified computational models with which to interrogate the contributions of 
different perceptual and behavioural parameters to the neural activations revealed by 
neuroimaging. 
7.3.1 Neural implementation of uncertainty computations 
While the focus of this thesis has been to characterise the relative contributions of NA, 
ACh and DA to learning and response modulation under uncertainty, parallel lines of 
work focus on how computations of uncertainty are implemented at a neural coding level 
(Ma and Jazayeri, 2014; Pouget et al., 2016). Three types of neural code have been 
proposed (Sanger, 1996; Pouget et al., 2003; Ma et al., 2006). First, in probabilistic 
population coding, uncertainty is represented implicitly in neuronal population activity. 
For instance, increased uncertainty may correspond to a lower total spike count. Second, 
in sampling coding, the activity of a neuron at a given time-point is a sample from the 
belief distribution that is to be represented, and the probability of a variable of interest is 
directly mapped onto neuronal firing rate. Third, in explicit population coding, the activity 
of a neuron tuned to a stimulus feature is monotonically related to the probability density 
of that feature. Higher uncertainty is represented by a wider activation pattern across the 
population. The details of how the brain represents probability distributions are currently 
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unknown (Pouget et al., 2013), but, in addition to animal work, human neuroimaging 
methods such as fMRI repetition suppression hold the potential to elucidate the 
underlying neural mechanisms employed by the noradrenergic, cholinergic and 
dopaminergic systems (Barron et al., 2016). The use of fMRI will also help to isolate the 
precise neural networks that support uncertainty encoding (Behrens et al., 2007; Iglesias 
et al., 2013; Payzan-LeNestour et al., 2013; Silvetti et al., 2013; McGuire et al., 2014; 
Diaconescu et al., 2017). 
7.4 Combining pharmacology and behavioural genetics 
As I addressed in Chapter 5, behavioural genetics holds the potential to extend the 
insights offered by pharmacological and neuroimaging investigations of the 
neuromodulatory contributions to learning and response modulation. Importantly, a 
further reason to combine pharmacology and behavioural genetics is that individual 
behavioural responses to pharmacological manipulations can depend strongly on 
baseline neurotransmission (Kimberg et al., 1997; Mehta et al., 2004a; Roesch-Ely et 
al., 2005; Frank and O’Reilly, 2006; Cools et al., 2007b; Clatworthy et al., 2009). Since 
multiple genes are thought to modulate baseline neuromodulatory function, there is 
strong reason to predict that individual differences in noradrenergic, cholinergic and 
dopaminergic drug effects are, at least in part, genetic.  
For instance, it has been demonstrated that the direction of cognitive effects produced 
by pharmacological catechol-O-methyltransferase (COMT) inhibition under tolcapone is 
determined by an individual’s COMT Val158Met genotype (Farrell et al., 2012). 
Specifically, tolcapone improves working memory performance in Val carriers but impairs 
performance in Met carriers. This is thought to be due to an inverted-U relationship 
between cortical DA neurotransmission and cognitive function (Figure 7.1). Val/Val 
homozygotes show higher baseline COMT activity, and thus lower baseline DA 
neurotransmission, than Met/Met homozygotes (Männistö and Kaakkola, 1999; Chen et 
al., 2004). Due to the supposed inverted-U relationship between cortical DA and 
cognitive function, Val/Val homozygotes show inferior baseline working memory 
performance compared to Met carriers. COMT inhibition under tolcapone increases 
cortical DA neurotransmission in all individuals but the different baseline DA levels 
between individuals, and the inverted-U relationship between DA and working memory, 
mean that the functional consequences of this shift differ between COMT genotypes. 
Val/Val individuals move closer to optimal performance, while Met individuals move past 
the peak, resulting in a deterioration in working memory performance. 
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Similarly, amphetamines, which alter catecholaminergic neurotransmission by blocking 
the action of transporters at dopaminergic, serotonergic and noradrenergic neurons, 
show variable effects in individuals with different COMT genotypes (Mattay et al., 2003). 
Moreover, pharmacological DA D2-receptor stimulation generally improves task 
performance in individuals with low baseline working memory span (Kimberg et al., 1997; 
Frank and O’Reilly, 2006), high impulsivity (Cools et al., 2007b) or low baseline DA 
synthesis (Cools et al., 2009), but impairs performance in those showing the opposite 
baseline trait. Further, the modulatory effect of atomoxetine, which upregulates 
catecholamines such as DA and NA, on an individual’s learning rate is dependent on 
their learning rate at baseline (Jepma et al., 2016), potentially indicative of inter-individual 
genetic variations in baseline NA neurotransmission and an inverted-U relationship 
between NA and cognitive function. 
 
Figure 7.1 COMT genotype determines the direction of cognitive effects produced 
by pharmacological COMT inhibition. An inverted-U relationship between cortical DA 
neurotransmission and cognitive function has been proposed. Val/Val homozygotes 
show higher COMT activity and lower DA neurotransmission than Met/Met homozygotes. 
As such, they sit further to the left on the curve at baseline, showing inferior cognitive 
performance. COMT inhibition under tolcapone shifts all individuals to the right because 
DA neurotransmission increases. The functional correlates of this shift differ between 
genotypes. In an n-back working memory task, Val/Val individuals move closer to optimal 
performance, while Met/Met individuals move to the right of the peak, resulting in 
declining performance. A similar effect on risk aversion is observed during a gambling 
task. Figure adapted from Farrell et al., 2012.  
Combining behavioural genetics and pharmacology will therefore help to improve our 
mechanistic understanding of the neuromodulatory contributions to learning and action 
in uncertain environments. The methodologies implemented in this thesis can be applied 
to large cohorts of healthy individuals, facilitating a refined insight into the contributions 
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of the different neuromodulatory systems, and the impact of different pharmacological 
interventions, in individuals with different genotypes. Again, the conclusions of studies 
adopting this strategy will only be as sophisticated as the computational models used to 
interrogate learning and behaviour. The approach also has clinical relevance since 
dopaminergic, noradrenergic and cholinergic drugs are used to treat a wide range of 
neurological and psychiatric disorders. This means that elucidating the relationship 
between baseline levels of neurotransmission and pharmacological responses will aid 
the development of personalised therapeutic strategies. 
7.5 Functional overlaps between the noradrenergic, cholinergic 
and dopaminergic systems 
It important to note that there are functional overlaps between the noradrenergic, 
cholinergic and dopaminergic systems, which limit the confidence with which the findings 
of this thesis can be inferred. For example, the noradrenergic LC receives inputs from 
several brain regions, some of them supplying dopaminergic (substantial nigra/ventral 
tegmental area; SN/VTA) and cholinergic (pedunculopontine tegmental nucleus; PPN) 
neuromodulatory influences (Samuels and Szabadi, 2008). Combining imaging of the 
functional activity in the SN/VTA, PPN and LC with pharmacological manipulatuons of 
DA and NA could offer fruitful insight by elucidating the interaction between the regions, 
the neuromodulatory underprinnings of these interactions, during learning and response 
modulation under uncertainty. 
There is also considerable neurophysiological evidence that the catecholamines NA and 
DA have similar, partially overlapping, post-synaptic effects by boosting the efficacy of 
synaptic interactions between neurons, thus increasing cortical neural gain (Sutton et al., 
1967; Servan-Schreiber et al., 1990; Berridge and Waterhouse, 2003; Winterer and 
Weinberger, 2004; Aston-Jones and Cohen, 2005a). By selectively increasing gain 
following unexpected outcomes, the catecholamine systems are in a position to promote 
belief updating in a strongly stimulus-driven manner. Chapter 4 offered important insight 
into the neuromodulators’ relative roles by establishing the impact of pharmacological 
NA, ACh and DA manipulations on learning and action under uncertainty. Nonetheless, 
the complex interactions and dependencies between the noradrenergic, cholinergic and 
dopaminergic systems mean that future corroborative studies using a range of drugs that 
target different receptor sub-types, combined with behavioural genetics and 
neuroimaging approaches, are required to characterise the neuromodulatory 
mechanisms in more detail.  
7. General discussion 
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7.6 Insights into neurological disorders 
By characterising uncertainty computations and response modulation, the methodology 
reported in this thesis holds the potential to offer fresh insight into the numerous 
neurological and psychiatric disorders in which there is dysregulation of processes 
dependent on NA, ACh and DA (Iglesias et al., 2016). Further, the development of 
behavioural paradigms with the power to detect aberrant neuromodulatory function might 
offer clinically relevant diagnostic tools. As discussed previously, patients with 
Parkinson’s disease, and therefore nigrostriatal dopaminergic depletions, show an 
impaired ability to make adaptive responses to unexpected sensory events that occur 
within a broadly predictable context and thus elicit a large sensory prediction error (Galea 
et al., 2012). It is possible that patients demonstrate these deficits early in their disease 
course (Braak et al., 2003; Anderson, 2004; Santangelo et al., 2017), meaning that tasks 
such as the PSRTT may offer a useful foundation for developing diagnostic behavioural 
markers of a dopaminergic disease state. Moreover, there has been a recent move to 
integrate computational neuroscience into psychiatry in an effort to better elucidate the 
pathophysiological mechanisms of disorders such as schizophrenia, which is also linked 
to (primarily cortical) dopaminergic dysfunction (Friston et al., 2014). Pinpointing the 
relative contributions of the neuromodulatory systems to learning and action in healthy 
individuals holds the potential to identify aberrant neuromodulatory processing in 
psychiatric disorders through assessment of learning and behaviour in tasks, such as 
the PSRTT and the PLT, within a unified computational framework of uncertainty, such 
as that offered by the HGF.  
7.7 Concluding Remarks 
By adopting a unified computational framework to characterise individual learning and 
action under irreducible, estimation and volatility uncertainty, it is possible to utilise 
neuropharmacology and behavioural genetics to identify the contributions of different 
neuromodulatory systems to perceptual belief updating and response modulation in 
dynamic probabilistic environments. The experiments presented in this thesis offer a 
foundation for future work combining pharmacology, behavioural genetics and 
neuroimaging to pinpoint the specific neurophysiological mechanisms by which the 
human brain supports learning and action in uncertain environments at cellular, network 
and behavioural levels. 
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